data_1tkw_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1tkw _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.416 HD22 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.445 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.63 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.63 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.416 ' HB3' HD22 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.445 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.66 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.66 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.438 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.51 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.479 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.724 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.596 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.655 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.51 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.462 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.462 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.596 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.476 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.789 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.789 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.669 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.543 ' CB ' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.435 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.807 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' B' ' 7' ' ' GLN . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.752 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' B' ' 3' ' ' ILE . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.425 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.44 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.563 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.467 HD12 HG21 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.475 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.805 HG11 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.805 ' HD2' HG11 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.415 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.416 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.535 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . 0.467 HG21 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.423 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . 0.582 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.533 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.66 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . 0.469 HD13 HD22 ' B' ' 113' ' ' LEU . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.42 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD13 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.537 HD13 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' SER . . . . . 0.437 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.437 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.44 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . 0.469 HD22 HD13 ' B' ' 83' ' ' LEU . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.425 HD11 HG23 ' B' ' 126' ' ' ILE . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.807 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . 0.425 HG23 HD11 ' B' ' 115' ' ' ILE . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.535 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.431 ' HG2' HG12 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . 0.427 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . 0.427 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.431 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.478 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.563 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.413 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.415 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.669 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.659 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.501 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.413 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 169' ' ' THR . . . . . 0.415 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . 0.455 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.724 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.52 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.52 HG23 ' HB ' ' B' ' 194' ' ' ILE . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.404 HD13 HG21 ' B' ' 228' ' ' THR . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . 0.582 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.423 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . 0.463 HG11 HD11 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.463 HD11 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.455 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.404 HG21 HD13 ' B' ' 207' ' ' ILE . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.644 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.623 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.623 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.473 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.6 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.6 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.563 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.47 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.878 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.675 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.662 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.662 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.496 HG23 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.47 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.761 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.508 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.447 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.491 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.491 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.675 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.499 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.559 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.646 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 31.9 m170 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.69 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.631 ' HA2' ' CD1' ' B' ' 160' ' ' TYR . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.854 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.473 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.69 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.459 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.938 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.416 HG23 ' CE1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.872 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.418 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.456 ' HA ' HD23 ' B' ' 26' ' ' LEU . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.454 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.408 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.403 ' O ' HG22 ' B' ' 33' ' ' ILE . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.453 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.595 HG11 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.595 ' HD2' HG11 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.48 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.617 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.453 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.408 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.761 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.721 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.721 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . 0.426 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.51 ' HB3' HD13 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.418 HG23 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.51 HD13 ' HB3' ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.938 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.426 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.617 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.436 HG12 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.557 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.768 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.693 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.768 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.434 ' HH ' ' HG3' ' B' ' 208' ' ' PRO . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 174' ' ' THR . . . . . 0.422 HG22 ' OD1' ' B' ' 205' ' ' ASP . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . 0.542 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . 0.486 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.878 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . 0.422 ' OD1' HG22 ' B' ' 174' ' ' THR . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.434 ' HG3' ' HH ' ' B' ' 171' ' ' TYR . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.418 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.466 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.466 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.525 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.417 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.438 ' HB3' HD13 ' B' ' 40' ' ' LEU . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . 0.4 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.435 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.629 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.629 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.551 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.613 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.613 ' CG2' HD22 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.406 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.438 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.471 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.615 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.643 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.643 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.532 HG23 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.461 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.5 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.494 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.494 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.615 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.43 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.731 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 36.0 m80 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.742 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.435 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.439 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.977 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.872 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.411 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.411 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.433 ' HG3' HG23 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.451 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.453 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.622 HG11 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.474 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.621 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.453 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.461 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.461 HD13 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' SER . . . . . 0.405 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.405 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.433 HG23 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.977 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.621 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.43 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.407 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.43 HG12 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.407 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.55 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.682 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.619 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.677 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.471 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.414 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.403 HD23 HG22 ' B' ' 228' ' ' THR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.431 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.403 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.522 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.522 ' HD3' ' O ' ' B' ' 229' ' ' SER . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 55.0 t30 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.406 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.441 ' HB3' HD13 ' B' ' 40' ' ' LEU . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.411 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.67 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.67 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.436 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HE3' ' HB3' ' A' ' 2' ' ' ASP . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.635 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.635 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.474 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.431 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.477 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.546 ' HB2' ' CB ' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.635 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.63 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.63 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.52 HG23 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.474 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.428 ' HE1' ' HB3' ' A' ' 61' ' ' ASP . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.428 ' HB3' ' HE1' ' A' ' 57' ' ' MET . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.513 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.531 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.531 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.635 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.448 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.714 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.714 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.894 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 1.051 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.436 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.432 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.907 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 1.051 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.44 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.417 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.443 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.417 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.452 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.729 HG11 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.729 ' HD2' HG11 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.455 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.405 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.639 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.452 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.417 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.474 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.723 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.478 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.478 HD13 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' SER . . . . . 0.54 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.54 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.44 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.426 HD11 HG23 ' B' ' 126' ' ' ILE . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.907 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . 0.426 HG23 HD11 ' B' ' 115' ' ' ILE . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.639 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.431 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . 0.406 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . 0.406 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.431 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.405 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.57 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.444 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.434 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.894 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.698 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.426 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.444 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 169' ' ' THR . . . . . 0.434 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.546 ' CB ' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.426 ' CG ' HD13 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.44 ' HB ' HG23 ' B' ' 203' ' ' VAL . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' B' ' 194' ' ' ILE . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.426 HD13 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.417 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.417 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.405 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.413 ' HB3' HD13 ' B' ' 40' ' ' LEU . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.619 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.619 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.446 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.415 HG22 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.613 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.536 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.531 HD22 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.531 ' CG2' HD22 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.452 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.485 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.643 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.631 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.631 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.485 HG23 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.457 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.828 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.423 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.512 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.415 ' HG2' HG22 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.485 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.485 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.643 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.491 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.48 ' HB2' ' HB2' ' B' ' 62' ' ' ALA . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.558 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.471 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 1.069 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.675 ' HB1' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.446 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.43 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.911 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.911 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.428 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.428 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.424 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.444 ' HA ' HD23 ' B' ' 26' ' ' LEU . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.451 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.423 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.4 ' O ' HG22 ' B' ' 33' ' ' ILE . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.448 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.598 HG11 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.598 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.487 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.632 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.423 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.48 ' HB2' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.828 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.423 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . 0.405 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.402 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.402 HD13 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.424 HG23 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.491 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.845 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.405 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.632 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.404 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.402 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.404 HG12 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.402 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.402 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.786 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 1.069 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.611 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . 0.426 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.485 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.426 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.452 HD23 HG22 ' B' ' 228' ' ' THR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.438 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.438 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.452 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.521 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.408 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.402 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.44 ' HB3' HD13 ' B' ' 40' ' ' LEU . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.631 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.631 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.443 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.404 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.624 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.548 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.454 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.723 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.63 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.646 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.646 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.464 HG23 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.454 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.48 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.459 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.461 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.63 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.502 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.594 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.579 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.474 ' HB3' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.932 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.4 ' HA ' ' CE2' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.443 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.447 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.671 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.413 ' HD1' ' HA ' ' B' ' 4' ' ' PHE . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.406 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.406 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.42 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.422 ' HA ' HD23 ' B' ' 26' ' ' LEU . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.452 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.448 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.536 HG11 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.536 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.466 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.622 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.594 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.728 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.728 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.414 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.46 ' HB3' HD13 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.42 HG23 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.46 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.671 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.622 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.932 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.703 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.566 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.723 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.43 HD23 HG22 ' B' ' 228' ' ' THR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.432 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.432 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.43 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.519 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.519 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.407 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.452 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.417 ' HB3' HD13 ' B' ' 40' ' ' LEU . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.616 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.616 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.465 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.426 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.464 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.651 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.651 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.63 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.809 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.688 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.688 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.425 ' HB3' ' HE1' ' A' ' 57' ' ' MET . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . 0.448 ' HB3' ' HE3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.426 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.709 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.809 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.433 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.724 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.738 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.531 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.709 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.738 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.495 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.531 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.599 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.599 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . 0.547 ' HB1' ' ND2' ' B' ' 232' ' ' ASN . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.423 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.406 HG21 ' O ' ' B' ' 237' ' ' GLY . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.609 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.599 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.665 HG11 HD12 ' B' ' 243' ' ' ILE . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.542 HG21 HD13 ' B' ' 243' ' ' ILE . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . 0.591 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.599 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . 0.713 HG21 HG23 ' B' ' 150' ' ' VAL . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.609 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.468 HD12 ' CG1' ' B' ' 71' ' ' VAL . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.434 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . 0.482 ' HB3' HD12 ' B' ' 57' ' ' LEU . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . 0.482 HD12 ' HB3' ' B' ' 54' ' ' ASP . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.565 HG22 ' HB2' ' B' ' 231' ' ' PRO . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.558 ' N ' HD13 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.468 ' CG1' HD12 ' B' ' 51' ' ' ILE . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.55 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.652 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.652 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . 0.551 ' HB2' HD23 ' B' ' 113' ' ' LEU . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . 0.447 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . 0.415 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . 0.415 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.591 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.818 ' HB3' HD13 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . 0.536 ' ND2' ' HA ' ' B' ' 110' ' ' LYS . 6.8 m-20 -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . 0.536 ' HA ' ' ND2' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . 0.551 HD23 ' HB2' ' B' ' 83' ' ' LEU . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.818 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.41 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.427 HG21 ' O ' ' B' ' 71' ' ' VAL . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.527 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 130' ' ' ILE . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.447 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 128' ' ' PHE . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . 0.666 ' HB2' HD12 ' B' ' 144' ' ' LEU . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' B' ' 142' ' ' HIS . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.533 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.412 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . 0.713 HG23 HG21 ' B' ' 49' ' ' VAL . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.518 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.694 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.476 ' HH ' ' HG3' ' B' ' 208' ' ' PRO . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . 0.409 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . 0.503 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . 0.458 ' O ' HG22 ' B' ' 178' ' ' ILE . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . 0.408 HD13 HG22 ' B' ' 182' ' ' ILE . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.483 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . 0.424 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.569 ' HB3' ' OD1' ' A' ' 44' ' ' ASP . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.483 ' CE2' ' HG2' ' B' ' 184' ' ' ARG . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . 0.407 HD12 HD11 ' B' ' 207' ' ' ILE . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG21 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.55 HG21 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . 0.486 HD13 HG23 ' B' ' 204' ' ' ILE . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.47 HD13 ' CD2' ' B' ' 213' ' ' LEU . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.476 ' HG3' ' HH ' ' B' ' 171' ' ' TYR . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.644 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.529 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . 0.402 HD21 ' HA ' ' B' ' 214' ' ' LEU . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.46 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.409 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.46 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.529 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.624 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.644 ' HG3' ' CD2' ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . 0.547 ' ND2' ' HB1' ' B' ' 27' ' ' ALA . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . 0.665 HD12 HG11 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . 0.557 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . 0.557 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.631 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.631 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.419 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.4 ' HB3' HD22 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.636 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.636 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.51 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.655 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.655 ' CG2' HD22 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.45 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.589 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.639 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.639 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.518 HG23 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.455 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.415 ' HE2' ' HG ' ' A' ' 63' ' ' LEU . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.56 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.415 ' HG ' ' HE2' ' A' ' 57' ' ' MET . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.497 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.512 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.512 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.589 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.484 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.729 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.484 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.906 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.433 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.849 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.604 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.455 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.56 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.42 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.451 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.572 HG11 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.572 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.409 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.647 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 125' ' ' GLU . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.42 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.729 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.56 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.705 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.705 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . 0.425 HD13 HD22 ' B' ' 113' ' ' LEU . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.545 ' HA ' HD13 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.545 HD13 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.492 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.417 ' HB3' ' CD1' ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.9 p30 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.455 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . 0.425 HD22 HD13 ' B' ' 83' ' ' LEU . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.417 ' CD1' ' HB3' ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.849 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' B' ' 49' ' ' VAL . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.647 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.443 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . 0.409 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . 0.406 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.443 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.56 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.434 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.906 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.699 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.745 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.434 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.535 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.535 HG23 ' HB ' ' B' ' 194' ' ' ILE . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.471 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . 0.427 HG11 HD11 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.427 HD11 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.535 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.615 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.615 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.45 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.635 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.635 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.43 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.46 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.492 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.65 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.644 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.644 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.49 HG23 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.433 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.424 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.452 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.65 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.758 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.758 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.765 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 26.3 m170 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.689 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.731 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.434 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.452 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.875 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.875 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . 0.467 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . 0.467 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.422 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.403 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.487 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.692 HG11 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.692 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.497 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.415 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.487 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.418 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.403 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.687 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.687 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.419 ' HA ' HD13 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.45 ' HB3' HD13 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.45 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.817 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.434 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.541 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . 0.415 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . 0.411 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.468 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.403 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.547 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.571 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . 0.45 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.431 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.421 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.45 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.421 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.404 ' HG1' HD21 ' B' ' 211' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.62 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.62 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.618 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.426 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.416 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.616 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.616 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.502 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.502 ' CG2' HD22 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.42 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.458 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.825 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.757 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.641 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.641 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.493 HG23 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.445 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.488 ' HE2' ' HG ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.555 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.555 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.488 ' HG ' ' HE2' ' A' ' 57' ' ' MET . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.504 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.416 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.483 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . 0.483 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 1.053 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.64 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.769 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.426 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.755 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.539 ' CE2' ' HD2' ' B' ' 1' ' ' TYR . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . 0.442 ' HG3' HG23 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.459 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.619 HG11 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.619 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.428 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.633 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' B' ' 125' ' ' GLU . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.406 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 1.053 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.494 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.713 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.713 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . 0.481 ' HA ' HD13 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.481 HD13 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' SER . . . . . 0.425 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.425 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.442 HG23 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.749 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' B' ' 49' ' ' VAL . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.633 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.42 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . 0.404 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.42 HG12 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.543 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.858 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 164' ' ' SER . . . . . 0.404 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 166' ' ' SER . . . . . 0.858 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.825 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.472 ' HB ' HG23 ' B' ' 203' ' ' VAL . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' B' ' 194' ' ' ILE . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.42 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.419 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.534 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.534 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 46.9 t30 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.408 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . 0.405 ' HB3' HD13 ' B' ' 40' ' ' LEU . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.416 HD22 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.445 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.63 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.63 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.416 ' HB3' HD22 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.445 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.66 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.66 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.438 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.51 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.479 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.724 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.596 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.655 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.51 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.462 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.462 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.596 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.476 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.789 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.789 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 1.002 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.543 ' CB ' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.435 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.807 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' B' ' 7' ' ' GLN . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.752 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' B' ' 3' ' ' ILE . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.425 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.44 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.563 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.467 HD12 HG21 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.475 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.805 HG11 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.805 ' HD2' HG11 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.415 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.416 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.535 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . 0.467 HG21 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.423 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.423 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . 0.582 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.458 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.533 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.66 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . 0.469 HD13 HD22 ' B' ' 113' ' ' LEU . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.42 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD13 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.537 HD13 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' SER . . . . . 0.437 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.437 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.44 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.469 HD22 HD13 ' B' ' 83' ' ' LEU . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.425 HD11 HG23 ' B' ' 126' ' ' ILE . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.807 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . 0.425 HG23 HD11 ' B' ' 115' ' ' ILE . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.535 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.431 ' HG2' HG12 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . 0.427 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . 0.427 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.431 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.478 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.563 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.827 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.415 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.669 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.659 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.501 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.413 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 169' ' ' THR . . . . . 0.415 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . 0.455 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.724 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.52 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.52 HG23 ' HB ' ' B' ' 194' ' ' ILE . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.404 HD13 HG21 ' B' ' 228' ' ' THR . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . 0.582 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.423 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . 0.463 HG11 HD11 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.463 HD11 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.455 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.404 HG21 HD13 ' B' ' 207' ' ' ILE . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.644 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.002 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.623 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.623 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.473 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.6 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.6 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.563 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.47 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.878 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.675 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.662 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.662 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.496 HG23 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.47 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.761 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.508 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.447 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.491 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.491 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.675 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.499 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.559 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.646 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 31.9 m170 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.69 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.838 ' HA3' ' CMD' ' B' ' 253' ' ' HEC . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.854 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.473 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.69 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.459 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.938 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.416 HG23 ' CE1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.872 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.418 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.456 ' HA ' HD23 ' B' ' 26' ' ' LEU . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.454 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.408 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.403 ' O ' HG22 ' B' ' 33' ' ' ILE . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.453 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.595 HG11 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.595 ' HD2' HG11 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.48 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.617 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.453 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.408 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.761 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.521 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.721 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.721 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . 0.426 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.51 ' HB3' HD13 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.418 HG23 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.51 HD13 ' HB3' ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.938 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.426 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.617 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.436 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.436 HG12 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.557 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.583 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.768 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.693 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.768 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.434 ' HH ' ' HG3' ' B' ' 208' ' ' PRO . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 174' ' ' THR . . . . . 0.422 HG22 ' OD1' ' B' ' 205' ' ' ASP . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . 0.542 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . 0.486 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.878 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.542 HG22 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . 0.422 ' OD1' HG22 ' B' ' 174' ' ' THR . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.434 ' HG3' ' HH ' ' B' ' 171' ' ' TYR . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.418 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.466 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.466 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.525 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.417 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.438 ' HB3' HD13 ' B' ' 40' ' ' LEU . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . 0.4 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.633 ' CMA' ' C3A' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.627 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.435 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.629 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.629 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.551 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.613 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.613 ' CG2' HD22 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.406 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.438 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.471 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.615 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.643 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.643 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.532 HG23 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.461 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.5 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.494 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.494 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.615 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.43 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.731 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 36.0 m80 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.742 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.435 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.439 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.977 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.872 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.411 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.411 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.433 ' HG3' HG23 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.451 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.453 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.622 HG11 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.474 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.621 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.453 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.461 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.461 HD13 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' SER . . . . . 0.405 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.405 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.433 HG23 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.977 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.621 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.43 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.407 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.43 HG12 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.407 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.55 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.585 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.682 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.619 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.677 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.471 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.414 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.403 HD23 HG22 ' B' ' 228' ' ' THR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.431 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.403 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.522 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.522 ' HD3' ' O ' ' B' ' 229' ' ' SER . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 55.0 t30 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.406 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.441 ' HB3' HD13 ' B' ' 40' ' ' LEU . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.548 ' CMB' HMB1 ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.411 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.67 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.67 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.436 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HE3' ' HB3' ' A' ' 2' ' ' ASP . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.635 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.635 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.474 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.431 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.477 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.546 ' HB2' ' CB ' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.635 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.63 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.63 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.52 HG23 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.474 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.428 ' HE1' ' HB3' ' A' ' 61' ' ' ASP . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.428 ' HB3' ' HE1' ' A' ' 57' ' ' MET . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.513 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.531 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.531 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.635 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.448 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.714 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.714 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.894 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 1.051 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.436 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.432 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.907 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 1.051 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.44 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.417 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.443 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.417 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.452 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.729 HG11 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.729 ' HD2' HG11 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.455 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.405 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.639 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.452 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.417 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.516 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.474 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.723 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.478 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.478 HD13 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' SER . . . . . 0.54 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.54 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.44 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.426 HD11 HG23 ' B' ' 126' ' ' ILE . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.907 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . 0.426 HG23 HD11 ' B' ' 115' ' ' ILE . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.639 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.431 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . 0.406 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . 0.406 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.431 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.405 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.57 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.677 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.434 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.894 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.698 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.426 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.444 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 169' ' ' THR . . . . . 0.434 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.546 ' CB ' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.426 ' CG ' HD13 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.44 ' HB ' HG23 ' B' ' 203' ' ' VAL . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' B' ' 194' ' ' ILE . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.426 HD13 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.417 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.417 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.405 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.413 ' HB3' HD13 ' B' ' 40' ' ' LEU . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.559 ' CMC' HMC2 ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.619 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.619 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.446 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.415 HG22 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.613 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.536 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.531 HD22 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.531 ' CG2' HD22 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.452 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.485 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.643 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.631 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.631 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.485 HG23 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.457 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.828 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.423 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.512 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.415 ' HG2' HG22 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.485 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.485 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.643 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.491 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.48 ' HB2' ' HB2' ' B' ' 62' ' ' ALA . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.558 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.471 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 1.069 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.675 ' HB1' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.446 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.43 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.911 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.911 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.428 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.428 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.424 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.444 ' HA ' HD23 ' B' ' 26' ' ' LEU . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.451 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.423 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.4 ' O ' HG22 ' B' ' 33' ' ' ILE . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.448 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.598 HG11 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.598 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.487 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.632 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.423 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.48 ' HB2' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.828 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.423 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.524 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . 0.405 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.402 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.402 HD13 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.491 ' HB3' HD13 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.424 HG23 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.491 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.845 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.405 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.632 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.404 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.402 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.404 HG12 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.402 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.402 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.556 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.786 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 1.069 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.611 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . 0.426 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.485 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.426 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.452 HD23 HG22 ' B' ' 228' ' ' THR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.438 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.438 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.452 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.521 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.408 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.402 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.44 ' HB3' HD13 ' B' ' 40' ' ' LEU . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.579 ' CMD' HMD1 ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.631 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.631 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.443 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.404 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.624 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.548 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.454 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.723 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.63 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.646 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.646 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.464 HG23 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.454 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.48 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.459 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.461 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.63 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.502 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.594 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.579 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.474 ' HB3' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.932 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.4 ' HA ' ' CE2' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.443 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.447 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.671 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.413 ' HD1' ' HA ' ' B' ' 4' ' ' PHE . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.406 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.406 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.42 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.422 ' HA ' HD23 ' B' ' 26' ' ' LEU . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.452 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.448 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.536 HG11 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.536 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.466 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.622 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.594 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.524 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.728 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.728 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.414 ' HA ' HD13 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.46 ' HB3' HD13 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.42 HG23 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.46 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.671 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.622 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.605 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.932 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.703 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.566 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.723 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.43 HD23 HG22 ' B' ' 228' ' ' THR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.432 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.432 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.43 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.519 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.519 ' HD3' ' O ' ' B' ' 229' ' ' SER . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.407 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.452 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.417 ' HB3' HD13 ' B' ' 40' ' ' LEU . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.528 ' CBB' HBB2 ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.616 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.616 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.465 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.426 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.464 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.651 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.651 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.63 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.809 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.688 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.688 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.425 ' HB3' ' HE1' ' A' ' 57' ' ' MET . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . 0.448 ' HB3' ' HE3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.426 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.709 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.809 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.433 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.724 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.738 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.531 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.709 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.738 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.495 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.531 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.599 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.599 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . 0.547 ' HB1' ' ND2' ' B' ' 232' ' ' ASN . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.423 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.406 HG21 ' O ' ' B' ' 237' ' ' GLY . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.609 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.599 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.665 HG11 HD12 ' B' ' 243' ' ' ILE . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.542 HG21 HD13 ' B' ' 243' ' ' ILE . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . 0.591 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.599 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . 0.713 HG21 HG23 ' B' ' 150' ' ' VAL . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.609 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.468 HD12 ' CG1' ' B' ' 71' ' ' VAL . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.434 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . 0.482 ' HB3' HD12 ' B' ' 57' ' ' LEU . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . 0.482 HD12 ' HB3' ' B' ' 54' ' ' ASP . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.565 HG22 ' HB2' ' B' ' 231' ' ' PRO . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.558 ' N ' HD13 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.487 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.468 ' CG1' HD12 ' B' ' 51' ' ' ILE . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.55 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.652 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.652 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . 0.551 ' HB2' HD23 ' B' ' 113' ' ' LEU . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . 0.447 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . 0.415 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . 0.415 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.591 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.818 ' HB3' HD13 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . 0.536 ' ND2' ' HA ' ' B' ' 110' ' ' LYS . 6.8 m-20 -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . 0.536 ' HA ' ' ND2' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.551 HD23 ' HB2' ' B' ' 83' ' ' LEU . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.818 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.41 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.427 HG21 ' O ' ' B' ' 71' ' ' VAL . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.527 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 130' ' ' ILE . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.447 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 128' ' ' PHE . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . 0.666 ' HB2' HD12 ' B' ' 144' ' ' LEU . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' B' ' 142' ' ' HIS . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.533 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.412 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . 0.713 HG23 HG21 ' B' ' 49' ' ' VAL . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.518 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.528 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.694 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.476 ' HH ' ' HG3' ' B' ' 208' ' ' PRO . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . 0.409 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . 0.503 ' HB3' HG22 ' B' ' 203' ' ' VAL . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . 0.458 ' O ' HG22 ' B' ' 178' ' ' ILE . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . 0.408 HD13 HG22 ' B' ' 182' ' ' ILE . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.483 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . 0.424 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.569 ' HB3' ' OD1' ' A' ' 44' ' ' ASP . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.483 ' CE2' ' HG2' ' B' ' 184' ' ' ARG . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . 0.407 HD12 HD11 ' B' ' 207' ' ' ILE . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG21 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.55 HG21 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . 0.486 HD13 HG23 ' B' ' 204' ' ' ILE . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.47 HD13 ' CD2' ' B' ' 213' ' ' LEU . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.476 ' HG3' ' HH ' ' B' ' 171' ' ' TYR . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.644 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.529 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . 0.402 HD21 ' HA ' ' B' ' 214' ' ' LEU . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.46 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.409 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.46 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.529 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.624 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.644 ' HG3' ' CD2' ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . 0.547 ' ND2' ' HB1' ' B' ' 27' ' ' ALA . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . 0.665 HD12 HG11 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . 0.557 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . 0.557 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 0.621 HMD1 ' CD1' ' B' ' 160' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.631 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.631 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.419 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.4 ' HB3' HD22 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.636 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.636 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.51 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.655 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.655 ' CG2' HD22 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.45 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.589 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.639 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.639 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.518 HG23 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.455 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.415 ' HE2' ' HG ' ' A' ' 63' ' ' LEU . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.56 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.415 ' HG ' ' HE2' ' A' ' 57' ' ' MET . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.497 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.512 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.512 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.589 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.484 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.729 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.484 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.906 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.433 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.849 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.604 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.455 ' HG3' HG23 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.56 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.42 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.451 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.572 HG11 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.572 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.409 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.647 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 125' ' ' GLU . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.42 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.729 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.56 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.513 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.705 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.705 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . 0.425 HD13 HD22 ' B' ' 113' ' ' LEU . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.545 ' HA ' HD13 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.545 HD13 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.492 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.417 ' HB3' ' CD1' ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.9 p30 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.455 HG23 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.425 HD22 HD13 ' B' ' 83' ' ' LEU . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.417 ' CD1' ' HB3' ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.849 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' B' ' 49' ' ' VAL . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.647 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.443 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . 0.409 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . 0.406 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.443 HG12 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.56 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.538 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.906 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.699 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.745 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.434 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.535 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.535 HG23 ' HB ' ' B' ' 194' ' ' ILE . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.471 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . 0.427 HG11 HD11 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.427 HD11 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.535 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.53 ' CBC' HBC2 ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.615 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.615 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.45 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.635 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.635 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.43 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.46 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.492 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.65 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.644 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.644 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.49 HG23 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.433 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.424 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.452 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.65 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.758 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.758 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.765 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 26.3 m170 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.781 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.731 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.434 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.452 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.875 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.519 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.875 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . 0.467 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . 0.467 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.422 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.403 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.487 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.692 HG11 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.692 ' HD2' HG11 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.497 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.415 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.541 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.487 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.418 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.457 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.403 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.687 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.687 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB2' ' B' ' 129' ' ' PRO . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.419 ' HA ' HD13 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.45 ' HB3' HD13 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.45 HD13 ' HB3' ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.817 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.434 ' HB2' ' HB1' ' B' ' 84' ' ' ALA . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.541 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . 0.415 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . 0.411 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . . . . . . . . . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.468 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.403 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.547 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.768 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.571 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . 0.45 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . . . . . . . . . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.431 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.421 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.45 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.421 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.404 ' HG1' HD21 ' B' ' 211' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.62 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.62 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 0.781 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HB1' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.618 ' HB2' ' HB1' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.426 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.416 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.616 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.616 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.502 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.502 ' CG2' HD22 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.42 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.458 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.825 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.757 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.641 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.641 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.493 HG23 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.445 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.488 ' HE2' ' HG ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.555 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.555 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.488 ' HG ' ' HE2' ' A' ' 57' ' ' MET . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.504 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.416 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.483 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.483 ' OH ' ' O ' ' A' ' 76' ' ' ASN . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 1.053 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.64 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.769 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.496 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.426 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.755 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.539 ' CE2' ' HD2' ' B' ' 1' ' ' TYR . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . 0.442 ' HG3' HG23 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.459 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.619 HG11 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.619 ' HD2' HG11 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.428 ' N ' HD21 ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.633 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' B' ' 125' ' ' GLU . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.418 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.406 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 1.053 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.521 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.494 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.713 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.713 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . 0.481 ' HA ' HD13 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.481 HD13 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' SER . . . . . 0.425 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.425 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . . . . . . . . . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.442 HG23 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.749 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' B' ' 49' ' ' VAL . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.633 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.42 ' HG2' HG12 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . 0.404 ' OD1' ' HB2' ' B' ' 136' ' ' ALA . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' B' ' 134' ' ' ASP . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.42 HG12 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.543 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.597 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.858 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 164' ' ' SER . . . . . 0.404 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 166' ' ' SER . . . . . 0.858 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.825 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.472 ' HB ' HG23 ' B' ' 203' ' ' VAL . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' B' ' 194' ' ' ILE . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.42 HD22 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . . . . . . . . . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.419 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.534 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.534 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 46.9 t30 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.408 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . 0.405 ' HB3' HD13 ' B' ' 40' ' ' LEU . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 253' ' ' HEC . . . . . 1.547 ' CMA' ' C3A' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.419 HD21 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.537 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.513 ' CD1' HG21 ' B' ' 3' ' ' ILE . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.433 HG13 ' HG2' ' A' ' 71' ' ' GLU . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.419 ' HB3' HD21 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.492 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.462 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.732 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.732 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.45 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.507 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.522 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.75 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.614 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.731 ' HG2' HG21 ' A' ' 50' ' ' VAL . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.731 HG21 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.507 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.492 HG22 ' HB3' ' A' ' 30' ' ' LYS . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG2' HG13 ' A' ' 28' ' ' VAL . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.451 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.797 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.797 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.591 HE21 ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.689 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.657 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.806 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.421 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.7 HG23 ' CD1' ' B' ' 4' ' ' PHE . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.775 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.429 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.426 HD12 ' HB3' ' B' ' 238' ' ' GLN . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.421 HD12 ' HB2' ' B' ' 158' ' ' GLN . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.576 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.475 HD12 HG22 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.622 HG13 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.464 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.432 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.534 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 49' ' ' VAL . . . . . 0.475 HG22 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.439 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.439 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.405 ' HA ' ' HE ' ' B' ' 156' ' ' ARG . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.591 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.627 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.44 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.441 HG13 ' O ' ' B' ' 74' ' ' VAL . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.543 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.672 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.672 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 84' ' ' ALA . . . . . 0.401 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.416 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.64 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 90' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 91' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.46 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 97' ' ' ILE . . . . . 0.451 HG22 ' O ' ' B' ' 127' ' ' THR . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.618 HD22 HD11 ' B' ' 115' ' ' ILE . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.442 ' HB3' HD12 ' B' ' 112' ' ' ILE . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.618 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.806 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 127' ' ' THR . . . . . 0.451 ' O ' HG22 ' B' ' 97' ' ' ILE . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 129' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.534 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.46 ' HG2' HG11 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.46 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.47 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.502 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.576 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.44 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.423 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.421 ' HB2' HD12 ' B' ' 26' ' ' LEU . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.53 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.423 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.419 HG22 ' O ' ' B' ' 166' ' ' SER . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 172' ' ' ASN . . . . . 0.478 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.639 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.459 HD12 ' HG3' ' B' ' 217' ' ' GLU . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.75 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.452 ' CG ' HD11 ' B' ' 213' ' ' LEU . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.541 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.462 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 175' ' ' ALA . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.627 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.541 HD22 HD11 ' B' ' 192' ' ' ILE . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.459 ' HG3' HD12 ' B' ' 182' ' ' ILE . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.478 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.649 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.649 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.426 ' HB3' HD12 ' B' ' 19' ' ' ILE . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.47 HG22 ' HG2' ' B' ' 145' ' ' LYS . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.673 HD12 ' HE1' ' B' ' 4' ' ' PHE . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.495 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.405 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.412 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.424 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.662 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.559 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.508 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.514 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.951 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.684 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.672 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.723 ' HG2' HG21 ' A' ' 50' ' ' VAL . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.723 HG21 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.508 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.815 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.407 HD22 ' HB3' ' A' ' 68' ' ' GLU . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.407 ' HB3' HD22 ' A' ' 63' ' ' LEU . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.412 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.48 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.485 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.684 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.574 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.458 ' CG ' HD13 ' A' ' 12' ' ' LEU . 52.5 m-70 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.894 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.636 ' HA2' ' CD1' ' B' ' 160' ' ' TYR . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 1.075 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.495 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.894 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.476 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.943 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.659 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 1.075 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 6' ' ' GLN . . . . . 0.401 ' HA ' ' CZ ' ' B' ' 105' ' ' TYR . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.476 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.464 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.514 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.514 ' HD2' HG13 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.41 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.624 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.464 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' B' ' 57' ' ' LEU . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.4 HD13 ' N ' ' B' ' 67' ' ' GLY . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.815 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 67' ' ' GLY . . . . . 0.4 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.468 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.406 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.512 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' B' ' 86' ' ' PRO . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.751 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.401 ' CZ ' ' HA ' ' B' ' 6' ' ' GLN . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.476 HG21 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.751 HD11 HD22 ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.943 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.624 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.483 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.422 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.483 HG11 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.422 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.542 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.406 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.403 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.559 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.468 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.405 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.765 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.727 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.765 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.452 ' OD1' ' ND2' ' B' ' 232' ' ' ASN . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.477 HG22 ' O ' ' B' ' 166' ' ' SER . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.488 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.441 HD12 ' HG3' ' B' ' 217' ' ' GLU . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 185' ' ' LYS . . . . . 0.485 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.951 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.472 ' CG ' HD11 ' B' ' 213' ' ' LEU . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.488 HG21 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.551 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.53 HD23 HG22 ' B' ' 228' ' ' THR . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.534 HG11 HD13 ' B' ' 221' ' ' ILE . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.441 ' HG3' HD12 ' B' ' 182' ' ' ILE . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.534 HD13 HG11 ' B' ' 215' ' ' VAL . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.512 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.479 HD21 HG12 ' B' ' 221' ' ' ILE . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.53 HG22 HD23 ' B' ' 213' ' ' LEU . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.551 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 232' ' ' ASN . . . . . 0.452 ' ND2' ' OD1' ' B' ' 168' ' ' ASN . 7.4 t-20 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.442 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.542 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.592 ' CD1' HG21 ' B' ' 3' ' ' ILE . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.488 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.432 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.667 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.667 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.546 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.642 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.642 ' CG2' HD21 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.405 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.479 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.613 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.638 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.714 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.714 HG21 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.488 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 68' ' ' GLU . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.506 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.408 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.488 ' HG2' HG13 ' A' ' 28' ' ' VAL . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.484 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.613 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.495 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.457 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.558 ' HA ' ' HE2' ' B' ' 1' ' ' TYR . 76.6 m-70 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.71 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 1.037 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.981 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.688 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 1.037 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.416 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.416 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.469 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.568 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.568 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.626 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.412 HD13 ' N ' ' B' ' 67' ' ' GLY . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' GLY . . . . . 0.412 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.443 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.754 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.754 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.575 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.575 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' SER . . . . . 0.422 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.422 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.699 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.699 HD11 HD22 ' B' ' 100' ' ' LEU . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.981 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.626 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.435 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.435 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.52 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.554 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.433 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.71 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.694 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.4 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.425 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.529 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' B' ' 217' ' ' GLU . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.479 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.477 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.4 HD11 HD22 ' B' ' 213' ' ' LEU . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 175' ' ' ALA . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.406 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.547 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.477 HD11 ' CG ' ' B' ' 190' ' ' TYR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.482 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.476 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.438 HD21 HG12 ' B' ' 221' ' ' ILE . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.42 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.547 ' HG3' HD21 ' B' ' 211' ' ' LEU . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.52 HG22 ' HG2' ' B' ' 145' ' ' LYS . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.425 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.506 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.421 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.68 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.68 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.49 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.425 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.517 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.591 ' HB2' ' HB2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.645 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.633 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.746 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.746 HG21 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.49 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.523 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.441 HG22 ' HB3' ' A' ' 30' ' ' LYS . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.506 ' HG2' HG13 ' A' ' 28' ' ' VAL . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.645 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.456 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.734 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.734 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.511 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.923 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 1.064 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.429 HG12 ' OE1' ' A' ' 88' ' ' GLN . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.909 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 1.064 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.469 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 238' ' ' GLN . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.413 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.463 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.43 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.428 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.643 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.43 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.511 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.476 HD23 ' CA ' ' B' ' 155' ' ' GLY . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.475 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.742 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.742 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 90' ' ' SER . . . . . 0.56 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.56 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 97' ' ' ILE . . . . . 0.423 HG22 ' O ' ' B' ' 127' ' ' THR . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.721 HD22 HD11 ' B' ' 115' ' ' ILE . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.41 ' HB3' HD12 ' B' ' 112' ' ' ILE . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.469 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.721 HD11 HD22 ' B' ' 100' ' ' LEU . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.909 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 127' ' ' THR . . . . . 0.423 ' O ' HG22 ' B' ' 97' ' ' ILE . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.643 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.428 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.421 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.421 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.53 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.41 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.573 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.476 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.451 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.438 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.923 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.707 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.451 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 8.4 t30 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.438 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 172' ' ' ASN . . . . . 0.406 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.466 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.54 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.477 HD12 ' HG3' ' B' ' 217' ' ' GLU . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.591 ' HB2' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.457 ' CG ' HD11 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.44 HD11 HD22 ' B' ' 213' ' ' LEU . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.54 HG21 ' HB3' ' B' ' 175' ' ' ALA . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.42 HD13 ' CD2' ' B' ' 213' ' ' LEU . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.457 HD11 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.513 HG11 HD13 ' B' ' 221' ' ' ILE . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.477 ' HG3' HD12 ' B' ' 182' ' ' ILE . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.513 HD13 HG11 ' B' ' 215' ' ' VAL . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.406 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.459 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.466 HD11 ' HA ' ' B' ' 173' ' ' ALA . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.54 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 232' ' ' ASN . . . . . 0.403 ' OD1' ' ND2' ' B' ' 168' ' ' ASN . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.41 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.414 ' HB3' HD12 ' B' ' 19' ' ' ILE . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.53 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.521 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.521 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.593 HD11 HG21 ' B' ' 3' ' ' ILE . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.427 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.673 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.673 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.559 HD21 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.506 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.644 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.736 HG21 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.885 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.421 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.488 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.644 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.49 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 85' ' ' SER . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.56 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 55.2 m-70 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 1.094 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 1.112 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.93 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.664 HG23 ' CD1' ' B' ' 4' ' ' PHE . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 1.112 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.432 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.48 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.441 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.461 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.551 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.551 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.408 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.636 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' B' ' 57' ' ' LEU . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.885 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.421 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.448 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.743 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.743 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.724 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.48 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.724 HD11 HD22 ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.851 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.636 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.43 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.43 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.411 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.407 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.558 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.448 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.819 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 1.094 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.624 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.401 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.428 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.458 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.506 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.426 HD12 ' HG3' ' B' ' 217' ' ' GLU . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.506 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.506 HG21 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.442 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.572 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.527 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.426 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.527 HD13 HG11 ' B' ' 215' ' ' VAL . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.485 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.473 HD21 HG12 ' B' ' 221' ' ' ILE . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.474 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.572 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.433 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.528 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.475 HG13 ' HG2' ' A' ' 71' ' ' GLU . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.437 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.678 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.678 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.494 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.718 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.632 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.648 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.695 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.695 HG21 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.419 ' HG3' ' H ' ' A' ' 59' ' ' GLU . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.475 ' HG2' HG13 ' A' ' 28' ' ' VAL . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.489 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.632 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.985 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.598 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.985 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.947 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.772 ' HB1' ' HZ ' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.69 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.772 ' HZ ' ' HB1' ' A' ' 90' ' ' ALA . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.471 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.586 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.586 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.427 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.627 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.415 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.985 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.744 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.744 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.544 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.676 HD22 HD11 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.475 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.676 HD11 HD22 ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.69 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.627 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.48 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.419 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.48 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 142' ' ' HIS . . . . . 0.412 ' HB2' HD12 ' B' ' 144' ' ' LEU . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.419 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' B' ' 142' ' ' HIS . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.544 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.549 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.947 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.704 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.583 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.416 HG22 ' O ' ' B' ' 166' ' ' SER . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.519 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.718 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.496 ' CG ' HD11 ' B' ' 213' ' ' LEU . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.407 HD11 HD22 ' B' ' 213' ' ' LEU . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.519 HG21 ' HB3' ' B' ' 175' ' ' ALA . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.422 HD13 ' CD2' ' B' ' 213' ' ' LEU . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.616 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' B' ' 190' ' ' TYR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.517 HG11 HD13 ' B' ' 221' ' ' ILE . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.517 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.477 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.417 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.528 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.616 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.44 ' CB ' HG22 ' A' ' 69' ' ' THR . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.482 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.717 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.476 ' HB3' HD23 ' A' ' 62' ' ' LEU . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.492 ' N ' HD12 ' A' ' 39' ' ' ILE . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.658 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.835 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.703 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.754 ' HG2' HG21 ' A' ' 50' ' ' VAL . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.754 HG21 ' HG2' ' A' ' 47' ' ' PRO . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.476 HD23 ' HB3' ' A' ' 38' ' ' ASN . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 30' ' ' LYS . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.55 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.835 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.509 ' CG ' ' NE2' ' A' ' 88' ' ' GLN . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.43 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.753 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.753 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.509 ' NE2' ' CG ' ' A' ' 83' ' ' TYR . 31.6 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.526 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.55 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.737 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.617 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.617 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.461 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 13' ' ' ARG . . . . . 0.445 ' HE ' ' HA2' ' B' ' 17' ' ' GLY . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' HE ' ' B' ' 13' ' ' ARG . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.407 HG21 HG11 ' B' ' 74' ' ' VAL . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.63 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.611 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.517 HG13 ' HD2' ' B' ' 36' ' ' PRO . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.517 ' HD2' HG13 ' B' ' 35' ' ' VAL . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.482 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 46' ' ' GLU . . . . . 0.542 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.611 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.63 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.454 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 73' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.407 HG11 HG21 ' B' ' 19' ' ' ILE . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.421 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.555 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.653 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.653 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 84' ' ' ALA . . . . . 0.402 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' B' ' 88' ' ' ARG . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.404 ' CG ' ' HG2' ' B' ' 85' ' ' PRO . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 91' ' ' PRO . . . . . 0.418 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 92' ' ' GLU . . . . . 0.418 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.542 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 94' ' ' LYS . . . . . 0.412 ' HE2' ' HB2' ' B' ' 94' ' ' LYS . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 95' ' ' GLU . . . . . 0.454 ' H ' ' HG2' ' B' ' 95' ' ' GLU . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.645 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 104' ' ' ASN . . . . . 0.4 ' OD1' ' HA ' ' B' ' 110' ' ' LYS . 0.8 OUTLIER -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 110' ' ' LYS . . . . . 0.4 ' HA ' ' OD1' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.461 HG21 ' HG3' ' B' ' 12' ' ' PRO . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.645 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.422 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.547 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 129' ' ' PRO . . . . . 0.402 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.402 ' HG2' HG11 ' B' ' 141' ' ' VAL . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' B' ' 136' ' ' ALA . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 136' ' ' ALA . . . . . 0.437 ' HB3' ' OD1' ' B' ' 134' ' ' ASP . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.402 HG11 ' HG2' ' B' ' 133' ' ' PRO . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.518 ' HG2' HG22 ' B' ' 244' ' ' VAL . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.421 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.512 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.708 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.708 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.412 ' O ' HG22 ' B' ' 169' ' ' THR . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.412 HG22 ' O ' ' B' ' 166' ' ' SER . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' B' ' 226' ' ' PRO . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 172' ' ' ASN . . . . . 0.431 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.485 ' HB2' HD21 ' B' ' 227' ' ' LEU . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.491 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 186' ' ' GLU . . . . . 0.438 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.588 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.525 ' CD2' HD11 ' B' ' 213' ' ' LEU . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG22 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.845 HD21 ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.593 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.492 HG11 HD13 ' B' ' 221' ' ' ILE . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.431 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.496 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.421 ' HB3' HG11 ' B' ' 170' ' ' VAL . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' B' ' 173' ' ' ALA . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.593 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.628 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.845 ' HG3' HD21 ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 243' ' ' ILE . . . . . 0.475 HD12 HG13 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.518 HG22 ' HG2' ' B' ' 145' ' ' LYS . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 249' ' ' LEU . . . . . 0.566 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 250' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD21 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.544 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.413 ' HB3' HD21 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.702 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.702 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.695 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.695 ' CG2' HD21 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.443 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.527 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.581 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.713 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.713 HG21 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.401 ' HB2' HD22 ' A' ' 38' ' ' ASN . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.593 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.507 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 30' ' ' LYS . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.544 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.5 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.581 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.794 ' O ' ' HB1' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.899 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.411 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.45 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.854 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.483 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.614 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.42 HD12 ' HB2' ' B' ' 158' ' ' GLN . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.571 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.465 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.591 HG13 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.591 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.453 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.434 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.65 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.465 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.402 HD13 HG13 ' B' ' 71' ' ' VAL . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.794 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.593 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.451 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.402 HG13 HD13 ' B' ' 51' ' ' ILE . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.65 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.65 HD12 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 90' ' ' SER . . . . . 0.511 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.511 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 97' ' ' ILE . . . . . 0.442 HG22 ' O ' ' B' ' 127' ' ' THR . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.644 HD22 HD11 ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 108' ' ' ASN . . . . . 0.459 ' ND2' ' HG2' ' B' ' 109' ' ' LYS . 5.2 p-10 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.459 ' HG2' ' ND2' ' B' ' 108' ' ' ASN . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.644 HD11 HD22 ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.854 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 127' ' ' THR . . . . . 0.442 ' O ' HG22 ' B' ' 97' ' ' ILE . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.65 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 142' ' ' HIS . . . . . 0.461 ' HB2' HD12 ' B' ' 144' ' ' LEU . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.461 HD12 ' HB2' ' B' ' 142' ' ' HIS . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.503 ' HG2' HG22 ' B' ' 244' ' ' VAL . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.571 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.441 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.443 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.42 ' HB2' HD12 ' B' ' 26' ' ' LEU . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.899 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.739 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 164' ' ' SER . . . . . 0.405 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.757 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.443 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.471 HG22 ' O ' ' B' ' 166' ' ' SER . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.574 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' B' ' 217' ' ' GLU . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.497 ' CG ' HD11 ' B' ' 213' ' ' LEU . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.497 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.443 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' B' ' 175' ' ' ALA . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.431 HD13 ' CD2' ' B' ' 213' ' ' LEU . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.487 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.497 HD11 ' CG ' ' B' ' 190' ' ' TYR . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.5 HG11 HD13 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.422 ' HG3' HD12 ' B' ' 182' ' ' ILE . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.5 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.434 ' HB3' HG13 ' B' ' 221' ' ' ILE . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.543 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.503 HG22 ' HG2' ' B' ' 145' ' ' LYS . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.534 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.478 ' CD1' HG21 ' B' ' 3' ' ' ILE . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.469 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.674 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.674 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.435 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.461 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.528 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.72 ' HG2' HG21 ' A' ' 50' ' ' VAL . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.72 HG21 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.427 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.469 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.78 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.78 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.5 ' HA ' ' HE2' ' B' ' 1' ' ' TYR . 42.5 m-70 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.717 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.732 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.469 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.891 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.629 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.891 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.47 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 238' ' ' GLN . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.5 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.644 HG13 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.644 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.433 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.543 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.5 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.435 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.435 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.423 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.431 HG13 ' O ' ' B' ' 74' ' ' VAL . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.534 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.696 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.547 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.547 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.664 HD22 HD11 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.47 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.664 HD11 HD22 ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.82 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.459 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.523 ' HG2' HG22 ' B' ' 244' ' ' VAL . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.486 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.542 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.423 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.717 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.701 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.599 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.414 HG22 ' O ' ' B' ' 166' ' ' SER . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 172' ' ' ASN . . . . . 0.474 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.564 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.46 HD12 ' HG3' ' B' ' 217' ' ' GLU . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.409 HD11 HD22 ' B' ' 213' ' ' LEU . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' B' ' 175' ' ' ALA . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.419 HD13 ' CD2' ' B' ' 213' ' ' LEU . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.536 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.543 HG11 HD13 ' B' ' 221' ' ' ILE . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.46 ' HG3' HD12 ' B' ' 182' ' ' ILE . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.543 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.474 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.456 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.437 HD21 HG12 ' B' ' 221' ' ' ILE . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.421 HG22 HD23 ' B' ' 213' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.625 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.625 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.415 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 243' ' ' ILE . . . . . 0.401 HD12 ' CG1' ' B' ' 35' ' ' VAL . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.523 HG22 ' HG2' ' B' ' 145' ' ' LYS . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.531 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.579 HD12 ' CE1' ' B' ' 4' ' ' PHE . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.514 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.426 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.684 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.684 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.552 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.552 ' CG2' HD21 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.409 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.824 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.821 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.722 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.722 HG21 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.479 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.479 ' CB ' HD22 ' A' ' 38' ' ' ASN . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.565 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.565 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 68' ' ' GLU . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.4 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.412 HG22 ' HB3' ' A' ' 30' ' ' LYS . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.514 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.468 ' HB3' HG12 ' A' ' 93' ' ' VAL . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.788 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.974 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.468 HG12 ' HB3' ' A' ' 83' ' ' TYR . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.766 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.579 ' CE1' HD12 ' A' ' 12' ' ' LEU . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.471 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.472 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.421 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.641 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.472 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.441 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.974 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' LEU . . . . . 0.459 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.733 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.733 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 90' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.441 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.661 HD22 HD11 ' B' ' 115' ' ' ILE . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.661 HD11 HD22 ' B' ' 100' ' ' LEU . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.766 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.641 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.485 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 134' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.417 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.485 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 142' ' ' HIS . . . . . 0.406 ' HB2' HD12 ' B' ' 144' ' ' LEU . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.417 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.406 HD12 ' HB2' ' B' ' 142' ' ' HIS . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.545 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 155' ' ' GLY . . . . . 0.426 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.884 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 164' ' ' SER . . . . . 0.411 ' HB3' ' CE2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 166' ' ' SER . . . . . 0.884 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 169' ' ' THR . . . . . 0.49 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.411 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.544 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.434 HD12 ' HG3' ' B' ' 217' ' ' GLU . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.824 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.486 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 192' ' ' ILE . . . . . 0.433 HD11 HD22 ' B' ' 213' ' ' LEU . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 175' ' ' ALA . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.538 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.486 HD11 ' CG ' ' B' ' 190' ' ' TYR . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.52 HG11 HD13 ' B' ' 221' ' ' ILE . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.434 ' HG3' HD12 ' B' ' 182' ' ' ILE . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.52 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.462 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.411 HD11 ' HA ' ' B' ' 173' ' ' ALA . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.542 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.419 HD21 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.537 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.513 ' CD1' HG21 ' B' ' 3' ' ' ILE . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.433 HG13 ' HG2' ' A' ' 71' ' ' GLU . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.419 ' HB3' HD21 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.492 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.462 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.732 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.732 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.45 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.507 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.522 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.75 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.614 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.731 ' HG2' HG21 ' A' ' 50' ' ' VAL . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.731 HG21 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.507 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.492 HG22 ' HB3' ' A' ' 30' ' ' LYS . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG2' HG13 ' A' ' 28' ' ' VAL . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.451 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.797 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.797 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.591 HE21 ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 1.031 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.657 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.806 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.421 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.7 HG23 ' CD1' ' B' ' 4' ' ' PHE . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.775 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.429 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.426 HD12 ' HB3' ' B' ' 238' ' ' GLN . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.421 HD12 ' HB2' ' B' ' 158' ' ' GLN . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.576 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.475 HD12 HG22 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.622 HG13 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.464 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.432 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.534 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 49' ' ' VAL . . . . . 0.475 HG22 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.439 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.439 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.405 ' HA ' ' HE ' ' B' ' 156' ' ' ARG . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.591 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.627 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.44 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.463 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.441 HG13 ' O ' ' B' ' 74' ' ' VAL . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.543 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.672 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.672 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' ALA . . . . . 0.401 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.416 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.64 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 91' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.46 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' ILE . . . . . 0.451 HG22 ' O ' ' B' ' 127' ' ' THR . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.618 HD22 HD11 ' B' ' 115' ' ' ILE . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.442 ' HB3' HD12 ' B' ' 112' ' ' ILE . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.618 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.806 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 127' ' ' THR . . . . . 0.451 ' O ' HG22 ' B' ' 97' ' ' ILE . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 129' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.534 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.46 ' HG2' HG11 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.46 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.47 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.502 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.576 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.44 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.852 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.421 ' HB2' HD12 ' B' ' 26' ' ' LEU . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.53 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.423 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.419 HG22 ' O ' ' B' ' 166' ' ' SER . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 172' ' ' ASN . . . . . 0.478 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.639 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.459 HD12 ' HG3' ' B' ' 217' ' ' GLU . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.75 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.452 ' CG ' HD11 ' B' ' 213' ' ' LEU . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.541 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.462 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 175' ' ' ALA . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.627 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.541 HD22 HD11 ' B' ' 192' ' ' ILE . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.459 ' HG3' HD12 ' B' ' 182' ' ' ILE . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.478 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.649 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.649 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.426 ' HB3' HD12 ' B' ' 19' ' ' ILE . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.47 HG22 ' HG2' ' B' ' 145' ' ' LYS . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 1.031 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.673 HD12 ' HE1' ' B' ' 4' ' ' PHE . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.495 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.405 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.412 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.424 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.662 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.559 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.508 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.514 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.951 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.684 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.672 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.723 ' HG2' HG21 ' A' ' 50' ' ' VAL . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.723 HG21 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.508 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.815 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.407 HD22 ' HB3' ' A' ' 68' ' ' GLU . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.407 ' HB3' HD22 ' A' ' 63' ' ' LEU . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.412 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.48 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.485 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.684 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.574 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.654 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 31.9 m170 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.894 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 1.041 ' HA3' HMD1 ' B' ' 253' ' ' HEC . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 1.075 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.495 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.894 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.476 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.943 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.659 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 1.075 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' GLN . . . . . 0.401 ' HA ' ' CZ ' ' B' ' 105' ' ' TYR . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.476 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.464 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.514 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.514 ' HD2' HG13 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.41 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.624 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.464 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' B' ' 57' ' ' LEU . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.4 HD13 ' N ' ' B' ' 67' ' ' GLY . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.815 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 67' ' ' GLY . . . . . 0.4 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.468 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.521 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.406 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.512 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' B' ' 86' ' ' PRO . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.751 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.401 ' CZ ' ' HA ' ' B' ' 6' ' ' GLN . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.476 HG21 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.751 HD11 HD22 ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.943 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.624 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.483 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.422 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.483 HG11 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.422 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.542 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.406 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.405 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.559 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.468 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.603 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.405 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.765 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.727 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.765 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.452 ' OD1' ' ND2' ' B' ' 232' ' ' ASN . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.477 HG22 ' O ' ' B' ' 166' ' ' SER . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.488 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.441 HD12 ' HG3' ' B' ' 217' ' ' GLU . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 185' ' ' LYS . . . . . 0.485 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.951 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.472 ' CG ' HD11 ' B' ' 213' ' ' LEU . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.488 HG21 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.551 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.53 HD23 HG22 ' B' ' 228' ' ' THR . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.534 HG11 HD13 ' B' ' 221' ' ' ILE . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.441 ' HG3' HD12 ' B' ' 182' ' ' ILE . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.534 HD13 HG11 ' B' ' 215' ' ' VAL . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.512 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.479 HD21 HG12 ' B' ' 221' ' ' ILE . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.53 HG22 HD23 ' B' ' 213' ' ' LEU . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.551 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 232' ' ' ASN . . . . . 0.452 ' ND2' ' OD1' ' B' ' 168' ' ' ASN . 7.4 t-20 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.442 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.542 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 1.633 ' C3A' ' CMA' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.592 ' CD1' HG21 ' B' ' 3' ' ' ILE . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.488 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.432 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.667 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.667 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.546 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.642 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.642 ' CG2' HD21 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.405 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.479 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.613 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.638 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.714 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.714 HG21 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.488 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 68' ' ' GLU . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.506 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.408 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.488 ' HG2' HG13 ' A' ' 28' ' ' VAL . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.484 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.613 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.495 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.457 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.741 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 36.0 m80 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.71 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 1.037 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.981 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.688 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 1.037 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.416 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.416 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.469 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.568 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.568 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.626 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.412 HD13 ' N ' ' B' ' 67' ' ' GLY . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' GLY . . . . . 0.412 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.443 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.754 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.754 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.575 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.575 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' SER . . . . . 0.422 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.422 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.699 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.699 HD11 HD22 ' B' ' 100' ' ' LEU . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.981 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.626 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.435 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.435 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.52 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.554 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.433 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.603 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.71 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.694 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.4 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.425 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.529 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' B' ' 217' ' ' GLU . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.479 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.477 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.4 HD11 HD22 ' B' ' 213' ' ' LEU . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 175' ' ' ALA . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.406 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.547 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.477 HD11 ' CG ' ' B' ' 190' ' ' TYR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.482 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.476 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.438 HD21 HG12 ' B' ' 221' ' ' ILE . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.42 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.547 ' HG3' HD21 ' B' ' 211' ' ' LEU . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.52 HG22 ' HG2' ' B' ' 145' ' ' LYS . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.603 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.506 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.421 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.68 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.68 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.49 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.425 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.517 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.591 ' HB2' ' HB2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.645 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.633 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.746 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.746 HG21 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.49 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.523 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.441 HG22 ' HB3' ' A' ' 30' ' ' LYS . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.506 ' HG2' HG13 ' A' ' 28' ' ' VAL . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.645 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.456 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.734 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.734 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.511 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.923 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 1.064 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.429 HG12 ' OE1' ' A' ' 88' ' ' GLN . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.909 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 1.064 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.469 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 238' ' ' GLN . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.413 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.463 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.43 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.428 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.643 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.43 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.511 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.476 HD23 ' CA ' ' B' ' 155' ' ' GLY . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.475 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.742 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.742 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 90' ' ' SER . . . . . 0.56 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.56 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 97' ' ' ILE . . . . . 0.423 HG22 ' O ' ' B' ' 127' ' ' THR . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.721 HD22 HD11 ' B' ' 115' ' ' ILE . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.41 ' HB3' HD12 ' B' ' 112' ' ' ILE . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.469 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.721 HD11 HD22 ' B' ' 100' ' ' LEU . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.909 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 127' ' ' THR . . . . . 0.423 ' O ' HG22 ' B' ' 97' ' ' ILE . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.643 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.428 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.421 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.421 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.53 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.41 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.573 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.476 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.7 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.438 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.923 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.707 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.451 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 8.4 t30 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.438 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 172' ' ' ASN . . . . . 0.406 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.466 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.54 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.477 HD12 ' HG3' ' B' ' 217' ' ' GLU . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.591 ' HB2' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.457 ' CG ' HD11 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.44 HD11 HD22 ' B' ' 213' ' ' LEU . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.54 HG21 ' HB3' ' B' ' 175' ' ' ALA . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.42 HD13 ' CD2' ' B' ' 213' ' ' LEU . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.457 HD11 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.513 HG11 HD13 ' B' ' 221' ' ' ILE . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.477 ' HG3' HD12 ' B' ' 182' ' ' ILE . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.513 HD13 HG11 ' B' ' 215' ' ' VAL . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.406 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.459 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.466 HD11 ' HA ' ' B' ' 173' ' ' ALA . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.54 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 232' ' ' ASN . . . . . 0.403 ' OD1' ' ND2' ' B' ' 168' ' ' ASN . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.41 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.414 ' HB3' HD12 ' B' ' 19' ' ' ILE . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.53 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.888 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.521 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.521 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.593 HD11 HG21 ' B' ' 3' ' ' ILE . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.427 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.673 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.673 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.559 HD21 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.506 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.644 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.736 HG21 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.885 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.421 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.488 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.644 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.49 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 85' ' ' SER . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.56 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.473 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 1.094 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 1.112 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.93 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.664 HG23 ' CD1' ' B' ' 4' ' ' PHE . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 1.112 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.432 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.48 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.441 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.461 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.551 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.551 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.408 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.636 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' B' ' 57' ' ' LEU . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.885 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.421 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.448 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.525 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.743 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.743 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.724 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.48 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.724 HD11 HD22 ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.851 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.636 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.43 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.43 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.411 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.407 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.558 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.448 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.574 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.819 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 1.094 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.624 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.401 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.428 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.458 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.506 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.426 HD12 ' HG3' ' B' ' 217' ' ' GLU . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.506 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.506 HG21 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.442 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.572 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.527 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.426 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.527 HD13 HG11 ' B' ' 215' ' ' VAL . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.485 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.473 HD21 HG12 ' B' ' 221' ' ' ILE . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.474 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.572 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.433 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.574 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.528 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.475 HG13 ' HG2' ' A' ' 71' ' ' GLU . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.437 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.678 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.678 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.494 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.718 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.632 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.648 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.695 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.695 HG21 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.419 ' HG3' ' H ' ' A' ' 59' ' ' GLU . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.475 ' HG2' HG13 ' A' ' 28' ' ' VAL . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.489 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.632 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.985 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.598 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.985 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.947 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.772 ' HB1' ' HZ ' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.69 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.772 ' HZ ' ' HB1' ' A' ' 90' ' ' ALA . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.471 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.586 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.586 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.427 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.627 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.415 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.985 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.525 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.744 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.744 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.544 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.676 HD22 HD11 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.475 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.676 HD11 HD22 ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.69 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.627 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.48 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.419 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.48 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 142' ' ' HIS . . . . . 0.412 ' HB2' HD12 ' B' ' 144' ' ' LEU . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.419 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' B' ' 142' ' ' HIS . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.544 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.42 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.549 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.622 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.947 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.704 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.583 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.416 HG22 ' O ' ' B' ' 166' ' ' SER . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.519 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.718 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.496 ' CG ' HD11 ' B' ' 213' ' ' LEU . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.407 HD11 HD22 ' B' ' 213' ' ' LEU . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.519 HG21 ' HB3' ' B' ' 175' ' ' ALA . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.422 HD13 ' CD2' ' B' ' 213' ' ' LEU . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.616 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' B' ' 190' ' ' TYR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.517 HG11 HD13 ' B' ' 221' ' ' ILE . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.517 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.477 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.417 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.528 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.616 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.644 ' O1D' ' N ' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.44 ' CB ' HG22 ' A' ' 69' ' ' THR . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.482 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.717 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.476 ' HB3' HD23 ' A' ' 62' ' ' LEU . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.492 ' N ' HD12 ' A' ' 39' ' ' ILE . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.658 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.835 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.703 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.754 ' HG2' HG21 ' A' ' 50' ' ' VAL . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.754 HG21 ' HG2' ' A' ' 47' ' ' PRO . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.476 HD23 ' HB3' ' A' ' 38' ' ' ASN . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 30' ' ' LYS . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.55 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.835 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.509 ' CG ' ' NE2' ' A' ' 88' ' ' GLN . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.43 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.753 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.753 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.509 ' NE2' ' CG ' ' A' ' 83' ' ' TYR . 31.6 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.526 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.55 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.737 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.617 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.617 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.461 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ARG . . . . . 0.445 ' HE ' ' HA2' ' B' ' 17' ' ' GLY . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' HE ' ' B' ' 13' ' ' ARG . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.407 HG21 HG11 ' B' ' 74' ' ' VAL . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.63 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.611 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.517 HG13 ' HD2' ' B' ' 36' ' ' PRO . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.517 ' HD2' HG13 ' B' ' 35' ' ' VAL . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.482 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 46' ' ' GLU . . . . . 0.542 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.611 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.63 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.454 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.493 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 73' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.407 HG11 HG21 ' B' ' 19' ' ' ILE . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.421 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.555 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.653 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.653 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 84' ' ' ALA . . . . . 0.402 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' B' ' 88' ' ' ARG . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.404 ' CG ' ' HG2' ' B' ' 85' ' ' PRO . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 91' ' ' PRO . . . . . 0.418 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 92' ' ' GLU . . . . . 0.418 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.542 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 94' ' ' LYS . . . . . 0.412 ' HE2' ' HB2' ' B' ' 94' ' ' LYS . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 95' ' ' GLU . . . . . 0.454 ' H ' ' HG2' ' B' ' 95' ' ' GLU . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.645 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ASN . . . . . 0.4 ' OD1' ' HA ' ' B' ' 110' ' ' LYS . 0.8 OUTLIER -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 110' ' ' LYS . . . . . 0.4 ' HA ' ' OD1' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.461 HG21 ' HG3' ' B' ' 12' ' ' PRO . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.645 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.422 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.547 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 129' ' ' PRO . . . . . 0.402 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.402 ' HG2' HG11 ' B' ' 141' ' ' VAL . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' B' ' 136' ' ' ALA . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 136' ' ' ALA . . . . . 0.437 ' HB3' ' OD1' ' B' ' 134' ' ' ASP . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.402 HG11 ' HG2' ' B' ' 133' ' ' PRO . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.518 ' HG2' HG22 ' B' ' 244' ' ' VAL . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.421 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.512 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.547 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.708 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.708 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.412 ' O ' HG22 ' B' ' 169' ' ' THR . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.412 HG22 ' O ' ' B' ' 166' ' ' SER . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' B' ' 226' ' ' PRO . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 172' ' ' ASN . . . . . 0.431 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.485 ' HB2' HD21 ' B' ' 227' ' ' LEU . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.491 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 186' ' ' GLU . . . . . 0.438 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.588 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.525 ' CD2' HD11 ' B' ' 213' ' ' LEU . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG22 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.845 HD21 ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.593 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.492 HG11 HD13 ' B' ' 221' ' ' ILE . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.431 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.496 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.421 ' HB3' HG11 ' B' ' 170' ' ' VAL . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' B' ' 173' ' ' ALA . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.593 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.628 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.845 ' HG3' HD21 ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 243' ' ' ILE . . . . . 0.475 HD12 HG13 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.518 HG22 ' HG2' ' B' ' 145' ' ' LYS . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 249' ' ' LEU . . . . . 0.566 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 250' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.547 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD21 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.544 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.413 ' HB3' HD21 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.702 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.702 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.695 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.695 ' CG2' HD21 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.443 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.527 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.581 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.713 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.713 HG21 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.401 ' HB2' HD22 ' A' ' 38' ' ' ASN . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.593 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.507 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 30' ' ' LYS . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.544 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.5 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.581 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.794 ' O ' ' HB1' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.899 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.411 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.45 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.854 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.483 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.614 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.42 HD12 ' HB2' ' B' ' 158' ' ' GLN . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.571 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.465 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.591 HG13 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.591 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.453 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.434 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.65 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.465 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.402 HD13 HG13 ' B' ' 71' ' ' VAL . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.794 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.593 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.451 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.513 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.402 HG13 HD13 ' B' ' 51' ' ' ILE . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.65 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.65 HD12 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 90' ' ' SER . . . . . 0.511 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.511 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 97' ' ' ILE . . . . . 0.442 HG22 ' O ' ' B' ' 127' ' ' THR . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.644 HD22 HD11 ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 108' ' ' ASN . . . . . 0.459 ' ND2' ' HG2' ' B' ' 109' ' ' LYS . 5.2 p-10 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.459 ' HG2' ' ND2' ' B' ' 108' ' ' ASN . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.644 HD11 HD22 ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.854 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 127' ' ' THR . . . . . 0.442 ' O ' HG22 ' B' ' 97' ' ' ILE . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.65 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 142' ' ' HIS . . . . . 0.461 ' HB2' HD12 ' B' ' 144' ' ' LEU . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.461 HD12 ' HB2' ' B' ' 142' ' ' HIS . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.503 ' HG2' HG22 ' B' ' 244' ' ' VAL . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.571 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.441 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.554 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.42 ' HB2' HD12 ' B' ' 26' ' ' LEU . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.899 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.739 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 164' ' ' SER . . . . . 0.405 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.757 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.443 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.471 HG22 ' O ' ' B' ' 166' ' ' SER . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.574 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' B' ' 217' ' ' GLU . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.497 ' CG ' HD11 ' B' ' 213' ' ' LEU . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.497 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.443 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' B' ' 175' ' ' ALA . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.431 HD13 ' CD2' ' B' ' 213' ' ' LEU . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.487 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.497 HD11 ' CG ' ' B' ' 190' ' ' TYR . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.5 HG11 HD13 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.422 ' HG3' HD12 ' B' ' 182' ' ' ILE . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.5 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.434 ' HB3' HG13 ' B' ' 221' ' ' ILE . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.543 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.503 HG22 ' HG2' ' B' ' 145' ' ' LYS . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.554 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.534 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.478 ' CD1' HG21 ' B' ' 3' ' ' ILE . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.469 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.674 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.674 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.435 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.461 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.528 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.72 ' HG2' HG21 ' A' ' 50' ' ' VAL . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.72 HG21 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.427 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.469 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.78 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.78 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.775 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 26.3 m170 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.775 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.732 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.469 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.891 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.629 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.891 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.47 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 238' ' ' GLN . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.5 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.644 HG13 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.644 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.433 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.543 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.5 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.435 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.435 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.423 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.461 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.431 HG13 ' O ' ' B' ' 74' ' ' VAL . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.534 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.696 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.547 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.547 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.664 HD22 HD11 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.47 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.664 HD11 HD22 ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.82 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.459 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.523 ' HG2' HG22 ' B' ' 244' ' ' VAL . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.486 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.542 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.423 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.792 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.717 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.701 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.599 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.414 HG22 ' O ' ' B' ' 166' ' ' SER . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 172' ' ' ASN . . . . . 0.474 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.564 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.46 HD12 ' HG3' ' B' ' 217' ' ' GLU . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.409 HD11 HD22 ' B' ' 213' ' ' LEU . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' B' ' 175' ' ' ALA . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.419 HD13 ' CD2' ' B' ' 213' ' ' LEU . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.536 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.543 HG11 HD13 ' B' ' 221' ' ' ILE . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.46 ' HG3' HD12 ' B' ' 182' ' ' ILE . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.543 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.474 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.456 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.437 HD21 HG12 ' B' ' 221' ' ' ILE . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.421 HG22 HD23 ' B' ' 213' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.625 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.625 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.415 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 243' ' ' ILE . . . . . 0.401 HD12 ' CG1' ' B' ' 35' ' ' VAL . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.523 HG22 ' HG2' ' B' ' 145' ' ' LYS . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 0.792 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.531 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.579 HD12 ' CE1' ' B' ' 4' ' ' PHE . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.514 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.426 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.684 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.684 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.552 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.552 ' CG2' HD21 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.409 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.824 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.821 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.722 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.722 HG21 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.479 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.479 ' CB ' HD22 ' A' ' 38' ' ' ASN . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.565 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.565 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 68' ' ' GLU . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.4 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.412 HG22 ' HB3' ' A' ' 30' ' ' LYS . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.514 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.468 ' HB3' HG12 ' A' ' 93' ' ' VAL . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.788 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.645 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.974 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.468 HG12 ' HB3' ' A' ' 83' ' ' TYR . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.766 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.579 ' CE1' HD12 ' A' ' 12' ' ' LEU . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.471 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.472 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.421 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.641 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.472 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.441 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.974 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' LEU . . . . . 0.459 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.733 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.733 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 90' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.441 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.661 HD22 HD11 ' B' ' 115' ' ' ILE . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.661 HD11 HD22 ' B' ' 100' ' ' LEU . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.766 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.641 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.485 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 134' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.417 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.485 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 142' ' ' HIS . . . . . 0.406 ' HB2' HD12 ' B' ' 144' ' ' LEU . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.417 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.406 HD12 ' HB2' ' B' ' 142' ' ' HIS . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.411 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.545 ' O ' ' HG2' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 155' ' ' GLY . . . . . 0.426 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.615 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.884 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 164' ' ' SER . . . . . 0.411 ' HB3' ' CE2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 166' ' ' SER . . . . . 0.884 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 169' ' ' THR . . . . . 0.49 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.411 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.544 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.434 HD12 ' HG3' ' B' ' 217' ' ' GLU . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.824 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.486 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 192' ' ' ILE . . . . . 0.433 HD11 HD22 ' B' ' 213' ' ' LEU . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 175' ' ' ALA . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.538 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.486 HD11 ' CG ' ' B' ' 190' ' ' TYR . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.52 HG11 HD13 ' B' ' 221' ' ' ILE . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.434 ' HG3' HD12 ' B' ' 182' ' ' ILE . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.52 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.462 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.411 HD11 ' HA ' ' B' ' 173' ' ' ALA . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.542 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 253' ' ' HEC . . . . . 1.547 ' C3A' ' CMA' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.419 HD21 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.537 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.513 ' CD1' HG21 ' B' ' 3' ' ' ILE . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.433 HG13 ' HG2' ' A' ' 71' ' ' GLU . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.419 ' HB3' HD21 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.492 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.462 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.732 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.732 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.45 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.507 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.522 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.75 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.614 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.731 ' HG2' HG21 ' A' ' 50' ' ' VAL . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.731 HG21 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.507 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.492 HG22 ' HB3' ' A' ' 30' ' ' LYS . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG2' HG13 ' A' ' 28' ' ' VAL . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.451 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.797 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.797 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.591 HE21 ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.689 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.657 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.806 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.421 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.7 HG23 ' CD1' ' B' ' 4' ' ' PHE . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.775 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.429 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.426 HD12 ' HB3' ' B' ' 238' ' ' GLN . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.421 HD12 ' HB2' ' B' ' 158' ' ' GLN . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.576 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.475 HD12 HG22 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.622 HG13 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.464 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.432 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.534 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . 0.475 HG22 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.439 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.439 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.405 ' HA ' ' HE ' ' B' ' 156' ' ' ARG . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.591 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.627 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.44 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.441 ' O ' HG13 ' B' ' 74' ' ' VAL . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.543 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.672 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.672 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . 0.401 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.416 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.64 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.46 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . 0.451 HG22 ' O ' ' B' ' 127' ' ' THR . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.618 HD22 HD11 ' B' ' 115' ' ' ILE . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.442 ' HB3' HD12 ' B' ' 112' ' ' ILE . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.618 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.806 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . 0.451 ' O ' HG22 ' B' ' 97' ' ' ILE . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.534 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.46 ' HG2' HG11 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.46 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.47 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.502 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.576 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.44 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.423 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.421 ' HB2' HD12 ' B' ' 26' ' ' LEU . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.53 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.423 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.419 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . 0.478 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.639 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.459 HD12 ' HG3' ' B' ' 217' ' ' GLU . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.75 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.452 ' CG ' HD11 ' B' ' 213' ' ' LEU . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.541 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.462 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 175' ' ' ALA . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.627 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.541 HD22 HD11 ' B' ' 192' ' ' ILE . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.459 ' HG3' HD12 ' B' ' 182' ' ' ILE . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.478 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.649 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.649 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.426 ' HB3' HD12 ' B' ' 19' ' ' ILE . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.47 HG22 ' HG2' ' B' ' 145' ' ' LYS . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.673 HD12 ' HE1' ' B' ' 4' ' ' PHE . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.495 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.405 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.412 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.424 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.662 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.559 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.508 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.514 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.951 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.684 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.672 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.723 ' HG2' HG21 ' A' ' 50' ' ' VAL . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.723 HG21 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.508 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.815 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.407 HD22 ' HB3' ' A' ' 68' ' ' GLU . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.407 ' HB3' HD22 ' A' ' 63' ' ' LEU . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.412 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.48 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.485 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.684 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.574 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.654 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 31.9 m170 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.894 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.636 ' HA2' ' CD1' ' B' ' 160' ' ' TYR . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 1.075 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.495 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.894 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.476 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.943 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.659 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 1.075 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . 0.401 ' HA ' ' CZ ' ' B' ' 105' ' ' TYR . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.476 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.464 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.514 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.514 ' HD2' HG13 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.41 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.624 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.464 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' B' ' 57' ' ' LEU . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.4 HD13 ' N ' ' B' ' 67' ' ' GLY . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.815 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . 0.4 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.468 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.406 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.512 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' B' ' 86' ' ' PRO . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.751 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.401 ' CZ ' ' HA ' ' B' ' 6' ' ' GLN . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.476 HG21 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.751 HD11 HD22 ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.943 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.624 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.483 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.422 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.483 HG11 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.422 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.542 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.406 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.403 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.559 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.468 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.405 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.765 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.727 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.765 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.405 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.477 HG22 ' O ' ' B' ' 166' ' ' SER . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.488 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.441 HD12 ' HG3' ' B' ' 217' ' ' GLU . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . 0.485 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.951 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.472 ' CG ' HD11 ' B' ' 213' ' ' LEU . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.488 HG21 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.551 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.53 HD23 HG22 ' B' ' 228' ' ' THR . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.534 HG11 HD13 ' B' ' 221' ' ' ILE . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.441 ' HG3' HD12 ' B' ' 182' ' ' ILE . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.534 HD13 HG11 ' B' ' 215' ' ' VAL . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.512 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.479 HD21 HG12 ' B' ' 221' ' ' ILE . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.53 HG22 HD23 ' B' ' 213' ' ' LEU . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.551 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.442 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.542 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.592 ' CD1' HG21 ' B' ' 3' ' ' ILE . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.488 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.432 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.667 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.667 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.546 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.642 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.642 ' CG2' HD21 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.405 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.479 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.613 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.638 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.714 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.714 HG21 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.488 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 68' ' ' GLU . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.506 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.408 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.488 ' HG2' HG13 ' A' ' 28' ' ' VAL . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.484 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.613 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.495 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.457 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.741 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 36.0 m80 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.71 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 1.037 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.981 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.688 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 1.037 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.416 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.416 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.469 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.568 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.568 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.626 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.412 HD13 ' N ' ' B' ' 67' ' ' GLY . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . 0.412 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.443 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.754 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.754 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.575 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.575 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . 0.422 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.422 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.699 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.699 HD11 HD22 ' B' ' 100' ' ' LEU . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.981 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.626 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.435 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.435 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.52 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.433 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.71 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.694 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.4 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.425 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.529 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' B' ' 217' ' ' GLU . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.479 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.477 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.4 HD11 HD22 ' B' ' 213' ' ' LEU . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 175' ' ' ALA . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.406 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.547 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.477 HD11 ' CG ' ' B' ' 190' ' ' TYR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.482 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.476 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.438 HD21 HG12 ' B' ' 221' ' ' ILE . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.42 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.547 ' HG3' HD21 ' B' ' 211' ' ' LEU . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 55.0 t30 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.52 HG22 ' HG2' ' B' ' 145' ' ' LYS . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.425 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.506 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.421 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.68 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.68 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.49 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.425 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.517 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.591 ' HB2' ' HB2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.645 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.633 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.746 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.746 HG21 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.49 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.523 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.441 HG22 ' HB3' ' A' ' 30' ' ' LYS . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.506 ' HG2' HG13 ' A' ' 28' ' ' VAL . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.645 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.456 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.734 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.734 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.511 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.923 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 1.064 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.429 HG12 ' OE1' ' A' ' 88' ' ' GLN . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.909 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 1.064 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.469 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 238' ' ' GLN . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.413 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.463 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.43 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.428 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.643 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.43 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.429 ' HB ' HD22 ' B' ' 168' ' ' ASN . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.511 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.476 HD23 ' CA ' ' B' ' 155' ' ' GLY . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.475 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.742 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.742 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . 0.56 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.56 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . 0.423 HG22 ' O ' ' B' ' 127' ' ' THR . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.721 HD22 HD11 ' B' ' 115' ' ' ILE . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.41 ' HB3' HD12 ' B' ' 112' ' ' ILE . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.469 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.721 HD11 HD22 ' B' ' 100' ' ' LEU . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.909 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . 0.423 ' O ' HG22 ' B' ' 97' ' ' ILE . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.643 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.428 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.421 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.421 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.53 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.41 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.573 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.476 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.451 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.438 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.923 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.707 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.451 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.438 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . 0.406 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.466 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.54 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.477 HD12 ' HG3' ' B' ' 217' ' ' GLU . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.591 ' HB2' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.457 ' CG ' HD11 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.44 HD11 HD22 ' B' ' 213' ' ' LEU . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.54 HG21 ' HB3' ' B' ' 175' ' ' ALA . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.42 HD13 ' CD2' ' B' ' 213' ' ' LEU . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.457 HD11 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.513 HG11 HD13 ' B' ' 221' ' ' ILE . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.477 ' HG3' HD12 ' B' ' 182' ' ' ILE . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.513 HD13 HG11 ' B' ' 215' ' ' VAL . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.406 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.459 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.466 HD11 ' HA ' ' B' ' 173' ' ' ALA . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.54 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.41 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.414 ' HB3' HD12 ' B' ' 19' ' ' ILE . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.53 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.521 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.521 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.593 HD11 HG21 ' B' ' 3' ' ' ILE . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.427 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.673 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.673 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.559 HD21 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.506 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.644 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.736 HG21 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.885 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.421 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.488 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.644 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.49 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 85' ' ' SER . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.56 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.473 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 1.094 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 1.112 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.93 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.664 HG23 ' CD1' ' B' ' 4' ' ' PHE . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 1.112 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.432 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.48 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.441 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.461 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.551 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.551 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.408 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.636 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' B' ' 57' ' ' LEU . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.885 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.421 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.448 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.743 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.743 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.724 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.48 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.724 HD11 HD22 ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.851 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.636 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.43 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.43 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.411 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.407 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.448 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.819 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 1.094 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.624 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.401 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.428 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.458 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.506 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.426 HD12 ' HG3' ' B' ' 217' ' ' GLU . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.506 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.506 HG21 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.442 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.572 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.527 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.426 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.527 HD13 HG11 ' B' ' 215' ' ' VAL . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.485 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.473 HD21 HG12 ' B' ' 221' ' ' ILE . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.474 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.572 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.433 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.528 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.475 HG13 ' HG2' ' A' ' 71' ' ' GLU . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.437 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.678 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.678 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.494 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.718 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.632 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.648 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.695 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.695 HG21 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.419 ' HG3' ' H ' ' A' ' 59' ' ' GLU . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.475 ' HG2' HG13 ' A' ' 28' ' ' VAL . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.489 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.632 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.985 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.598 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.985 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.947 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.772 ' HB1' ' HZ ' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.69 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.772 ' HZ ' ' HB1' ' A' ' 90' ' ' ALA . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.471 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.586 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.586 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.427 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.627 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.415 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.985 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.744 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.744 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.544 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.676 HD22 HD11 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.475 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.676 HD11 HD22 ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.69 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.627 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.48 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.419 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.48 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . 0.412 ' HB2' HD12 ' B' ' 144' ' ' LEU . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.419 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' B' ' 142' ' ' HIS . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.544 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.947 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.704 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.583 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.416 HG22 ' O ' ' B' ' 166' ' ' SER . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.519 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.718 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.496 ' CG ' HD11 ' B' ' 213' ' ' LEU . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.407 HD11 HD22 ' B' ' 213' ' ' LEU . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.519 HG21 ' HB3' ' B' ' 175' ' ' ALA . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.422 HD13 ' CD2' ' B' ' 213' ' ' LEU . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.616 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' B' ' 190' ' ' TYR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.517 HG11 HD13 ' B' ' 221' ' ' ILE . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.517 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.477 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.417 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.528 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.616 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.44 ' CB ' HG22 ' A' ' 69' ' ' THR . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.482 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.717 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.476 ' HB3' HD23 ' A' ' 62' ' ' LEU . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.492 ' N ' HD12 ' A' ' 39' ' ' ILE . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.658 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.835 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.703 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.754 ' HG2' HG21 ' A' ' 50' ' ' VAL . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.754 HG21 ' HG2' ' A' ' 47' ' ' PRO . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.476 HD23 ' HB3' ' A' ' 38' ' ' ASN . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . 0.429 ' HB3' ' HE3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 30' ' ' LYS . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.55 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.835 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.43 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.753 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.753 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.725 HE21 ' HB1' ' B' ' 62' ' ' ALA . 15.8 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.526 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.55 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.737 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.617 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.617 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.461 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . 0.445 ' HE ' ' HA2' ' B' ' 17' ' ' GLY . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' HE ' ' B' ' 13' ' ' ARG . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.407 HG21 HG11 ' B' ' 74' ' ' VAL . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.63 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.611 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.517 HG13 ' HD2' ' B' ' 36' ' ' PRO . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.517 ' HD2' HG13 ' B' ' 35' ' ' VAL . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.482 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . 0.542 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.611 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.63 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.454 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.725 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.407 HG11 HG21 ' B' ' 19' ' ' ILE . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.421 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.555 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.653 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.653 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . 0.402 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' B' ' 88' ' ' ARG . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.404 ' CG ' ' HG2' ' B' ' 85' ' ' PRO . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . 0.418 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . 0.418 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.542 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . 0.412 ' HE2' ' HB2' ' B' ' 94' ' ' LYS . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . 0.454 ' H ' ' HG2' ' B' ' 95' ' ' GLU . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.645 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . 0.549 ' ND2' ' HA ' ' B' ' 110' ' ' LYS . 6.8 m-20 -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . 0.549 ' HA ' ' ND2' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.461 HG21 ' HG3' ' B' ' 12' ' ' PRO . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.645 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.422 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.547 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . 0.402 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.402 ' HG2' HG11 ' B' ' 141' ' ' VAL . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' B' ' 136' ' ' ALA . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . 0.437 ' HB3' ' OD1' ' B' ' 134' ' ' ASP . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.402 HG11 ' HG2' ' B' ' 133' ' ' PRO . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.518 ' HG2' HG22 ' B' ' 244' ' ' VAL . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.421 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.708 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.708 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.412 ' O ' HG22 ' B' ' 169' ' ' THR . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.412 HG22 ' O ' ' B' ' 166' ' ' SER . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' B' ' 226' ' ' PRO . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . 0.431 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.485 ' HB2' HD21 ' B' ' 227' ' ' LEU . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.491 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . 0.438 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.588 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.525 ' CD2' HD11 ' B' ' 213' ' ' LEU . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG22 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.845 HD21 ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.593 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.492 HG11 HD13 ' B' ' 221' ' ' ILE . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.431 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.496 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.421 ' HB3' HG11 ' B' ' 170' ' ' VAL . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' B' ' 173' ' ' ALA . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.593 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.628 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.845 ' HG3' HD21 ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . 0.475 HD12 HG13 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.518 HG22 ' HG2' ' B' ' 145' ' ' LYS . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . 0.566 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD21 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.544 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.413 ' HB3' HD21 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.702 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.702 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.695 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.695 ' CG2' HD21 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.443 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.527 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.581 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.713 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.713 HG21 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.401 ' HB2' HD22 ' A' ' 38' ' ' ASN . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.593 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.507 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 30' ' ' LYS . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.544 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.5 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.581 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.794 ' O ' ' HB1' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.899 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.411 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.45 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.854 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.483 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.614 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.42 HD12 ' HB2' ' B' ' 158' ' ' GLN . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.571 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.465 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.591 HG13 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.591 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.453 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.434 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.65 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.465 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.402 HD13 HG13 ' B' ' 71' ' ' VAL . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.794 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.593 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.451 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.402 HG13 HD13 ' B' ' 51' ' ' ILE . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.65 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.65 HD12 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . 0.511 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.511 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . 0.442 HG22 ' O ' ' B' ' 127' ' ' THR . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.644 HD22 HD11 ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.9 p30 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.644 HD11 HD22 ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.854 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . 0.442 ' O ' HG22 ' B' ' 97' ' ' ILE . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.65 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . 0.461 ' HB2' HD12 ' B' ' 144' ' ' LEU . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.461 HD12 ' HB2' ' B' ' 142' ' ' HIS . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.503 ' HG2' HG22 ' B' ' 244' ' ' VAL . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.571 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.441 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.443 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.42 ' HB2' HD12 ' B' ' 26' ' ' LEU . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.899 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.739 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . 0.405 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.757 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.443 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.471 HG22 ' O ' ' B' ' 166' ' ' SER . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.574 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' B' ' 217' ' ' GLU . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.497 ' CG ' HD11 ' B' ' 213' ' ' LEU . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.497 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.443 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' B' ' 175' ' ' ALA . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.431 HD13 ' CD2' ' B' ' 213' ' ' LEU . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.487 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.497 HD11 ' CG ' ' B' ' 190' ' ' TYR . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.5 HG11 HD13 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.422 ' HG3' HD12 ' B' ' 182' ' ' ILE . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.5 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.434 ' HB3' HG13 ' B' ' 221' ' ' ILE . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.543 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.503 HG22 ' HG2' ' B' ' 145' ' ' LYS . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.534 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.478 ' CD1' HG21 ' B' ' 3' ' ' ILE . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.469 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.674 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.674 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.435 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.461 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.528 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.72 ' HG2' HG21 ' A' ' 50' ' ' VAL . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.72 HG21 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.427 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.469 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.78 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.78 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.775 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 26.3 m170 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.717 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.732 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.469 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.891 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.629 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.891 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.47 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 238' ' ' GLN . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.5 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.644 HG13 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.644 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.433 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.543 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.5 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.435 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.435 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.423 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.431 ' O ' HG13 ' B' ' 74' ' ' VAL . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.534 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.696 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.547 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.547 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.664 HD22 HD11 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.47 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.664 HD11 HD22 ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.82 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.459 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.523 ' HG2' HG22 ' B' ' 244' ' ' VAL . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.486 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.542 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.423 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.717 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.701 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.599 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.414 HG22 ' O ' ' B' ' 166' ' ' SER . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . 0.474 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.564 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.46 HD12 ' HG3' ' B' ' 217' ' ' GLU . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.409 HD11 HD22 ' B' ' 213' ' ' LEU . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' B' ' 175' ' ' ALA . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.419 HD13 ' CD2' ' B' ' 213' ' ' LEU . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.536 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.543 HG11 HD13 ' B' ' 221' ' ' ILE . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.46 ' HG3' HD12 ' B' ' 182' ' ' ILE . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.543 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.474 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.456 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.437 HD21 HG12 ' B' ' 221' ' ' ILE . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.421 HG22 HD23 ' B' ' 213' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.625 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.625 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.415 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . 0.401 HD12 ' CG1' ' B' ' 35' ' ' VAL . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.523 HG22 ' HG2' ' B' ' 145' ' ' LYS . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.531 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.579 HD12 ' CE1' ' B' ' 4' ' ' PHE . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.514 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.426 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.684 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.684 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.552 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.552 ' CG2' HD21 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.409 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.824 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.821 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.722 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.722 HG21 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.479 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.479 ' CB ' HD22 ' A' ' 38' ' ' ASN . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.565 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.565 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 68' ' ' GLU . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.4 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.412 HG22 ' HB3' ' A' ' 30' ' ' LYS . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.514 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.468 ' HB3' HG12 ' A' ' 93' ' ' VAL . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.788 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.645 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.974 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.468 HG12 ' HB3' ' A' ' 83' ' ' TYR . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.766 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.579 ' CE1' HD12 ' A' ' 12' ' ' LEU . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.471 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.472 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.421 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.641 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.472 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.441 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.974 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . 0.459 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.733 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.733 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.441 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.661 HD22 HD11 ' B' ' 115' ' ' ILE . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.661 HD11 HD22 ' B' ' 100' ' ' LEU . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.766 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.641 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.485 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.417 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.485 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . 0.406 ' HB2' HD12 ' B' ' 144' ' ' LEU . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.417 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.406 HD12 ' HB2' ' B' ' 142' ' ' HIS . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . 0.426 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . . . . . . . . . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.884 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . 0.411 ' HB3' ' CE2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . 0.884 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . 0.49 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.411 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.544 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.434 HD12 ' HG3' ' B' ' 217' ' ' GLU . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.824 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.486 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . 0.433 HD11 HD22 ' B' ' 213' ' ' LEU . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 175' ' ' ALA . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.538 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.486 HD11 ' CG ' ' B' ' 190' ' ' TYR . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.52 HG11 HD13 ' B' ' 221' ' ' ILE . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.434 ' HG3' HD12 ' B' ' 182' ' ' ILE . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.52 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.462 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.411 HD11 ' HA ' ' B' ' 173' ' ' ALA . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.542 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 46.9 t30 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 6.2 tt . . . . . 0 N--CA 1.5 2.035 0 CA-C-O 121.245 0.545 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -102.62 131.23 49.53 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.711 -0.618 . . . . 0.0 109.464 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.8 t -122.98 125.01 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 13.1 mt -83.84 134.88 34.69 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.478 0.656 . . . . 0.0 110.802 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.419 HD21 ' HB3' ' A' ' 29' ' ' PHE . 15.3 mt -95.31 96.4 9.13 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.53 125.11 5.56 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 107.488 -2.245 . . . . 0.0 107.488 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.08 167.88 18.32 Favored 'General case' 0 N--CA 1.505 2.295 0 O-C-N 121.508 -0.995 . . . . 0.0 110.905 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.15 -15.81 63.93 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.465 -0.772 . . . . 0.0 110.706 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 39.5 p-10 -97.0 9.88 40.8 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.333 -0.855 . . . . 0.0 109.426 178.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.97 9.56 80.44 Favored Glycine 0 N--CA 1.499 2.867 0 O-C-N 121.625 -0.672 . . . . 0.0 111.643 179.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.537 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 7.6 m -70.5 141.15 51.98 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-N 118.586 1.193 . . . . 0.0 109.43 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.513 ' CD1' HG21 ' B' ' 3' ' ' ILE . 74.9 mt -84.7 85.41 7.44 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.08 155.43 32.58 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.319 0.58 . . . . 0.0 110.871 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -85.4 132.0 34.3 Favored 'General case' 0 N--CA 1.501 2.088 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 52.2 t -124.55 107.24 29.48 Favored Pre-proline 0 N--CA 1.508 2.472 0 O-C-N 120.862 -1.148 . . . . 0.0 110.03 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.437 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.5 Cg_endo -79.46 166.69 77.55 Favored 'Cis proline' 0 N--CA 1.491 1.37 0 O-C-N 123.325 1.171 . . . . 0.0 111.462 -1.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 p -100.74 -30.91 11.46 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.412 -0.805 . . . . 0.0 109.948 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -121.83 119.98 33.21 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -153.04 166.74 31.48 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.44 0.638 . . . . 0.0 110.334 -177.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.3 m -121.42 145.98 47.36 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 3.9 pt -140.03 161.21 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 CA-C-O 121.31 0.576 . . . . 0.0 109.578 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -87.81 161.93 43.01 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -67.06 132.33 27.74 Favored 'Trans proline' 0 C--N 1.319 -1.0 0 C-N-CA 121.552 1.501 . . . . 0.0 111.154 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.98 -10.16 74.86 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -69.02 139.39 54.94 Favored 'General case' 0 N--CA 1.504 2.238 0 CA-C-N 118.51 1.155 . . . . 0.0 108.614 179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ttmm -89.49 142.76 27.38 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.932 0.872 . . . . 0.0 112.208 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.79 117.14 54.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.433 HG13 ' HG2' ' A' ' 71' ' ' GLU . 19.1 t -102.69 102.31 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.312 -0.867 . . . . 0.0 109.787 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.419 ' HB3' HD21 ' A' ' 5' ' ' LEU . 78.0 m-85 -83.5 118.75 23.98 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 178.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.492 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -118.73 132.6 56.15 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.168 -0.957 . . . . 0.0 111.51 -178.106 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -60.89 121.95 13.66 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -118.47 -55.15 2.24 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.532 -0.73 . . . . 0.0 111.09 -178.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.462 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.0 149.2 22.98 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.222 -0.924 . . . . 0.0 111.022 -178.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 14.1 80.23 Favored Glycine 0 N--CA 1.503 3.125 0 O-C-N 121.766 -0.584 . . . . 0.0 111.686 178.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.732 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.9 p90 -68.38 170.63 7.45 Favored Pre-proline 0 N--CA 1.509 2.519 0 O-C-N 121.368 -1.078 . . . . 0.0 109.645 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.732 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -66.49 152.06 81.67 Favored 'Cis proline' 0 N--CA 1.497 1.729 0 O-C-N 122.644 0.812 . . . . 0.0 114.064 3.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.4 m-70 -138.56 164.05 30.43 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.694 179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -153.21 163.26 40.2 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -121.17 114.44 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.649 0.738 . . . . 0.0 109.202 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.45 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 2.1 t -120.74 126.92 75.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.507 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.1 m-85 -87.25 133.75 33.63 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.522 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.7 OUTLIER -69.07 112.22 5.55 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.411 0.624 . . . . 0.0 109.489 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.75 ' HB2' ' HG2' ' B' ' 187' ' ' LYS . 6.7 pt-20 -57.05 -28.6 62.7 Favored 'General case' 0 N--CA 1.502 2.136 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.645 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -94.3 3.86 54.65 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.412 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.614 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.4 OUTLIER -131.66 38.06 3.6 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.918 -1.114 . . . . 0.0 111.9 -179.055 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 2.8 pt -130.47 168.62 16.19 Favored Pre-proline 0 N--CA 1.505 2.291 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 177.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.731 ' HG2' HG21 ' A' ' 50' ' ' VAL . 21.3 Cg_endo -60.77 141.02 93.71 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.449 1.432 . . . . 0.0 111.835 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.8 m -54.3 136.42 43.37 Favored 'General case' 0 N--CA 1.503 2.221 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.533 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.78 -8.58 79.55 Favored Glycine 0 N--CA 1.502 3.075 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.47 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.731 HG21 ' HG2' ' A' ' 47' ' ' PRO . 96.1 t -81.45 134.28 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 CA-C-N 119.099 1.45 . . . . 0.0 109.963 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -86.99 111.23 20.65 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.06 -23.75 67.27 Favored 'General case' 0 N--CA 1.504 2.27 0 O-C-N 121.511 -0.743 . . . . 0.0 111.77 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.7 p -69.44 -22.97 63.62 Favored 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.364 -0.835 . . . . 0.0 110.411 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.91 -17.32 44.12 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.528 -0.733 . . . . 0.0 111.638 -179.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.3 pt -123.42 5.41 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.461 0 O-C-N 120.873 -1.142 . . . . 0.0 112.85 -177.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.507 ' OG ' ' HB2' ' A' ' 41' ' ' PHE . 3.5 m -130.85 162.16 30.22 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 120.84 -1.163 . . . . 0.0 112.559 -178.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 17.1 mtp -83.27 160.04 21.81 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 t -73.47 147.14 44.4 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -55.46 -26.74 44.02 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.623 -0.673 . . . . 0.0 110.313 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.59 -6.85 54.13 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 122.038 -0.414 . . . . 0.0 111.132 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -88.93 145.95 25.21 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 120.924 -1.11 . . . . 0.0 109.444 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 50.8 mt -142.25 148.01 37.41 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.367 -0.833 . . . . 0.0 113.02 -178.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.6 mt -98.56 106.71 19.02 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 102.582 -3.118 . . . . 0.0 102.582 173.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.44 12.57 22.96 Favored 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.478 -1.389 . . . . 0.0 113.645 -174.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.37 144.85 51.19 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.53 -1.356 . . . . 0.0 109.534 178.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.11 130.02 44.24 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-O 121.207 0.527 . . . . 0.0 109.74 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.89 -15.51 60.63 Favored Glycine 0 N--CA 1.502 3.044 0 CA-C-O 119.79 -0.45 . . . . 0.0 112.236 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -61.39 139.41 58.2 Favored 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.281 1.541 . . . . 0.0 108.582 179.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.492 HG22 ' HB3' ' A' ' 30' ' ' LYS . 42.6 p -128.88 154.61 46.33 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.587 -177.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 90.6 t80 -129.16 117.9 21.54 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG2' HG13 ' A' ' 28' ' ' VAL . 35.6 mt-10 -107.83 142.41 37.93 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.451 -0.78 . . . . 0.0 110.95 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.0 p -149.44 142.98 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.499 0.666 . . . . 0.0 109.805 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.36 124.53 49.15 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 17.0 mt -100.56 139.74 35.81 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 29.4 p -115.95 -41.17 3.22 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.396 -0.815 . . . . 0.0 110.755 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -67.24 136.68 55.35 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.399 -0.813 . . . . 0.0 109.751 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -80.36 153.78 28.14 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.538 -0.726 . . . . 0.0 110.363 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 136.21 -170.65 23.16 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -102.66 137.55 40.73 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.908 -0.76 . . . . 0.0 109.909 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.451 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 19.0 m-85 -120.47 119.8 34.04 Favored 'General case' 0 N--CA 1.496 1.86 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 55.3 m -97.06 127.62 43.2 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -129.4 168.05 16.87 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.269 0.557 . . . . 0.0 109.632 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -163.11 163.95 25.55 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.895 0.855 . . . . 0.0 111.589 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 47.9 t -94.29 119.76 33.54 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.797 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 59.6 p -56.02 -49.42 93.21 Favored Pre-proline 0 N--CA 1.509 2.507 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -175.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.797 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 30.6 Cg_endo -71.12 -30.25 16.45 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 C-N-CA 120.864 1.043 . . . . 0.0 112.316 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -110.89 22.14 15.67 Favored 'General case' 0 N--CA 1.511 2.604 0 O-C-N 120.749 -1.22 . . . . 0.0 112.502 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.591 HE21 ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.33 -40.86 92.16 Favored 'General case' 0 N--CA 1.514 2.732 0 O-C-N 120.427 -1.421 . . . . 0.0 109.559 179.514 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 1.031 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -67.85 -25.64 74.13 Favored Glycine 0 N--CA 1.507 3.411 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.657 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . . . -67.41 -20.07 65.47 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.989 -0.712 . . . . 0.0 109.787 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.09 9.54 36.55 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.1 ttt -76.79 78.69 3.4 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.0 165.45 31.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.04 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -161.36 171.68 37.42 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -147.77 128.62 14.38 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.2 p -115.38 139.95 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 24.1 m -114.34 121.56 44.0 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 78.5 t -93.3 110.07 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 20.4 p30 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.02 -178.201 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.806 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 2.4 m-30 . . . . . 0 C--O 1.22 -0.453 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.421 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 28.1 Cg_endo -64.53 -20.51 65.86 Favored 'Trans proline' 0 CA--C 1.546 1.087 0 C-N-CA 122.338 2.026 . . . . 0.0 111.382 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.7 HG23 ' CD1' ' B' ' 4' ' ' PHE . 1.7 tp -78.57 -26.3 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.512 -0.742 . . . . 0.0 110.361 179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.775 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.5 OUTLIER -72.44 -36.23 68.5 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.994 -1.066 . . . . 0.0 108.965 -179.669 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 9' ' ' TYR . . . -72.79 -41.13 65.32 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -66.08 -38.75 89.04 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.974 -0.454 . . . . 0.0 110.495 179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -68.76 -29.21 67.55 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -137.08 22.13 3.02 Favored 'General case' 0 N--CA 1.511 2.59 0 O-C-N 120.068 -1.645 . . . . 0.0 113.775 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.429 ' HB2' ' O ' ' B' ' 5' ' ' ALA . 55.9 m-85 -138.0 105.09 5.43 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 176.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -58.15 -42.01 84.99 Favored 'General case' 0 N--CA 1.515 2.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.598 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -121.12 132.5 24.19 Favored Pre-proline 0 N--CA 1.503 2.205 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -74.76 -19.22 18.7 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.092 1.861 . . . . 0.0 113.673 -176.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 -102.25 126.45 49.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.083 -1.01 . . . . 0.0 109.49 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -87.38 170.4 11.42 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.761 -0.587 . . . . 0.0 109.886 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.35 -27.09 67.11 Favored 'General case' 0 N--CA 1.508 2.441 0 O-C-N 121.513 -0.742 . . . . 0.0 111.801 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 p -74.71 -14.87 60.79 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.103 -0.998 . . . . 0.0 109.998 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.63 3.95 58.23 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 69.8 mtt-85 -91.86 138.03 31.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.806 -0.82 . . . . 0.0 109.863 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.426 HD12 ' HB3' ' B' ' 238' ' ' GLN . 15.5 mt -80.84 140.04 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 23.6 m -57.45 -9.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.586 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -175.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 m -71.0 -26.76 63.27 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-N 121.285 1.857 . . . . 0.0 108.794 178.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.95 -8.72 24.18 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 122.206 -0.309 . . . . 0.0 111.456 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -75.52 -30.78 59.9 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.52 -0.737 . . . . 0.0 109.901 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 m -114.1 -35.8 4.94 Favored 'General case' 0 N--CA 1.514 2.76 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -85.71 92.77 8.68 Favored 'General case' 0 N--CA 1.505 2.296 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 178.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.421 HD12 ' HB2' ' B' ' 158' ' ' GLN . 18.5 mt -87.32 -19.76 27.77 Favored 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -172.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.39 139.57 32.92 Favored 'General case' 0 N--CA 1.505 2.313 0 CA-C-N 121.164 1.802 . . . . 0.0 109.389 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.5 t -95.44 127.81 41.79 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.357 -0.84 . . . . 0.0 110.307 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.576 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 4.8 mttp -140.63 148.72 54.28 Favored Pre-proline 0 N--CA 1.498 1.972 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -68.11 141.31 52.25 Favored 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 122.475 2.116 . . . . 0.0 115.456 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.3 t -127.69 143.18 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.2 154.8 45.42 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.118 -0.989 . . . . 0.0 109.931 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.475 HD12 HG22 ' B' ' 49' ' ' VAL . 2.0 tt -146.04 121.61 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.541 -0.724 . . . . 0.0 110.257 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.9 OUTLIER -106.74 123.36 48.02 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.23 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.622 HG13 ' HD2' ' B' ' 36' ' ' PRO . 54.6 t -132.06 146.99 64.03 Favored Pre-proline 0 N--CA 1.497 1.895 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.622 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -62.73 139.12 73.25 Favored 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 121.173 1.248 . . . . 0.0 110.257 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -51.99 -41.62 62.31 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 122.118 -0.364 . . . . 0.0 111.517 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.28 152.23 39.6 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.775 -0.578 . . . . 0.0 109.654 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -135.62 157.48 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.464 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.7 mm? -96.54 162.35 23.66 Favored Pre-proline 0 N--CA 1.493 1.701 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.432 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 22.8 Cg_endo -62.87 137.2 61.45 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 C-N-CA 122.484 2.123 . . . . 0.0 112.389 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.02 46.05 22.54 Favored 'General case' 0 N--CA 1.514 2.758 0 C-N-CA 123.604 0.762 . . . . 0.0 112.319 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.7 p -127.03 145.32 50.76 Favored 'General case' 0 N--CA 1.503 2.216 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 177.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.52 133.52 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.37 -0.831 . . . . 0.0 109.624 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.534 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.4 p90 -131.31 166.54 21.01 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 178.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -115.71 133.65 55.82 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.214 -0.928 . . . . 0.0 111.286 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.35 102.28 11.58 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 105.893 -1.891 . . . . 0.0 105.893 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 13.8 p -92.5 121.24 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.387 -177.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . 0.475 HG22 HD12 ' B' ' 33' ' ' ILE . 51.4 t -103.63 132.31 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.439 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 27.0 mttm -112.28 123.61 50.65 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 121.727 0.775 . . . . 0.0 110.121 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 11.4 mt -120.24 77.0 24.87 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 105.507 -2.034 . . . . 0.0 105.507 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.439 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.0 Cg_endo -79.98 145.43 17.61 Favored 'Trans proline' 0 N--CA 1.48 0.719 0 C-N-CA 122.78 2.32 . . . . 0.0 113.672 -175.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -162.9 153.14 16.25 Favored 'General case' 0 N--CA 1.501 2.105 0 CA-C-N 115.222 -0.899 . . . . 0.0 108.648 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -64.21 120.77 12.75 Favored 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.4 mtm -79.63 2.59 21.91 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -93.47 2.05 56.6 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 120.293 -1.504 . . . . 0.0 107.753 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 35.7 mt -77.69 136.14 38.15 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.602 0.715 . . . . 0.0 111.139 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -121.55 124.26 43.96 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -93.27 168.49 11.05 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.098 0.475 . . . . 0.0 110.094 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 30.1 t -86.13 113.41 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.405 ' HA ' ' HE ' ' B' ' 156' ' ' ARG . 0.9 OUTLIER -70.35 168.11 16.68 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.512 -0.743 . . . . 0.0 109.59 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.591 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.16 -8.8 1.7 Allowed 'General case' 0 N--CA 1.506 2.345 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -115.12 16.0 17.04 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 120.583 -1.323 . . . . 0.0 111.525 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.627 ' HA3' ' HE ' ' B' ' 209' ' ' ARG . . . 94.22 -30.41 7.71 Favored Glycine 0 N--CA 1.503 3.12 0 O-C-N 120.92 -1.113 . . . . 0.0 111.672 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -68.74 158.24 34.67 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 118.534 1.167 . . . . 0.0 109.906 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -100.44 140.62 34.44 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.511 -0.743 . . . . 0.0 109.115 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.73 -171.65 19.12 Favored Glycine 0 N--CA 1.502 3.047 0 C-N-CA 120.197 -1.001 . . . . 0.0 111.16 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.87 15.92 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 122.008 -0.701 . . . . 0.0 110.664 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.44 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -100.34 157.71 16.42 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.654 0.74 . . . . 0.0 110.772 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.463 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 13.3 m-80 -114.89 152.77 31.7 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.59 153.51 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-O 122.03 0.919 . . . . 0.0 110.638 -178.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.86 152.46 24.0 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 107.844 -2.102 . . . . 0.0 107.844 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -151.83 157.14 41.51 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.369 -1.077 . . . . 0.0 111.69 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.441 ' O ' HG13 ' B' ' 74' ' ' VAL . 11.2 p -127.65 118.52 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 178.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.0 tp -104.28 120.83 42.04 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.585 -0.697 . . . . 0.0 109.421 -179.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 13.9 mt -102.96 107.39 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.543 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 9.2 mt -101.76 165.05 14.67 Favored Pre-proline 0 N--CA 1.492 1.672 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.672 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.0 Cg_endo -70.87 155.98 61.29 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.098 1.865 . . . . 0.0 109.526 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -62.02 133.89 55.92 Favored 'General case' 0 N--CA 1.505 2.275 0 O-C-N 121.369 -0.832 . . . . 0.0 110.247 -179.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 113.0 -38.41 3.24 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.672 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 38.5 m-85 -77.37 139.87 39.82 Favored 'General case' 0 N--CA 1.501 2.08 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -151.54 172.74 15.54 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.459 -0.775 . . . . 0.0 109.921 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.3 tp -62.23 130.48 45.57 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.73 -0.607 . . . . 0.0 109.571 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . 0.401 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.22 139.43 97.69 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.779 -0.576 . . . . 0.0 109.467 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.416 ' O ' HG13 ' B' ' 89' ' ' ILE . 30.2 Cg_endo -70.41 159.92 51.29 Favored 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 122.019 1.813 . . . . 0.0 109.908 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.64 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.6 Cg_endo -63.49 -33.66 67.78 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.43 2.086 . . . . 0.0 113.291 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -70.19 -25.25 63.34 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.347 -0.846 . . . . 0.0 110.495 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -92.06 -5.99 51.83 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 111.083 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.64 HD12 ' HA ' ' B' ' 86' ' ' PRO . 53.6 mt -87.44 124.09 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.197 0 O-C-N 120.92 -1.113 . . . . 0.0 109.65 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . 0.46 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 77.8 p -68.04 160.53 73.98 Favored Pre-proline 0 N--CA 1.504 2.265 0 O-C-N 122.069 -0.394 . . . . 0.0 110.414 -179.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' B' ' 90' ' ' SER . 32.5 Cg_endo -71.86 -30.53 13.97 Favored 'Trans proline' 0 N--CA 1.483 0.885 0 C-N-CA 122.131 1.887 . . . . 0.0 110.067 178.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.5 -21.44 62.76 Favored 'General case' 0 N--CA 1.502 2.173 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 177.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.46 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 17.8 ttm -95.58 -30.55 13.75 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.5 -32.72 74.47 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.482 -0.761 . . . . 0.0 110.572 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -77.15 -27.29 53.75 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 120.993 -1.067 . . . . 0.0 108.541 178.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.84 -41.26 75.14 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 122.057 -0.402 . . . . 0.0 110.013 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . 0.451 HG22 ' O ' ' B' ' 127' ' ' THR . 4.0 pt -79.85 5.51 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.506 2.367 0 O-C-N 121.211 -0.931 . . . . 0.0 110.37 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.34 -112.15 3.43 Favored Glycine 0 N--CA 1.504 3.169 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -146.86 43.21 1.16 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.618 HD22 HD11 ' B' ' 115' ' ' ILE . 14.8 mt -78.25 148.41 33.93 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.35 0.595 . . . . 0.0 110.612 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.2 p -111.34 100.96 9.47 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -78.97 124.6 28.41 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -107.32 153.05 23.31 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.627 -0.671 . . . . 0.0 110.122 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -78.15 140.77 39.0 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 25.9 t80 -51.16 -39.83 57.24 Favored 'General case' 0 N--CA 1.509 2.485 0 O-C-N 120.8 -1.187 . . . . 0.0 108.398 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.2 mtt85 -151.82 155.49 33.84 Favored Pre-proline 0 N--CA 1.5 2.03 0 N-CA-C 104.292 -2.484 . . . . 0.0 104.292 176.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -61.57 -23.84 77.11 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 C-N-CA 121.441 1.427 . . . . 0.0 112.673 -176.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -86.63 -22.94 25.89 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.497 -0.752 . . . . 0.0 109.622 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.442 ' HB3' HD12 ' B' ' 112' ' ' ILE . 27.1 mmtt -93.64 86.64 5.23 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -84.03 -7.48 59.38 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.293 -0.879 . . . . 0.0 109.97 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -99.19 3.53 46.45 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.508 -0.745 . . . . 0.0 111.481 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.6 mt -120.57 116.12 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.4 mt -112.51 142.93 44.49 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.534 0.683 . . . . 0.0 111.256 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 m -127.26 147.15 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.618 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -147.36 146.0 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.57 167.66 15.21 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.806 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 39.4 Cg_endo -73.92 134.34 35.06 Favored 'Cis proline' 0 N--CA 1.489 1.234 0 O-C-N 123.619 1.326 . . . . 0.0 112.39 0.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.5 m -127.81 151.6 75.81 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.99 129.35 25.61 Favored 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.418 1.412 . . . . 0.0 111.912 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.97 -37.04 94.05 Favored Glycine 0 N--CA 1.501 2.972 0 CA-C-N 115.285 -0.871 . . . . 0.0 112.732 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -56.37 -32.24 64.56 Favored 'General case' 0 N--CA 1.514 2.742 0 CA-C-N 118.755 1.278 . . . . 0.0 110.612 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.1 mmmt -98.33 -36.79 9.88 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -119.9 56.83 0.94 Allowed 'General case' 0 N--CA 1.497 1.884 0 C-N-CA 118.33 -1.348 . . . . 0.0 114.035 -175.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 2.6 m -72.42 -32.52 66.4 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 175.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -116.58 126.25 53.02 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 176.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 8.6 mt -116.18 142.96 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.654 -0.654 . . . . 0.0 109.605 -177.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . 0.451 ' O ' HG22 ' B' ' 97' ' ' ILE . 7.0 m -110.14 116.32 31.33 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -97.7 118.85 63.62 Favored Pre-proline 0 N--CA 1.496 1.863 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.7 Cg_endo -81.08 105.97 1.71 Allowed 'Trans proline' 0 N--CA 1.478 0.574 0 C-N-CA 122.056 1.837 . . . . 0.0 108.514 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.534 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.8 mm -107.61 143.66 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.683 -0.636 . . . . 0.0 110.548 -177.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 9.5 tp -104.03 121.37 43.03 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.93 137.17 76.31 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.46 ' HG2' HG11 ' B' ' 141' ' ' VAL . 33.8 Cg_endo -72.99 174.79 11.4 Favored 'Trans proline' 0 N--CA 1.48 0.701 0 C-N-CA 122.525 2.15 . . . . 0.0 111.292 -179.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 11.5 t70 -125.54 123.05 24.93 Favored Pre-proline 0 N--CA 1.489 1.512 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -66.4 -28.77 46.25 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.145 1.896 . . . . 0.0 111.6 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -71.27 -18.44 62.43 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.682 -0.636 . . . . 0.0 109.318 178.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.71 16.04 13.59 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.61 -0.681 . . . . 0.0 110.035 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -156.5 109.93 2.66 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -74.53 -12.77 60.56 Favored 'General case' 0 N--CA 1.503 2.223 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -175.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -99.88 -5.35 28.56 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 120.48 -1.387 . . . . 0.0 109.871 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.46 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -97.2 130.92 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 177.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -129.31 166.34 19.66 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.389 -0.819 . . . . 0.0 110.567 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -77.64 95.42 4.59 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 8.0 mt -146.37 177.7 8.82 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.744 0.783 . . . . 0.0 110.647 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.47 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -91.34 122.82 34.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 176.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.502 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.5 m-85 -113.82 140.16 24.4 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.52 -0.738 . . . . 0.0 111.176 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -81.08 141.54 13.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.949 2.432 . . . . 0.0 110.97 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 24.1 mt -126.65 125.41 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -114.36 140.4 48.68 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.331 -0.856 . . . . 0.0 110.092 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.7 p -132.67 144.67 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.673 0.749 . . . . 0.0 110.872 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.11 121.18 4.35 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -119.71 133.41 10.0 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.439 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.5 t-20 -133.53 143.48 48.77 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.623 -0.927 . . . . 0.0 110.872 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.576 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.2 OUTLIER -138.09 127.98 25.46 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 177.303 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.44 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.4 164.36 24.54 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.852 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 11.2 mtm105 -79.51 143.67 34.67 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.675 0.75 . . . . 0.0 110.488 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.51 175.51 43.47 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -178.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.421 ' HB2' HD12 ' B' ' 26' ' ' LEU . 1.2 mp0 -103.53 -30.84 10.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.737 -0.86 . . . . 0.0 111.475 -178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 24.0 mt -118.28 142.21 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.313 0 O-C-N 121.057 -1.027 . . . . 0.0 111.029 -178.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.689 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 4.0 m-30 -91.34 169.74 10.9 Favored Pre-proline 0 N--CA 1.503 2.214 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.8 Cg_endo -64.44 -10.65 24.93 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 122.005 1.803 . . . . 0.0 113.742 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -98.74 -3.53 35.56 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 120.727 -1.233 . . . . 0.0 109.452 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.98 -7.1 57.03 Favored Glycine 0 N--CA 1.503 3.129 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 2.1 m -71.4 143.71 50.05 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.742 -0.858 . . . . 0.0 110.41 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.5 mttt -83.86 152.17 24.72 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.53 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 4.4 p -96.06 179.92 4.9 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -87.49 15.39 6.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.245 -0.909 . . . . 0.0 109.473 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.423 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -111.1 41.62 1.8 Allowed 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.419 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 5.7 t -149.46 173.88 13.09 Favored 'General case' 0 N--CA 1.497 1.879 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -79.97 138.46 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.701 -0.624 . . . . 0.0 109.503 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -102.13 116.76 33.36 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . 0.478 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 75.5 m-20 -98.82 151.94 20.26 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.645 0.736 . . . . 0.0 111.359 -177.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -68.24 130.84 44.12 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.2 p -82.3 -3.15 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.752 -0.593 . . . . 0.0 110.13 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.639 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -154.49 149.69 27.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.38 -0.825 . . . . 0.0 110.053 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.06 170.49 43.38 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 177.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.95 -151.02 20.82 Favored Glycine 0 N--CA 1.499 2.84 0 O-C-N 120.921 -1.341 . . . . 0.0 110.814 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.6 tt -122.89 136.82 58.44 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 122.032 -0.687 . . . . 0.0 109.184 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 14.0 mt -74.74 113.22 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.094 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -90.62 -18.36 25.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.671 -0.643 . . . . 0.0 110.667 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -162.36 144.02 10.66 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.418 -0.802 . . . . 0.0 111.619 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.459 HD12 ' HG3' ' B' ' 217' ' ' GLU . 75.4 mt -130.15 100.69 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.1 tp -88.13 108.03 19.06 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 110.671 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 55.0 mtt85 -74.13 119.06 17.83 Favored 'General case' 0 N--CA 1.496 1.873 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -75.81 152.54 37.27 Favored 'General case' 0 N--CA 1.497 1.888 0 CA-C-O 122.436 1.112 . . . . 0.0 113.009 -175.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -52.24 -57.73 8.8 Favored 'General case' 0 N--CA 1.504 2.251 0 CA-C-N 114.447 -1.251 . . . . 0.0 112.854 -178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.75 ' HG2' ' HB2' ' A' ' 43' ' ' GLU . 8.1 tptt -93.35 20.13 7.47 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.268 -0.895 . . . . 0.0 111.902 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.61 157.29 22.46 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.83 168.58 30.9 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.452 ' CG ' HD11 ' B' ' 213' ' ' LEU . 55.9 m-85 -141.46 159.4 42.3 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.402 -1.058 . . . . 0.0 111.787 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -125.0 104.61 8.66 Favored 'General case' 0 N--CA 1.495 1.795 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.541 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -101.23 122.24 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.47 -0.769 . . . . 0.0 110.758 -177.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 2.6 m -96.8 120.16 36.62 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.462 ' HB ' HG23 ' B' ' 203' ' ' VAL . 14.5 mt -109.66 127.02 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 55.8 t -98.54 98.09 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -71.96 86.17 1.0 Allowed 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.77 -29.03 66.47 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.87 -0.519 . . . . 0.0 111.228 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 23.2 m -70.7 -35.42 72.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.631 -0.668 . . . . 0.0 110.554 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 44.9 m-80 -106.74 4.47 27.73 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.545 -0.722 . . . . 0.0 110.642 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 50.87 47.68 24.25 Favored 'General case' 0 N--CA 1.51 2.527 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.6 ttp-105 -130.54 142.77 50.47 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.185 0.517 . . . . 0.0 110.232 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 25.8 tt0 -111.81 125.82 54.42 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 175' ' ' ALA . 6.7 m -126.25 146.83 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.249 0 O-C-N 121.613 -0.679 . . . . 0.0 109.345 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 7.4 mt -118.91 110.37 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.19 125.33 35.93 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 19.7 mt -97.69 132.08 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 109.651 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 24.9 mt -114.78 131.32 23.5 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -75.15 166.29 29.33 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 122.655 2.236 . . . . 0.0 112.064 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.627 ' HE ' ' HA3' ' B' ' 64' ' ' GLY . 13.9 ptm180 -73.67 158.78 34.09 Favored 'General case' 0 N--CA 1.502 2.164 0 CA-C-O 121.397 0.618 . . . . 0.0 111.052 -179.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.1 -5.15 68.24 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.35 141.88 48.09 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.951 -0.734 . . . . 0.0 109.395 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -107.67 142.44 37.63 Favored 'General case' 0 N--CA 1.497 1.919 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.541 HD22 HD11 ' B' ' 192' ' ' ILE . 8.1 mt -78.25 150.71 33.36 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.847 0.832 . . . . 0.0 112.008 -176.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 23.6 mt -111.81 4.82 18.65 Favored 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 9.6 m -120.75 158.4 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.279 -0.888 . . . . 0.0 112.123 -177.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.7 m -123.08 162.47 22.37 Favored 'General case' 0 N--CA 1.498 1.931 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.459 ' HG3' HD12 ' B' ' 182' ' ' ILE . 49.8 mt-10 -65.14 139.69 58.71 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.447 -0.783 . . . . 0.0 109.012 179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 88.2 0.01 83.26 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.395 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -88.35 145.38 25.85 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 118.671 1.235 . . . . 0.0 109.989 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 30.4 m -87.13 123.89 32.67 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.3 tp -112.58 147.24 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.899 -0.501 . . . . 0.0 109.827 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -99.63 163.9 12.3 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.5 tp -63.47 135.99 57.28 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.039 -1.038 . . . . 0.0 109.442 179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.478 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.2 OUTLIER 69.1 13.36 8.7 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.973 -0.455 . . . . 0.0 111.27 179.594 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -74.47 132.79 78.05 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 177.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -63.23 118.28 5.19 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.074 1.85 . . . . 0.0 111.7 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 49.7 mt -91.98 -13.09 31.62 Favored 'General case' 0 N--CA 1.499 2.001 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.68 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 4.1 p -134.43 170.44 15.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.422 -0.798 . . . . 0.0 110.171 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.649 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 15.9 m -77.53 161.67 27.71 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -88.36 105.38 9.32 Favored Pre-proline 0 N--CA 1.503 2.222 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 177.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.649 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.1 Cg_endo -83.09 10.87 3.47 Favored 'Trans proline' 0 N--CA 1.489 1.215 0 C-N-CA 122.946 2.43 . . . . 0.0 113.378 -176.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -88.09 119.79 28.81 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 110.455 -179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.51 -0.04 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.18 -161.86 28.46 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 169.65 162.97 22.89 Favored Glycine 0 N--CA 1.496 2.656 0 C-N-CA 120.232 -0.985 . . . . 0.0 111.056 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.439 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 81.6 t80 -115.64 145.96 42.25 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.49 159.11 27.85 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.426 ' HB3' HD12 ' B' ' 19' ' ' ILE . 17.9 pt20 -136.72 150.14 48.26 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.779 -0.836 . . . . 0.0 109.736 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -144.23 172.2 25.4 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -144.41 153.63 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.544 -0.974 . . . . 0.0 109.882 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.13 165.29 26.07 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -126.51 125.78 42.61 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.0 tt -116.33 142.84 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.47 HG22 ' HG2' ' B' ' 145' ' ' LYS . 16.2 t -104.91 107.03 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.181 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 7.8 tp -68.67 108.35 3.34 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 175.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 14.3 tt0 -94.78 144.03 25.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -173.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.36 134.52 73.4 Favored Pre-proline 0 N--CA 1.485 1.32 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.48 -1.56 7.61 Favored 'Trans proline' 0 CA--C 1.548 1.2 0 C-N-CA 121.468 1.445 . . . . 0.0 111.836 -179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.6 mt -110.72 -129.8 0.3 Allowed 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 176.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.505 2.29 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.218 178.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 1.031 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 16.8 tt . . . . . 0 N--CA 1.503 2.193 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -102.14 136.31 42.19 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.698 179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 86.1 t -126.73 126.54 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.6 mt -85.6 136.63 33.31 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.699 0.761 . . . . 0.0 110.703 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.8 mt -95.4 103.26 15.12 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 177.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.69 122.75 5.01 Favored Glycine 0 N--CA 1.48 1.588 0 N-CA-C 107.263 -2.335 . . . . 0.0 107.263 -176.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 167.14 22.3 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.233 -1.157 . . . . 0.0 111.194 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -65.85 -12.43 54.29 Favored 'General case' 0 N--CA 1.513 2.717 0 O-C-N 120.562 -1.336 . . . . 0.0 112.254 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 47.7 p-10 -99.2 11.94 37.61 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 177.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.98 8.06 86.31 Favored Glycine 0 N--CA 1.5 2.926 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.2 m -66.39 144.31 56.61 Favored 'General case' 0 N--CA 1.506 2.358 0 CA-C-N 119.46 1.63 . . . . 0.0 109.537 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.673 HD12 ' HE1' ' B' ' 4' ' ' PHE . 11.1 mt -85.34 85.68 7.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.407 . . . . 0.0 107.941 179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.55 156.47 36.67 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.435 -0.791 . . . . 0.0 111.944 -178.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.495 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 76.3 m-85 -87.4 136.81 32.79 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 54.0 t -131.45 107.61 14.57 Favored Pre-proline 0 N--CA 1.49 1.545 0 C-N-CA 116.187 -2.205 . . . . 0.0 110.544 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 31.8 Cg_endo -77.52 167.62 78.67 Favored 'Cis proline' 0 CA--C 1.577 2.63 0 C-N-CA 124.275 -1.135 . . . . 0.0 111.521 0.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 p -104.45 -22.85 13.24 Favored 'General case' 0 N--CA 1.51 2.571 0 O-C-N 121.022 -1.049 . . . . 0.0 109.825 179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -127.85 123.01 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -155.81 168.45 27.16 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 119.466 -0.894 . . . . 0.0 111.021 -177.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.7 m -121.88 150.21 42.29 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.929 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.7 pt -141.15 162.22 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.674 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.405 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 13.0 m -89.71 163.67 31.93 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 177.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 21.3 Cg_endo -63.5 136.59 55.41 Favored 'Trans proline' 0 CA--C 1.559 1.74 0 C-N-CA 120.667 0.912 . . . . 0.0 114.04 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.12 -9.42 60.74 Favored Glycine 0 N--CA 1.509 3.541 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -68.96 142.68 54.62 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 119.79 -2.006 . . . . 0.0 107.417 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.3 ttmm -91.0 145.58 24.58 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 117.411 -1.716 . . . . 0.0 112.335 -177.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.9 mt -113.7 120.72 64.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.412 HG22 ' HG2' ' A' ' 71' ' ' GLU . 38.9 t -106.15 107.79 23.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 118.561 -1.256 . . . . 0.0 108.512 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -87.53 123.93 32.94 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -122.27 131.49 53.95 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 118.01 -1.476 . . . . 0.0 111.599 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.36 14.29 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -119.4 -53.25 2.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.504 -0.747 . . . . 0.0 110.464 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.424 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.66 151.11 23.67 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.051 -1.031 . . . . 0.0 112.473 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.67 14.96 81.97 Favored Glycine 1 N--CA 1.517 4.08 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.662 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.0 p90 -68.73 170.93 7.05 Favored Pre-proline 0 N--CA 1.512 2.634 0 O-C-N 120.313 -1.698 . . . . 0.0 108.281 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 24.1 Cg_endo -65.94 154.99 80.43 Favored 'Cis proline' 0 N--CA 1.498 1.739 0 C-N-CA 125.048 -0.813 . . . . 0.0 113.541 2.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.559 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.62 163.15 35.74 Favored 'General case' 0 N--CA 1.501 2.121 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.753 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.434 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 11.6 p-10 -151.55 172.08 16.58 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.3 mp -127.71 119.14 50.98 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 C-N-CA 118.478 -1.289 . . . . 0.0 107.919 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.508 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 42.7 t -123.77 132.06 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 29.6 m-85 -89.69 137.14 32.59 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 119.068 -1.053 . . . . 0.0 109.283 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.514 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.2 t70 -72.05 113.81 9.48 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 118.387 -1.325 . . . . 0.0 108.619 -179.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.951 ' HB2' ' HB3' ' B' ' 187' ' ' LYS . 0.1 OUTLIER -57.14 -29.19 63.38 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.756 -179.704 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.758 ' OD1' ' O ' ' B' ' 188' ' ' GLY . 5.5 m-20 -93.79 4.24 54.22 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.391 -0.818 . . . . 0.0 110.157 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.684 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.48 41.89 3.04 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.833 -178.543 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.672 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.1 pt -134.37 165.49 36.33 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 177.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.723 ' HG2' HG21 ' A' ' 50' ' ' VAL . 19.0 Cg_endo -56.88 142.56 92.97 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 120.897 1.065 . . . . 0.0 111.822 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.1 m -55.63 136.04 50.72 Favored 'General case' 0 N--CA 1.518 2.928 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.51 -10.92 73.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.723 HG21 ' HG2' ' A' ' 47' ' ' PRO . 93.0 t -79.3 132.42 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.423 0 CA-C-N 119.59 1.695 . . . . 0.0 111.047 -175.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -84.21 113.68 21.26 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 118.349 -1.34 . . . . 0.0 107.694 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.02 -24.3 66.0 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.085 -1.009 . . . . 0.0 112.016 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.3 p -67.06 -25.99 66.52 Favored 'General case' 0 N--CA 1.511 2.575 0 O-C-N 121.173 -0.954 . . . . 0.0 110.024 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -79.96 -17.95 51.65 Favored 'General case' 0 N--CA 1.514 2.752 0 O-C-N 120.655 -1.278 . . . . 0.0 112.667 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -122.07 3.26 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.248 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -177.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.508 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -129.29 164.16 24.12 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.686 -1.258 . . . . 0.0 113.401 -179.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 31.2 mtp -85.92 161.49 19.01 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -73.24 153.89 40.44 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 116.635 -2.026 . . . . 0.0 107.239 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.815 ' HB3' ' CG ' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -61.19 -30.13 70.23 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 118.476 -1.29 . . . . 0.0 111.814 -178.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -85.91 -3.53 58.94 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.913 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -92.78 145.78 24.14 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.68 -1.263 . . . . 0.0 109.234 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 84.2 mt -141.12 149.12 41.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 111.819 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.407 HD22 ' HB3' ' A' ' 68' ' ' GLU . 48.1 mt -100.94 110.13 22.14 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 101.121 -3.659 . . . . 0.0 101.121 173.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.515 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.98 13.86 17.07 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 117.213 -1.795 . . . . 0.0 113.806 -174.159 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.86 146.1 51.03 Favored 'General case' 0 N--CA 1.511 2.602 0 O-C-N 120.294 -1.504 . . . . 0.0 108.121 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.44 133.22 55.9 Favored 'General case' 0 N--CA 1.507 2.383 0 C-N-CA 120.794 -0.362 . . . . 0.0 111.591 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.54 -16.94 60.17 Favored Glycine 0 N--CA 1.5 2.917 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.276 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.407 ' HB3' HD22 ' A' ' 63' ' ' LEU . 21.3 mt-10 -62.75 142.39 58.18 Favored 'General case' 0 N--CA 1.51 2.567 0 CA-C-N 120.056 1.928 . . . . 0.0 108.093 -177.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 67.6 p -129.18 156.63 43.61 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 118.127 -1.429 . . . . 0.0 112.774 -177.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -131.46 122.41 26.18 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.412 ' HG2' HG22 ' A' ' 28' ' ' VAL . 17.2 mt-10 -114.15 143.64 44.47 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.405 -177.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.32 144.46 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 CA-C-O 121.59 0.709 . . . . 0.0 110.824 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.61 130.9 56.67 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 41.6 mt -106.94 142.41 36.61 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -117.65 -40.04 3.07 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.522 -1.361 . . . . 0.0 110.468 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.48 ' O ' ' OH ' ' A' ' 80' ' ' TYR . 60.5 m-80 -66.77 134.17 51.62 Favored 'General case' 0 N--CA 1.508 2.461 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.236 -179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.13 154.53 31.15 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.271 -0.893 . . . . 0.0 110.976 -177.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.45 21.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 118.808 -1.663 . . . . 0.0 109.15 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -99.36 141.74 31.75 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.029 -1.277 . . . . 0.0 110.378 -179.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.485 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.2 m-85 -122.61 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.925 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.684 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 51.1 m -98.09 134.36 41.28 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -134.69 168.73 18.48 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.452 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.498 ' CB ' ' OE1' ' A' ' 88' ' ' GLN . 31.5 p90 -160.19 166.09 30.34 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 119.003 -1.079 . . . . 0.0 111.801 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.496 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.3 t -95.54 126.46 40.84 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 103.192 -2.892 . . . . 0.0 103.192 175.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.712 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 4.4 p -61.98 -50.44 80.84 Favored Pre-proline 0 N--CA 1.504 2.232 0 C-N-CA 118.204 -1.398 . . . . 0.0 114.751 -175.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.574 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.4 Cg_endo -69.97 -19.58 34.95 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 121.825 1.683 . . . . 0.0 112.655 -178.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.654 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 31.9 m170 -119.94 17.91 12.52 Favored 'General case' 0 N--CA 1.508 2.456 0 CA-C-N 118.691 0.678 . . . . 0.0 112.544 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.894 ' OE1' HG12 ' A' ' 93' ' ' VAL . 1.6 tp-100 -59.95 -43.57 94.92 Favored 'General case' 0 N--CA 1.526 3.369 0 O-C-N 120.526 -1.359 . . . . 0.0 108.892 177.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 1.041 ' HA3' HMD1 ' B' ' 253' ' ' HEC . . . -63.86 -25.71 69.45 Favored Glycine 0 CA--C 1.548 2.155 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 178.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 1.075 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -78.93 -1.21 34.2 Favored 'General case' 0 N--CA 1.483 1.181 0 O-C-N 119.514 -2.168 . . . . 0.0 111.885 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.29 7.45 59.38 Favored Glycine 0 C--N 1.291 -1.961 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.495 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.6 ttt -77.26 84.83 3.71 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.809 1.804 . . . . 0.0 106.61 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.894 HG12 ' OE1' ' A' ' 88' ' ' GLN . 34.0 m -136.28 165.61 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.88 174.64 36.71 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 118.272 -1.918 . . . . 0.0 108.614 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.4 ttpp -149.15 129.53 13.82 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 118.852 1.326 . . . . 0.0 107.923 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.476 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.7 p -116.11 142.64 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.427 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 63.0 m -113.63 126.64 55.49 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.482 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.5 t -96.4 115.47 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 28.0 p30 . . . . . 0 N--CA 1.482 1.17 0 C-N-CA 118.856 -1.138 . . . . 0.0 111.213 -176.783 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.943 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 22.1 m-85 . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.85 -26.4 73.79 Favored 'Trans proline' 0 N--CA 1.481 0.742 0 C-N-CA 121.348 1.365 . . . . 0.0 111.614 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.659 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.6 tp -70.96 -29.95 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 121.909 -0.494 . . . . 0.0 110.528 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 1.075 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 5.6 m-30 -69.97 -34.36 73.27 Favored 'General case' 0 N--CA 1.534 3.77 0 O-C-N 121.366 -0.834 . . . . 0.0 110.433 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.445 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.29 -44.18 47.04 Favored 'General case' 0 N--CA 1.495 1.812 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 177.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . 0.401 ' HA ' ' CZ ' ' B' ' 105' ' ' TYR . 40.0 mt-30 -61.35 -47.03 87.73 Favored 'General case' 0 N--CA 1.512 2.628 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -60.73 -28.9 69.02 Favored 'General case' 0 N--CA 1.501 2.103 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.23 26.1 2.02 Favored 'General case' 0 N--CA 1.521 3.112 0 CA-C-N 122.173 2.261 . . . . 0.0 113.837 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.445 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.8 m-85 -139.99 111.62 7.31 Favored 'General case' 0 N--CA 1.527 3.418 0 N-CA-C 103.651 -2.722 . . . . 0.0 103.651 174.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.26 -39.41 89.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.395 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -122.17 135.42 25.42 Favored Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 104.715 -2.328 . . . . 0.0 104.715 177.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.476 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.3 Cg_endo -78.23 -16.84 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.936 0 C-N-CA 121.448 1.432 . . . . 0.0 112.298 -175.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -102.48 126.39 49.51 Favored 'General case' 0 N--CA 1.508 2.472 0 CA-C-N 120.166 1.348 . . . . 0.0 110.667 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -86.63 168.69 13.39 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.859 -1.15 . . . . 0.0 110.092 -178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.7 -24.71 64.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.971 -1.081 . . . . 0.0 110.947 -179.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.3 p -76.56 -14.31 60.02 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.824 -1.172 . . . . 0.0 109.303 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.61 5.62 58.77 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.562 0.696 . . . . 0.0 110.235 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 45.4 mt -81.23 139.25 18.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -55.81 -10.96 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.529 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -177.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.15 -25.8 63.63 Favored 'General case' 0 N--CA 1.52 3.038 0 CA-C-N 123.454 2.843 . . . . 0.0 109.425 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.0 -7.59 18.0 Favored 'General case' 0 N--CA 1.5 2.038 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.558 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -76.84 -29.38 55.86 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.027 -1.046 . . . . 0.0 109.154 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.97 -28.94 5.77 Favored 'General case' 1 N--CA 1.541 4.099 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.03 92.41 9.21 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 104.945 -2.243 . . . . 0.0 104.945 175.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.2 mt -84.8 -17.9 36.67 Favored 'General case' 0 N--CA 1.503 2.214 0 N-CA-C 115.532 1.679 . . . . 0.0 115.532 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.41 140.57 29.4 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.311 2.323 . . . . 0.0 111.014 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.4 t -93.18 131.96 37.77 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 121.997 0.903 . . . . 0.0 109.696 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -142.87 150.58 53.83 Favored Pre-proline 0 C--N 1.3 -1.581 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.9 Cg_endo -72.6 140.75 33.28 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 N-CA-C 116.629 1.742 . . . . 0.0 116.629 -176.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 96.2 t -124.87 145.44 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 112.734 -2.03 . . . . 0.0 107.239 177.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 5.1 t70 -131.47 155.24 47.71 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.219 -0.926 . . . . 0.0 109.437 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.9 tt -147.55 120.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.719 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.464 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.0 mp0 -105.62 130.72 53.6 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 177.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.514 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.2 t -139.08 146.93 51.56 Favored Pre-proline 0 C--N 1.299 -1.593 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.514 ' HD2' HG13 ' B' ' 35' ' ' VAL . 24.2 Cg_endo -61.33 146.34 97.38 Favored 'Trans proline' 0 C--N 1.322 -0.851 0 O-C-N 122.664 0.823 . . . . 0.0 110.124 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.95 -37.85 80.74 Favored 'General case' 0 N--CA 1.509 2.524 0 O-C-N 121.856 -0.528 . . . . 0.0 111.133 -178.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.69 154.49 41.5 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.655 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 m -139.84 158.86 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.26 35.41 Favored Pre-proline 0 N--CA 1.491 1.612 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.112 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.41 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -54.1 141.77 68.0 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.845 1.697 . . . . 0.0 112.501 179.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 1.3 t70 48.46 49.27 18.44 Favored 'General case' 0 N--CA 1.515 2.779 0 C-N-CA 124.392 1.077 . . . . 0.0 112.608 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.3 p -128.61 146.95 50.71 Favored 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.1 t -88.85 139.53 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.617 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.624 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 49.4 p90 -137.95 166.47 23.98 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.26 49.75 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 118.621 -1.232 . . . . 0.0 111.784 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.41 111.13 21.94 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 176.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.464 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 3.6 p -100.96 122.53 53.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 116.57 -2.052 . . . . 0.0 111.247 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.2 t -104.5 134.32 46.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 119.629 -0.828 . . . . 0.0 109.177 -178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 42.9 mttm -113.1 126.3 55.32 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.756 -0.778 . . . . 0.0 109.419 179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 18.4 mt -122.99 77.0 50.5 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.4 Cg_endo -81.5 145.21 14.67 Favored 'Trans proline' 0 N--CA 1.48 0.73 0 C-N-CA 122.346 2.03 . . . . 0.0 114.084 -174.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -159.95 154.12 23.42 Favored 'General case' 0 N--CA 1.508 2.448 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.025 179.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -65.39 123.45 19.66 Favored 'General case' 0 CA--C 1.561 1.376 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 177.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 5.8 mtm -81.47 5.64 17.13 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 120.376 -1.452 . . . . 0.0 114.781 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -94.46 0.77 55.61 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 120.048 -1.657 . . . . 0.0 106.897 176.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' B' ' 57' ' ' LEU . 63.3 mt -74.9 134.69 41.57 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.527 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -121.0 128.04 52.33 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 178.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -97.74 172.48 7.66 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 120.314 -0.554 . . . . 0.0 109.736 -178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 t -87.68 113.54 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.4 HD13 ' N ' ' B' ' 67' ' ' GLY . 6.5 mp -69.86 166.49 19.34 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.687 -1.258 . . . . 0.0 108.798 -179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.712 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -58.33 -5.1 0.45 Allowed 'General case' 0 N--CA 1.514 2.745 0 O-C-N 120.737 -1.227 . . . . 0.0 113.033 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.815 ' CG ' ' HB3' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -118.59 16.14 13.7 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 120.017 -1.677 . . . . 0.0 111.527 -177.481 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.04 -30.9 7.06 Favored Glycine 0 N--CA 1.512 3.762 0 O-C-N 121.217 -0.927 . . . . 0.0 110.938 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -69.13 158.92 33.92 Favored 'General case' 0 N--CA 1.509 2.512 0 CA-C-N 119.152 1.476 . . . . 0.0 110.493 -179.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -101.77 140.16 36.44 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . 0.4 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -151.71 -173.28 21.31 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.159 -1.496 . . . . 0.0 112.054 -178.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.6 167.24 21.54 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.183 0.516 . . . . 0.0 110.689 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.468 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.0 mp -97.5 157.66 15.89 Favored 'General case' 0 N--CA 1.499 2.021 0 CA-C-O 121.709 0.766 . . . . 0.0 112.098 -178.081 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.521 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 29.5 m-80 -115.88 154.5 29.61 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.262 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.83 159.46 15.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.619 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.36 157.01 27.95 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 177.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.37 160.03 42.56 Favored 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 118.032 -1.467 . . . . 0.0 111.791 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 8.4 p -128.75 122.38 56.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 tp -107.4 123.84 48.96 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 117.951 -1.5 . . . . 0.0 110.119 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.406 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.4 mt -104.91 109.63 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 C-N-CA 118.885 -1.126 . . . . 0.0 108.801 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.3 mt -104.83 161.75 21.85 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.925 -0.484 . . . . 0.0 109.784 -178.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.736 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.33 157.88 57.93 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 121.732 1.621 . . . . 0.0 109.176 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -64.94 136.29 56.65 Favored 'General case' 0 N--CA 1.508 2.456 0 O-C-N 121.62 -0.675 . . . . 0.0 110.464 -178.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.82 2.75 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.735 -2.146 . . . . 0.0 107.735 -177.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.736 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.9 m-85 -77.61 140.49 39.66 Favored 'General case' 0 N--CA 1.504 2.253 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -154.09 170.8 20.27 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.686 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 10.9 tp -60.65 129.38 41.27 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 120.146 -0.622 . . . . 0.0 110.36 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.61 137.38 96.44 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.639 -0.663 . . . . 0.0 109.638 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.71 157.74 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.199 0 C-N-CA 122.203 1.935 . . . . 0.0 108.93 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.512 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.9 Cg_endo -60.63 -38.22 73.73 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.11 2.54 . . . . 0.0 113.673 -178.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -65.38 -25.97 67.8 Favored 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.305 -0.872 . . . . 0.0 110.799 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 37.4 mmm-85 -91.51 -4.39 55.53 Favored 'General case' 0 N--CA 1.517 2.893 0 O-C-N 121.21 -0.931 . . . . 0.0 110.631 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' B' ' 86' ' ' PRO . 71.1 mt -88.82 122.67 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.057 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 24.5 p -66.6 157.67 82.08 Favored Pre-proline 0 N--CA 1.497 1.9 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.244 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -68.83 -35.7 15.25 Favored 'Trans proline' 0 N--CA 1.484 0.928 0 C-N-CA 122.721 2.281 . . . . 0.0 109.188 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -66.52 -19.69 65.84 Favored 'General case' 0 N--CA 1.511 2.584 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 28.8 ttm -97.69 -31.06 12.46 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.2 tppt? -65.89 -30.87 71.54 Favored 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.4 -0.813 . . . . 0.0 111.182 -178.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -75.78 -33.85 60.2 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.12 -43.31 98.78 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.401 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 8.3 pt -78.8 7.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.505 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.217 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.63 -112.19 2.92 Favored Glycine 0 N--CA 1.504 3.203 0 O-C-N 121.144 -0.972 . . . . 0.0 110.769 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -149.6 43.84 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 178.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.751 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.71 148.64 32.99 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.412 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.8 p -111.98 106.73 15.49 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -84.44 129.38 34.87 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.493 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -112.09 155.05 24.49 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 118.687 -1.205 . . . . 0.0 112.125 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -80.0 145.43 32.55 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 117.847 -1.541 . . . . 0.0 107.267 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.401 ' CZ ' ' HA ' ' B' ' 6' ' ' GLN . 47.6 t80 -57.83 -38.84 76.32 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.255 -1.528 . . . . 0.0 107.5 -179.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 15.2 mtt85 -151.25 156.06 34.92 Favored Pre-proline 0 C--N 1.295 -1.77 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 176.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.67 -25.28 75.11 Favored 'Trans proline' 0 C--N 1.315 -1.198 0 CA-C-N 118.708 0.574 . . . . 0.0 112.956 -178.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -83.89 -21.55 31.89 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.61 -1.306 . . . . 0.0 109.383 178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.7 mmtt -94.05 84.1 4.43 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 122.047 0.927 . . . . 0.0 109.615 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 17.7 mttm -81.46 -8.58 59.75 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.605 -0.685 . . . . 0.0 110.207 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -101.05 11.7 39.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.358 -0.839 . . . . 0.0 111.297 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.476 HG21 ' HG3' ' B' ' 12' ' ' PRO . 46.0 mt -125.46 115.41 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.477 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.4 mt -113.46 142.54 45.78 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.298 -1.361 . . . . 0.0 111.957 -176.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.59 149.29 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-O 121.559 0.695 . . . . 0.0 109.992 178.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.751 HD11 HD22 ' B' ' 100' ' ' LEU . 10.7 tt -150.2 145.41 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.44 165.72 15.33 Favored Glycine 0 N--CA 1.476 1.31 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.943 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.7 Cg_endo -73.44 135.3 39.32 Favored 'Cis proline' 0 C--N 1.315 -1.205 0 O-C-N 124.593 1.838 . . . . 0.0 113.141 -0.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 m -129.13 149.05 71.54 Favored Pre-proline 0 N--CA 1.501 2.111 0 N-CA-C 105.578 -2.008 . . . . 0.0 105.578 177.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.06 129.7 29.69 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 121.277 1.318 . . . . 0.0 113.075 -177.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.0 -37.44 94.97 Favored Glycine 1 N--CA 1.522 4.406 0 CA-C-N 115.771 -0.649 . . . . 0.0 112.769 -178.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -56.32 -36.89 69.22 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.173 -1.192 . . . . 0.0 110.113 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -93.93 -37.58 11.63 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -177.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 77.9 m-85 -117.61 50.78 1.09 Allowed 'General case' 0 N--CA 1.508 2.438 0 O-C-N 120.717 -1.239 . . . . 0.0 113.887 -175.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 16.2 m -67.75 -29.16 68.31 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 119.729 -1.857 . . . . 0.0 106.789 176.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -117.22 126.85 53.42 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.514 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 34.4 mt -118.5 143.46 29.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.603 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 21.4 m -110.05 117.05 32.72 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.298 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -99.68 117.83 62.99 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -81.93 109.93 2.02 Favored 'Trans proline' 0 N--CA 1.45 -1.087 0 N-CA-C 107.607 -1.728 . . . . 0.0 107.607 -177.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.624 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.1 mm -110.1 143.48 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.396 0 CA-C-O 121.638 0.733 . . . . 0.0 111.394 -177.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.5 tp -103.35 121.67 43.24 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.94 134.88 67.81 Favored Pre-proline 0 N--CA 1.483 1.197 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.928 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.483 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.8 178.14 4.89 Favored 'Trans proline' 0 C--N 1.328 -0.532 0 O-C-N 123.604 1.318 . . . . 0.0 111.378 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.9 t70 -129.25 118.99 19.4 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.422 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.4 Cg_endo -62.17 -35.6 74.07 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.159 1.906 . . . . 0.0 111.665 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.91 -18.87 64.64 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.451 -0.781 . . . . 0.0 109.585 177.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.4 m -120.98 20.27 11.57 Favored 'General case' 0 N--CA 1.524 3.236 0 O-C-N 120.889 -1.132 . . . . 0.0 110.932 -178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -160.92 108.26 1.51 Allowed 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -72.95 -10.72 60.1 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.25 -1.82 28.22 Favored 'General case' 0 N--CA 1.512 2.667 0 CA-C-N 122.128 2.24 . . . . 0.0 109.679 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.483 HG11 ' HG2' ' B' ' 133' ' ' PRO . 44.0 t -98.92 130.47 47.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 177.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 68.2 m-70 -129.78 167.83 17.49 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.058 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.422 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 68.1 m-85 -78.32 101.73 7.34 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 21.0 mt -154.08 177.09 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.173 -1.011 . . . . 0.0 112.096 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.542 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.45 129.22 36.65 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 117.874 -1.531 . . . . 0.0 107.072 177.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -120.98 139.08 28.62 Favored Pre-proline 0 C--N 1.307 -1.24 0 C-N-CA 117.463 -1.695 . . . . 0.0 111.625 -175.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -79.01 146.86 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.404 0 C-N-CA 121.356 1.37 . . . . 0.0 111.363 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.9 mt -130.3 128.15 63.74 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.374 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.406 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 89.6 m-85 -118.05 140.8 49.23 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 118.539 -1.264 . . . . 0.0 110.546 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.51 145.22 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 CA-C-O 122.316 1.055 . . . . 0.0 111.641 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.22 6.75 Favored Glycine 0 N--CA 1.474 1.232 0 N-CA-C 106.123 -2.791 . . . . 0.0 106.123 177.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.12 133.26 7.48 Favored Glycine 0 C--N 1.294 -1.799 0 C-N-CA 118.346 -1.883 . . . . 0.0 110.131 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.405 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 20.2 t-20 -132.88 144.13 49.97 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.794 0.807 . . . . 0.0 112.552 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.559 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.07 126.71 27.16 Favored 'General case' 0 N--CA 1.5 2.037 0 CA-C-N 114.581 -1.19 . . . . 0.0 107.917 177.093 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.468 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.69 159.01 22.72 Favored Glycine 0 C--N 1.303 -1.293 0 C-N-CA 117.892 -2.099 . . . . 0.0 110.256 179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.603 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.9 mtm105 -75.73 140.66 42.56 Favored 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.693 0.759 . . . . 0.0 110.648 179.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.61 172.62 45.32 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.405 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 5.9 mp0 -99.35 -30.46 12.2 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.702 -0.881 . . . . 0.0 111.693 179.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.9 mt -118.02 143.27 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.136 0 O-C-N 120.582 -1.324 . . . . 0.0 112.969 -177.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.765 ' HE1' ' HB3' ' B' ' 166' ' ' SER . 0.1 OUTLIER -91.32 169.44 11.46 Favored Pre-proline 0 N--CA 1.491 1.583 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.419 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.727 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.4 Cg_endo -60.64 -14.83 33.38 Favored 'Trans proline' 0 CA--C 1.557 1.641 0 C-N-CA 122.169 1.913 . . . . 0.0 112.411 176.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.19 -4.49 45.87 Favored 'General case' 0 N--CA 1.528 3.446 0 CA-C-N 120.52 1.509 . . . . 0.0 110.431 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.09 -9.99 54.91 Favored Glycine 0 N--CA 1.509 3.56 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -69.04 142.63 54.5 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.699 -0.883 . . . . 0.0 111.11 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -83.96 151.3 25.12 Favored 'General case' 0 N--CA 1.502 2.141 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.331 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.765 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 79.5 p -96.39 177.45 5.69 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -85.85 17.13 3.58 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.427 -1.709 . . . . 0.0 108.684 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.405 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 5.8 t-20 -112.66 45.49 1.31 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.969 0.89 . . . . 0.0 108.706 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.477 HG22 ' O ' ' B' ' 166' ' ' SER . 6.1 t -153.64 172.4 17.3 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.6 t -77.29 142.73 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 121.77 -0.581 . . . . 0.0 110.024 179.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -104.8 122.21 45.26 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -103.33 152.11 21.95 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 117.847 -1.541 . . . . 0.0 111.356 -175.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.15 131.43 46.14 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.699 -0.626 . . . . 0.0 109.348 178.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 22.7 p -82.95 -5.35 59.02 Favored 'General case' 0 N--CA 1.51 2.547 0 O-C-N 121.411 -0.805 . . . . 0.0 109.701 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.488 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.21 151.43 31.87 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.415 0.626 . . . . 0.0 111.243 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 171.13 45.34 Favored Glycine 0 N--CA 1.48 1.596 0 N-CA-C 107.391 -2.284 . . . . 0.0 107.391 177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.69 -156.55 24.26 Favored Glycine 0 C--N 1.3 -1.458 0 C-N-CA 116.924 -2.56 . . . . 0.0 111.318 -178.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 6.8 tt -121.44 135.93 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.037 -1.098 . . . . 0.0 108.037 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 41.7 mt -75.12 116.34 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.213 179.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.9 p -92.84 -18.44 22.85 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.177 -0.952 . . . . 0.0 110.513 -178.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -161.16 145.88 13.71 Favored 'General case' 0 N--CA 1.503 2.176 0 CA-C-O 122.487 1.137 . . . . 0.0 113.232 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.441 HD12 ' HG3' ' B' ' 217' ' ' GLU . 67.1 mt -131.44 100.3 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 177.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 14.7 tp -87.78 108.95 19.38 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.611 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 39.8 mtt85 -74.59 120.77 20.6 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 177.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . 0.485 ' HD2' ' HB3' ' A' ' 44' ' ' ASP . 15.5 mttt -77.53 151.62 34.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.811 -1.181 . . . . 0.0 113.099 -175.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -49.2 -58.3 5.26 Favored 'General case' 0 N--CA 1.511 2.581 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.264 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.951 ' HB3' ' HB2' ' A' ' 43' ' ' GLU . 9.3 tptt -95.12 21.19 8.09 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.424 -1.422 . . . . 0.0 111.339 -177.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . 0.758 ' O ' ' OD1' ' A' ' 44' ' ' ASP . . . 108.75 155.58 17.35 Favored Glycine 0 N--CA 1.496 2.694 0 C-N-CA 119.733 -1.222 . . . . 0.0 111.197 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.55 170.42 31.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.234 -1.547 . . . . 0.0 109.234 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.472 ' CG ' HD11 ' B' ' 213' ' ' LEU . 64.7 m-85 -141.53 161.77 37.1 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-O 122.103 0.954 . . . . 0.0 112.37 -179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -126.27 110.93 13.97 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 105.221 -2.141 . . . . 0.0 105.221 176.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 96.3 mt -107.71 122.85 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 118.603 -1.239 . . . . 0.0 110.486 -176.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 23.3 m -96.05 122.94 39.42 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.823 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 43.4 mt -112.19 128.29 68.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.2 t -98.55 100.86 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -73.72 88.62 1.75 Allowed 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.33 -32.38 71.19 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.499 -0.751 . . . . 0.0 110.847 -177.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 56.0 m -67.58 -35.2 78.55 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.762 -0.587 . . . . 0.0 111.51 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -106.04 3.36 28.13 Favored 'General case' 0 N--CA 1.515 2.822 0 O-C-N 121.796 -0.565 . . . . 0.0 110.319 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 50.14 50.44 18.58 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.7 ttp-105 -133.52 141.81 47.92 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.66 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -112.1 129.43 56.23 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.488 HG21 ' HB3' ' B' ' 175' ' ' ALA . 30.4 m -129.67 147.96 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.648 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 70.5 mt -120.28 111.28 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 CA-C-O 121.986 0.898 . . . . 0.0 109.935 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -92.37 128.34 38.18 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.8 mt -99.46 135.14 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.117 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 50.1 mt -117.0 132.4 23.47 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -76.08 165.85 28.95 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.372 2.715 . . . . 0.0 111.926 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -74.69 154.64 38.35 Favored 'General case' 0 N--CA 1.512 2.636 0 CA-C-O 121.578 0.704 . . . . 0.0 112.855 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.58 -6.79 61.07 Favored Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.598 -2.201 . . . . 0.0 107.598 -178.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.551 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.79 142.79 46.29 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 122.061 -0.67 . . . . 0.0 110.125 178.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -110.01 139.03 45.57 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.709 0.766 . . . . 0.0 109.13 178.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.53 HD23 HG22 ' B' ' 228' ' ' THR . 21.7 mt -73.94 151.0 40.48 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.427 -0.795 . . . . 0.0 113.035 -178.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 60.5 mt -111.71 5.27 19.1 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.534 HG11 HD13 ' B' ' 221' ' ' ILE . 10.8 m -119.81 157.0 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 119.065 -1.054 . . . . 0.0 113.324 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 67.2 m -122.22 156.9 32.79 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.378 179.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.441 ' HG3' HD12 ' B' ' 182' ' ' ILE . 85.4 mt-10 -61.09 143.17 55.93 Favored 'General case' 0 N--CA 1.5 2.073 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.76 -4.32 86.35 Favored Glycine 0 N--CA 1.503 3.138 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -86.76 144.05 27.25 Favored 'General case' 0 N--CA 1.508 2.471 0 O-C-N 121.02 -1.282 . . . . 0.0 110.852 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.6 m -87.01 123.94 32.65 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.481 0.657 . . . . 0.0 109.262 179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.534 HD13 HG11 ' B' ' 215' ' ' VAL . 2.7 tp -112.91 149.88 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-O 121.385 0.612 . . . . 0.0 109.591 -179.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -103.19 160.92 14.23 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 16.5 tp -60.54 138.75 57.99 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.545 -1.262 . . . . 0.0 109.209 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.32 14.25 9.59 Favored 'General case' 0 N--CA 1.513 2.679 0 O-C-N 121.495 -0.753 . . . . 0.0 111.718 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.512 ' HB3' HG13 ' B' ' 221' ' ' ILE . 17.7 tt0 -76.53 125.44 87.43 Favored Pre-proline 0 N--CA 1.509 2.499 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -55.92 124.25 15.82 Favored 'Trans proline' 0 N--CA 1.482 0.851 0 C-N-CA 121.482 1.455 . . . . 0.0 110.774 -177.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.479 HD21 HG12 ' B' ' 221' ' ' ILE . 82.4 mt -98.5 -11.79 21.92 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.448 0.642 . . . . 0.0 110.291 -177.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.53 HG22 HD23 ' B' ' 213' ' ' LEU . 44.2 p -135.76 168.23 19.67 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 122.125 0.964 . . . . 0.0 111.435 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 39.3 m -72.83 162.01 30.01 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.859 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -91.14 107.06 18.47 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 177.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.551 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.8 Cg_endo -85.98 13.57 2.7 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 121.466 1.444 . . . . 0.0 112.912 -175.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.61 119.52 30.92 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-N 119.128 0.876 . . . . 0.0 111.152 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.61 3.05 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.788 0 C-N-CA 123.382 0.673 . . . . 0.0 109.798 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -163.13 25.3 Favored Glycine 0 N--CA 1.499 2.836 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.442 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.78 164.22 26.13 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.21 147.66 42.3 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.84 160.9 28.45 Favored Glycine 0 N--CA 1.483 1.814 0 N-CA-C 108.334 -1.906 . . . . 0.0 108.334 178.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -138.47 155.04 48.8 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.532 -0.981 . . . . 0.0 108.956 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.28 174.77 29.59 Favored Glycine 0 C--N 1.292 -1.909 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -146.35 158.3 43.87 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.619 -1.632 . . . . 0.0 110.183 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.23 171.04 15.08 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -129.79 133.99 47.3 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 177.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 13.4 tt -124.27 143.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 C-N-CA 119.191 -1.003 . . . . 0.0 109.404 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.542 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.6 t -103.94 110.96 31.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.306 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.7 tp -72.73 114.17 10.57 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 103.295 -2.854 . . . . 0.0 103.295 175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -100.99 142.03 33.04 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -172.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -72.95 129.15 86.91 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 175.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -66.08 -0.74 4.37 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.207 1.271 . . . . 0.0 111.11 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.4 mt -111.13 -128.97 0.29 Allowed 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.109 -1.424 . . . . 0.0 109.522 177.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 1.633 ' CMA' ' C3A' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 14.2 tt . . . . . 0 N--CA 1.502 2.148 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -102.13 136.13 42.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.081 -1.012 . . . . 0.0 108.842 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.71 126.33 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -85.17 136.6 33.46 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 121.568 0.699 . . . . 0.0 110.833 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.39 103.17 15.02 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 177.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.54 123.16 5.07 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.184 -2.367 . . . . 0.0 107.184 -176.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.5 166.8 22.91 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.959 -1.318 . . . . 0.0 111.012 -177.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -65.65 -12.62 54.95 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.662 -1.273 . . . . 0.0 112.181 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.1 p-10 -99.43 11.89 37.87 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.91 8.19 86.17 Favored Glycine 0 N--CA 1.501 2.971 0 O-C-N 121.018 -1.051 . . . . 0.0 111.166 178.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.44 144.2 56.65 Favored 'General case' 0 N--CA 1.503 2.178 0 CA-C-N 119.425 1.613 . . . . 0.0 109.669 -178.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.592 ' CD1' HG21 ' B' ' 3' ' ' ILE . 65.6 mt -84.97 85.2 7.51 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.201 -1.562 . . . . 0.0 107.881 179.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.14 156.2 36.76 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.136 -0.977 . . . . 0.0 111.998 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.4 m-85 -86.87 136.74 32.85 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.17 108.34 15.02 Favored Pre-proline 0 N--CA 1.493 1.716 0 C-N-CA 116.572 -2.051 . . . . 0.0 110.361 -177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -76.06 167.42 80.23 Favored 'Cis proline' 0 CA--C 1.562 1.921 0 C-N-CA 124.302 -1.124 . . . . 0.0 112.552 -1.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -104.35 -22.88 13.27 Favored 'General case' 0 N--CA 1.508 2.465 0 O-C-N 120.82 -1.175 . . . . 0.0 109.966 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -128.26 122.72 32.37 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -155.86 168.22 27.9 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.776 -177.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.6 m -121.6 150.32 41.87 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.077 -1.049 . . . . 0.0 109.005 178.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.37 162.61 21.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 C-N-CA 119.782 -0.767 . . . . 0.0 109.734 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 m -89.61 164.1 30.58 Favored Pre-proline 0 C--N 1.307 -1.249 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.5 136.65 55.71 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 120.714 0.943 . . . . 0.0 114.029 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.55 -8.94 60.36 Favored Glycine 0 N--CA 1.51 3.63 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -178.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -69.24 142.61 54.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 119.988 -1.889 . . . . 0.0 107.416 -177.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -91.02 145.31 24.81 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 117.688 -1.605 . . . . 0.0 112.421 -177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -113.46 120.7 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.488 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.7 t -106.09 107.57 23.0 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 C-N-CA 118.613 -1.235 . . . . 0.0 108.506 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -87.17 123.93 32.74 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 178.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.58 131.15 53.7 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 118.035 -1.466 . . . . 0.0 111.766 -178.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -59.78 122.2 13.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -119.54 -53.21 2.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.474 -0.766 . . . . 0.0 110.519 -178.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.432 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.52 150.66 23.48 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.969 -1.082 . . . . 0.0 112.217 -178.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.71 15.16 81.81 Favored Glycine 0 N--CA 1.514 3.876 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.667 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.08 171.05 7.15 Favored Pre-proline 0 N--CA 1.514 2.769 0 O-C-N 120.267 -1.726 . . . . 0.0 108.538 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.667 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.8 Cg_endo -65.35 154.58 78.11 Favored 'Cis proline' 0 N--CA 1.494 1.553 0 C-N-CA 125.075 -0.802 . . . . 0.0 114.018 2.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.546 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -144.91 163.26 34.67 Favored 'General case' 0 N--CA 1.499 2.01 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.642 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.42 171.14 17.99 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.735 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -126.93 118.88 51.7 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 118.858 -1.137 . . . . 0.0 107.931 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.642 ' CG2' HD21 ' A' ' 38' ' ' ASN . 57.5 t -123.13 132.0 72.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.405 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 28.9 m-85 -90.02 137.18 32.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.021 -1.072 . . . . 0.0 108.857 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.8 t70 -71.45 114.72 9.82 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.552 -1.259 . . . . 0.0 109.069 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.479 ' HG3' ' HB3' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -57.57 -28.87 63.96 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.247 -0.908 . . . . 0.0 111.115 -179.666 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -93.71 4.7 53.54 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.22 -0.925 . . . . 0.0 110.722 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.613 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.7 41.92 3.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.789 -1.195 . . . . 0.0 110.982 -179.106 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.638 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.5 pt -134.42 165.75 34.38 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.714 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -56.87 142.6 92.86 Favored 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 120.969 1.113 . . . . 0.0 111.96 -179.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.0 m -55.72 136.03 51.09 Favored 'General case' 0 N--CA 1.514 2.767 0 N-CA-C 113.442 0.905 . . . . 0.0 113.442 -178.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.36 -10.86 73.03 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.714 HG21 ' HG2' ' A' ' 47' ' ' PRO . 99.1 t -79.19 132.61 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.443 0 CA-C-N 119.66 1.73 . . . . 0.0 111.128 -176.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -84.55 113.55 21.32 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.04 -24.22 65.97 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 120.845 -1.159 . . . . 0.0 111.991 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.7 p -67.11 -25.98 66.47 Favored 'General case' 0 N--CA 1.509 2.515 0 O-C-N 121.127 -0.983 . . . . 0.0 110.077 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.1 mttm -79.89 -18.25 51.1 Favored 'General case' 0 N--CA 1.513 2.682 0 O-C-N 120.878 -1.139 . . . . 0.0 112.468 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.8 pt -121.76 3.1 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.535 -0.728 . . . . 0.0 112.93 -177.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.488 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.75 164.57 22.7 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 120.581 -1.324 . . . . 0.0 113.357 -179.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 23.0 mtp -86.32 161.41 18.75 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 t -73.11 152.68 41.09 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 117.038 -1.865 . . . . 0.0 107.643 178.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.694 ' HG2' ' OD1' ' B' ' 63' ' ' ASN . 0.0 OUTLIER -59.46 -30.03 68.22 Favored 'General case' 0 C--N 1.291 -1.943 0 C-N-CA 118.887 -1.125 . . . . 0.0 111.422 -179.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -85.99 -4.61 59.21 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.199 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -92.32 145.71 24.27 Favored 'General case' 0 N--CA 1.508 2.446 0 O-C-N 120.544 -1.347 . . . . 0.0 109.44 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.3 mt -140.97 148.89 41.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.101 -0.999 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 68' ' ' GLU . 34.9 mt -100.52 110.39 22.55 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 173.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.506 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.15 13.49 16.81 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 117.393 -1.723 . . . . 0.0 114.042 -174.396 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.61 146.02 50.98 Favored 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.395 -1.441 . . . . 0.0 108.163 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.14 133.01 55.71 Favored 'General case' 0 N--CA 1.505 2.292 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.711 -179.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.36 -16.6 60.79 Favored Glycine 0 N--CA 1.5 2.922 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.395 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.408 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.6 mt-10 -63.06 142.52 58.35 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.115 1.958 . . . . 0.0 108.197 -177.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.7 p -128.93 156.89 43.02 Favored 'General case' 0 N--CA 1.496 1.838 0 C-N-CA 118.495 -1.282 . . . . 0.0 112.952 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.65 121.68 24.72 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 104.306 -2.479 . . . . 0.0 104.306 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.488 ' HG2' HG13 ' A' ' 28' ' ' VAL . 22.5 mt-10 -113.9 143.93 43.88 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.397 -177.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.0 144.12 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.717 0.77 . . . . 0.0 110.884 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.33 130.79 56.75 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 35.7 mt -106.78 142.42 36.44 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.5 p -117.77 -39.88 3.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.452 -1.405 . . . . 0.0 110.541 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 58.1 m-80 -67.08 134.18 51.33 Favored 'General case' 0 N--CA 1.509 2.501 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.189 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.33 31.83 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.408 -0.807 . . . . 0.0 111.044 -177.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.78 -173.28 21.89 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -99.33 141.63 31.86 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.088 -1.242 . . . . 0.0 110.425 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.484 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.6 m-85 -122.68 122.3 38.46 Favored 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.613 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 70.0 m -98.36 134.14 41.78 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -134.71 168.2 19.45 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.6 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -159.73 166.2 30.97 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.511 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.495 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 20.8 t -95.08 126.13 40.21 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 103.017 -2.957 . . . . 0.0 103.017 175.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.457 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 1.2 p -62.07 -48.35 88.5 Favored Pre-proline 0 N--CA 1.512 2.669 0 O-C-N 120.204 -1.56 . . . . 0.0 114.54 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.685 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -71.25 -24.19 23.43 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.869 1.712 . . . . 0.0 111.722 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.741 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 36.0 m80 -115.36 18.35 16.1 Favored 'General case' 0 N--CA 1.51 2.555 0 CA-C-N 119.491 1.042 . . . . 0.0 112.652 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.17 -41.17 92.27 Favored 'General case' 0 N--CA 1.52 3.05 0 O-C-N 120.335 -1.478 . . . . 0.0 109.331 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.71 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -64.77 -27.99 72.77 Favored Glycine 0 N--CA 1.483 1.771 0 C-N-CA 119.562 -1.304 . . . . 0.0 110.75 178.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 1.037 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.71 -12.75 61.47 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.989 -1.301 . . . . 0.0 111.515 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.66 9.43 40.64 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 -177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.5 ttt -77.8 84.71 4.11 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-N 119.809 1.805 . . . . 0.0 106.681 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.2 m -137.13 165.3 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.44 174.61 36.34 Favored Glycine 0 N--CA 1.492 2.37 0 C-N-CA 118.585 -1.769 . . . . 0.0 108.774 178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -149.05 129.48 13.86 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 118.723 1.261 . . . . 0.0 108.017 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.1 p -116.29 142.14 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 C-N-CA 119.095 -1.042 . . . . 0.0 109.45 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 52.2 m -113.36 126.7 55.65 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 118.432 -1.307 . . . . 0.0 109.491 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.9 t -96.57 115.31 35.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 178.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.9 p30 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 120.913 -1.117 . . . . 0.0 111.143 -176.85 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.981 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 11.0 m-85 . . . . . 0 C--O 1.224 -0.264 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.83 -27.27 77.65 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.531 1.487 . . . . 0.0 111.684 178.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.688 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.4 tp -71.23 -28.48 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.407 0 O-C-N 121.985 -0.447 . . . . 0.0 110.646 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 1.037 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 0.4 OUTLIER -70.27 -35.62 73.88 Favored 'General case' 0 N--CA 1.537 3.883 0 O-C-N 121.017 -1.052 . . . . 0.0 109.641 -178.391 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.416 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.1 -44.33 54.34 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.58 -46.79 88.35 Favored 'General case' 0 N--CA 1.509 2.494 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -60.68 -29.23 69.18 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 113.61 0.967 . . . . 0.0 113.61 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -140.99 26.54 2.03 Favored 'General case' 0 N--CA 1.52 3.067 0 CA-C-N 122.008 2.186 . . . . 0.0 114.106 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.416 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 91.2 m-85 -140.06 111.89 7.45 Favored 'General case' 0 N--CA 1.524 3.241 0 N-CA-C 103.369 -2.826 . . . . 0.0 103.369 174.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -66.71 -39.44 88.05 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.231 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -122.29 135.15 25.23 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 177.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.473 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.6 Cg_endo -78.27 -16.43 13.79 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.488 1.459 . . . . 0.0 112.356 -175.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -102.87 126.51 50.05 Favored 'General case' 0 N--CA 1.508 2.453 0 CA-C-N 120.104 1.32 . . . . 0.0 110.288 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -86.91 168.51 13.33 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.852 -1.155 . . . . 0.0 109.94 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 -24.92 63.96 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.067 -1.02 . . . . 0.0 111.067 -179.111 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.1 p -76.5 -14.15 60.05 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 120.808 -1.182 . . . . 0.0 109.174 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.76 59.06 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -91.06 137.9 32.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.595 0.712 . . . . 0.0 110.114 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 37.7 mt -81.14 139.13 18.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 178.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -55.76 -11.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.547 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 -176.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -70.05 -25.99 63.81 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.196 2.725 . . . . 0.0 109.064 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.91 -7.58 17.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.67 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -76.79 -29.32 55.99 Favored 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.038 -1.038 . . . . 0.0 109.052 178.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.1 m -118.31 -28.57 5.74 Favored 'General case' 0 N--CA 1.539 3.99 0 O-C-N 121.852 -0.53 . . . . 0.0 109.654 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.36 92.24 9.06 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 175.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 49.1 mt -84.57 -17.99 37.03 Favored 'General case' 0 N--CA 1.501 2.116 0 N-CA-C 115.819 1.785 . . . . 0.0 115.819 -173.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.42 140.69 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.097 2.226 . . . . 0.0 110.749 -178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 4.9 t -93.38 131.9 38.12 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.122 -0.987 . . . . 0.0 109.588 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.469 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 9.1 mttp -143.26 150.24 51.22 Favored Pre-proline 0 C--N 1.3 -1.561 0 N-CA-C 105.084 -2.191 . . . . 0.0 105.084 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.08 140.9 35.31 Favored 'Trans proline' 0 C--N 1.317 -1.102 0 N-CA-C 116.384 1.648 . . . . 0.0 116.384 -175.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.22 145.3 32.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 112.725 -2.034 . . . . 0.0 107.146 177.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -131.47 155.3 47.62 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.103 -0.998 . . . . 0.0 109.41 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.0 tt -147.6 120.31 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.538 -0.726 . . . . 0.0 110.847 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.9 mp0 -105.3 130.63 53.39 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.568 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.0 t -139.42 146.26 47.63 Favored Pre-proline 0 C--N 1.296 -1.726 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.568 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.6 Cg_endo -60.65 146.28 97.42 Favored 'Trans proline' 0 C--N 1.321 -0.92 0 O-C-N 122.653 0.817 . . . . 0.0 110.42 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.83 -37.96 80.69 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.932 -0.48 . . . . 0.0 111.048 -178.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.25 41.05 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.156 -0.617 . . . . 0.0 109.639 -179.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.4 158.93 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.74 156.29 35.35 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.851 -0.531 . . . . 0.0 109.91 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.2 Cg_endo -53.88 141.47 66.49 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.954 1.77 . . . . 0.0 112.707 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 48.58 49.18 18.85 Favored 'General case' 0 N--CA 1.514 2.733 0 CA-C-N 114.865 -1.061 . . . . 0.0 112.699 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.3 p -128.25 147.36 50.59 Favored 'General case' 0 N--CA 1.505 2.279 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 32.6 t -89.38 139.59 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.339 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.626 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.6 p90 -137.93 166.51 23.86 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.87 139.3 49.88 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 118.718 -1.193 . . . . 0.0 111.599 -178.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.61 111.48 22.51 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 6.2 p -101.5 122.57 53.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 116.769 -1.972 . . . . 0.0 110.907 -176.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.9 t -104.41 134.27 46.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.531 -0.731 . . . . 0.0 109.085 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 44.1 mttm -113.22 126.2 55.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.815 -0.754 . . . . 0.0 109.372 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.6 mt -122.94 77.07 50.08 Favored Pre-proline 0 N--CA 1.493 1.708 0 N-CA-C 104.529 -2.397 . . . . 0.0 104.529 178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.6 Cg_endo -81.61 145.18 14.49 Favored 'Trans proline' 0 N--CA 1.48 0.7 0 C-N-CA 122.482 2.122 . . . . 0.0 113.932 -174.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -160.2 154.11 22.94 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.04 178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.33 123.28 19.16 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.62 5.75 17.21 Favored 'General case' 0 N--CA 1.509 2.515 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -175.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -94.65 0.79 55.38 Favored 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.16 -1.588 . . . . 0.0 106.761 176.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 59.6 mt -75.0 134.73 41.38 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.452 -0.794 . . . . 0.0 111.53 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -120.94 127.85 52.21 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 178.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -97.67 172.21 7.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.897 -0.502 . . . . 0.0 109.786 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 18.0 t -87.56 113.7 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.412 HD13 ' N ' ' B' ' 67' ' ' GLY . 5.8 mp -70.24 166.5 19.93 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.772 -1.205 . . . . 0.0 109.396 -179.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.66 -8.23 0.54 Allowed 'General case' 0 N--CA 1.514 2.752 0 O-C-N 121.032 -1.043 . . . . 0.0 112.832 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.694 ' OD1' ' HG2' ' A' ' 59' ' ' GLU . 4.5 p30 -116.88 17.04 15.16 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 119.798 -1.814 . . . . 0.0 111.986 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.93 -30.59 7.36 Favored Glycine 1 N--CA 1.516 4.033 0 O-C-N 120.888 -1.132 . . . . 0.0 111.106 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.7 mmmm -68.99 158.9 33.82 Favored 'General case' 0 N--CA 1.511 2.623 0 O-C-N 120.63 -1.512 . . . . 0.0 110.414 -179.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -101.39 140.52 35.57 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . 0.412 ' N ' HD13 ' B' ' 61' ' ' LEU . . . -152.14 -173.38 21.7 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 119.161 -1.495 . . . . 0.0 111.934 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.42 167.19 21.69 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 122.192 -0.593 . . . . 0.0 110.863 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.443 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.33 157.45 15.97 Favored 'General case' 0 N--CA 1.5 2.069 0 CA-C-O 121.721 0.772 . . . . 0.0 112.053 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 25.4 m-80 -115.6 154.65 29.05 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 178.057 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.45 158.89 16.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.709 -1.244 . . . . 0.0 110.597 -178.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.12 157.08 27.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 178.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.35 160.27 42.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.846 -1.385 . . . . 0.0 111.775 -178.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.18 122.17 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 177.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 tp -107.37 123.97 49.13 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.299 -1.36 . . . . 0.0 109.754 -178.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.6 mt -105.19 109.47 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.639 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.485 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.7 mt -104.67 161.77 21.8 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.754 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.1 Cg_endo -65.86 158.04 55.94 Favored 'Trans proline' 0 N--CA 1.479 0.66 0 C-N-CA 121.793 1.662 . . . . 0.0 109.231 177.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.34 136.35 56.43 Favored 'General case' 0 N--CA 1.504 2.273 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.334 -178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.98 -39.73 2.78 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -177.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.754 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.52 140.95 39.84 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -154.39 170.89 20.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.384 -0.823 . . . . 0.0 110.653 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.1 tp -61.03 129.3 40.71 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.146 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.57 137.38 96.37 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 109.55 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.85 157.56 61.37 Favored 'Trans proline' 0 CA--C 1.549 1.249 0 C-N-CA 122.215 1.943 . . . . 0.0 108.944 179.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.575 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.5 Cg_endo -60.46 -38.36 74.34 Favored 'Trans proline' 0 N--CA 1.502 1.971 0 C-N-CA 123.096 2.531 . . . . 0.0 113.55 -178.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.34 -26.17 67.92 Favored 'General case' 0 N--CA 1.512 2.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.754 179.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 33.2 mmm-85 -91.09 -4.57 56.16 Favored 'General case' 0 N--CA 1.516 2.852 0 O-C-N 121.242 -0.911 . . . . 0.0 110.795 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.575 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.7 mt -88.72 122.52 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.088 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . 0.422 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 25.1 p -66.54 157.66 81.86 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.233 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.77 -36.04 14.82 Favored 'Trans proline' 0 N--CA 1.484 0.936 0 C-N-CA 122.724 2.283 . . . . 0.0 109.269 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.05 -20.04 66.05 Favored 'General case' 0 N--CA 1.511 2.586 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 177.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.422 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 26.6 ttm -97.59 -30.89 12.59 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.138 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -65.79 -30.94 71.65 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.505 -0.747 . . . . 0.0 111.2 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.82 -34.01 60.1 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 -43.11 98.78 Favored 'General case' 0 N--CA 1.51 2.56 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.341 -179.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.4 pt -78.66 7.31 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.507 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.72 -112.26 2.99 Favored Glycine 0 N--CA 1.504 3.194 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -149.6 44.01 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.699 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -78.73 148.58 32.99 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.436 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 17.2 p -111.97 107.04 15.89 Favored 'General case' 0 N--CA 1.496 1.852 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 177.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 54.0 m-85 -84.69 129.52 34.82 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.1 mm-40 -111.85 155.4 23.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.777 -177.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -80.21 145.55 32.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 44.4 t80 -58.02 -38.36 76.04 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.314 -1.491 . . . . 0.0 107.681 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 13.6 mtt85 -151.62 155.99 34.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 102.65 -3.093 . . . . 0.0 102.65 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -62.63 -25.94 75.5 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 120.36 0.706 . . . . 0.0 112.671 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -83.8 -21.13 32.22 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.563 -1.336 . . . . 0.0 109.514 178.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.8 mmtt -94.31 84.26 4.36 Favored 'General case' 0 N--CA 1.501 2.11 0 CA-C-O 121.907 0.86 . . . . 0.0 109.223 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 19.9 mttm -81.69 -8.42 59.7 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.526 -0.734 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -101.0 11.59 39.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.408 -0.808 . . . . 0.0 111.446 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.473 HG21 ' HG3' ' B' ' 12' ' ' PRO . 45.8 mt -125.65 115.48 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.394 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.7 mt -113.52 142.53 45.83 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.609 -1.236 . . . . 0.0 111.805 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 25.5 m -127.6 149.18 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 121.532 0.682 . . . . 0.0 109.827 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.699 HD11 HD22 ' B' ' 100' ' ' LEU . 12.2 tt -150.03 145.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.17 165.72 15.54 Favored Glycine 0 N--CA 1.477 1.397 0 N-CA-C 108.107 -1.997 . . . . 0.0 108.107 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.981 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 33.9 Cg_endo -73.34 135.14 38.55 Favored 'Cis proline' 0 N--CA 1.491 1.371 0 O-C-N 124.608 1.846 . . . . 0.0 113.222 -0.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.2 m -128.98 149.1 71.56 Favored Pre-proline 0 N--CA 1.5 2.052 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.14 129.54 28.97 Favored 'Trans proline' 0 CA--C 1.554 1.487 0 C-N-CA 121.39 1.393 . . . . 0.0 113.214 -177.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.85 -37.55 95.08 Favored Glycine 1 N--CA 1.521 4.306 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.801 -178.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 13.3 mm-40 -56.23 -37.02 69.16 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 120.931 -1.335 . . . . 0.0 110.029 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.3 mmmt -93.61 -37.74 11.71 Favored 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 113.963 1.097 . . . . 0.0 113.963 -177.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -117.49 50.66 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.709 -1.245 . . . . 0.0 114.041 -175.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 10.1 m -67.74 -28.84 67.97 Favored 'General case' 0 N--CA 1.516 2.846 0 O-C-N 119.994 -1.691 . . . . 0.0 106.809 176.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -117.76 126.88 53.26 Favored 'General case' 0 N--CA 1.498 1.964 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 28.0 mt -118.57 143.51 29.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.295 -178.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.8 m -110.28 116.64 31.84 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.57 -0.852 . . . . 0.0 110.099 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -99.09 118.15 63.1 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.97 109.96 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 N-CA-C 107.705 -1.69 . . . . 0.0 107.705 -177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.626 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.6 mm -110.06 143.63 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-O 121.671 0.748 . . . . 0.0 111.402 -177.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.6 tp -103.48 121.69 43.36 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.06 135.08 67.16 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.513 -0.875 . . . . 0.0 108.898 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.99 178.1 5.06 Favored 'Trans proline' 0 C--N 1.326 -0.634 0 O-C-N 123.599 1.315 . . . . 0.0 111.421 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.7 t70 -129.18 119.16 19.55 Favored Pre-proline 0 N--CA 1.495 1.795 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.435 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.9 Cg_endo -61.92 -36.28 73.06 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.325 2.017 . . . . 0.0 111.602 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.44 -19.11 64.43 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.542 -0.724 . . . . 0.0 109.718 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -120.89 20.39 11.61 Favored 'General case' 0 N--CA 1.523 3.2 0 O-C-N 120.951 -1.093 . . . . 0.0 110.936 -179.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -160.9 108.2 1.51 Allowed 'General case' 0 N--CA 1.504 2.226 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -72.93 -10.92 60.33 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.16 -1.83 28.34 Favored 'General case' 0 N--CA 1.514 2.74 0 CA-C-N 121.827 2.103 . . . . 0.0 109.713 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.5 t -98.87 130.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -129.78 167.93 17.33 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.98 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.435 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 57.9 m-85 -78.54 101.95 7.65 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 175.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 17.2 mt -154.08 177.12 11.43 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 122.111 0.958 . . . . 0.0 111.816 -174.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.52 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.55 129.38 36.7 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 106.884 -1.525 . . . . 0.0 106.884 177.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -121.0 139.04 28.59 Favored Pre-proline 0 C--N 1.305 -1.36 0 O-C-N 120.251 -1.531 . . . . 0.0 111.547 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -78.96 146.73 20.68 Favored 'Trans proline' 0 C--O 1.219 -0.449 0 C-N-CA 121.551 1.501 . . . . 0.0 111.313 178.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 60.9 mt -130.31 127.9 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.242 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.8 m-85 -117.79 141.09 48.81 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 118.649 -1.22 . . . . 0.0 110.538 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.4 p -132.8 145.16 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 122.339 1.066 . . . . 0.0 111.573 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.2 128.2 6.73 Favored Glycine 0 N--CA 1.477 1.371 0 N-CA-C 105.963 -2.855 . . . . 0.0 105.963 177.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.13 133.3 7.5 Favored Glycine 0 C--N 1.294 -1.757 0 C-N-CA 118.464 -1.826 . . . . 0.0 110.064 -178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.4 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.16 50.01 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.883 0.849 . . . . 0.0 112.521 -179.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.31 126.43 26.23 Favored 'General case' 0 N--CA 1.498 1.96 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 177.192 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.433 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.79 158.99 22.61 Favored Glycine 0 N--CA 1.479 1.504 0 C-N-CA 118.097 -2.001 . . . . 0.0 110.511 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.603 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 15.3 mtm105 -75.85 140.9 42.49 Favored 'General case' 0 N--CA 1.509 2.518 0 CA-C-O 121.811 0.815 . . . . 0.0 110.454 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 172.32 46.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.31 -30.55 12.17 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.792 -0.829 . . . . 0.0 111.76 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.6 mt -117.97 142.11 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.849 0 O-C-N 120.784 -1.197 . . . . 0.0 112.185 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.71 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 10.8 m-30 -92.31 168.13 13.44 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -59.7 -14.82 28.37 Favored 'Trans proline' 0 CA--C 1.559 1.77 0 C-N-CA 121.802 1.668 . . . . 0.0 113.744 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -95.48 -3.92 45.89 Favored 'General case' 0 N--CA 1.527 3.416 0 CA-C-N 120.37 1.441 . . . . 0.0 110.431 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.22 -9.87 54.35 Favored Glycine 0 N--CA 1.509 3.526 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -69.3 142.04 54.18 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.748 -0.854 . . . . 0.0 111.039 -176.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 49.4 mttt -81.43 154.85 26.17 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 120.061 -0.656 . . . . 0.0 109.343 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.694 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 6.7 p -99.14 179.47 4.59 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -87.61 18.12 4.18 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.031 -1.468 . . . . 0.0 109.133 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.4 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -113.02 45.74 1.32 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 6.2 t -153.75 172.35 17.45 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.046 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.7 t -77.14 142.93 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.864 -0.522 . . . . 0.0 109.994 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.99 122.29 45.55 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -103.44 152.04 22.1 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 118.181 -1.408 . . . . 0.0 111.31 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.425 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.45 46.15 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.262 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 16.5 p -83.02 -4.98 58.91 Favored 'General case' 0 N--CA 1.512 2.645 0 O-C-N 121.444 -0.785 . . . . 0.0 109.756 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.529 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.37 151.28 31.52 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.553 0.692 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.44 170.6 44.71 Favored Glycine 0 N--CA 1.482 1.764 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.34 -156.25 24.46 Favored Glycine 0 C--N 1.299 -1.482 0 C-N-CA 117.252 -2.404 . . . . 0.0 111.333 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.66 135.91 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.08 116.39 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.1 p -92.92 -18.45 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.254 -0.904 . . . . 0.0 110.443 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 12.0 ttmt -161.35 145.82 13.34 Favored 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 122.474 1.131 . . . . 0.0 113.05 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.482 HD12 ' HG3' ' B' ' 217' ' ' GLU . 68.3 mt -131.36 100.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.0 tp -88.06 108.89 19.46 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.434 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.98 120.51 20.61 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 177.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 39.2 mtmt -77.39 151.87 34.63 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.309 -174.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -50.12 -58.39 5.65 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.2 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.479 ' HB3' ' HG3' ' A' ' 43' ' ' GLU . 9.4 tptt -92.41 18.65 8.13 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 120.808 -1.183 . . . . 0.0 111.457 -177.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.32 154.45 19.27 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.413 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.28 29.26 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 -179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.477 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.8 m-85 -141.0 162.09 36.31 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 122.136 0.97 . . . . 0.0 112.203 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.57 111.02 13.87 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 105.015 -2.217 . . . . 0.0 105.015 176.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.4 HD11 HD22 ' B' ' 213' ' ' LEU . 91.9 mt -107.76 122.76 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.722 -1.236 . . . . 0.0 110.42 -176.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 13.4 m -96.08 122.87 39.37 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 33.2 mt -112.24 128.09 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 87.0 t -98.62 101.11 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -74.09 89.03 1.95 Allowed 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 106.438 -1.69 . . . . 0.0 106.438 179.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.5 -32.5 71.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.401 -0.812 . . . . 0.0 110.855 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 43.1 m -67.38 -35.36 79.17 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.684 -0.635 . . . . 0.0 111.577 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -106.35 3.85 27.94 Favored 'General case' 0 N--CA 1.515 2.817 0 O-C-N 121.651 -0.656 . . . . 0.0 110.218 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 49.94 50.85 17.72 Favored 'General case' 0 N--CA 1.507 2.384 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 23.1 ttp-105 -133.82 141.45 47.45 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.478 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -111.82 129.65 56.07 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 175' ' ' ALA . 28.4 m -129.95 147.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.557 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 52.6 mt -120.45 111.27 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.986 0.898 . . . . 0.0 109.844 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.33 128.5 38.2 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.5 mt -99.7 135.03 36.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.049 -1.06 . . . . 0.0 109.002 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.406 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.9 mt -116.84 132.2 23.54 Favored Pre-proline 0 N--CA 1.492 1.661 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.24 165.61 29.15 Favored 'Trans proline' 0 N--CA 1.486 1.073 0 C-N-CA 123.271 2.647 . . . . 0.0 111.89 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -73.9 154.29 39.47 Favored 'General case' 0 N--CA 1.511 2.602 0 CA-C-O 121.71 0.767 . . . . 0.0 112.667 -178.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.37 -6.94 61.59 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.547 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.5 142.96 46.01 Favored 'General case' 0 N--CA 1.481 1.112 0 O-C-N 122.054 -0.674 . . . . 0.0 110.027 179.0 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -110.06 139.0 45.65 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.477 HD11 ' CG ' ' B' ' 190' ' ' TYR . 18.6 mt -74.13 150.91 40.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.54 -0.725 . . . . 0.0 112.874 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.6 mt -111.47 5.26 19.45 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.523 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.02 157.11 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.068 -1.053 . . . . 0.0 113.38 -178.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -122.23 156.76 33.1 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.364 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.482 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.4 mt-10 -61.05 143.2 55.84 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.503 3.121 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.837 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -86.84 144.34 27.06 Favored 'General case' 0 N--CA 1.509 2.506 0 O-C-N 120.96 -1.318 . . . . 0.0 110.825 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.0 m -86.88 124.03 32.65 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.523 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.33 149.3 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-O 121.342 0.591 . . . . 0.0 109.712 -179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.4 mttp -102.28 161.31 13.8 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.7 tp -60.81 138.52 58.12 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.777 -1.169 . . . . 0.0 109.103 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.38 14.28 9.62 Favored 'General case' 0 N--CA 1.513 2.68 0 O-C-N 121.503 -0.748 . . . . 0.0 111.745 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.476 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.3 tt0 -76.44 125.77 87.12 Favored Pre-proline 0 N--CA 1.507 2.422 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.9 124.14 15.55 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 121.547 1.498 . . . . 0.0 110.758 -178.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.438 HD21 HG12 ' B' ' 221' ' ' ILE . 80.8 mt -98.34 -11.88 22.05 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.254 0.55 . . . . 0.0 110.155 -177.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.42 HG22 HD23 ' B' ' 213' ' ' LEU . 32.6 p -135.67 168.62 18.94 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.902 0.858 . . . . 0.0 111.532 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 34.9 m -72.88 162.18 29.81 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.795 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -91.04 107.16 19.02 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.547 ' HG3' HD21 ' B' ' 211' ' ' LEU . 48.5 Cg_endo -86.22 13.73 2.65 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.622 1.548 . . . . 0.0 112.88 -175.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 55.0 t30 -90.72 119.54 31.04 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.198 -0.939 . . . . 0.0 110.983 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 30.1 m -111.67 3.18 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.771 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.709 178.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.5 -162.93 25.3 Favored Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.23 26.03 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 -179.456 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.4 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.2 t80 -117.37 147.46 42.62 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.64 161.22 28.5 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 108.264 -1.935 . . . . 0.0 108.264 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -138.64 154.98 48.67 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.527 -0.984 . . . . 0.0 108.9 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.12 175.02 29.39 Favored Glycine 0 C--N 1.292 -1.913 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.79 158.04 43.82 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 117.816 -1.554 . . . . 0.0 110.208 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.07 171.07 15.05 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -130.04 133.81 46.97 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 177.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.1 tt -124.45 143.11 39.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.189 -1.004 . . . . 0.0 109.302 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.52 HG22 ' HG2' ' B' ' 145' ' ' LYS . 13.6 t -103.86 110.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.279 -179.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.2 tp -72.67 114.3 10.66 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 103.031 -2.952 . . . . 0.0 103.031 175.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -101.12 141.87 33.38 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 115.31 1.596 . . . . 0.0 115.31 -172.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -72.85 129.49 86.59 Favored Pre-proline 0 N--CA 1.496 1.829 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -66.23 -0.8 4.55 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 121.192 1.261 . . . . 0.0 111.328 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.6 mt -111.03 -128.84 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 117.334 -1.317 . . . . 0.0 109.374 177.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.603 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 N--CA 1.499 2.001 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' HB3' ' HE3' ' A' ' 30' ' ' LYS . 8.2 m-20 -102.21 135.97 42.88 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.139 -0.975 . . . . 0.0 109.055 179.039 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -126.66 125.94 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.3 mt -85.07 136.67 33.46 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.499 -0.751 . . . . 0.0 110.703 -178.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.44 102.68 14.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 177.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.39 123.59 5.13 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 107.379 -2.288 . . . . 0.0 107.379 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.45 166.74 22.99 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.013 -1.287 . . . . 0.0 110.638 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -65.68 -13.1 58.56 Favored 'General case' 0 N--CA 1.509 2.514 0 O-C-N 121.069 -1.02 . . . . 0.0 112.046 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 33.4 p-10 -99.38 11.72 38.32 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 177.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.58 85.82 Favored Glycine 0 N--CA 1.5 2.937 0 O-C-N 121.055 -1.028 . . . . 0.0 111.414 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 51.8 m -66.56 143.9 56.76 Favored 'General case' 0 N--CA 1.505 2.285 0 CA-C-N 119.198 1.499 . . . . 0.0 109.497 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 40.3 mt -84.79 84.55 7.65 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.369 -1.457 . . . . 0.0 108.061 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.81 156.49 37.78 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.121 -0.987 . . . . 0.0 111.797 -177.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.457 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.8 m-85 -86.97 136.84 32.78 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 60.1 t -130.76 107.24 15.44 Favored Pre-proline 0 N--CA 1.496 1.835 0 C-N-CA 117.338 -1.745 . . . . 0.0 110.601 -178.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 32.8 Cg_endo -77.43 167.48 79.17 Favored 'Cis proline' 0 CA--C 1.562 1.92 0 O-C-N 123.241 1.127 . . . . 0.0 111.915 0.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.5 p -104.23 -23.26 13.27 Favored 'General case' 0 N--CA 1.51 2.533 0 O-C-N 121.434 -0.791 . . . . 0.0 110.113 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -128.02 122.31 31.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.94 168.12 28.24 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.498 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 m -121.92 150.24 42.28 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 119.544 -0.862 . . . . 0.0 108.996 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.3 pt -141.51 162.91 20.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.452 -0.78 . . . . 0.0 109.454 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.6 m -89.78 163.23 33.44 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 106.189 -1.782 . . . . 0.0 106.189 177.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -63.21 136.62 56.8 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 121.021 1.147 . . . . 0.0 113.624 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -8.41 61.08 Favored Glycine 0 N--CA 1.503 3.162 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -68.98 141.91 54.79 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.338 -1.683 . . . . 0.0 107.676 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -90.81 144.82 25.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.346 -1.471 . . . . 0.0 112.367 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.2 mt -113.46 120.23 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 177.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.506 HG13 ' HG2' ' A' ' 71' ' ' GLU . 23.0 t -105.9 107.44 22.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 118.625 -1.23 . . . . 0.0 108.687 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -87.24 123.6 32.42 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 178.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -123.0 130.8 53.27 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 118.243 -1.383 . . . . 0.0 111.5 -177.968 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.75 121.54 11.93 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -119.15 -53.72 2.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.681 -0.637 . . . . 0.0 110.675 -177.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.421 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.13 150.45 24.0 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.068 -1.02 . . . . 0.0 111.98 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.84 15.12 81.89 Favored Glycine 0 N--CA 1.507 3.368 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.68 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -69.03 171.05 7.1 Favored Pre-proline 0 N--CA 1.512 2.656 0 O-C-N 120.649 -1.501 . . . . 0.0 108.546 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.68 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 26.5 Cg_endo -65.74 154.55 79.6 Favored 'Cis proline' 0 N--CA 1.495 1.589 0 O-C-N 122.503 0.738 . . . . 0.0 113.952 2.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -144.33 163.45 33.69 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 115.153 -0.93 . . . . 0.0 108.588 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 27.4 p-10 -151.25 171.23 17.76 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -127.44 118.4 49.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.49 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 4.4 t -124.06 130.68 73.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.425 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.2 m-85 -89.35 137.26 32.48 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.904 -1.122 . . . . 0.0 108.978 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.517 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -72.09 114.8 10.59 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.32 -179.261 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.591 ' HB2' ' HB2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.42 -29.25 67.62 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.387 -178.854 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -92.67 3.38 55.7 Favored 'General case' 0 N--CA 1.51 2.529 0 O-C-N 121.273 -0.892 . . . . 0.0 110.305 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.645 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -133.35 42.05 3.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.769 -1.207 . . . . 0.0 111.29 -178.495 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.633 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.6 pt -134.27 165.78 34.16 Favored Pre-proline 0 N--CA 1.495 1.781 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 176.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.746 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.5 Cg_endo -56.95 142.48 93.57 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 121.181 1.254 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 45.7 m -55.81 136.14 51.38 Favored 'General case' 0 N--CA 1.511 2.598 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.99 -10.53 73.65 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.746 HG21 ' HG2' ' A' ' 47' ' ' PRO . 94.5 t -79.02 132.42 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.512 0 CA-C-N 119.481 1.641 . . . . 0.0 111.089 -177.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -84.72 112.71 20.73 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.71 -24.51 66.25 Favored 'General case' 0 N--CA 1.512 2.635 0 O-C-N 120.865 -1.147 . . . . 0.0 111.877 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 26.0 p -66.88 -26.0 66.67 Favored 'General case' 0 N--CA 1.506 2.331 0 O-C-N 121.197 -0.94 . . . . 0.0 110.358 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? -79.76 -18.59 50.71 Favored 'General case' 0 N--CA 1.508 2.459 0 O-C-N 121.185 -0.947 . . . . 0.0 112.35 -178.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -121.77 3.02 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.317 0 O-C-N 121.229 -0.919 . . . . 0.0 112.817 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.49 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.5 m -128.84 164.66 22.59 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 120.201 -1.562 . . . . 0.0 112.93 -178.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.9 mtp -85.5 161.45 19.36 Favored 'General case' 0 N--CA 1.478 0.972 0 N-CA-C 106.638 -1.615 . . . . 0.0 106.638 177.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.98 152.22 41.46 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.843 -1.543 . . . . 0.0 107.372 177.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -59.01 -29.57 67.35 Favored 'General case' 0 N--CA 1.511 2.61 0 O-C-N 120.572 -1.33 . . . . 0.0 110.016 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.45 -4.5 59.18 Favored 'General case' 0 N--CA 1.506 2.352 0 C-N-CA 123.101 0.56 . . . . 0.0 111.942 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -92.22 145.83 24.19 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 120.537 -1.352 . . . . 0.0 109.33 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 61.0 mt -140.99 148.96 41.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.181 -0.949 . . . . 0.0 111.946 -178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 22.5 mt -100.46 109.85 22.0 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 100.936 -3.727 . . . . 0.0 100.936 173.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.523 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.73 13.01 17.22 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 117.4 -1.72 . . . . 0.0 114.067 -174.444 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.39 146.17 50.87 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 120.586 -1.321 . . . . 0.0 108.434 178.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.28 133.02 55.72 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.765 -0.584 . . . . 0.0 111.372 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.56 -15.92 62.25 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 120.017 -1.087 . . . . 0.0 111.245 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -62.9 142.03 58.46 Favored 'General case' 0 N--CA 1.512 2.628 0 CA-C-N 120.039 1.92 . . . . 0.0 108.263 -178.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.441 HG22 ' HB3' ' A' ' 30' ' ' LYS . 66.6 p -128.73 157.29 41.82 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.53 -1.268 . . . . 0.0 112.694 -177.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -131.59 122.03 25.38 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 104.485 -2.413 . . . . 0.0 104.485 175.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.506 ' HG2' HG13 ' A' ' 28' ' ' VAL . 27.5 mt-10 -114.05 143.48 44.69 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.512 -177.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.9 p -149.98 144.56 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-O 121.873 0.844 . . . . 0.0 110.502 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.71 130.6 56.43 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.5 mt -106.73 142.04 37.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.3 p -117.66 -40.18 3.06 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.595 -1.315 . . . . 0.0 110.774 -179.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -67.01 134.72 52.49 Favored 'General case' 0 N--CA 1.506 2.375 0 O-C-N 120.972 -1.08 . . . . 0.0 110.138 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.08 154.22 31.54 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.587 -0.696 . . . . 0.0 110.938 -178.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.47 -173.18 21.84 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -99.34 141.25 32.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.436 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.1 m-85 -122.81 121.92 37.42 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.645 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 75.5 m -98.15 134.05 41.74 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -135.23 168.34 19.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.145 -0.972 . . . . 0.0 109.627 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.456 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 19.3 p90 -160.5 166.31 29.36 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.395 -179.088 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.515 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 18.5 t -95.46 125.69 40.24 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 103.452 -2.796 . . . . 0.0 103.452 174.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.734 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 80.8 p -62.0 -47.82 90.07 Favored Pre-proline 0 N--CA 1.515 2.781 0 O-C-N 120.401 -1.437 . . . . 0.0 114.824 -175.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.734 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.51 -19.13 25.22 Favored 'Trans proline' 0 N--CA 1.497 1.733 0 C-N-CA 122.242 1.961 . . . . 0.0 112.682 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -121.4 17.74 11.38 Favored 'General case' 0 N--CA 1.509 2.511 0 O-C-N 121.45 -0.781 . . . . 0.0 112.001 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.511 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -59.37 -41.88 90.33 Favored 'General case' 0 N--CA 1.514 2.747 0 O-C-N 120.614 -1.304 . . . . 0.0 109.282 178.726 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.923 ' HA2' ' CE1' ' B' ' 160' ' ' TYR . . . -69.9 -25.68 75.29 Favored Glycine 0 C--O 1.207 -1.585 0 C-N-CA 118.885 -1.626 . . . . 0.0 109.989 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 1.064 ' O ' ' HZ ' ' B' ' 4' ' ' PHE . . . -73.79 -2.23 22.66 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 120.265 -1.726 . . . . 0.0 108.761 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.9 8.0 58.34 Favored Glycine 0 N--CA 1.481 1.679 0 O-C-N 120.49 -1.381 . . . . 0.0 109.718 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.457 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.8 ttt -77.88 84.62 4.17 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.429 HG12 ' OE1' ' A' ' 88' ' ' GLN . 18.0 m -136.85 165.16 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.57 174.58 36.45 Favored Glycine 0 N--CA 1.49 2.266 0 C-N-CA 118.906 -1.616 . . . . 0.0 109.13 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -149.01 129.72 14.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.203 -1.174 . . . . 0.0 108.158 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.9 p -116.55 142.16 31.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.173 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 35.6 m -113.54 126.23 55.07 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.106 -1.037 . . . . 0.0 109.259 179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.7 t -96.33 114.72 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 24.0 p30 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.069 -1.019 . . . . 0.0 111.176 -176.69 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.909 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 1.3 m-30 . . . . . 0 C--O 1.221 -0.411 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.96 -26.65 75.73 Favored 'Trans proline' 0 CA--C 1.539 0.761 0 C-N-CA 121.538 1.492 . . . . 0.0 110.98 177.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 5.5 tp -70.14 -31.15 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 O-C-N 121.752 -0.592 . . . . 0.0 110.315 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 1.064 ' HZ ' ' O ' ' A' ' 90' ' ' ALA . 2.3 m-30 -69.33 -33.84 73.73 Favored 'General case' 0 N--CA 1.511 2.583 0 O-C-N 121.276 -0.89 . . . . 0.0 111.52 -178.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.92 -42.93 47.38 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -61.79 -46.62 88.75 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 121.175 0.512 . . . . 0.0 109.879 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -61.09 -28.89 69.41 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 -178.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -140.86 26.37 2.07 Favored 'General case' 0 N--CA 1.518 2.947 0 CA-C-N 121.788 2.085 . . . . 0.0 114.426 -177.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -140.12 112.09 7.56 Favored 'General case' 0 N--CA 1.518 2.933 0 N-CA-C 103.157 -2.905 . . . . 0.0 103.157 174.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -66.62 -39.39 88.29 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 -175.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -122.47 135.06 25.23 Favored Pre-proline 0 C--N 1.306 -1.299 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.469 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.8 Cg_endo -77.9 -16.88 14.17 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 121.753 1.635 . . . . 0.0 112.85 -175.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.68 126.35 49.74 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 120.555 -1.341 . . . . 0.0 110.059 -179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.7 168.44 13.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.111 -0.993 . . . . 0.0 110.004 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.4 -25.16 64.05 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.344 -0.848 . . . . 0.0 111.388 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.6 p -76.17 -14.51 60.16 Favored 'General case' 0 N--CA 1.513 2.685 0 O-C-N 120.917 -1.115 . . . . 0.0 109.291 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.34 5.77 59.05 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 63.2 mtt-85 -91.3 138.1 31.85 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.352 0.596 . . . . 0.0 109.984 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 238' ' ' GLN . 25.8 mt -81.42 139.2 18.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -56.12 -10.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.26 0 N-CA-C 115.023 1.49 . . . . 0.0 115.023 -176.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 2.5 m -69.69 -26.54 64.41 Favored 'General case' 0 N--CA 1.523 3.182 0 CA-C-N 122.234 2.288 . . . . 0.0 109.474 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.82 -7.66 17.34 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.551 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -77.15 -29.11 54.43 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.029 -1.045 . . . . 0.0 109.036 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 3.7 m -118.66 -28.25 5.69 Favored 'General case' 0 N--CA 1.533 3.692 0 O-C-N 121.351 -0.843 . . . . 0.0 109.219 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -89.68 91.85 8.83 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 176.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.413 ' HB2' ' OE1' ' B' ' 158' ' ' GLN . 32.1 mt -84.7 -18.21 36.0 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -173.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.28 140.63 29.34 Favored 'General case' 0 N--CA 1.516 2.855 0 CA-C-N 121.928 2.149 . . . . 0.0 110.533 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.3 t -93.3 131.72 38.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 109.745 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.463 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 8.3 mttp -143.65 149.28 46.4 Favored Pre-proline 0 C--N 1.299 -1.608 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.43 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 31.3 Cg_endo -71.01 140.88 38.91 Favored 'Trans proline' 0 C--N 1.318 -1.027 0 N-CA-C 116.663 1.755 . . . . 0.0 116.663 -175.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.47 145.51 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-N 113.185 -1.825 . . . . 0.0 106.856 177.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.45 155.21 47.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.09 -1.006 . . . . 0.0 109.503 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.5 tt -147.51 120.66 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.45 -0.781 . . . . 0.0 110.677 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.47 130.44 53.55 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' B' ' 36' ' ' PRO . 14.3 t -139.14 146.18 48.13 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 -178.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' B' ' 35' ' ' VAL . 23.7 Cg_endo -61.09 146.43 97.65 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 N-CA-C 110.008 -0.805 . . . . 0.0 110.008 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.63 -38.35 81.1 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-O 121.167 0.508 . . . . 0.0 110.891 -177.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.78 154.32 41.24 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.558 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.5 158.82 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.58 156.63 34.98 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.744 -0.598 . . . . 0.0 109.869 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.428 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.0 Cg_endo -54.27 141.22 71.43 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 C-N-CA 122.118 1.879 . . . . 0.0 112.695 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 48.66 48.88 19.43 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-N 115.021 -0.99 . . . . 0.0 113.143 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 34.1 p -128.0 147.59 50.51 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.26 139.37 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.144 -1.023 . . . . 0.0 109.333 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.643 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.7 p90 -137.82 166.35 24.22 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.75 139.34 49.78 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.877 -1.129 . . . . 0.0 111.351 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.72 111.44 22.41 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 105.209 -2.145 . . . . 0.0 105.209 176.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 8.1 p -101.53 122.61 53.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 117.309 -1.756 . . . . 0.0 110.853 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.33 133.77 47.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm -113.28 126.28 55.22 Favored 'General case' 0 N--CA 1.487 1.39 0 CA-C-O 121.838 0.827 . . . . 0.0 109.353 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.3 mt -122.82 77.06 48.88 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 104.473 -2.417 . . . . 0.0 104.473 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.43 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.8 Cg_endo -81.47 145.15 14.68 Favored 'Trans proline' 0 N--CA 1.478 0.569 0 C-N-CA 122.508 2.138 . . . . 0.0 114.172 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -160.33 154.12 22.69 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.32 122.85 18.09 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 10.1 mtm -81.26 5.21 17.84 Favored 'General case' 0 N--CA 1.509 2.482 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 -175.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -94.4 0.55 55.52 Favored 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.242 -1.536 . . . . 0.0 106.929 176.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 49.2 mt -75.43 134.8 40.81 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.764 0.792 . . . . 0.0 111.43 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -120.8 127.75 52.24 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -97.67 171.87 8.06 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.873 -0.517 . . . . 0.0 109.732 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.429 ' HB ' HD22 ' B' ' 168' ' ' ASN . 21.8 t -87.64 113.88 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.006 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 mp -70.6 166.57 20.38 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.086 -1.009 . . . . 0.0 109.425 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.511 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -56.31 -10.34 0.88 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.367 -0.833 . . . . 0.0 112.768 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -115.21 18.98 15.93 Favored 'General case' 0 N--CA 1.508 2.469 0 O-C-N 119.924 -1.735 . . . . 0.0 112.049 -178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.51 -30.43 6.89 Favored Glycine 0 N--CA 1.513 3.802 0 O-C-N 120.74 -1.225 . . . . 0.0 111.159 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -69.09 158.87 33.98 Favored 'General case' 0 N--CA 1.51 2.557 0 O-C-N 120.934 -1.333 . . . . 0.0 110.387 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -101.49 140.27 36.0 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.93 -173.13 21.31 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.31 -1.424 . . . . 0.0 111.993 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.43 167.28 21.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 122.122 -0.634 . . . . 0.0 110.845 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.476 HD23 ' CA ' ' B' ' 155' ' ' GLY . 5.9 mp -97.33 157.53 15.93 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.435 0.636 . . . . 0.0 112.119 -178.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.1 m-80 -115.95 154.31 30.03 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.2 158.59 16.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.917 -1.115 . . . . 0.0 110.527 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.4 157.08 28.02 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 107.537 -2.225 . . . . 0.0 107.537 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.52 160.15 42.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.803 -1.41 . . . . 0.0 111.541 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 9.2 p -129.15 122.08 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 8.8 tp -107.51 123.68 48.78 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.63 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.96 109.32 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.475 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.3 mt -104.44 161.92 21.4 Favored Pre-proline 0 N--CA 1.493 1.691 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.742 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.1 Cg_endo -66.35 158.25 56.12 Favored 'Trans proline' 0 N--CA 1.48 0.69 0 C-N-CA 121.711 1.608 . . . . 0.0 109.016 177.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.44 136.19 56.16 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.631 -0.668 . . . . 0.0 109.947 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.04 -39.43 2.88 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 107.751 -2.139 . . . . 0.0 107.751 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.742 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.7 m-85 -77.7 140.85 39.59 Favored 'General case' 0 N--CA 1.504 2.266 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -154.1 171.18 19.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.481 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.3 tp -61.09 129.32 40.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.898 -0.501 . . . . 0.0 110.103 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.62 137.32 96.45 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.81 -0.556 . . . . 0.0 109.519 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -69.0 157.44 61.84 Favored 'Trans proline' 0 CA--C 1.551 1.331 0 C-N-CA 122.238 1.959 . . . . 0.0 108.986 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.4 Cg_endo -60.25 -38.38 76.23 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 123.087 2.524 . . . . 0.0 113.631 -178.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -65.41 -26.18 67.87 Favored 'General case' 0 N--CA 1.511 2.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.836 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 29.6 mmm-85 -91.0 -4.61 56.3 Favored 'General case' 0 N--CA 1.513 2.723 0 O-C-N 121.249 -0.907 . . . . 0.0 110.837 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 60.3 mt -88.97 122.65 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.153 -0.967 . . . . 0.0 109.93 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . 0.56 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 83.1 p -66.66 157.76 81.98 Favored Pre-proline 0 N--CA 1.494 1.767 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.204 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -69.03 -35.92 13.81 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 C-N-CA 122.71 2.273 . . . . 0.0 109.409 178.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.89 -20.25 66.16 Favored 'General case' 0 N--CA 1.508 2.445 0 CA-C-O 121.258 0.551 . . . . 0.0 109.522 177.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.56 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 13.4 ttm -97.49 -30.94 12.6 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.87 -30.9 71.58 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.664 -0.648 . . . . 0.0 111.096 -178.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -76.03 -33.86 59.65 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.5 -42.99 98.5 Favored 'General case' 0 N--CA 1.511 2.591 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.145 -179.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . 0.423 HG22 ' O ' ' B' ' 127' ' ' THR . 4.6 pt -78.84 7.62 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.496 0 O-C-N 122.211 -0.306 . . . . 0.0 110.339 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.27 2.99 Favored Glycine 0 N--CA 1.503 3.124 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -149.52 44.11 0.94 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.721 HD22 HD11 ' B' ' 115' ' ' ILE . 18.5 mt -78.82 149.0 32.66 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.427 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.7 p -112.1 107.08 15.88 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 177.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -84.51 129.69 34.83 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.9 mm-40 -111.96 155.55 23.54 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.431 1.11 . . . . 0.0 111.029 -178.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 25.3 m-20 -80.28 145.27 32.24 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -57.63 -38.68 75.41 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.657 -1.277 . . . . 0.0 107.722 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -151.83 155.44 33.8 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 102.751 -3.055 . . . . 0.0 102.751 176.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_endo -61.65 -26.1 79.84 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 120.72 0.947 . . . . 0.0 113.093 -178.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.06 -21.31 31.6 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.565 -1.335 . . . . 0.0 109.451 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.41 ' HB3' HD12 ' B' ' 112' ' ' ILE . 30.7 mmtt -94.38 84.52 4.38 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.796 0.808 . . . . 0.0 108.887 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 16.3 mttm -81.73 -8.5 59.7 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.544 -0.723 . . . . 0.0 109.903 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -100.99 11.55 39.41 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.149 -0.969 . . . . 0.0 111.264 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.469 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.2 mt -126.05 115.84 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 18.9 mt -113.78 142.5 45.99 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.674 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.65 149.33 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 CA-C-O 121.731 0.777 . . . . 0.0 109.541 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.721 HD11 HD22 ' B' ' 100' ' ' LEU . 11.9 tt -150.15 145.17 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.28 165.87 15.51 Favored Glycine 0 N--CA 1.48 1.567 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.909 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.29 135.05 38.1 Favored 'Cis proline' 0 N--CA 1.488 1.157 0 O-C-N 124.024 1.539 . . . . 0.0 113.35 -0.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 m -128.85 149.1 71.36 Favored Pre-proline 0 N--CA 1.497 1.883 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 177.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -61.1 129.38 28.4 Favored 'Trans proline' 0 CA--C 1.556 1.586 0 C-N-CA 121.506 1.471 . . . . 0.0 113.205 -177.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.83 -37.44 94.88 Favored Glycine 0 N--CA 1.515 3.903 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.882 -177.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -56.13 -36.97 68.84 Favored 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.007 -1.29 . . . . 0.0 110.042 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.56 -37.88 11.67 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -177.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -117.62 50.66 1.1 Allowed 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 114.265 1.209 . . . . 0.0 114.265 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 5.6 m -67.85 -28.97 68.0 Favored 'General case' 0 N--CA 1.514 2.733 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 176.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -118.1 126.8 52.97 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 176.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 15.4 mt -118.45 143.16 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.0 110.141 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . 0.423 ' O ' HG22 ' B' ' 97' ' ' ILE . 11.0 m -110.1 116.87 32.33 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.915 179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -99.15 118.84 61.96 Favored Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.6 109.83 1.84 Allowed 'Trans proline' 0 C--N 1.325 -0.687 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.643 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 12.6 mm -110.08 143.8 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 CA-C-O 121.749 0.785 . . . . 0.0 111.14 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.4 tp -103.52 122.06 44.14 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.0 135.44 67.08 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -70.25 178.08 5.25 Favored 'Trans proline' 0 C--N 1.325 -0.68 0 C-N-CA 121.456 1.438 . . . . 0.0 111.392 -178.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.428 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.9 t70 -129.38 119.21 19.37 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.421 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.2 Cg_endo -61.88 -36.09 74.49 Favored 'Trans proline' 0 N--CA 1.489 1.239 0 C-N-CA 122.399 2.066 . . . . 0.0 111.642 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.95 64.64 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.498 -0.751 . . . . 0.0 109.871 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.63 19.96 11.83 Favored 'General case' 0 N--CA 1.519 2.979 0 O-C-N 121.119 -0.988 . . . . 0.0 110.938 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -160.96 108.09 1.49 Allowed 'General case' 0 N--CA 1.503 2.225 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 178.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 78.4 mttt -73.08 -10.69 60.05 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -103.0 -2.07 28.22 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 119.753 -1.842 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.9 t -99.09 130.82 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 83.2 m-70 -129.57 167.84 17.32 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.843 -0.743 . . . . 0.0 111.031 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.421 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 55.7 m-85 -78.57 102.37 7.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 105.226 -2.139 . . . . 0.0 105.226 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 11.6 mt -154.32 177.18 11.43 Favored 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 122.112 0.958 . . . . 0.0 111.239 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.53 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.4 mttm -90.74 128.92 36.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 177.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -120.55 139.09 28.26 Favored Pre-proline 0 C--N 1.304 -1.411 0 O-C-N 120.609 -1.307 . . . . 0.0 111.547 -175.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -79.28 146.73 19.98 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 121.521 1.48 . . . . 0.0 111.193 178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 38.8 mt -130.41 128.0 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 178.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.6 m-85 -118.06 140.85 49.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.915 -1.116 . . . . 0.0 110.54 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.67 145.31 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 CA-C-O 122.428 1.109 . . . . 0.0 111.253 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.17 128.21 6.74 Favored Glycine 0 N--CA 1.48 1.569 0 N-CA-C 105.813 -2.915 . . . . 0.0 105.813 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.97 133.09 7.44 Favored Glycine 0 N--CA 1.482 1.759 0 C-N-CA 118.841 -1.647 . . . . 0.0 110.064 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.41 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.5 t-20 -132.64 144.0 50.05 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.936 0.874 . . . . 0.0 112.315 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.573 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -136.24 126.82 27.01 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.58 -1.266 . . . . 0.0 107.58 176.83 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.476 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.61 159.16 22.82 Favored Glycine 0 N--CA 1.483 1.784 0 C-N-CA 118.502 -1.808 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.7 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.4 mtm105 -76.1 141.06 42.09 Favored 'General case' 0 N--CA 1.506 2.329 0 CA-C-O 121.665 0.745 . . . . 0.0 110.421 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.17 171.98 47.85 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.438 ' CG ' ' HB ' ' B' ' 169' ' ' THR . 1.0 OUTLIER -98.87 -31.17 11.98 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.867 -0.784 . . . . 0.0 111.79 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.22 142.13 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.608 0 O-C-N 120.73 -1.231 . . . . 0.0 111.843 -177.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.923 ' CE1' ' HA2' ' A' ' 89' ' ' GLY . 38.7 m-85 -91.76 169.18 11.64 Favored Pre-proline 0 N--CA 1.49 1.561 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.707 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.2 Cg_endo -60.88 -15.22 37.01 Favored 'Trans proline' 0 CA--C 1.552 1.392 0 C-N-CA 122.617 2.212 . . . . 0.0 113.682 179.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -94.93 -4.08 47.48 Favored 'General case' 0 N--CA 1.517 2.906 0 CA-C-N 119.899 1.227 . . . . 0.0 110.204 178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 102.78 -9.76 55.48 Favored Glycine 0 N--CA 1.507 3.385 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.03 142.22 54.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.685 -0.891 . . . . 0.0 111.153 -177.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 26.2 mttt -81.5 154.0 26.53 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 160' ' ' TYR . 90.6 p -99.06 178.58 4.88 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -86.68 18.44 3.39 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 118.386 -1.326 . . . . 0.0 109.333 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.451 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -113.25 45.64 1.36 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 122.089 0.947 . . . . 0.0 108.531 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.438 ' HB ' ' CG ' ' B' ' 158' ' ' GLN . 6.2 t -153.49 172.5 17.04 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.14 142.69 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.658 -0.651 . . . . 0.0 109.841 179.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -104.93 122.28 45.48 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . 0.406 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 77.0 m-20 -103.42 151.46 22.77 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.459 -175.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.466 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.2 131.37 45.98 Favored 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 14.3 p -83.0 -4.93 58.85 Favored 'General case' 0 N--CA 1.51 2.538 0 O-C-N 121.379 -0.826 . . . . 0.0 109.753 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.54 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.33 151.52 31.89 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.686 0.755 . . . . 0.0 110.738 179.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.61 170.43 44.19 Favored Glycine 0 N--CA 1.486 2.016 0 N-CA-C 106.862 -2.495 . . . . 0.0 106.862 176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.46 -155.8 24.29 Favored Glycine 0 N--CA 1.481 1.654 0 C-N-CA 117.672 -2.204 . . . . 0.0 111.092 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 4.2 tt -121.83 136.3 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 19.8 mt -75.17 116.34 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 33.4 p -92.68 -18.6 22.79 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.332 -0.855 . . . . 0.0 110.368 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.9 ttmt -161.34 146.0 13.47 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.195 0.997 . . . . 0.0 112.529 -179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.477 HD12 ' HG3' ' B' ' 217' ' ' GLU . 69.1 mt -131.59 100.43 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 9.0 tp -88.04 109.02 19.52 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.325 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 47.6 mtt85 -75.16 120.65 20.95 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 177.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -77.27 151.72 34.94 Favored 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.174 -1.011 . . . . 0.0 113.304 -175.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -49.84 -58.08 6.1 Favored 'General case' 0 N--CA 1.505 2.317 0 CA-C-N 114.949 -1.023 . . . . 0.0 113.433 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.591 ' HB2' ' HB2' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -94.21 19.92 8.74 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.144 -0.973 . . . . 0.0 111.658 -177.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.21 154.41 19.45 Favored Glycine 0 N--CA 1.493 2.449 0 O-C-N 120.896 -1.127 . . . . 0.0 110.798 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.38 171.19 29.43 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.457 ' CG ' HD11 ' B' ' 213' ' ' LEU . 52.8 m-85 -141.44 161.92 36.73 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 122.211 1.005 . . . . 0.0 112.016 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.6 110.95 13.77 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.44 HD11 HD22 ' B' ' 213' ' ' LEU . 84.7 mt -107.45 122.83 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.789 -1.194 . . . . 0.0 110.446 -176.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 4.3 m -96.36 122.65 39.47 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 24.1 mt -111.89 128.29 68.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 59.7 t -98.8 101.21 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -74.24 89.15 2.02 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 106.114 -1.81 . . . . 0.0 106.114 179.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.46 -32.46 71.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.402 -0.811 . . . . 0.0 110.965 -177.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 36.0 m -67.45 -35.44 79.22 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.811 -0.556 . . . . 0.0 111.646 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -106.16 3.79 28.31 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 121.432 -0.793 . . . . 0.0 110.23 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 50.04 50.81 17.84 Favored 'General case' 0 N--CA 1.509 2.478 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 19.3 ttp-105 -133.76 141.62 47.58 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 114.838 -1.073 . . . . 0.0 110.248 -177.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -112.09 129.6 56.17 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.54 HG21 ' HB3' ' B' ' 175' ' ' ALA . 19.6 m -129.93 148.12 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 16.3 mt -120.61 111.39 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.855 0.836 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -92.46 128.3 38.26 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 26.0 mt -99.65 134.63 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.205 -0.934 . . . . 0.0 109.075 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.42 HD13 ' CD2' ' B' ' 213' ' ' LEU . 38.9 mt -116.66 131.92 23.64 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.12 165.57 29.4 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.132 2.555 . . . . 0.0 111.888 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -74.15 154.24 39.19 Favored 'General case' 0 N--CA 1.508 2.462 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.62 -6.75 60.96 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 107.749 -2.14 . . . . 0.0 107.749 -178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.92 142.81 46.29 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 122.02 -0.694 . . . . 0.0 109.954 179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -110.07 138.98 45.69 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.8 0.81 . . . . 0.0 109.036 178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.457 HD11 ' CG ' ' B' ' 190' ' ' TYR . 14.2 mt -74.2 150.41 40.38 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-O 121.619 0.723 . . . . 0.0 112.86 -177.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 36.4 mt -111.41 5.43 19.65 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.513 HG11 HD13 ' B' ' 221' ' ' ILE . 11.4 m -120.4 157.0 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.291 -0.964 . . . . 0.0 113.254 -177.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 39.3 m -122.05 156.95 32.45 Favored 'General case' 0 N--CA 1.497 1.897 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.359 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.477 ' HG3' HD12 ' B' ' 182' ' ' ILE . 57.6 mt-10 -61.08 143.14 55.99 Favored 'General case' 0 N--CA 1.504 2.26 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.81 -4.34 86.35 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.95 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -86.74 144.53 27.05 Favored 'General case' 0 N--CA 1.507 2.379 0 O-C-N 120.987 -1.302 . . . . 0.0 111.005 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 31.5 m -87.08 124.02 32.77 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.513 HD13 HG11 ' B' ' 215' ' ' VAL . 3.2 tp -113.22 149.37 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-O 121.363 0.602 . . . . 0.0 109.577 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 12.7 mttp -102.15 161.56 13.59 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.93 138.44 58.16 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 118.994 -1.082 . . . . 0.0 109.057 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.406 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 66.22 14.55 9.71 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.668 -0.645 . . . . 0.0 111.85 -179.671 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.459 ' HB3' HG13 ' B' ' 221' ' ' ILE . 8.4 tt0 -76.34 126.43 86.42 Favored Pre-proline 0 N--CA 1.507 2.389 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 178.057 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -56.57 124.3 15.92 Favored 'Trans proline' 0 N--CA 1.483 0.856 0 C-N-CA 121.509 1.472 . . . . 0.0 110.557 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.466 HD11 ' HA ' ' B' ' 173' ' ' ALA . 70.3 mt -98.19 -11.98 22.16 Favored 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.42 0.628 . . . . 0.0 109.951 -177.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 17.4 p -135.66 168.71 18.76 Favored 'General case' 0 N--CA 1.494 1.768 0 CA-C-O 122.012 0.91 . . . . 0.0 111.023 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.54 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 25.8 m -72.74 162.42 29.5 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.749 178.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -91.02 107.21 19.35 Favored Pre-proline 0 N--CA 1.495 1.819 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' B' ' 229' ' ' SER . 46.3 Cg_endo -85.85 13.29 2.79 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 121.744 1.629 . . . . 0.0 112.807 -175.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -90.39 119.2 30.48 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.153 -0.967 . . . . 0.0 111.05 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.5 3.07 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.658 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.667 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.22 -162.89 25.54 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.42 164.2 25.75 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 120.333 -0.937 . . . . 0.0 110.765 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.41 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.4 t80 -117.41 147.75 42.4 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.58 161.34 28.51 Favored Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 178.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.414 ' HB3' HD12 ' B' ' 19' ' ' ILE . 15.6 pt20 -138.3 155.21 48.8 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.437 -1.037 . . . . 0.0 108.984 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.27 174.68 29.61 Favored Glycine 0 C--N 1.29 -1.987 0 N-CA-C 108.252 -1.939 . . . . 0.0 108.252 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.61 157.87 43.8 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 118.197 -1.401 . . . . 0.0 110.275 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.36 170.63 15.76 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -130.05 133.87 47.0 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.3 tt -124.39 143.14 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.15 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.53 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.91 31.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.109 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.0 tp -72.83 113.97 10.45 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 175.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -100.9 142.18 32.74 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -72.95 129.82 85.95 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 175.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -66.33 -1.05 4.91 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.328 1.352 . . . . 0.0 111.389 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.1 mt -111.14 -128.83 0.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 117.386 -1.293 . . . . 0.0 109.196 177.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.888 HBD2 ' HA3' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.6 tt . . . . . 0 N--CA 1.502 2.161 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -102.07 136.23 42.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.115 -0.991 . . . . 0.0 108.765 179.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 93.0 t -126.79 126.48 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.4 mt -85.49 136.64 33.34 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-O 121.654 0.74 . . . . 0.0 110.79 -178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 15.1 mt -95.43 103.33 15.19 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.109 -2.182 . . . . 0.0 105.109 177.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.48 123.1 5.04 Favored Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.109 -2.396 . . . . 0.0 107.109 -176.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.521 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.52 166.96 22.66 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.064 -1.256 . . . . 0.0 111.055 -177.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -65.76 -12.51 54.55 Favored 'General case' 0 N--CA 1.513 2.708 0 O-C-N 120.619 -1.301 . . . . 0.0 112.244 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.0 p-10 -99.37 11.98 37.61 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 177.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.93 8.09 86.3 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.048 -1.032 . . . . 0.0 111.183 178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.521 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.39 144.24 56.65 Favored 'General case' 0 N--CA 1.503 2.2 0 CA-C-N 119.462 1.631 . . . . 0.0 109.52 -178.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.593 HD11 HG21 ' B' ' 3' ' ' ILE . 85.7 mt -84.99 85.18 7.51 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.257 -1.527 . . . . 0.0 107.67 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.26 156.29 36.76 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.14 -0.975 . . . . 0.0 111.882 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 77.5 m-85 -86.99 136.86 32.77 Favored 'General case' 0 N--CA 1.482 1.125 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 61.4 t -131.27 108.15 14.87 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 116.346 -2.141 . . . . 0.0 110.347 -177.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 36.3 Cg_endo -76.5 167.63 79.53 Favored 'Cis proline' 0 CA--C 1.567 2.168 0 C-N-CA 124.293 -1.128 . . . . 0.0 112.031 -0.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.9 p -104.57 -22.89 13.19 Favored 'General case' 0 N--CA 1.509 2.501 0 O-C-N 120.873 -1.142 . . . . 0.0 109.9 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -128.07 122.77 32.92 Favored 'General case' 0 N--CA 1.493 1.725 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 178.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -155.83 168.31 27.62 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.903 -177.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 45.4 m -121.57 150.39 41.73 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 119.085 -1.046 . . . . 0.0 108.963 178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.9 pt -141.36 162.4 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.699 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.2 m -89.69 163.87 31.24 Favored Pre-proline 0 C--N 1.308 -1.2 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.41 136.74 56.51 Favored 'Trans proline' 0 CA--C 1.558 1.682 0 C-N-CA 120.707 0.938 . . . . 0.0 114.015 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.74 -9.19 60.16 Favored Glycine 0 N--CA 1.51 3.568 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -178.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.6 tt0 -69.19 142.69 54.23 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 119.969 -1.9 . . . . 0.0 107.392 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.9 ttmm -90.9 145.25 24.89 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 117.683 -1.607 . . . . 0.0 112.36 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.6 mt -113.67 120.64 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 177.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 71' ' ' GLU . 32.7 t -106.06 107.6 23.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 C-N-CA 118.751 -1.18 . . . . 0.0 108.549 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -87.24 124.16 33.02 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 105.929 -1.878 . . . . 0.0 105.929 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.42 131.29 53.8 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 118.165 -1.414 . . . . 0.0 111.733 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.24 122.43 14.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 32.6 t30 -119.51 -53.32 2.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.448 -0.783 . . . . 0.0 110.593 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.427 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.53 150.79 23.58 Favored 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.234 -178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.61 15.09 81.84 Favored Glycine 0 N--CA 1.515 3.922 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.673 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.2 p90 -68.96 170.99 7.13 Favored Pre-proline 0 N--CA 1.513 2.719 0 O-C-N 120.281 -1.717 . . . . 0.0 108.43 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.673 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.4 Cg_endo -65.84 154.84 80.05 Favored 'Cis proline' 0 N--CA 1.494 1.552 0 C-N-CA 125.045 -0.815 . . . . 0.0 113.847 2.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -145.43 163.2 35.36 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.559 HD21 ' CG2' ' A' ' 40' ' ' VAL . 2.6 p-10 -151.73 172.02 16.77 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.55 119.06 51.06 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.096 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 38' ' ' ASN . 69.9 t -123.39 132.31 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -90.09 137.21 32.53 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.06 -1.056 . . . . 0.0 108.87 179.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 2.4 t70 -71.47 114.84 9.97 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.998 -178.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.506 ' OE2' ' HB3' ' B' ' 187' ' ' LYS . 2.7 pt-20 -57.36 -29.04 63.7 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.174 -0.954 . . . . 0.0 111.002 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -93.81 4.6 53.69 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.357 -0.839 . . . . 0.0 110.808 -179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.644 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.67 41.97 3.0 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.864 -1.147 . . . . 0.0 110.88 -179.018 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -134.48 165.65 35.13 Favored Pre-proline 0 N--CA 1.495 1.794 0 N-CA-C 105.19 -2.152 . . . . 0.0 105.19 177.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.7 Cg_endo -56.86 142.7 92.75 Favored 'Trans proline' 0 C--N 1.318 -1.03 0 C-N-CA 120.946 1.097 . . . . 0.0 111.903 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.7 m -55.86 136.09 51.64 Favored 'General case' 0 N--CA 1.514 2.771 0 N-CA-C 113.474 0.916 . . . . 0.0 113.474 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.9 72.97 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.736 HG21 ' HG2' ' A' ' 47' ' ' PRO . 98.0 t -79.22 132.54 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.488 0 CA-C-N 119.595 1.698 . . . . 0.0 111.031 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -84.44 113.49 21.23 Favored 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 118.49 -1.284 . . . . 0.0 107.574 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.92 -24.29 66.07 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 120.894 -1.129 . . . . 0.0 111.984 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 86.7 p -67.14 -25.97 66.44 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 121.079 -1.013 . . . . 0.0 110.051 178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.4 mtpm? -79.86 -18.11 51.54 Favored 'General case' 0 N--CA 1.513 2.716 0 O-C-N 120.829 -1.17 . . . . 0.0 112.565 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.2 pt -121.94 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.418 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.1 m -128.98 164.37 23.33 Favored 'General case' 0 N--CA 1.51 2.556 0 O-C-N 120.708 -1.245 . . . . 0.0 113.38 -179.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 mtp -85.63 161.02 19.45 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.4 t -72.68 152.46 41.69 Favored 'General case' 0 CA--C 1.485 -1.533 0 C-N-CA 116.449 -2.1 . . . . 0.0 105.668 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.885 ' HB3' ' HB3' ' B' ' 63' ' ' ASN . 0.3 OUTLIER -63.2 -28.62 70.17 Favored 'General case' 0 C--N 1.25 -3.753 0 C-N-CA 119.044 -1.062 . . . . 0.0 112.073 -178.186 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.421 ' OE1' ' HG3' ' B' ' 65' ' ' LYS . 0.8 OUTLIER -85.94 -3.84 59.02 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.576 179.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -91.98 145.57 24.43 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.932 -1.105 . . . . 0.0 109.355 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 81.2 mt -141.13 148.98 40.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.891 -178.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.7 110.48 22.59 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 100.915 -3.735 . . . . 0.0 100.915 173.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.0 OUTLIER -115.15 13.51 16.82 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 117.443 -1.703 . . . . 0.0 114.016 -174.344 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.74 146.11 50.99 Favored 'General case' 0 N--CA 1.51 2.545 0 O-C-N 120.376 -1.452 . . . . 0.0 108.141 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -59.18 133.07 55.76 Favored 'General case' 0 N--CA 1.505 2.306 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.71 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.43 -16.74 60.53 Favored Glycine 0 N--CA 1.501 3.008 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.348 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -62.96 142.54 58.31 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-N 120.041 1.92 . . . . 0.0 108.103 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 68.9 p -129.07 156.87 43.16 Favored 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 118.321 -1.352 . . . . 0.0 112.752 -177.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -131.65 121.97 25.2 Favored 'General case' 0 N--CA 1.485 1.294 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 175.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 28' ' ' VAL . 18.6 mt-10 -113.91 143.91 43.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.364 -177.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.92 144.16 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.642 0.734 . . . . 0.0 110.863 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.32 130.84 56.79 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 38.4 mt -106.86 142.39 36.56 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 p -117.79 -39.9 3.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.472 -1.393 . . . . 0.0 110.472 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -66.99 134.14 51.35 Favored 'General case' 0 N--CA 1.509 2.476 0 C-N-CA 119.538 -0.865 . . . . 0.0 110.233 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.98 154.38 31.59 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 110.985 -177.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.32 21.87 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.008 -1.568 . . . . 0.0 109.187 179.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -99.39 141.7 31.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.062 -1.257 . . . . 0.0 110.412 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.488 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 20.9 m-85 -122.78 122.3 38.36 Favored 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.644 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 57.8 m -98.24 134.33 41.43 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -134.68 168.07 19.69 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.215 -0.994 . . . . 0.0 109.395 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -159.53 165.99 31.79 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.229 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.49 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 17.0 t -94.95 126.13 40.08 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 85' ' ' SER . 1.4 p -61.51 -49.36 87.44 Favored Pre-proline 0 N--CA 1.51 2.527 0 O-C-N 120.351 -1.468 . . . . 0.0 114.542 -175.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.56 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.4 Cg_endo -71.28 -20.27 28.2 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.434 2.089 . . . . 0.0 112.516 -179.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.473 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -119.91 17.66 12.57 Favored 'General case' 0 N--CA 1.509 2.481 0 CA-C-N 118.86 0.754 . . . . 0.0 112.004 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.3 -41.18 88.39 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.624 -1.298 . . . . 0.0 107.934 177.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 1.094 ' O ' ' HD2' ' B' ' 161' ' ' PRO . . . -62.99 -37.42 94.93 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 118.21 -1.948 . . . . 0.0 110.445 178.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 1.112 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.88 -8.56 22.8 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.242 -1.74 . . . . 0.0 112.871 -177.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.51 41.78 Favored Glycine 0 C--N 1.302 -1.333 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -178.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.6 ttt -78.02 84.92 4.26 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 119.711 1.755 . . . . 0.0 106.842 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.6 m -137.15 165.34 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -178.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.41 174.61 36.32 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 118.584 -1.769 . . . . 0.0 108.816 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.7 ttpp -148.9 129.76 14.26 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 118.738 1.269 . . . . 0.0 108.002 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.446 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.1 p -116.49 142.11 31.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.304 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.6 m -113.26 126.83 55.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 118.412 -1.315 . . . . 0.0 109.507 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.2 t -96.64 115.34 35.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 25.2 p30 . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.136 -176.875 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.93 ' HD2' ' CZ ' ' B' ' 4' ' ' PHE . 24.1 m-85 . . . . . 0 C--O 1.223 -0.304 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -57.63 -26.89 74.75 Favored 'Trans proline' 0 N--CA 1.483 0.892 0 C-N-CA 121.433 1.422 . . . . 0.0 111.429 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.664 HG23 ' CD1' ' B' ' 4' ' ' PHE . 4.6 tp -71.11 -29.84 38.31 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.342 0 O-C-N 122.055 -0.403 . . . . 0.0 110.485 178.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 1.112 ' CZ ' ' HB2' ' A' ' 90' ' ' ALA . 2.1 m-30 -68.62 -36.0 78.05 Favored 'General case' 0 N--CA 1.53 3.547 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -178.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -74.49 -44.09 52.99 Favored 'General case' 0 N--CA 1.501 2.077 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.79 -46.43 89.58 Favored 'General case' 0 N--CA 1.508 2.453 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.95 -29.01 69.38 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.09 26.34 2.03 Favored 'General case' 0 N--CA 1.521 3.085 0 CA-C-N 122.097 2.226 . . . . 0.0 114.012 -177.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.432 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 93.7 m-85 -139.93 111.81 7.45 Favored 'General case' 0 N--CA 1.524 3.257 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 174.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.63 -39.28 88.22 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.319 -175.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -122.33 135.17 25.26 Favored Pre-proline 0 C--N 1.304 -1.379 0 N-CA-C 104.763 -2.31 . . . . 0.0 104.763 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.48 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.5 Cg_endo -78.09 -16.94 13.82 Favored 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 121.546 1.497 . . . . 0.0 112.302 -175.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -102.59 126.35 49.63 Favored 'General case' 0 N--CA 1.508 2.425 0 CA-C-N 120.058 1.299 . . . . 0.0 110.522 -179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -86.72 168.5 13.49 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.818 -1.176 . . . . 0.0 110.025 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.54 -24.86 64.04 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 120.997 -1.064 . . . . 0.0 110.987 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.7 p -76.56 -14.15 60.03 Favored 'General case' 0 N--CA 1.516 2.865 0 O-C-N 120.844 -1.16 . . . . 0.0 109.234 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.49 5.71 58.88 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 23.0 mtt-85 -91.04 137.91 32.0 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.605 0.717 . . . . 0.0 110.239 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.89 139.4 18.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.03 -11.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -177.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.11 -25.94 63.73 Favored 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 123.213 2.733 . . . . 0.0 109.117 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.07 -7.4 17.27 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.648 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 72.8 m-20 -76.83 -29.4 55.91 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.052 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.13 -28.79 5.75 Favored 'General case' 1 N--CA 1.54 4.044 0 O-C-N 121.958 -0.464 . . . . 0.0 109.751 177.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -89.27 92.39 9.14 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 104.828 -2.286 . . . . 0.0 104.828 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 51.6 mt -84.86 -17.83 36.73 Favored 'General case' 0 N--CA 1.503 2.203 0 N-CA-C 115.693 1.738 . . . . 0.0 115.693 -173.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.54 140.67 29.28 Favored 'General case' 0 N--CA 1.521 3.094 0 CA-C-N 122.189 2.268 . . . . 0.0 110.792 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.6 t -93.36 131.94 38.06 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.206 -0.934 . . . . 0.0 109.652 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.47 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.8 mttp -143.2 150.2 51.33 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.099 -2.186 . . . . 0.0 105.099 178.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.441 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.3 Cg_endo -72.33 140.79 34.29 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 116.495 1.69 . . . . 0.0 116.495 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 95.6 t -124.87 145.49 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 CA-C-N 112.649 -2.069 . . . . 0.0 107.16 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.9 t70 -131.56 155.35 47.64 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.149 -0.97 . . . . 0.0 109.376 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.2 tt -147.69 120.36 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 C-N-CA 119.853 -0.739 . . . . 0.0 110.753 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.461 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.2 mp0 -105.39 130.77 53.42 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.551 HG13 ' HD2' ' B' ' 36' ' ' PRO . 2.6 t -139.39 146.63 49.29 Favored Pre-proline 0 C--N 1.297 -1.714 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.551 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -61.03 146.32 97.89 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 O-C-N 122.751 0.869 . . . . 0.0 110.319 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.8 -37.95 80.59 Favored 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.807 -0.558 . . . . 0.0 111.023 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.93 154.34 41.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.124 -0.631 . . . . 0.0 109.587 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 10.7 m -139.6 158.93 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.432 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.87 156.26 35.36 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.944 -0.473 . . . . 0.0 110.015 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.408 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.9 Cg_endo -53.8 141.53 65.4 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 122.004 1.803 . . . . 0.0 112.619 179.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 48.45 49.17 18.54 Favored 'General case' 0 N--CA 1.513 2.685 0 CA-C-N 114.858 -1.065 . . . . 0.0 112.734 -179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 28.1 p -128.22 147.3 50.57 Favored 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 176.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t -89.13 139.63 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.432 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.636 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.1 p90 -137.94 166.41 24.12 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.7 139.34 49.75 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 118.635 -1.226 . . . . 0.0 111.657 -178.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.5 111.36 22.32 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 4.6 p -101.43 122.53 53.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 116.688 -2.005 . . . . 0.0 111.018 -176.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 50.9 t -104.34 134.26 46.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 C-N-CA 119.938 -0.705 . . . . 0.0 109.136 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 44.1 mttm -113.16 126.31 55.29 Favored 'General case' 0 N--CA 1.488 1.427 0 C-N-CA 119.736 -0.785 . . . . 0.0 109.358 179.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 17.4 mt -122.99 76.99 50.56 Favored Pre-proline 0 N--CA 1.494 1.754 0 N-CA-C 104.546 -2.39 . . . . 0.0 104.546 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 35.1 Cg_endo -81.52 145.24 14.65 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 122.418 2.079 . . . . 0.0 113.978 -174.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 29.9 p90 -160.2 153.96 22.72 Favored 'General case' 0 N--CA 1.508 2.434 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.039 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -65.18 123.19 18.88 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.1 mtm -81.61 5.81 17.01 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 114.873 1.434 . . . . 0.0 114.873 -175.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -94.58 0.77 55.45 Favored 'General case' 0 N--CA 1.509 2.512 0 O-C-N 120.18 -1.575 . . . . 0.0 106.794 176.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.407 HD23 ' HA ' ' B' ' 57' ' ' LEU . 62.5 mt -75.19 134.64 41.16 Favored 'General case' 0 N--CA 1.492 1.625 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.581 -178.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -120.82 127.97 52.42 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 120.39 -0.524 . . . . 0.0 109.744 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.0 t -87.54 113.55 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.8 mp -69.65 165.93 20.18 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 109.21 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 85' ' ' SER . . . -55.05 -3.97 0.06 Allowed 'General case' 0 N--CA 1.517 2.898 0 O-C-N 120.909 -1.119 . . . . 0.0 112.416 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.885 ' HB3' ' HB3' ' A' ' 59' ' ' GLU . 1.1 p30 -122.7 15.14 10.19 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 118.441 -1.304 . . . . 0.0 114.468 -176.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.6 -32.64 6.1 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -179.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.421 ' HG3' ' OE1' ' A' ' 60' ' ' GLU . 2.6 mmmm -69.78 158.79 34.79 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-N 119.665 1.733 . . . . 0.0 110.63 -178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.9 mttm -101.23 140.37 35.62 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.86 -173.36 21.49 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.079 -1.534 . . . . 0.0 111.944 -179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.48 167.24 21.59 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.226 0.536 . . . . 0.0 110.789 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.448 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.2 mp -97.61 157.42 16.04 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-O 121.8 0.809 . . . . 0.0 112.063 -178.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.525 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 27.3 m-80 -115.42 154.58 28.99 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.0 16.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.594 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 107.641 -2.183 . . . . 0.0 107.641 178.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.34 160.22 42.64 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.205 -1.398 . . . . 0.0 111.753 -178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.19 122.11 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.19 124.02 49.12 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.199 -1.4 . . . . 0.0 109.979 -178.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.411 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.1 mt -105.08 109.51 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.083 -1.047 . . . . 0.0 108.718 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.4 mt -104.74 161.72 21.95 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.942 -0.474 . . . . 0.0 109.757 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.743 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.7 Cg_endo -66.08 158.02 56.61 Favored 'Trans proline' 0 N--CA 1.479 0.657 0 C-N-CA 121.703 1.602 . . . . 0.0 109.204 177.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -65.15 136.27 56.48 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.39 -178.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.67 2.8 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.743 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.8 m-85 -77.7 140.79 39.58 Favored 'General case' 0 N--CA 1.504 2.242 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -154.3 170.9 20.19 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.438 -0.789 . . . . 0.0 110.642 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 9.3 tp -60.96 129.58 42.14 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.226 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.68 137.41 96.55 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.609 -0.682 . . . . 0.0 109.538 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.83 157.64 61.06 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.204 1.936 . . . . 0.0 108.914 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.537 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.2 Cg_endo -60.54 -38.3 74.08 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 123.09 2.527 . . . . 0.0 113.551 -178.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -65.39 -25.97 67.79 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.283 -0.886 . . . . 0.0 110.822 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 35.4 mmm-85 -91.32 -4.5 55.76 Favored 'General case' 0 N--CA 1.517 2.877 0 O-C-N 121.305 -0.872 . . . . 0.0 110.703 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' B' ' 86' ' ' PRO . 67.8 mt -88.72 122.69 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.073 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 19.9 p -66.6 157.64 82.2 Favored Pre-proline 0 N--CA 1.496 1.859 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.19 179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -68.84 -35.83 14.89 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.684 2.256 . . . . 0.0 109.205 178.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -66.27 -19.99 65.98 Favored 'General case' 0 N--CA 1.512 2.663 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 26.0 ttm -97.61 -30.77 12.66 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -65.93 -30.92 71.58 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.518 -0.738 . . . . 0.0 111.154 -178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -75.88 -33.8 59.97 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.84 98.37 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.323 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.521 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.8 -112.3 3.04 Favored Glycine 0 N--CA 1.504 3.21 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -149.63 44.04 0.93 Allowed 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.724 HD22 HD11 ' B' ' 115' ' ' ILE . 19.0 mt -78.82 148.65 32.79 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.381 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 13.6 p -112.01 106.94 15.74 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -84.59 129.45 34.84 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -111.88 155.31 23.85 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 118.681 -1.207 . . . . 0.0 111.894 -177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.13 145.58 32.28 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 117.98 -1.488 . . . . 0.0 107.092 178.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -57.97 -38.62 76.38 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.294 -1.504 . . . . 0.0 107.546 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.3 mtt85 -151.47 156.0 34.58 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 176.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -62.6 -25.71 75.54 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 CA-C-N 118.818 0.614 . . . . 0.0 112.75 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -84.07 -20.85 31.94 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.583 -1.323 . . . . 0.0 109.487 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.0 mmtt -94.42 84.25 4.32 Favored 'General case' 0 N--CA 1.5 2.057 0 CA-C-O 121.933 0.873 . . . . 0.0 109.366 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 18.8 mttm -81.59 -8.55 59.73 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -101.04 11.65 39.18 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 111.402 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.48 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.2 mt -125.52 115.63 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.401 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 177.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.3 mt -113.77 142.5 45.98 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.849 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.54 149.21 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.86 178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.724 HD11 HD22 ' B' ' 100' ' ' LEU . 12.0 tt -149.96 145.47 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.13 165.98 15.65 Favored Glycine 0 N--CA 1.477 1.425 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.851 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.8 Cg_endo -73.23 134.92 37.5 Favored 'Cis proline' 0 N--CA 1.491 1.336 0 O-C-N 124.66 1.874 . . . . 0.0 113.198 -0.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.7 m -128.75 149.14 71.31 Favored Pre-proline 0 N--CA 1.503 2.209 0 N-CA-C 105.504 -2.035 . . . . 0.0 105.504 177.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.15 129.63 29.29 Favored 'Trans proline' 0 CA--C 1.552 1.42 0 C-N-CA 121.329 1.353 . . . . 0.0 113.213 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.91 -37.54 95.08 Favored Glycine 1 N--CA 1.521 4.346 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.733 -177.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 15.3 mm-40 -56.24 -36.95 69.1 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.107 -1.231 . . . . 0.0 110.029 -179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.77 -37.7 11.65 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 113.866 1.062 . . . . 0.0 113.866 -177.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -117.49 50.65 1.09 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.7 -1.25 . . . . 0.0 114.019 -175.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 21.3 m -67.69 -29.09 68.28 Favored 'General case' 0 N--CA 1.516 2.858 0 O-C-N 119.894 -1.754 . . . . 0.0 106.783 176.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -117.46 126.93 53.46 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.411 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.7 mt -118.29 143.56 28.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.423 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 19.1 m -110.27 116.62 31.81 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.14 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -99.12 118.16 63.04 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.25 109.99 1.95 Allowed 'Trans proline' 0 N--CA 1.452 -0.943 0 N-CA-C 107.644 -1.714 . . . . 0.0 107.644 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.636 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.0 mm -110.16 143.72 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.252 0 CA-C-O 121.625 0.726 . . . . 0.0 111.419 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.75 43.47 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.97 135.04 67.51 Favored Pre-proline 0 N--CA 1.482 1.153 0 C-N-CA 119.443 -0.903 . . . . 0.0 108.94 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.484 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.21 4.89 Favored 'Trans proline' 0 C--N 1.326 -0.616 0 O-C-N 123.652 1.343 . . . . 0.0 111.418 -178.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 14.1 t70 -129.34 119.09 19.37 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.43 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.8 Cg_endo -61.89 -36.11 74.3 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 122.267 1.978 . . . . 0.0 111.646 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.69 -18.89 64.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.492 -0.755 . . . . 0.0 109.657 177.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.3 m -120.93 20.16 11.62 Favored 'General case' 0 N--CA 1.523 3.207 0 O-C-N 121.029 -1.044 . . . . 0.0 110.868 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -160.87 108.24 1.52 Allowed 'General case' 0 N--CA 1.504 2.25 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -72.89 -10.82 60.22 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -177.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.22 -1.88 28.17 Favored 'General case' 0 N--CA 1.513 2.716 0 CA-C-N 121.99 2.177 . . . . 0.0 109.72 179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.484 HG11 ' HG2' ' B' ' 133' ' ' PRO . 46.4 t -98.93 130.54 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 177.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -129.72 167.86 17.39 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.694 -0.803 . . . . 0.0 110.924 -178.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.43 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 64.5 m-85 -78.4 101.94 7.51 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 175.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.0 mt -154.36 177.12 11.5 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.83 -175.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.52 129.22 36.7 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 177.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 47.1 m-85 -120.95 139.12 28.66 Favored Pre-proline 0 C--N 1.306 -1.31 0 C-N-CA 117.774 -1.57 . . . . 0.0 111.573 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.96 146.92 20.83 Favored 'Trans proline' 0 C--O 1.219 -0.433 0 C-N-CA 121.417 1.411 . . . . 0.0 111.337 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 66.5 mt -130.43 127.98 63.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.411 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 90.6 m-85 -117.88 140.99 48.93 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 118.515 -1.274 . . . . 0.0 110.51 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.76 145.15 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 122.348 1.071 . . . . 0.0 111.558 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.13 128.27 6.77 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 105.991 -2.844 . . . . 0.0 105.991 177.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.11 133.29 7.5 Favored Glycine 0 C--N 1.294 -1.75 0 C-N-CA 118.412 -1.852 . . . . 0.0 110.119 -178.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.407 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 21.4 t-20 -132.9 144.25 50.04 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.905 0.859 . . . . 0.0 112.449 -179.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.23 126.46 26.43 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.157 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.448 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.87 159.0 22.54 Favored Glycine 0 N--CA 1.477 1.418 0 C-N-CA 118.028 -2.034 . . . . 0.0 110.4 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.574 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.0 mtm105 -75.84 140.83 42.45 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 121.764 0.792 . . . . 0.0 110.546 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.69 172.39 45.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.8 mp0 -99.48 -30.57 12.09 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.774 -0.839 . . . . 0.0 111.651 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 19.5 mt -118.4 143.14 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.514 2.751 0 CA-C-O 122.607 1.194 . . . . 0.0 112.305 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.819 ' CG ' ' HA2' ' A' ' 89' ' ' GLY . 12.2 m-30 -92.23 166.59 16.91 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 179.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 1.094 ' HD2' ' O ' ' A' ' 89' ' ' GLY . 19.4 Cg_endo -59.31 -15.26 28.44 Favored 'Trans proline' 0 CA--C 1.558 1.699 0 C-N-CA 121.936 1.757 . . . . 0.0 113.099 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -95.23 -4.17 46.3 Favored 'General case' 0 N--CA 1.528 3.47 0 CA-C-N 120.633 1.561 . . . . 0.0 110.407 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.13 -10.0 54.75 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.5 m -69.31 142.09 54.14 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.793 -0.828 . . . . 0.0 111.059 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 45.4 mttt -81.69 155.22 25.67 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.705 178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.624 ' HB3' ' CE1' ' B' ' 160' ' ' TYR . 9.9 p -99.38 178.57 4.85 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 -87.09 17.55 4.16 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 117.865 -1.534 . . . . 0.0 108.817 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.401 ' O ' ' HG3' ' B' ' 158' ' ' GLN . 4.7 t-20 -112.96 45.85 1.3 Allowed 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.428 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.75 172.35 17.44 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.058 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 59.5 t -77.15 142.85 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.958 -0.464 . . . . 0.0 109.996 179.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -105.04 122.29 45.57 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -103.39 152.12 21.97 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.078 -1.449 . . . . 0.0 111.393 -175.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.458 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.43 46.12 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.5 p -82.96 -5.23 58.98 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.474 -0.766 . . . . 0.0 109.703 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.506 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.26 151.39 31.77 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.487 0.66 . . . . 0.0 111.15 179.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.55 170.39 44.26 Favored Glycine 0 N--CA 1.482 1.756 0 N-CA-C 107.241 -2.344 . . . . 0.0 107.241 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.38 -156.41 24.57 Favored Glycine 0 C--N 1.3 -1.438 0 C-N-CA 117.25 -2.405 . . . . 0.0 111.265 -178.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.6 tt -121.42 136.11 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 34.9 mt -75.02 116.41 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 C-N-CA 118.874 -1.13 . . . . 0.0 108.206 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.87 -18.49 22.75 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.205 -0.935 . . . . 0.0 110.494 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.7 ttmt -161.34 145.85 13.38 Favored 'General case' 0 N--CA 1.503 2.205 0 CA-C-O 122.488 1.137 . . . . 0.0 113.145 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.426 HD12 ' HG3' ' B' ' 217' ' ' GLU . 72.8 mt -131.34 100.34 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 13.1 tp -88.01 109.28 19.71 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.466 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -75.04 120.55 20.71 Favored 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 177.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.8 mtmt -77.3 151.9 34.81 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 118.937 -1.105 . . . . 0.0 113.263 -175.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -50.2 -58.33 5.84 Favored 'General case' 0 N--CA 1.511 2.594 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.137 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.506 ' HB3' ' OE2' ' A' ' 43' ' ' GLU . 10.2 tptt -92.64 18.77 8.22 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.779 -1.201 . . . . 0.0 111.251 -177.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.4 154.34 19.07 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.376 -1.392 . . . . 0.0 110.513 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.53 171.36 29.27 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.838 -1.705 . . . . 0.0 108.838 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 63.3 m-85 -141.29 162.02 36.48 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 122.068 0.937 . . . . 0.0 112.202 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -126.54 110.96 13.82 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.079 -2.193 . . . . 0.0 105.079 176.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 90.6 mt -107.61 122.78 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.789 -1.194 . . . . 0.0 110.491 -176.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 18.8 m -96.1 122.83 39.35 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 37.8 mt -111.97 128.31 68.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.1 t -98.7 100.99 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -73.93 88.91 1.86 Allowed 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.47 -32.48 71.44 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.447 -0.783 . . . . 0.0 110.828 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 49.7 m -67.52 -35.19 78.62 Favored 'General case' 0 N--CA 1.508 2.44 0 O-C-N 121.681 -0.637 . . . . 0.0 111.48 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.9 m-80 -106.34 3.7 27.8 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.764 -0.585 . . . . 0.0 110.358 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 50.05 50.7 18.05 Favored 'General case' 0 N--CA 1.507 2.386 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -133.78 141.52 47.52 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -111.98 129.42 56.2 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.506 HG21 ' HB3' ' B' ' 175' ' ' ALA . 34.3 m -129.64 148.06 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.599 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 63.6 mt -120.4 111.31 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 121.952 0.882 . . . . 0.0 109.922 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -92.34 128.46 38.2 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 29.3 mt -99.47 135.02 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.007 -1.077 . . . . 0.0 109.145 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.442 HD13 ' CD2' ' B' ' 213' ' ' LEU . 46.8 mt -116.73 132.39 23.42 Favored Pre-proline 0 N--CA 1.493 1.682 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.32 165.64 28.99 Favored 'Trans proline' 0 N--CA 1.486 1.066 0 C-N-CA 123.194 2.596 . . . . 0.0 111.858 -179.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 11.9 ptm180 -73.73 154.23 39.7 Favored 'General case' 0 N--CA 1.512 2.655 0 CA-C-O 121.721 0.772 . . . . 0.0 112.648 -178.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.3 -6.85 61.68 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.572 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.83 142.83 46.24 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 122.078 -0.66 . . . . 0.0 110.073 178.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -109.96 138.97 45.58 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.709 0.766 . . . . 0.0 109.078 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 20.5 mt -74.28 150.69 40.09 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.129 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 59.3 mt -111.66 5.59 19.38 Favored 'General case' 0 N--CA 1.496 1.863 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.527 HG11 HD13 ' B' ' 221' ' ' ILE . 11.2 m -120.14 157.13 22.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.037 -1.065 . . . . 0.0 113.272 -178.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 57.8 m -122.28 156.83 33.02 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.301 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.426 ' HG3' HD12 ' B' ' 182' ' ' ILE . 82.2 mt-10 -60.97 143.17 55.73 Favored 'General case' 0 N--CA 1.501 2.121 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.8 -4.39 86.31 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.977 -1.106 . . . . 0.0 110.798 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -86.81 144.25 27.12 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.986 -1.302 . . . . 0.0 110.825 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.5 m -86.96 124.08 32.77 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.527 HD13 HG11 ' B' ' 215' ' ' VAL . 2.9 tp -113.32 149.49 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-O 121.308 0.575 . . . . 0.0 109.626 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 21.5 mttp -102.49 161.37 13.77 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 14.3 tp -60.77 138.99 58.06 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.058 -179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.12 14.26 9.54 Favored 'General case' 0 N--CA 1.511 2.622 0 O-C-N 121.523 -0.736 . . . . 0.0 111.745 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.485 ' HB3' HG13 ' B' ' 221' ' ' ILE . 13.6 tt0 -76.46 125.75 87.12 Favored Pre-proline 0 N--CA 1.506 2.345 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 177.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -55.96 124.26 15.84 Favored 'Trans proline' 0 N--CA 1.482 0.848 0 C-N-CA 121.504 1.469 . . . . 0.0 110.755 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.473 HD21 HG12 ' B' ' 221' ' ' ILE . 78.2 mt -98.76 -11.56 21.77 Favored 'General case' 0 N--CA 1.508 2.449 0 CA-C-O 121.319 0.58 . . . . 0.0 110.26 -177.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.474 HG22 HD23 ' B' ' 213' ' ' LEU . 34.3 p -135.78 168.36 19.44 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.999 0.904 . . . . 0.0 111.334 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 37.4 m -72.8 162.16 29.83 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.748 178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -91.06 107.25 19.73 Favored Pre-proline 0 N--CA 1.491 1.582 0 N-CA-C 105.553 -2.018 . . . . 0.0 105.553 177.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.572 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.4 Cg_endo -86.09 13.43 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.622 0 C-N-CA 121.561 1.507 . . . . 0.0 112.844 -175.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -90.51 119.39 30.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.213 -0.929 . . . . 0.0 111.133 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.7 m -111.54 3.13 8.67 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.828 0 CA-C-N 115.723 -0.672 . . . . 0.0 109.719 178.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.51 -162.93 25.29 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.433 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.65 164.24 26.03 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.5 t80 -117.3 147.45 42.57 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.63 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.282 -1.927 . . . . 0.0 108.282 178.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -138.57 155.03 48.71 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.604 -0.939 . . . . 0.0 108.897 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.21 174.98 29.48 Favored Glycine 0 C--N 1.292 -1.868 0 N-CA-C 108.348 -1.901 . . . . 0.0 108.348 -179.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.67 158.09 43.84 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.724 -1.591 . . . . 0.0 110.236 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.16 171.02 15.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 178.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -129.92 133.89 47.14 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 14.5 tt -124.46 142.95 39.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.158 -1.017 . . . . 0.0 109.341 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.5 t -103.81 110.97 31.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.314 -179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.4 tp -72.7 114.19 10.56 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 103.178 -2.897 . . . . 0.0 103.178 175.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 30.3 tt0 -101.22 142.26 32.91 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 115.298 1.592 . . . . 0.0 115.298 -172.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -72.88 129.38 86.69 Favored Pre-proline 0 N--CA 1.496 1.833 0 N-CA-C 105.976 -1.861 . . . . 0.0 105.976 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -66.17 -0.86 4.55 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.266 1.311 . . . . 0.0 111.204 -177.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.1 mt -111.12 -128.9 0.29 Allowed 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 176.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 117.264 -1.351 . . . . 0.0 109.515 177.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.574 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.3 tt . . . . . 0 N--CA 1.503 2.183 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.15 136.29 42.25 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 119.207 -0.997 . . . . 0.0 108.732 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 80.4 t -126.72 126.53 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.6 mt -85.54 136.56 33.36 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.636 0.731 . . . . 0.0 110.748 -178.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.45 103.38 15.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 177.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.5 123.05 5.04 Favored Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.41 166.89 22.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.085 -1.244 . . . . 0.0 111.166 -177.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -65.74 -12.43 53.76 Favored 'General case' 0 N--CA 1.513 2.724 0 O-C-N 120.621 -1.3 . . . . 0.0 112.218 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.9 p-10 -99.54 12.13 37.3 Favored 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 177.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.97 8.0 86.4 Favored Glycine 0 N--CA 1.501 3.023 0 O-C-N 121.088 -1.007 . . . . 0.0 111.098 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.528 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 5.0 m -66.3 144.28 56.68 Favored 'General case' 0 N--CA 1.504 2.23 0 CA-C-N 119.499 1.649 . . . . 0.0 109.438 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.6 mt -84.98 85.13 7.51 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.324 -1.485 . . . . 0.0 107.511 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.34 156.27 36.61 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.105 -0.997 . . . . 0.0 111.779 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 78.0 m-85 -87.04 136.88 32.76 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.077 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 58.2 t -131.23 107.97 14.9 Favored Pre-proline 0 N--CA 1.491 1.59 0 C-N-CA 116.405 -2.118 . . . . 0.0 110.338 -177.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 33.9 Cg_endo -77.13 167.59 79.32 Favored 'Cis proline' 0 CA--C 1.572 2.382 0 C-N-CA 124.275 -1.136 . . . . 0.0 111.724 -0.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.7 p -104.39 -23.03 13.23 Favored 'General case' 0 N--CA 1.509 2.505 0 O-C-N 120.923 -1.11 . . . . 0.0 109.874 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -127.98 122.85 33.35 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.78 168.43 27.2 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.859 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 44.3 m -121.71 150.39 41.86 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.068 -1.053 . . . . 0.0 108.886 178.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 6.3 pt -141.42 162.35 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.9 -0.72 . . . . 0.0 109.754 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.9 m -89.52 163.84 31.82 Favored Pre-proline 0 C--N 1.308 -1.23 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 177.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -63.31 136.66 56.55 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 120.744 0.963 . . . . 0.0 114.025 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.76 -9.3 59.92 Favored Glycine 0 N--CA 1.508 3.474 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -178.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -69.17 142.77 54.23 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 120.035 -1.862 . . . . 0.0 107.364 -177.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.7 ttmm -90.96 145.32 24.81 Favored 'General case' 0 N--CA 1.496 1.848 0 C-N-CA 117.601 -1.64 . . . . 0.0 112.4 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.7 mt -113.62 120.83 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.475 HG13 ' HG2' ' A' ' 71' ' ' GLU . 30.2 t -106.2 107.68 23.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 118.762 -1.175 . . . . 0.0 108.483 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -87.25 124.14 33.0 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 105.869 -1.901 . . . . 0.0 105.869 178.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.52 131.26 53.76 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 118.171 -1.412 . . . . 0.0 111.682 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -60.27 122.48 14.61 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -119.48 -53.26 2.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.397 -0.814 . . . . 0.0 110.678 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.437 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.58 150.9 23.59 Favored 'General case' 0 N--CA 1.504 2.227 0 C-N-CA 119.243 -0.983 . . . . 0.0 112.28 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.59 15.05 81.86 Favored Glycine 0 N--CA 1.515 3.955 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.678 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.4 p90 -69.0 170.89 7.44 Favored Pre-proline 0 N--CA 1.513 2.709 0 O-C-N 120.303 -1.704 . . . . 0.0 108.457 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.678 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.1 Cg_endo -65.59 154.98 79.06 Favored 'Cis proline' 0 N--CA 1.496 1.671 0 C-N-CA 125.085 -0.798 . . . . 0.0 113.783 2.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.544 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.7 m-70 -145.55 163.18 35.55 Favored 'General case' 0 N--CA 1.5 2.055 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 19.0 p-10 -151.29 171.84 16.82 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -127.68 119.06 50.82 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 C-N-CA 118.572 -1.251 . . . . 0.0 107.748 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.494 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 38.2 t -123.91 131.54 72.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -89.37 137.73 32.06 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.108 -1.037 . . . . 0.0 109.235 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 3.3 t70 -72.17 115.5 11.49 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.511 -1.275 . . . . 0.0 108.368 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.718 ' HG3' ' HG2' ' B' ' 187' ' ' LYS . 0.0 OUTLIER -59.64 -28.39 67.19 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.455 -179.268 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -94.07 4.21 54.22 Favored 'General case' 0 N--CA 1.504 2.229 0 O-C-N 121.398 -0.814 . . . . 0.0 110.245 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.632 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.53 41.99 3.02 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.957 -1.089 . . . . 0.0 111.0 -178.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.648 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 7.2 pt -134.44 165.63 35.28 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 105.156 -2.164 . . . . 0.0 105.156 177.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.695 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.8 Cg_endo -56.98 142.61 93.85 Favored 'Trans proline' 0 C--N 1.318 -1.061 0 C-N-CA 120.902 1.068 . . . . 0.0 111.853 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 34.3 m -55.61 136.08 50.64 Favored 'General case' 0 N--CA 1.515 2.791 0 N-CA-C 113.559 0.948 . . . . 0.0 113.559 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.43 -10.94 72.87 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.695 HG21 ' HG2' ' A' ' 47' ' ' PRO . 90.6 t -79.21 132.65 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.447 0 CA-C-N 119.576 1.688 . . . . 0.0 111.01 -175.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -84.62 113.47 21.29 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.12 -24.1 65.88 Favored 'General case' 0 N--CA 1.51 2.532 0 O-C-N 120.927 -1.108 . . . . 0.0 112.146 -179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 88.7 p -67.04 -25.94 66.51 Favored 'General case' 0 N--CA 1.511 2.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.912 178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -79.76 -18.13 51.8 Favored 'General case' 0 N--CA 1.514 2.735 0 O-C-N 120.896 -1.128 . . . . 0.0 112.618 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.8 pt -121.93 3.17 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.357 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 0.9 OUTLIER -129.1 164.47 23.23 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.852 -1.155 . . . . 0.0 113.494 -179.174 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 32.6 mtp -86.12 161.76 18.73 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -72.8 153.65 41.0 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 116.852 -1.939 . . . . 0.0 107.911 178.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.419 ' HG3' ' H ' ' A' ' 59' ' ' GLU . 0.8 OUTLIER -60.37 -29.06 68.68 Favored 'General case' 0 N--CA 1.503 2.19 0 C-N-CA 118.636 -1.226 . . . . 0.0 110.42 -179.44 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -86.27 -4.92 59.26 Favored 'General case' 0 N--CA 1.507 2.408 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.87 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -92.37 146.13 23.93 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 120.378 -1.451 . . . . 0.0 109.379 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 79.1 mt -141.28 149.0 40.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.079 -1.013 . . . . 0.0 111.763 -178.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.7 mt -100.85 110.43 22.49 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 100.908 -3.738 . . . . 0.0 100.908 173.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -115.13 13.68 16.87 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 117.468 -1.693 . . . . 0.0 114.063 -174.341 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.79 146.17 50.99 Favored 'General case' 0 N--CA 1.511 2.592 0 O-C-N 120.315 -1.491 . . . . 0.0 108.036 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -59.24 133.21 55.89 Favored 'General case' 0 N--CA 1.506 2.335 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.64 -179.239 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.47 -16.87 60.29 Favored Glycine 0 N--CA 1.501 3.011 0 C-N-CA 119.616 -1.278 . . . . 0.0 110.326 179.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -62.94 142.6 58.26 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 120.019 1.91 . . . . 0.0 108.09 -177.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 63.4 p -129.18 156.81 43.33 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 118.359 -1.336 . . . . 0.0 112.731 -177.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -131.68 122.04 25.29 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 104.089 -2.56 . . . . 0.0 104.089 175.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.475 ' HG2' HG13 ' A' ' 28' ' ' VAL . 21.8 mt-10 -114.02 143.83 44.11 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.355 -177.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 144.29 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-O 121.614 0.721 . . . . 0.0 110.829 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.49 130.81 56.68 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 177.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 37.2 mt -106.85 142.47 36.43 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 p -117.78 -39.91 3.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.405 -1.434 . . . . 0.0 110.419 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -67.05 133.93 50.87 Favored 'General case' 0 N--CA 1.509 2.479 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.249 -179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.88 154.4 31.77 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.346 -0.846 . . . . 0.0 111.058 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.79 -173.23 21.92 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.976 -1.583 . . . . 0.0 109.174 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -99.49 141.64 32.01 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.104 -1.233 . . . . 0.0 110.388 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.489 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.5 m-85 -122.64 122.31 38.52 Favored 'General case' 0 N--CA 1.498 1.957 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.632 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 67.2 m -98.14 134.35 41.32 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 178.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -134.63 168.26 19.32 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.298 -0.961 . . . . 0.0 109.346 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -159.87 165.91 31.29 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.167 -1.013 . . . . 0.0 111.205 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.4 t -95.04 126.22 40.23 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 103.024 -2.954 . . . . 0.0 103.024 175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.985 ' O ' ' HB3' ' B' ' 62' ' ' ALA . 6.2 p -62.09 -47.86 89.56 Favored Pre-proline 0 N--CA 1.512 2.633 0 O-C-N 120.357 -1.464 . . . . 0.0 114.896 -175.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.598 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.2 Cg_endo -72.27 -18.86 26.35 Favored 'Trans proline' 0 N--CA 1.505 2.157 0 C-N-CA 122.309 2.006 . . . . 0.0 112.768 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -121.02 18.12 11.69 Favored 'General case' 0 N--CA 1.509 2.484 0 CA-C-N 118.632 0.651 . . . . 0.0 112.442 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.985 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -60.42 -42.99 97.18 Favored 'General case' 0 N--CA 1.52 3.057 0 O-C-N 120.534 -1.354 . . . . 0.0 109.437 177.815 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.947 ' HA2' ' CZ ' ' B' ' 160' ' ' TYR . . . -64.66 -28.52 73.38 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 178.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.772 ' HB1' ' HZ ' ' B' ' 4' ' ' PHE . . . -72.9 -8.89 57.7 Favored 'General case' 0 C--N 1.309 -1.175 0 O-C-N 120.107 -1.819 . . . . 0.0 111.045 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.59 8.67 45.62 Favored Glycine 0 N--CA 1.484 1.851 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.467 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.9 ttt -78.05 85.15 4.27 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 119.381 1.591 . . . . 0.0 106.806 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.23 165.41 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.65 36.41 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 118.465 -1.826 . . . . 0.0 108.761 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 27.6 ttpp -148.88 129.8 14.32 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 118.77 1.285 . . . . 0.0 108.021 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.8 p -116.39 142.18 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.323 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 54.6 m -113.39 126.8 55.76 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.481 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.0 t -96.56 115.43 35.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.483 1.219 0 O-C-N 120.912 -1.117 . . . . 0.0 111.227 -176.899 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.69 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 39.4 m-85 . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.85 -26.11 72.44 Favored 'Trans proline' 0 N--CA 1.483 0.873 0 C-N-CA 121.074 1.182 . . . . 0.0 111.336 178.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.7 tp -70.75 -31.46 45.93 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.372 0 O-C-N 121.995 -0.441 . . . . 0.0 110.369 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.772 ' HZ ' ' HB1' ' A' ' 90' ' ' ALA . 10.4 m-85 -68.07 -34.79 77.1 Favored 'General case' 0 N--CA 1.521 3.09 0 O-C-N 121.449 -0.782 . . . . 0.0 111.035 -178.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -75.41 -43.48 49.77 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -61.74 -46.71 88.44 Favored 'General case' 0 N--CA 1.51 2.564 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -60.84 -28.96 69.21 Favored 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -141.07 26.21 2.04 Favored 'General case' 0 N--CA 1.52 3.058 0 CA-C-N 122.097 2.226 . . . . 0.0 113.988 -177.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 94.1 m-85 -139.82 111.67 7.4 Favored 'General case' 0 N--CA 1.523 3.213 0 N-CA-C 103.615 -2.735 . . . . 0.0 103.615 174.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -66.49 -39.22 88.62 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.419 -175.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -122.42 135.22 25.35 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 177.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.2 Cg_endo -78.23 -16.79 13.66 Favored 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 121.468 1.446 . . . . 0.0 112.278 -175.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.9 ttp180 -102.6 126.37 49.66 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-N 120.143 1.338 . . . . 0.0 110.601 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -86.64 168.66 13.41 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.88 -1.138 . . . . 0.0 110.037 -178.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.84 -24.58 64.33 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.006 -1.059 . . . . 0.0 110.899 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.0 p -76.64 -14.26 59.99 Favored 'General case' 0 N--CA 1.516 2.845 0 O-C-N 120.893 -1.129 . . . . 0.0 109.15 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.51 5.73 58.86 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 35.8 mtt-85 -91.05 137.84 32.06 Favored 'General case' 0 N--CA 1.494 1.742 0 CA-C-O 121.611 0.72 . . . . 0.0 110.178 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 43.1 mt -80.85 139.47 18.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.1 m -56.16 -11.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.592 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 -176.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.12 -25.94 63.72 Favored 'General case' 0 N--CA 1.524 3.256 0 CA-C-N 123.319 2.781 . . . . 0.0 109.122 178.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.11 -7.39 17.39 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.0 m-20 -76.88 -29.41 55.77 Favored 'General case' 0 N--CA 1.505 2.321 0 O-C-N 121.062 -1.024 . . . . 0.0 109.05 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.7 m -117.87 -29.03 5.78 Favored 'General case' 1 N--CA 1.54 4.065 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 177.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -89.19 92.41 9.18 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 104.939 -2.245 . . . . 0.0 104.939 175.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 53.1 mt -84.81 -17.94 36.52 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 115.646 1.721 . . . . 0.0 115.646 -173.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.44 140.63 29.34 Favored 'General case' 0 N--CA 1.521 3.117 0 CA-C-N 122.229 2.286 . . . . 0.0 110.885 -178.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.1 t -93.31 131.83 38.08 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.237 -0.914 . . . . 0.0 109.736 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.471 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.2 mttp -143.01 150.27 52.24 Favored Pre-proline 0 C--N 1.299 -1.604 0 N-CA-C 105.154 -2.165 . . . . 0.0 105.154 178.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.7 Cg_endo -72.19 140.94 35.01 Favored 'Trans proline' 0 C--N 1.317 -1.093 0 N-CA-C 116.528 1.703 . . . . 0.0 116.528 -175.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 89.5 t -124.98 145.46 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.094 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 3.2 t70 -131.58 155.29 47.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.169 -0.957 . . . . 0.0 109.339 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 tt -147.68 120.29 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 CA-C-O 121.671 0.748 . . . . 0.0 110.786 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.46 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.7 mp0 -105.33 130.7 53.39 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.586 HG13 ' HD2' ' B' ' 36' ' ' PRO . 3.4 t -139.28 146.79 50.33 Favored Pre-proline 0 C--N 1.298 -1.657 0 N-CA-C 105.99 -1.856 . . . . 0.0 105.99 -179.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.586 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.2 Cg_endo -61.21 146.26 97.67 Favored 'Trans proline' 0 C--N 1.321 -0.887 0 O-C-N 122.783 0.886 . . . . 0.0 110.319 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -59.67 -38.11 80.62 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.852 -0.53 . . . . 0.0 111.071 -178.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.84 154.44 41.33 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.602 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.7 m -139.65 158.81 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.427 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.55 156.17 35.52 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 120.564 -0.454 . . . . 0.0 109.995 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.407 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 17.8 Cg_endo -54.07 141.64 68.06 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 121.824 1.683 . . . . 0.0 112.556 179.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 48.69 48.91 19.45 Favored 'General case' 0 N--CA 1.514 2.753 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.786 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 29.1 p -128.25 147.21 50.58 Favored 'General case' 0 N--CA 1.505 2.322 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 176.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 39.2 t -88.94 139.66 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 118.723 -1.191 . . . . 0.0 109.539 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.627 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -137.94 166.31 24.37 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.61 139.27 49.76 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 118.617 -1.233 . . . . 0.0 111.743 -178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.43 111.28 22.21 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 105.881 -1.896 . . . . 0.0 105.881 176.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.46 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 5.4 p -101.31 122.41 53.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 116.705 -1.998 . . . . 0.0 111.088 -176.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.2 134.37 45.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.55 -0.719 . . . . 0.0 109.161 -179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.415 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 47.4 mttm -113.23 126.3 55.27 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.721 -0.792 . . . . 0.0 109.347 178.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.99 76.9 50.49 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 104.539 -2.393 . . . . 0.0 104.539 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.54 145.34 14.67 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.35 2.033 . . . . 0.0 113.985 -174.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -160.18 154.11 22.97 Favored 'General case' 0 N--CA 1.508 2.435 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.022 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -65.28 123.04 18.51 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.6 mtm -81.26 5.55 16.79 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 120.335 -1.478 . . . . 0.0 114.804 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -94.57 0.84 55.53 Favored 'General case' 0 N--CA 1.51 2.542 0 O-C-N 120.142 -1.598 . . . . 0.0 106.905 176.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 60.7 mt -75.07 134.68 41.31 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.543 -178.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 45.7 mttm -120.93 127.97 52.33 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 178.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -97.75 172.27 7.79 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 120.367 -0.533 . . . . 0.0 109.709 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.4 t -87.52 113.4 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -70.01 166.44 19.67 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.827 -1.171 . . . . 0.0 109.309 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.985 ' HB3' ' O ' ' A' ' 85' ' ' SER . . . -58.0 -8.06 0.93 Allowed 'General case' 0 N--CA 1.51 2.527 0 O-C-N 120.995 -1.066 . . . . 0.0 112.226 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -115.33 18.15 16.21 Favored 'General case' 0 N--CA 1.511 2.598 0 O-C-N 119.725 -1.859 . . . . 0.0 111.681 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.99 -30.39 7.13 Favored Glycine 1 N--CA 1.521 4.352 0 O-C-N 120.703 -1.248 . . . . 0.0 110.723 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 mmmm -69.06 158.79 34.1 Favored 'General case' 0 N--CA 1.511 2.58 0 O-C-N 120.94 -1.329 . . . . 0.0 110.377 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.7 mttm -101.53 140.33 35.97 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.91 -173.35 21.52 Favored Glycine 0 N--CA 1.492 2.417 0 C-N-CA 118.996 -1.573 . . . . 0.0 111.893 -179.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.39 167.24 21.63 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-O 121.204 0.526 . . . . 0.0 110.842 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.4 mp -97.66 157.25 16.15 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 121.832 0.825 . . . . 0.0 112.038 -178.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.525 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 26.6 m-80 -115.34 154.6 28.86 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.28 159.04 16.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 C-N-CA 118.691 -1.203 . . . . 0.0 110.602 -178.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.22 157.02 27.93 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.594 -2.202 . . . . 0.0 107.594 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.32 160.25 42.66 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 118.152 -1.419 . . . . 0.0 111.807 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.18 122.05 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.1 tp -107.19 124.04 49.15 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 118.131 -1.428 . . . . 0.0 110.004 -178.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 15.7 mt -105.09 109.47 27.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.764 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.8 mt -104.73 161.73 21.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.744 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 28.5 Cg_endo -66.08 157.95 56.97 Favored 'Trans proline' 0 N--CA 1.48 0.683 0 C-N-CA 121.635 1.557 . . . . 0.0 109.183 177.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.04 136.36 56.67 Favored 'General case' 0 N--CA 1.506 2.348 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.471 -178.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.96 -39.78 2.76 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.64 -2.184 . . . . 0.0 107.64 -177.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.744 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.1 m-85 -77.62 140.71 39.68 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -154.22 170.92 20.1 Favored 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 119.764 -0.775 . . . . 0.0 110.646 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.4 tp -60.88 129.44 41.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.351 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.53 137.36 96.32 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.618 -0.676 . . . . 0.0 109.612 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.8 157.54 61.45 Favored 'Trans proline' 0 CA--C 1.548 1.213 0 C-N-CA 122.182 1.922 . . . . 0.0 108.953 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.544 ' HA ' HD12 ' B' ' 89' ' ' ILE . 22.8 Cg_endo -60.52 -38.18 75.14 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 123.035 2.49 . . . . 0.0 113.633 -178.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.53 -25.84 67.62 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.269 -0.894 . . . . 0.0 110.725 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 32.6 mmm-85 -91.41 -4.54 55.55 Favored 'General case' 0 N--CA 1.517 2.888 0 O-C-N 121.282 -0.886 . . . . 0.0 110.659 -179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.544 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.71 122.66 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 C-N-CA 119.251 -0.98 . . . . 0.0 110.099 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 17.8 p -66.66 157.69 82.3 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.974 -0.453 . . . . 0.0 110.112 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -68.9 -35.67 14.95 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.618 2.212 . . . . 0.0 109.218 178.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 -20.01 65.94 Favored 'General case' 0 N--CA 1.512 2.671 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 27.2 ttm -97.53 -30.78 12.68 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.07 -30.8 71.38 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.5 -0.75 . . . . 0.0 111.163 -178.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -75.87 -33.81 60.0 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.29 -43.16 98.68 Favored 'General case' 0 N--CA 1.509 2.493 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.312 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.9 pt -78.74 7.34 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.53 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.68 -112.24 2.96 Favored Glycine 0 N--CA 1.503 3.159 0 O-C-N 121.22 -0.925 . . . . 0.0 110.814 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -149.58 43.92 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.676 HD22 HD11 ' B' ' 115' ' ' ILE . 18.6 mt -78.72 148.59 33.0 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.452 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 22.6 p -112.01 106.87 15.66 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -84.48 129.36 34.87 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.503 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -111.96 155.17 24.17 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.972 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -80.03 145.54 32.44 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 117.964 -1.494 . . . . 0.0 107.13 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -57.95 -38.77 76.61 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.331 -1.48 . . . . 0.0 107.517 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 14.2 mtt85 -151.28 156.06 34.88 Favored Pre-proline 0 C--N 1.295 -1.766 0 N-CA-C 102.753 -3.054 . . . . 0.0 102.753 176.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -62.64 -25.59 75.35 Favored 'Trans proline' 0 C--N 1.315 -1.237 0 CA-C-N 118.764 0.594 . . . . 0.0 112.757 -178.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -84.0 -21.2 31.76 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.677 -1.265 . . . . 0.0 109.479 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.9 mmtt -94.32 84.13 4.33 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 122.024 0.916 . . . . 0.0 109.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 21.1 mttm -81.43 -8.7 59.77 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 121.551 -0.718 . . . . 0.0 110.07 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -100.9 11.72 39.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.439 -0.788 . . . . 0.0 111.501 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.475 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -125.52 115.58 43.89 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.382 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.9 mt -113.68 142.51 45.93 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 118.475 -1.29 . . . . 0.0 111.835 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 24.6 m -127.53 149.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.844 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.676 HD11 HD22 ' B' ' 100' ' ' LEU . 13.4 tt -149.73 145.69 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.73 166.0 15.96 Favored Glycine 0 N--CA 1.479 1.543 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.69 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 29.9 Cg_endo -73.48 134.79 36.96 Favored 'Cis proline' 0 N--CA 1.49 1.292 0 O-C-N 124.671 1.879 . . . . 0.0 113.255 -0.173 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -128.44 149.1 70.69 Favored Pre-proline 0 N--CA 1.504 2.263 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.17 129.71 29.56 Favored 'Trans proline' 0 CA--C 1.552 1.408 0 C-N-CA 121.329 1.352 . . . . 0.0 113.137 -176.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.98 -37.58 95.2 Favored Glycine 1 N--CA 1.521 4.325 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.737 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -56.29 -36.87 69.13 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.059 -1.26 . . . . 0.0 110.012 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -93.8 -37.75 11.61 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -117.47 50.67 1.09 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 120.753 -1.217 . . . . 0.0 114.063 -175.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 27.5 m -67.61 -29.22 68.5 Favored 'General case' 0 N--CA 1.516 2.848 0 O-C-N 119.867 -1.771 . . . . 0.0 106.799 176.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -117.43 126.81 53.27 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.426 175.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 30.2 mt -118.23 143.56 28.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 119.265 -0.974 . . . . 0.0 110.526 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 16.6 m -110.22 116.66 31.89 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.162 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -99.22 118.04 63.12 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.02 110.06 2.02 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 N-CA-C 107.599 -1.731 . . . . 0.0 107.599 -177.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.627 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.3 mm -110.28 143.58 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 CA-C-O 121.655 0.74 . . . . 0.0 111.45 -177.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -103.43 121.56 43.07 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.76 135.03 68.23 Favored Pre-proline 0 N--CA 1.482 1.173 0 C-N-CA 119.409 -0.916 . . . . 0.0 108.986 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.48 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.5 Cg_endo -69.9 178.15 4.95 Favored 'Trans proline' 0 C--N 1.326 -0.64 0 O-C-N 123.705 1.371 . . . . 0.0 111.36 -178.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.5 t70 -129.28 119.04 19.4 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.419 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 26.5 Cg_endo -62.06 -35.86 73.74 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 C-N-CA 122.179 1.919 . . . . 0.0 111.654 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.94 -18.63 64.43 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.515 -0.741 . . . . 0.0 109.673 177.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 m -121.09 20.19 11.49 Favored 'General case' 0 N--CA 1.523 3.179 0 O-C-N 120.966 -1.084 . . . . 0.0 110.842 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -160.87 108.2 1.51 Allowed 'General case' 0 N--CA 1.505 2.312 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -72.86 -10.89 60.31 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -177.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.14 -1.93 28.23 Favored 'General case' 0 N--CA 1.514 2.739 0 CA-C-N 122.073 2.215 . . . . 0.0 109.75 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.48 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -98.8 130.55 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . 0.412 ' HB2' HD12 ' B' ' 144' ' ' LEU . 76.6 m-70 -129.81 167.86 17.46 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.671 -0.812 . . . . 0.0 110.923 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.419 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 60.6 m-85 -78.44 101.81 7.48 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 175.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' B' ' 142' ' ' HIS . 18.6 mt -154.06 177.23 11.3 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.126 0.965 . . . . 0.0 111.8 -175.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.544 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.3 mttm -90.62 129.33 36.76 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.491 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -120.97 139.16 28.75 Favored Pre-proline 0 C--N 1.307 -1.268 0 C-N-CA 117.657 -1.617 . . . . 0.0 111.557 -175.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -79.0 146.83 20.65 Favored 'Trans proline' 0 C--O 1.22 -0.419 0 C-N-CA 121.365 1.376 . . . . 0.0 111.368 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 68.6 mt -130.35 127.96 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.7 m-85 -117.88 141.02 48.89 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.511 -1.276 . . . . 0.0 110.497 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.69 145.25 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 CA-C-O 122.346 1.07 . . . . 0.0 111.548 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.21 128.23 6.74 Favored Glycine 0 N--CA 1.476 1.309 0 N-CA-C 106.02 -2.832 . . . . 0.0 106.02 177.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.06 133.31 7.52 Favored Glycine 0 C--N 1.295 -1.744 0 C-N-CA 118.362 -1.875 . . . . 0.0 110.128 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.42 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 22.8 t-20 -132.89 144.28 50.06 Favored 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.879 0.847 . . . . 0.0 112.407 -179.207 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.5 OUTLIER -136.43 126.27 25.75 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-N 114.487 -1.233 . . . . 0.0 107.819 177.252 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.03 158.99 22.38 Favored Glycine 0 N--CA 1.477 1.422 0 C-N-CA 117.953 -2.07 . . . . 0.0 110.278 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.622 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 16.9 mtm105 -75.93 140.8 42.29 Favored 'General case' 0 N--CA 1.51 2.533 0 CA-C-O 121.766 0.793 . . . . 0.0 110.61 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.46 172.41 45.22 Favored Glycine 0 N--CA 1.493 2.442 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.633 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -99.5 -30.41 12.18 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.765 -0.844 . . . . 0.0 111.643 179.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.4 mt -118.19 142.04 34.65 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.945 0 O-C-N 120.76 -1.212 . . . . 0.0 112.353 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.947 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.3 m-30 -91.37 169.57 11.2 Favored Pre-proline 0 N--CA 1.492 1.65 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.704 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.3 Cg_endo -60.37 -14.81 31.83 Favored 'Trans proline' 0 CA--C 1.56 1.812 0 C-N-CA 121.66 1.573 . . . . 0.0 113.537 178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -95.55 -3.83 45.83 Favored 'General case' 0 N--CA 1.528 3.469 0 CA-C-N 120.683 1.583 . . . . 0.0 110.53 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.29 -10.17 54.25 Favored Glycine 0 N--CA 1.51 3.597 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.3 m -69.29 142.11 54.18 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.834 -0.803 . . . . 0.0 111.053 -176.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -81.87 155.04 25.53 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.756 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.583 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 1.0 OUTLIER -98.93 179.07 4.75 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 177.261 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -87.31 17.52 4.35 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 117.938 -1.505 . . . . 0.0 108.749 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -112.9 45.79 1.3 Allowed 'General case' 0 N--CA 1.498 1.974 0 CA-C-O 122.043 0.925 . . . . 0.0 108.636 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.416 HG22 ' O ' ' B' ' 166' ' ' SER . 7.0 t -153.72 172.35 17.43 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 179.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -77.17 142.77 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.974 -0.453 . . . . 0.0 110.018 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.86 122.22 45.33 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -103.33 152.09 21.97 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.994 -1.482 . . . . 0.0 111.44 -175.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.21 131.49 46.26 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 15.8 p -83.11 -5.07 58.98 Favored 'General case' 0 N--CA 1.511 2.617 0 O-C-N 121.414 -0.804 . . . . 0.0 109.725 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.519 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.34 151.24 31.49 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.485 0.659 . . . . 0.0 111.178 179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.48 170.15 44.11 Favored Glycine 0 N--CA 1.482 1.719 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.61 -156.37 24.68 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.207 -2.425 . . . . 0.0 111.232 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.7 tt -121.4 136.07 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.3 mt -75.12 116.31 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 118.826 -1.149 . . . . 0.0 108.214 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -92.8 -18.41 22.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.23 -0.919 . . . . 0.0 110.547 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 13.8 ttmt -161.32 145.88 13.44 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 122.47 1.129 . . . . 0.0 113.167 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 81.3 mt -131.32 100.46 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.2 tp -88.11 109.06 19.59 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.5 -179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 56.1 mtt85 -74.76 120.55 20.47 Favored 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.4 mtmt -77.36 151.82 34.72 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.862 -1.135 . . . . 0.0 113.227 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -49.82 -57.85 6.54 Favored 'General case' 0 N--CA 1.509 2.482 0 CA-C-N 115.245 -0.889 . . . . 0.0 113.153 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.718 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 6.6 mptt -94.52 20.65 8.14 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.654 -1.279 . . . . 0.0 111.296 -177.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.99 154.05 19.69 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.286 -1.435 . . . . 0.0 110.685 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.55 171.35 29.25 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.496 ' CG ' HD11 ' B' ' 213' ' ' LEU . 62.1 m-85 -141.23 161.99 36.57 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-O 122.127 0.965 . . . . 0.0 112.179 -179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.55 110.88 13.73 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.407 HD11 HD22 ' B' ' 213' ' ' LEU . 87.5 mt -107.58 122.7 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.808 -1.182 . . . . 0.0 110.519 -176.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.9 m -95.98 122.94 39.33 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 119.56 -0.856 . . . . 0.0 108.747 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.5 mt -112.2 128.2 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 82.8 t -98.59 100.88 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -73.8 89.03 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.63 -32.25 71.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.442 -0.786 . . . . 0.0 110.812 -177.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 45.9 m -67.73 -35.18 78.29 Favored 'General case' 0 N--CA 1.508 2.451 0 O-C-N 121.664 -0.647 . . . . 0.0 111.44 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 58.6 m-80 -106.31 3.74 27.92 Favored 'General case' 0 N--CA 1.515 2.811 0 O-C-N 121.791 -0.568 . . . . 0.0 110.358 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 50.04 50.66 18.13 Favored 'General case' 0 N--CA 1.506 2.352 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 24.5 ttp-105 -133.78 141.53 47.52 Favored 'General case' 0 N--CA 1.485 1.316 0 CA-C-N 114.726 -1.124 . . . . 0.0 110.51 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 33.6 tt0 -111.88 129.52 56.13 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.519 HG21 ' HB3' ' B' ' 175' ' ' ALA . 33.6 m -129.72 148.02 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.614 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 62.2 mt -120.43 111.2 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-O 122.012 0.91 . . . . 0.0 109.966 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -92.26 128.5 38.13 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 28.6 mt -99.64 135.03 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 118.963 -1.095 . . . . 0.0 109.032 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.422 HD13 ' CD2' ' B' ' 213' ' ' LEU . 45.0 mt -116.92 132.38 23.46 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -76.33 165.59 29.06 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.248 2.632 . . . . 0.0 111.95 -179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.54 154.19 39.95 Favored 'General case' 0 N--CA 1.513 2.701 0 CA-C-O 121.702 0.763 . . . . 0.0 112.713 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 98.11 -6.76 62.02 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 107.706 -2.158 . . . . 0.0 107.706 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.616 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.61 142.9 46.11 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 122.111 -0.641 . . . . 0.0 109.971 178.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -110.12 138.79 46.02 Favored 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.882 -0.727 . . . . 0.0 109.054 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' B' ' 190' ' ' TYR . 21.1 mt -73.85 150.83 40.73 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 53.2 mt -111.61 5.47 19.37 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.517 HG11 HD13 ' B' ' 221' ' ' ILE . 12.1 m -119.99 157.16 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.303 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.4 m -122.32 156.83 33.08 Favored 'General case' 0 N--CA 1.498 1.944 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.301 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -61.08 143.15 55.96 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.82 -4.28 86.4 Favored Glycine 0 N--CA 1.504 3.169 0 C-N-CA 120.0 -1.095 . . . . 0.0 110.753 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -86.92 144.17 27.08 Favored 'General case' 0 N--CA 1.509 2.494 0 O-C-N 120.936 -1.332 . . . . 0.0 110.816 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 27.8 m -86.83 124.1 32.7 Favored 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.517 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.31 149.49 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-O 121.388 0.613 . . . . 0.0 109.62 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 25.1 mttp -102.62 161.26 13.87 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 13.6 tp -60.73 138.92 58.05 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.059 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.2 14.25 9.56 Favored 'General case' 0 N--CA 1.513 2.691 0 O-C-N 121.502 -0.749 . . . . 0.0 111.726 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.477 ' HB3' HG13 ' B' ' 221' ' ' ILE . 11.6 tt0 -76.46 125.69 87.2 Favored Pre-proline 0 N--CA 1.507 2.384 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -55.92 124.08 15.4 Favored 'Trans proline' 0 N--CA 1.483 0.891 0 C-N-CA 121.478 1.452 . . . . 0.0 110.82 -178.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 78.7 mt -98.5 -11.55 22.16 Favored 'General case' 0 N--CA 1.508 2.459 0 CA-C-O 121.329 0.585 . . . . 0.0 110.32 -177.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.417 HG22 HD23 ' B' ' 213' ' ' LEU . 25.1 p -135.72 168.35 19.44 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.997 0.904 . . . . 0.0 111.31 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.528 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 35.4 m -72.85 162.15 29.84 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 114.781 -1.099 . . . . 0.0 108.742 178.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 -91.1 107.51 21.63 Favored Pre-proline 0 N--CA 1.489 1.516 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 177.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.616 ' HG3' HD21 ' B' ' 211' ' ' LEU . 49.2 Cg_endo -86.28 13.4 2.74 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 121.496 1.464 . . . . 0.0 112.855 -175.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 59.2 t30 -90.38 119.55 30.77 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.309 -0.869 . . . . 0.0 111.169 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.66 3.21 8.63 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.848 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.737 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.52 -162.87 25.26 Favored Glycine 0 N--CA 1.501 3.013 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.61 164.24 26.01 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -117.36 147.54 42.54 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.77 160.95 28.46 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -138.5 155.02 48.79 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.569 -0.959 . . . . 0.0 108.93 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.19 174.92 29.48 Favored Glycine 0 C--N 1.292 -1.872 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.56 158.1 43.84 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 117.709 -1.596 . . . . 0.0 110.258 179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.1 171.12 14.98 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -129.92 133.87 47.12 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.2 tt -124.37 143.01 39.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.392 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' B' ' 145' ' ' LYS . 14.1 t -103.86 110.97 31.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 118.951 -1.099 . . . . 0.0 110.338 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 11.0 tp -72.68 114.28 10.65 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 103.112 -2.921 . . . . 0.0 103.112 175.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -101.25 142.13 33.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -172.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -72.76 129.44 86.78 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 106.033 -1.839 . . . . 0.0 106.033 175.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -66.18 -1.02 4.73 Favored 'Trans proline' 0 CA--C 1.544 0.989 0 C-N-CA 121.329 1.352 . . . . 0.0 111.184 -177.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 15.8 mt -111.02 -128.96 0.29 Allowed 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 117.271 -1.347 . . . . 0.0 109.471 177.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.644 ' O1D' ' N ' ' A' ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 N--CA 1.503 2.181 0 CA-C-O 121.208 0.527 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -104.73 130.83 52.72 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.753 -0.592 . . . . 0.0 109.624 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 78.2 t -121.94 126.29 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.1 mt -84.54 134.88 34.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-O 121.424 0.63 . . . . 0.0 110.627 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 38.6 mt -95.42 94.28 7.72 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 106.387 -1.708 . . . . 0.0 106.387 177.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 103.54 126.11 5.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 107.264 -2.335 . . . . 0.0 107.264 -176.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -70.85 168.34 17.01 Favored 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.476 -1.014 . . . . 0.0 110.971 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -67.46 -16.44 64.22 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.588 -0.695 . . . . 0.0 110.522 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -95.91 8.5 43.45 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.301 -0.874 . . . . 0.0 109.864 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.52 9.54 75.29 Favored Glycine 0 N--CA 1.5 2.939 0 O-C-N 121.607 -0.683 . . . . 0.0 111.484 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 12.9 m -71.29 140.8 50.44 Favored 'General case' 0 N--CA 1.501 2.077 0 CA-C-N 118.347 1.073 . . . . 0.0 109.446 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.2 mt -84.89 85.71 7.44 Favored 'General case' 0 N--CA 1.499 2.0 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -156.9 155.26 31.1 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.378 0.609 . . . . 0.0 110.908 -178.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -84.07 131.53 34.79 Favored 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 t -124.09 106.78 30.86 Favored Pre-proline 0 N--CA 1.51 2.56 0 O-C-N 120.78 -1.2 . . . . 0.0 109.842 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -80.07 166.24 77.08 Favored 'Cis proline' 0 N--CA 1.491 1.331 0 O-C-N 123.419 1.221 . . . . 0.0 111.091 -1.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.3 p -99.38 -32.38 11.19 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.57 -0.706 . . . . 0.0 109.946 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -121.01 118.38 29.68 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -151.97 165.76 33.61 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.738 -0.601 . . . . 0.0 110.469 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -119.47 143.71 47.38 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.3 pt -137.44 161.38 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 CA-C-O 121.351 0.596 . . . . 0.0 109.609 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 27.9 m -87.84 161.38 44.58 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' SER . 35.2 Cg_endo -67.34 131.65 25.43 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 121.658 1.572 . . . . 0.0 110.913 -178.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.75 -11.44 72.11 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -67.8 138.05 55.86 Favored 'General case' 0 N--CA 1.507 2.398 0 CA-C-N 118.413 1.107 . . . . 0.0 109.013 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -88.71 142.08 27.98 Favored 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.952 0.882 . . . . 0.0 112.028 -178.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 49.1 mt -112.29 117.35 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' HG2' ' A' ' 71' ' ' GLU . 95.4 t -102.48 100.77 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.198 -0.939 . . . . 0.0 109.979 -179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -82.18 118.1 22.82 Favored 'General case' 0 N--CA 1.499 1.998 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.44 ' CB ' HG22 ' A' ' 69' ' ' THR . 1.5 ptpt -119.4 133.24 55.81 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.084 -1.01 . . . . 0.0 111.084 -178.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -60.37 121.66 12.6 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -117.85 -55.23 2.29 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.506 -0.746 . . . . 0.0 111.093 -178.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.482 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 148.98 22.42 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.242 -0.911 . . . . 0.0 110.863 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.8 15.69 77.05 Favored Glycine 0 N--CA 1.502 3.042 0 O-C-N 121.807 -0.558 . . . . 0.0 111.709 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.717 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.5 p90 -71.44 170.32 12.28 Favored Pre-proline 0 N--CA 1.507 2.397 0 O-C-N 121.507 -0.996 . . . . 0.0 109.257 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.8 Cg_endo -65.08 150.64 75.67 Favored 'Cis proline' 0 N--CA 1.497 1.7 0 N-CA-C 114.697 0.999 . . . . 0.0 114.697 3.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -137.42 162.91 32.36 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.476 ' HB3' HD23 ' A' ' 62' ' ' LEU . 1.0 OUTLIER -155.19 159.02 39.8 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 176.86 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.492 ' N ' HD12 ' A' ' 39' ' ' ILE . 5.4 mp -117.99 115.55 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.231 0 CA-C-O 121.582 0.706 . . . . 0.0 110.429 -177.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t -120.91 129.17 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 CA-C-O 121.505 0.669 . . . . 0.0 109.3 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HB3' ' A' ' 56' ' ' SER . 30.0 m-85 -88.56 130.65 35.2 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -65.69 113.3 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.658 ' CG ' HH12 ' B' ' 209' ' ' ARG . 15.1 pt-20 -61.79 -22.11 65.16 Favored 'General case' 0 N--CA 1.504 2.273 0 O-C-N 121.661 -0.649 . . . . 0.0 110.932 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' OD1' ' NH1' ' B' ' 209' ' ' ARG . 0.0 OUTLIER -92.68 -4.61 52.96 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.437 -0.789 . . . . 0.0 109.988 179.014 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.835 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.3 OUTLIER -126.55 39.03 4.01 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.001 -1.062 . . . . 0.0 112.522 -177.761 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.703 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 21.7 pt -130.15 168.16 17.84 Favored Pre-proline 0 N--CA 1.506 2.368 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 177.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.754 ' HG2' HG21 ' A' ' 50' ' ' VAL . 23.8 Cg_endo -60.9 140.72 91.86 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 121.33 1.353 . . . . 0.0 111.859 -178.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 m -54.48 136.11 44.87 Favored 'General case' 0 N--CA 1.501 2.106 0 CA-C-N 115.522 -0.763 . . . . 0.0 112.262 -177.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.46 -8.57 79.6 Favored Glycine 0 N--CA 1.501 2.985 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.588 178.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.754 HG21 ' HG2' ' A' ' 47' ' ' PRO . 76.7 t -81.53 134.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 CA-C-N 118.989 1.394 . . . . 0.0 109.84 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -86.85 112.25 21.56 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.473 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -65.8 -24.62 66.95 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.554 -0.716 . . . . 0.0 111.419 -178.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 9.8 p -68.33 -23.07 64.67 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.142 -0.974 . . . . 0.0 110.46 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.03 -17.82 41.94 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.738 -0.601 . . . . 0.0 111.618 -179.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -122.86 4.11 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.587 0 O-C-N 120.792 -1.193 . . . . 0.0 113.197 -176.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -130.96 162.38 29.86 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 120.805 -1.185 . . . . 0.0 112.162 -178.453 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 91.7 mtp -83.05 159.99 22.04 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.3 t -73.48 147.09 44.43 Favored 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.69 -23.43 28.63 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.743 -0.598 . . . . 0.0 110.312 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mp0 -93.43 -7.5 44.35 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.699 -0.625 . . . . 0.0 110.868 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -88.18 146.86 25.16 Favored 'General case' 0 N--CA 1.51 2.544 0 O-C-N 121.034 -1.041 . . . . 0.0 109.514 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.476 HD23 ' HB3' ' A' ' 38' ' ' ASN . 95.9 mt -142.97 147.37 35.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.151 -0.968 . . . . 0.0 113.236 -178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 48.9 mt -97.22 107.05 19.49 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 102.697 -3.075 . . . . 0.0 102.697 172.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -109.75 10.83 24.64 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 120.502 -1.374 . . . . 0.0 113.054 -175.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.18 144.27 51.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.605 -1.309 . . . . 0.0 110.274 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . 0.429 ' HB3' ' HE3' ' A' ' 66' ' ' LYS . 0.1 OUTLIER -61.7 126.84 28.76 Favored 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.361 0.6 . . . . 0.0 109.692 -179.723 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 102.12 -15.6 56.35 Favored Glycine 0 N--CA 1.502 3.055 0 CA-C-O 119.877 -0.401 . . . . 0.0 112.265 178.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -60.68 139.0 58.02 Favored 'General case' 0 N--CA 1.508 2.461 0 CA-C-N 118.948 1.374 . . . . 0.0 108.991 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 30' ' ' LYS . 64.6 p -128.18 153.74 46.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.166 -0.959 . . . . 0.0 112.647 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -129.12 113.71 15.44 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 28' ' ' VAL . 7.7 mt-10 -104.88 143.8 32.65 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.351 -0.843 . . . . 0.0 111.252 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.9 p -150.4 143.77 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.696 -0.627 . . . . 0.0 109.744 178.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -118.54 122.59 43.02 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 30.7 mt -99.14 140.64 33.0 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.561 -0.712 . . . . 0.0 109.191 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -40.21 3.14 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.651 -0.655 . . . . 0.0 110.751 -178.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -68.08 134.52 50.73 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 121.437 -0.789 . . . . 0.0 109.488 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.89 153.68 30.33 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.614 -0.679 . . . . 0.0 110.141 -178.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.51 -170.31 23.08 Favored Glycine 0 N--CA 1.499 2.838 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 59.8 mt-10 -103.36 136.52 42.96 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.816 -0.814 . . . . 0.0 110.077 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.55 ' HB2' HG13 ' A' ' 96' ' ' VAL . 20.5 m-85 -118.58 120.46 37.56 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.835 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 21.5 m -98.66 125.06 43.83 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -127.39 168.71 14.47 Favored 'General case' 0 N--CA 1.494 1.767 0 CA-C-O 121.138 0.494 . . . . 0.0 109.875 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -162.8 166.42 24.21 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-O 121.818 0.818 . . . . 0.0 111.405 -178.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.43 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.8 t -96.59 118.46 33.11 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 105.096 -2.187 . . . . 0.0 105.096 175.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.753 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 9.6 p -54.6 -51.33 79.43 Favored Pre-proline 0 N--CA 1.508 2.46 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -175.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.753 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 34.6 Cg_endo -73.1 -11.1 25.08 Favored 'Trans proline' 0 CA--C 1.547 1.174 0 C-N-CA 121.459 1.439 . . . . 0.0 113.167 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -131.12 20.49 4.89 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.539 -1.351 . . . . 0.0 111.01 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.725 HE21 ' HB1' ' B' ' 62' ' ' ALA . 15.8 tt0 -63.03 -37.72 88.34 Favored 'General case' 0 N--CA 1.506 2.364 0 O-C-N 120.756 -1.215 . . . . 0.0 108.416 179.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.513 ' CA ' ' CE1' ' B' ' 160' ' ' TYR . . . -66.99 -29.33 74.46 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.526 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -71.28 -13.06 61.77 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 122.014 -0.698 . . . . 0.0 110.347 178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.46 7.21 46.19 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . . . . . . . . . 14.6 ttt -76.74 79.02 3.36 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.5 m -132.73 164.76 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.553 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.38 169.32 36.16 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.615 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.1 ttpp -146.08 127.67 15.13 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.529 0.681 . . . . 0.0 109.244 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.55 HG13 ' HB2' ' A' ' 80' ' ' TYR . 2.8 p -114.65 138.63 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.104 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 90.7 m -113.64 120.65 41.61 Favored 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 58.5 t -92.43 109.39 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.2 p30 . . . . . 0 N--CA 1.5 2.068 0 CA-C-O 118.155 -0.926 . . . . 0.0 109.763 -178.349 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.737 ' OH ' ' O ' ' A' ' 86' ' ' PRO . 58.2 m-85 . . . . . 0 C--O 1.217 -0.613 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 30.8 Cg_endo -64.65 -17.97 61.21 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.97 1.78 . . . . 0.0 110.963 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.8 -29.04 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.603 -0.686 . . . . 0.0 109.909 178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 90' ' ' ALA . 20.3 m-30 -66.92 -42.91 84.56 Favored 'General case' 0 N--CA 1.506 2.33 0 O-C-N 121.29 -0.881 . . . . 0.0 109.034 179.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.617 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -68.44 -40.47 81.12 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -67.35 -38.82 85.44 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.797 -0.564 . . . . 0.0 110.44 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -68.35 -30.11 68.99 Favored 'General case' 0 N--CA 1.502 2.133 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -135.52 18.4 3.34 Favored 'General case' 0 N--CA 1.511 2.593 0 O-C-N 120.083 -1.636 . . . . 0.0 113.622 -178.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.617 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 96.5 m-85 -133.91 105.98 7.04 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.82 -40.57 84.54 Favored 'General case' 0 N--CA 1.519 3.018 0 O-C-N 120.916 -1.115 . . . . 0.0 111.599 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -122.34 131.08 24.45 Favored Pre-proline 0 N--CA 1.507 2.416 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.461 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.7 Cg_endo -74.23 -17.95 21.22 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.128 1.885 . . . . 0.0 113.717 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . 0.445 ' HE ' ' HA2' ' B' ' 17' ' ' GLY . 6.6 ttt180 -102.86 125.86 49.77 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.187 -0.946 . . . . 0.0 109.056 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -87.65 171.13 10.68 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.737 -0.602 . . . . 0.0 109.794 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.03 -27.7 68.52 Favored 'General case' 0 N--CA 1.51 2.553 0 O-C-N 121.48 -0.762 . . . . 0.0 111.848 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -73.89 -14.56 61.09 Favored 'General case' 0 N--CA 1.505 2.299 0 O-C-N 121.127 -0.983 . . . . 0.0 110.076 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' HE ' ' B' ' 13' ' ' ARG . . . 96.6 6.08 58.58 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 11.2 mtt-85 -96.88 136.12 37.89 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.722 -0.87 . . . . 0.0 109.858 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.407 HG21 HG11 ' B' ' 74' ' ' VAL . 92.5 mt -78.05 140.25 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 m -57.14 -9.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.525 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 m -70.47 -27.03 63.91 Favored 'General case' 0 N--CA 1.51 2.561 0 CA-C-N 121.207 1.821 . . . . 0.0 108.972 178.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.68 -9.48 27.92 Favored 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.946 -0.471 . . . . 0.0 111.341 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -74.9 -32.07 61.73 Favored 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.431 -0.793 . . . . 0.0 109.882 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 8.0 m -113.51 -35.98 5.08 Favored 'General case' 0 N--CA 1.509 2.499 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -84.74 93.58 8.48 Favored 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 50.0 mt -87.88 -20.93 25.32 Favored 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.787 2.143 . . . . 0.0 116.787 -171.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 140.72 32.61 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 121.269 1.849 . . . . 0.0 109.453 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 15.5 t -96.95 125.36 41.33 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.375 -0.828 . . . . 0.0 110.653 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 25.8 mttp -139.2 149.4 60.79 Favored Pre-proline 0 N--CA 1.5 2.054 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 177.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -66.88 139.63 52.44 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 122.896 2.397 . . . . 0.0 115.84 -172.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 12.8 t -126.69 141.21 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 177.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.63 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 38.7 t70 -127.25 152.41 47.44 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.252 -0.905 . . . . 0.0 109.795 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 10.0 tt -143.47 121.94 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.611 ' HB2' HG13 ' B' ' 48' ' ' VAL . 1.4 mt-10 -106.94 122.6 46.74 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.517 HG13 ' HD2' ' B' ' 36' ' ' PRO . 1.0 OUTLIER -130.47 149.89 74.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.517 ' HD2' HG13 ' B' ' 35' ' ' VAL . 28.3 Cg_endo -65.77 135.5 41.8 Favored 'Trans proline' 0 N--CA 1.483 0.863 0 C-N-CA 121.617 1.545 . . . . 0.0 110.182 179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -48.76 -42.75 36.57 Favored 'General case' 0 N--CA 1.505 2.282 0 O-C-N 122.081 -0.387 . . . . 0.0 111.591 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -144.2 152.87 41.46 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.725 -0.609 . . . . 0.0 109.767 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.23 156.59 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.482 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 2.6 mm? -95.14 164.18 19.94 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.482 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 27.6 Cg_endo -65.13 137.31 51.65 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.377 2.051 . . . . 0.0 111.911 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 14.2 t70 56.34 47.82 18.32 Favored 'General case' 0 N--CA 1.512 2.674 0 C-N-CA 123.337 0.655 . . . . 0.0 112.271 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.3 p -130.01 143.09 50.61 Favored 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -86.68 131.31 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.514 -0.741 . . . . 0.0 109.674 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -130.0 164.72 23.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . 0.542 ' HG2' ' HE2' ' B' ' 93' ' ' MET . 0.0 OUTLIER -113.59 134.23 54.83 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.006 -1.059 . . . . 0.0 111.535 -178.371 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -107.19 100.4 9.87 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 176.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.611 HG13 ' HB2' ' B' ' 34' ' ' GLU . 1.4 p -90.53 119.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 O-C-N 121.462 -0.774 . . . . 0.0 110.053 -177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 76.6 t -102.6 132.52 48.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.63 ' HB2' ' HB3' ' B' ' 32' ' ' ASP . 54.7 mttm -112.73 123.39 50.19 Favored 'General case' 0 N--CA 1.493 1.725 0 CA-C-O 121.724 0.774 . . . . 0.0 110.134 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.75 76.73 28.54 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 178.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.454 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 38.7 Cg_endo -80.19 144.44 16.53 Favored 'Trans proline' 0 N--CA 1.481 0.755 0 C-N-CA 122.998 2.465 . . . . 0.0 113.738 -175.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -163.15 149.94 12.57 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -60.09 119.64 8.22 Favored 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 178.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 3.2 mtm -79.36 1.83 23.8 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -93.21 3.06 56.3 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 120.316 -1.49 . . . . 0.0 107.545 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 70.8 mt -77.57 137.88 38.84 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.508 0.671 . . . . 0.0 110.629 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.6 mttm -123.79 121.96 36.79 Favored 'General case' 0 N--CA 1.491 1.625 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -90.68 170.57 10.03 Favored 'General case' 0 N--CA 1.498 1.959 0 CA-C-O 121.06 0.457 . . . . 0.0 110.395 -178.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 3.1 t -88.64 113.47 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' B' ' 61' ' ' LEU . 0.2 OUTLIER -70.04 167.88 16.67 Favored 'General case' 0 N--CA 1.5 2.046 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.315 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.725 ' HB1' HE21 ' A' ' 88' ' ' GLN . . . -59.25 -8.7 1.75 Allowed 'General case' 0 N--CA 1.505 2.306 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -114.96 15.69 17.25 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.702 -1.249 . . . . 0.0 111.999 -179.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -28.87 9.4 Favored Glycine 0 N--CA 1.501 3.03 0 O-C-N 120.852 -1.155 . . . . 0.0 111.643 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 10.3 mmmm -71.05 158.1 37.06 Favored 'General case' 0 N--CA 1.503 2.183 0 O-C-N 121.313 -1.11 . . . . 0.0 110.08 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -98.5 142.3 30.27 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.552 -0.717 . . . . 0.0 109.191 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.27 -172.31 20.73 Favored Glycine 0 N--CA 1.505 3.255 0 C-N-CA 120.393 -0.908 . . . . 0.0 110.996 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.21 172.15 13.99 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.919 -0.753 . . . . 0.0 110.631 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 7.0 mp -100.72 157.14 16.91 Favored 'General case' 0 N--CA 1.498 1.948 0 CA-C-O 121.489 0.661 . . . . 0.0 110.482 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.493 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 35.9 m-80 -114.99 152.27 32.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -113.81 153.38 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.997 0.903 . . . . 0.0 110.795 -178.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.97 150.89 22.53 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.801 -2.12 . . . . 0.0 107.801 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' B' ' 151' ' ' GLY . . . -150.7 156.83 42.1 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.263 -1.14 . . . . 0.0 111.814 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.407 HG11 HG21 ' B' ' 19' ' ' ILE . 6.3 p -127.3 116.89 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 25.4 tp -102.97 119.55 39.06 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.421 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 21.1 mt -102.67 107.16 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.555 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -101.02 165.36 14.34 Favored Pre-proline 0 N--CA 1.494 1.767 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.653 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 30.2 Cg_endo -71.41 156.39 58.54 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 122.116 1.878 . . . . 0.0 109.596 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -62.04 133.87 55.88 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 121.338 -0.852 . . . . 0.0 110.315 -178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.91 -38.06 3.38 Favored Glycine 0 N--CA 1.498 2.781 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.653 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.3 m-85 -77.69 139.75 39.47 Favored 'General case' 0 N--CA 1.502 2.126 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -151.7 171.95 16.87 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.372 -0.83 . . . . 0.0 109.995 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 25.1 tp -60.69 129.16 40.14 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . 0.402 ' HB3' ' HB2' ' B' ' 129' ' ' PRO . . . -64.27 139.29 97.67 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' B' ' 88' ' ' ARG . 29.7 Cg_endo -70.68 161.18 46.96 Favored 'Trans proline' 0 CA--C 1.545 1.063 0 C-N-CA 121.809 1.673 . . . . 0.0 110.012 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.85 -32.29 55.76 Favored 'Trans proline' 0 N--CA 1.487 1.114 0 C-N-CA 122.504 2.136 . . . . 0.0 113.406 -177.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -71.77 -23.89 61.67 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 121.249 -0.907 . . . . 0.0 110.284 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.404 ' CG ' ' HG2' ' B' ' 85' ' ' PRO . 41.5 mmm-85 -92.17 -8.13 46.45 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.693 -0.63 . . . . 0.0 111.138 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 87.9 mt -86.61 126.15 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.29 0 O-C-N 120.946 -1.097 . . . . 0.0 109.686 -179.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.63 160.17 80.74 Favored Pre-proline 0 N--CA 1.505 2.289 0 O-C-N 121.945 -0.472 . . . . 0.0 110.329 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . 0.418 ' HG2' ' OE2' ' B' ' 92' ' ' GLU . 35.4 Cg_endo -72.95 -26.42 15.37 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 122.174 1.916 . . . . 0.0 109.952 178.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . 0.418 ' OE2' ' HG2' ' B' ' 91' ' ' PRO . 14.1 mp0 -73.9 -21.43 60.08 Favored 'General case' 0 N--CA 1.501 2.085 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.542 ' HE2' ' HG2' ' B' ' 46' ' ' GLU . 35.7 ttm -95.3 -31.21 13.56 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.042 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . 0.412 ' HE2' ' HB2' ' B' ' 94' ' ' LYS . 1.8 tppt? -64.11 -35.88 82.2 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.538 -0.726 . . . . 0.0 110.448 -179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . 0.454 ' H ' ' HG2' ' B' ' 95' ' ' GLU . 11.8 pt-20 -75.45 -25.35 57.38 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.182 -0.949 . . . . 0.0 109.14 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.77 -40.1 69.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.964 -0.46 . . . . 0.0 109.8 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 19.2 pt -80.93 4.5 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 O-C-N 121.089 -1.007 . . . . 0.0 110.381 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.98 -113.23 4.86 Favored Glycine 0 N--CA 1.505 3.296 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -145.06 39.57 1.22 Allowed 'General case' 0 N--CA 1.497 1.888 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.645 HD22 HD11 ' B' ' 115' ' ' ILE . 18.8 mt -73.46 148.42 43.22 Favored 'General case' 0 N--CA 1.498 1.974 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.013 -178.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 95.7 p -111.81 100.27 8.79 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -78.19 122.57 25.84 Favored 'General case' 0 N--CA 1.507 2.378 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -106.04 153.21 22.36 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.598 -0.689 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . 0.549 ' ND2' ' HA ' ' B' ' 110' ' ' LYS . 6.8 m-20 -78.38 139.75 38.76 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 53.7 t80 -50.07 -40.8 46.53 Favored 'General case' 0 N--CA 1.508 2.435 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -151.84 156.44 34.28 Favored Pre-proline 0 N--CA 1.499 1.979 0 N-CA-C 104.942 -2.244 . . . . 0.0 104.942 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.18 -24.76 76.53 Favored 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 121.568 1.512 . . . . 0.0 112.208 -176.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -85.38 -24.6 27.48 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.647 -0.658 . . . . 0.0 109.776 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 41.5 mmtt -92.14 87.34 6.08 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.535 -0.728 . . . . 0.0 109.133 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . 0.549 ' HA ' ' ND2' ' B' ' 104' ' ' ASN . 21.5 mttm -84.6 -6.09 59.34 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.32 -0.862 . . . . 0.0 110.166 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 19.6 p-10 -100.5 1.71 41.34 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.446 -0.783 . . . . 0.0 111.405 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.461 HG21 ' HG3' ' B' ' 12' ' ' PRO . 73.3 mt -119.6 115.81 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.122 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -111.03 143.16 42.18 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-O 121.354 0.597 . . . . 0.0 111.095 -177.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 33.5 m -127.29 146.71 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.645 HD11 HD22 ' B' ' 100' ' ' LEU . 12.6 tt -146.24 147.22 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.7 170.4 17.98 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.422 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.3 Cg_endo -73.95 131.91 25.18 Favored 'Cis proline' 0 N--CA 1.487 1.118 0 O-C-N 123.67 1.353 . . . . 0.0 112.412 0.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.6 m -124.2 153.56 68.44 Favored Pre-proline 0 N--CA 1.498 1.97 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 177.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -63.72 129.49 25.05 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 121.411 1.408 . . . . 0.0 111.88 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.43 -37.29 94.26 Favored Glycine 0 N--CA 1.5 2.949 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.692 -177.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 21.7 mm-40 -56.37 -30.02 62.14 Favored 'General case' 0 N--CA 1.515 2.792 0 CA-C-N 118.677 1.238 . . . . 0.0 110.695 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -100.34 -38.99 8.22 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 122.094 -0.379 . . . . 0.0 111.792 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -116.8 57.13 0.79 Allowed 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 118.584 -1.246 . . . . 0.0 113.86 -175.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 14.6 m -72.04 -33.81 68.29 Favored 'General case' 0 N--CA 1.499 1.993 0 N-CA-C 106.363 -1.718 . . . . 0.0 106.363 175.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.547 ' HG3' ' O ' ' B' ' 125' ' ' GLU . 4.8 pt-20 -115.71 128.45 55.89 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 87.0 mt -118.32 141.62 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.436 0 O-C-N 121.183 -0.948 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 44.9 m -108.83 114.21 27.79 Favored 'General case' 0 N--CA 1.498 1.932 0 CA-C-O 121.408 0.623 . . . . 0.0 109.603 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -94.27 117.84 67.08 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . 0.402 ' HB2' ' HB3' ' B' ' 84' ' ' ALA . 35.4 Cg_endo -79.94 105.32 1.79 Allowed 'Trans proline' 0 N--CA 1.481 0.774 0 C-N-CA 121.987 1.791 . . . . 0.0 108.688 178.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 26.1 mm -107.8 142.02 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 O-C-N 121.607 -0.683 . . . . 0.0 110.837 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 19.1 tp -102.84 120.69 41.06 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -73.05 137.57 79.22 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.402 ' HG2' HG11 ' B' ' 141' ' ' VAL . 35.1 Cg_endo -73.64 173.16 14.36 Favored 'Trans proline' 0 N--CA 1.483 0.866 0 C-N-CA 122.701 2.268 . . . . 0.0 111.273 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' B' ' 136' ' ' ALA . 16.0 t70 -124.13 123.5 26.03 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -67.11 -28.37 41.04 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.312 2.008 . . . . 0.0 111.612 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . 0.437 ' HB3' ' OD1' ' B' ' 134' ' ' ASP . . . -71.37 -18.9 62.34 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 178.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 4.0 m -117.95 15.15 14.27 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.701 -0.624 . . . . 0.0 109.62 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -155.51 110.16 2.93 Favored 'General case' 0 N--CA 1.506 2.325 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -73.63 -14.92 61.26 Favored 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -176.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.61 -6.28 30.22 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.708 -1.245 . . . . 0.0 110.115 179.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.402 HG11 ' HG2' ' B' ' 133' ' ' PRO . 97.7 t -97.29 129.55 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.054 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -129.37 167.94 17.02 Favored 'General case' 0 N--CA 1.506 2.341 0 O-C-N 121.387 -0.821 . . . . 0.0 110.301 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' B' ' 247' ' ' ASP . 84.8 m-85 -77.53 89.74 3.88 Favored 'General case' 0 N--CA 1.503 2.202 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 177.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 22.2 mt -137.85 -179.49 5.79 Favored 'General case' 0 N--CA 1.503 2.184 0 CA-C-O 121.896 0.855 . . . . 0.0 110.641 -177.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.518 ' HG2' HG22 ' B' ' 244' ' ' VAL . 7.4 mttm -93.24 121.16 34.31 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 64.3 m-85 -111.85 139.85 22.71 Favored Pre-proline 0 N--CA 1.499 2.011 0 O-C-N 121.539 -0.726 . . . . 0.0 111.113 -177.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -81.35 139.66 11.71 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.198 2.599 . . . . 0.0 111.042 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.27 124.76 67.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.421 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 79.6 m-85 -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.552 -0.717 . . . . 0.0 110.002 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 13.3 p -134.24 143.92 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.587 0.708 . . . . 0.0 110.755 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' B' ' 73' ' ' ALA . . . -123.87 119.28 3.72 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 107.139 -2.384 . . . . 0.0 107.139 177.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -118.01 132.16 9.69 Favored Glycine 0 N--CA 1.504 3.184 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -131.14 146.05 52.2 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.607 -0.937 . . . . 0.0 110.485 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.6 OUTLIER -141.59 125.9 17.56 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 178.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 105.54 165.92 23.58 Favored Glycine 0 N--CA 1.502 3.047 0 N-CA-C 110.219 -1.153 . . . . 0.0 110.219 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.547 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 30.5 mtm105 -80.16 145.91 32.08 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.796 -0.826 . . . . 0.0 110.489 -179.145 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.95 177.79 37.87 Favored Glycine 0 N--CA 1.5 2.944 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 16.0 mp0 -106.19 -31.26 8.75 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.751 -0.852 . . . . 0.0 110.941 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 20.8 mt -118.77 144.01 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.33 -0.856 . . . . 0.0 110.678 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.708 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 37.8 m-85 -92.75 170.45 8.93 Favored Pre-proline 0 N--CA 1.5 2.049 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.708 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 29.7 Cg_endo -65.15 -10.26 25.03 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.112 1.875 . . . . 0.0 113.731 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -99.42 -4.02 32.43 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 120.696 -1.253 . . . . 0.0 109.22 177.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.71 56.78 Favored Glycine 0 N--CA 1.502 3.041 0 O-C-N 121.362 -0.836 . . . . 0.0 111.164 178.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.9 m -72.49 144.95 47.84 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.594 -0.945 . . . . 0.0 110.474 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 35.0 mttt -80.09 155.77 27.37 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.412 ' O ' HG22 ' B' ' 169' ' ' THR . 98.6 p -100.13 175.59 5.69 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 176.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -84.79 12.47 7.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 120.786 -1.196 . . . . 0.0 109.42 178.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.33 43.83 1.24 Allowed 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.412 HG22 ' O ' ' B' ' 166' ' ' SER . 8.8 t -150.87 173.78 13.85 Favored 'General case' 0 N--CA 1.5 2.06 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' B' ' 226' ' ' PRO . 99.1 t -79.57 138.3 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.596 -0.69 . . . . 0.0 109.413 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 15.6 m-85 -103.57 114.06 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . 0.431 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 93.0 m-20 -96.27 152.95 18.1 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.797 0.808 . . . . 0.0 111.675 -176.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.485 ' HB2' HD21 ' B' ' 227' ' ' LEU . . . -69.01 131.02 44.39 Favored 'General case' 0 N--CA 1.492 1.646 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.41 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 62.0 p -81.97 -4.94 57.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.772 -0.58 . . . . 0.0 110.189 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -153.38 149.24 27.62 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.333 -0.855 . . . . 0.0 109.926 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.64 169.32 40.83 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 108.039 -2.024 . . . . 0.0 108.039 178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 137.18 -150.0 20.49 Favored Glycine 0 N--CA 1.5 2.967 0 O-C-N 121.067 -1.255 . . . . 0.0 110.642 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 19.6 tt -121.69 138.33 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.858 -0.79 . . . . 0.0 109.536 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 80.1 mt -76.69 112.19 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.233 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 58.7 p -89.77 -17.43 28.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.732 -0.605 . . . . 0.0 110.804 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -163.26 142.56 8.51 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.234 -0.916 . . . . 0.0 111.319 -178.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 75.8 mt -128.59 100.68 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 176.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 48.2 tp -87.55 106.4 17.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.421 -0.8 . . . . 0.0 110.238 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.491 ' HG2' ' CE2' ' B' ' 190' ' ' TYR . 42.9 mtt85 -75.35 116.05 15.65 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 178.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -72.12 150.01 44.24 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.458 1.123 . . . . 0.0 113.138 -175.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . 0.438 ' OE2' ' HD3' ' B' ' 187' ' ' LYS . 5.8 tt0 -47.36 -56.99 5.79 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 114.429 -1.26 . . . . 0.0 112.903 -178.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.588 ' HG2' ' HG3' ' A' ' 43' ' ' GLU . 5.0 tptt -100.78 24.74 8.75 Favored 'General case' 0 N--CA 1.499 1.975 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -176.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 107.96 153.32 17.49 Favored Glycine 0 N--CA 1.504 3.199 0 O-C-N 120.813 -1.179 . . . . 0.0 110.444 178.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 98.92 167.52 30.61 Favored Glycine 0 N--CA 1.501 3.005 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.525 ' CD2' HD11 ' B' ' 213' ' ' LEU . 90.9 m-85 -137.65 161.59 36.06 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.514 -0.992 . . . . 0.0 111.297 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -129.08 100.05 5.49 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 78.5 mt -98.49 122.14 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 CA-C-O 121.681 0.753 . . . . 0.0 111.239 -176.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 47.9 m -96.12 120.74 36.95 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.55 ' HB ' HG22 ' B' ' 203' ' ' VAL . 66.5 mt -110.44 125.81 67.71 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 63.4 t -97.5 97.62 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -71.75 86.11 0.94 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.98 -27.94 65.87 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 122.012 -0.43 . . . . 0.0 111.309 -178.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 66.1 m -71.53 -35.81 70.8 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.636 -0.665 . . . . 0.0 110.293 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -106.85 4.74 27.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.465 -0.772 . . . . 0.0 110.834 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 51.06 47.71 24.38 Favored 'General case' 0 N--CA 1.511 2.619 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -130.58 140.71 50.45 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.89 -0.506 . . . . 0.0 110.372 -177.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -110.2 125.6 53.23 Favored 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' B' ' 194' ' ' ILE . 1.5 m -124.55 147.63 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.214 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 20.5 mt -120.08 110.57 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.297 -0.877 . . . . 0.0 108.938 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.81 123.54 35.27 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.5 mt -95.92 132.44 40.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.554 0.693 . . . . 0.0 109.628 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 55.6 mt -115.64 131.72 23.52 Favored Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.58 165.51 30.3 Favored 'Trans proline' 0 CA--C 1.536 0.621 0 C-N-CA 122.459 2.106 . . . . 0.0 111.864 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.659 ' NH1' ' OD1' ' A' ' 44' ' ' ASP . 10.0 ptm180 -72.42 160.18 32.75 Favored 'General case' 0 N--CA 1.502 2.15 0 CA-C-O 121.489 0.661 . . . . 0.0 110.927 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 93.59 -4.67 73.06 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.845 HD21 ' HG3' ' B' ' 231' ' ' PRO . 7.3 mt -117.19 142.41 47.06 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 122.202 -0.587 . . . . 0.0 109.483 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -110.64 139.94 45.45 Favored 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.593 HD23 HG22 ' B' ' 228' ' ' THR . 66.9 mt -75.33 152.56 38.13 Favored 'General case' 0 N--CA 1.501 2.081 0 CA-C-O 121.824 0.821 . . . . 0.0 112.106 -176.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 73.1 mt -112.69 2.4 16.08 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 177.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.492 HG11 HD13 ' B' ' 221' ' ' ILE . 15.2 m -118.55 159.26 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.123 0 O-C-N 121.409 -0.807 . . . . 0.0 111.907 -177.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 38.0 m -125.02 163.55 22.1 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 65.8 mt-10 -65.86 138.69 58.05 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.289 -0.882 . . . . 0.0 109.455 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 89.42 0.23 79.92 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -86.89 145.14 26.68 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 118.634 1.217 . . . . 0.0 109.812 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 16.3 m -87.27 124.39 33.28 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' B' ' 225' ' ' GLN . 2.7 tp -112.76 147.89 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.756 -0.59 . . . . 0.0 109.969 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 33.6 mttp -99.28 165.18 11.81 Favored 'General case' 0 N--CA 1.504 2.248 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 33.3 tp -65.37 134.02 52.63 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.156 -0.965 . . . . 0.0 109.378 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.431 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 71.07 13.09 6.93 Favored 'General case' 0 N--CA 1.506 2.349 0 O-C-N 122.101 -0.375 . . . . 0.0 111.113 179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.496 ' HB3' HG13 ' B' ' 221' ' ' ILE . 35.2 tt0 -74.7 133.9 76.17 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.421 ' HB3' HG11 ' B' ' 170' ' ' VAL . 25.0 Cg_endo -64.43 116.56 3.83 Favored 'Trans proline' 0 N--CA 1.486 1.071 0 C-N-CA 122.32 2.013 . . . . 0.0 112.1 -179.182 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' B' ' 173' ' ' ALA . 55.9 mt -89.13 -15.59 33.49 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.601 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.593 HG22 HD23 ' B' ' 213' ' ' LEU . 71.4 p -131.74 171.14 13.86 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.323 -0.861 . . . . 0.0 110.326 -178.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.628 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 73.4 m -79.22 161.13 26.57 Favored 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 178.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 40.1 t-20 -87.51 106.47 11.59 Favored Pre-proline 0 N--CA 1.505 2.279 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.845 ' HG3' HD21 ' B' ' 211' ' ' LEU . 40.3 Cg_endo -82.84 6.08 6.02 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.105 2.537 . . . . 0.0 113.174 -177.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -83.43 119.4 24.61 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.18 -0.95 . . . . 0.0 110.546 -178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 26.3 m -113.11 -0.86 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -100.13 -162.38 28.56 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 171.98 166.81 31.21 Favored Glycine 0 N--CA 1.497 2.726 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.034 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -119.66 141.82 49.02 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -142.86 156.73 26.53 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -135.72 147.83 48.62 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.806 -0.82 . . . . 0.0 110.007 179.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -141.35 173.46 23.37 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -144.63 152.7 40.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.531 -0.982 . . . . 0.0 109.743 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -135.77 164.32 28.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.415 -0.958 . . . . 0.0 108.415 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -125.98 123.77 39.24 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . 0.475 HD12 HG13 ' B' ' 35' ' ' VAL . 9.1 tt -114.1 143.32 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.518 HG22 ' HG2' ' B' ' 145' ' ' LYS . 27.2 t -105.62 106.23 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.751 -0.593 . . . . 0.0 109.967 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 19.8 tp -67.74 107.1 2.45 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 104.106 -2.553 . . . . 0.0 104.106 175.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -91.71 143.72 26.25 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 122.506 1.146 . . . . 0.0 114.075 -173.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.475 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 11.8 t0 -76.77 133.76 69.68 Favored Pre-proline 0 N--CA 1.486 1.334 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 175.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -67.36 -2.52 8.36 Favored 'Trans proline' 0 CA--C 1.546 1.115 0 C-N-CA 121.412 1.408 . . . . 0.0 111.878 -179.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . 0.566 ' O ' ' HG3' ' B' ' 250' ' ' ARG . 8.9 mt -110.48 -133.27 0.34 Allowed 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 176.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' B' ' 249' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.508 2.444 0 O-C-N 121.12 -0.988 . . . . 0.0 109.47 178.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.547 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 7.5 tt . . . . . 0 N--CA 1.5 2.062 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -102.01 135.98 42.64 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.143 -0.973 . . . . 0.0 108.876 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.2 t -126.6 126.29 68.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.44 136.52 33.41 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.597 0.713 . . . . 0.0 110.848 -178.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD21 ' HB3' ' A' ' 29' ' ' PHE . 13.6 mt -95.25 102.87 14.71 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 177.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.86 122.86 5.05 Favored Glycine 0 N--CA 1.478 1.48 0 N-CA-C 107.1 -2.4 . . . . 0.0 107.1 -176.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.44 167.06 22.44 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.012 -1.287 . . . . 0.0 111.163 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -65.66 -12.79 56.48 Favored 'General case' 0 N--CA 1.514 2.758 0 O-C-N 120.547 -1.346 . . . . 0.0 112.186 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 40.0 p-10 -99.24 11.85 37.89 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.22 7.93 86.09 Favored Glycine 0 N--CA 1.5 2.948 0 O-C-N 120.874 -1.141 . . . . 0.0 111.034 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.8 m -66.39 144.01 56.79 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 119.443 1.622 . . . . 0.0 109.589 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 54.3 mt -84.49 84.99 7.46 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.309 -1.494 . . . . 0.0 107.796 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.04 156.46 37.38 Favored 'General case' 0 N--CA 1.504 2.226 0 O-C-N 121.005 -1.059 . . . . 0.0 111.891 -177.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 80.5 m-85 -87.08 136.79 32.79 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 90.0 t -131.19 108.03 14.96 Favored Pre-proline 0 N--CA 1.492 1.662 0 C-N-CA 116.381 -2.128 . . . . 0.0 110.478 -177.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 37.5 Cg_endo -76.3 167.47 80.03 Favored 'Cis proline' 0 CA--C 1.563 1.945 0 C-N-CA 124.351 -1.104 . . . . 0.0 112.461 -0.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.1 p -104.46 -22.78 13.25 Favored 'General case' 0 N--CA 1.51 2.528 0 O-C-N 120.996 -1.065 . . . . 0.0 109.9 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -128.01 122.29 31.91 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -155.67 168.15 28.09 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.825 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.6 m -121.33 150.29 41.66 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.118 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 4.7 pt -141.14 162.56 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.702 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.46 164.3 30.24 Favored Pre-proline 0 C--N 1.309 -1.19 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 177.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -63.71 136.56 54.32 Favored 'Trans proline' 0 CA--C 1.559 1.735 0 C-N-CA 120.601 0.867 . . . . 0.0 114.039 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.38 60.74 Favored Glycine 0 N--CA 1.511 3.651 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 -178.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -69.27 142.58 54.1 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 119.906 -1.938 . . . . 0.0 107.594 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -90.76 145.05 25.12 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 117.574 -1.65 . . . . 0.0 112.504 -177.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 16.6 mt -113.67 120.51 63.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.544 HG13 ' HG2' ' A' ' 71' ' ' GLU . 20.7 t -105.83 107.31 22.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 118.529 -1.268 . . . . 0.0 108.73 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.413 ' HB3' HD21 ' A' ' 5' ' ' LEU . 69.4 m-85 -86.77 124.09 32.63 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 178.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.53 130.78 53.4 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 118.204 -1.398 . . . . 0.0 111.631 -178.341 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -60.03 122.33 14.08 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -119.54 -53.26 2.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.548 -0.72 . . . . 0.0 110.523 -178.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.4 150.6 23.64 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.17 -0.956 . . . . 0.0 112.428 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.79 15.15 81.85 Favored Glycine 0 N--CA 1.513 3.811 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.702 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.98 171.41 6.5 Favored Pre-proline 0 N--CA 1.512 2.661 0 O-C-N 120.256 -1.732 . . . . 0.0 108.423 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.702 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.76 154.63 79.7 Favored 'Cis proline' 0 N--CA 1.495 1.579 0 C-N-CA 124.869 -0.888 . . . . 0.0 113.978 2.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.5 m-70 -144.74 163.46 33.93 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.695 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.1 OUTLIER -151.85 170.13 20.56 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.719 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.2 mp -125.54 118.85 53.53 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 118.758 -1.177 . . . . 0.0 107.985 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.695 ' CG2' HD21 ' A' ' 38' ' ' ASN . 41.9 t -122.4 131.94 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.443 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 25.7 m-85 -89.99 137.2 32.54 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.965 -1.094 . . . . 0.0 108.837 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.527 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 0.8 OUTLIER -71.41 115.04 10.11 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.331 -1.348 . . . . 0.0 109.129 -178.697 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.48 -28.99 63.88 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.125 -0.984 . . . . 0.0 111.019 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -93.76 4.73 53.49 Favored 'General case' 0 N--CA 1.504 2.272 0 O-C-N 121.274 -0.891 . . . . 0.0 110.95 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.581 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -133.78 42.11 2.97 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 120.892 -1.13 . . . . 0.0 110.784 -179.133 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.64 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 3.2 pt -134.46 165.68 34.9 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 105.304 -2.11 . . . . 0.0 105.304 177.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.713 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.6 Cg_endo -57.21 142.56 94.59 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 120.912 1.075 . . . . 0.0 111.837 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 59.3 m -55.64 135.96 50.84 Favored 'General case' 0 N--CA 1.514 2.744 0 N-CA-C 113.507 0.928 . . . . 0.0 113.507 -177.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.96 73.01 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 178.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.713 HG21 ' HG2' ' A' ' 47' ' ' PRO . 89.1 t -79.13 132.48 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.494 0 CA-C-N 119.62 1.71 . . . . 0.0 111.151 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -84.5 113.56 21.31 Favored 'General case' 0 C--N 1.31 -1.137 0 C-N-CA 118.355 -1.338 . . . . 0.0 107.625 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.03 -24.36 66.0 Favored 'General case' 0 N--CA 1.513 2.697 0 O-C-N 120.855 -1.153 . . . . 0.0 112.064 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 p -67.12 -25.74 66.34 Favored 'General case' 0 N--CA 1.508 2.458 0 O-C-N 121.205 -0.934 . . . . 0.0 110.017 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 2.6 mttm -80.18 -17.96 50.96 Favored 'General case' 0 N--CA 1.515 2.777 0 O-C-N 120.824 -1.172 . . . . 0.0 112.583 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -122.09 3.22 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.393 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 2.1 m -128.89 164.41 23.16 Favored 'General case' 0 N--CA 1.51 2.561 0 O-C-N 120.646 -1.283 . . . . 0.0 113.242 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.401 ' HB2' HD22 ' A' ' 38' ' ' ASN . 4.5 mtp -86.68 161.78 18.27 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.6 t -72.29 153.54 41.47 Favored 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 116.974 -1.89 . . . . 0.0 108.131 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.593 ' HB3' ' CB ' ' B' ' 63' ' ' ASN . 2.1 mt-10 -60.94 -28.46 68.97 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 118.583 -1.247 . . . . 0.0 110.745 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -86.99 -4.84 59.21 Favored 'General case' 0 N--CA 1.506 2.368 0 C-N-CA 123.988 0.915 . . . . 0.0 111.403 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -92.21 145.95 24.09 Favored 'General case' 0 N--CA 1.51 2.548 0 O-C-N 120.536 -1.352 . . . . 0.0 109.269 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 ' HB2' ' A' ' 36' ' ' PRO . 56.9 mt -141.41 148.68 39.95 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.155 -0.965 . . . . 0.0 111.839 -178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 20.3 mt -100.53 109.99 22.13 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 101.219 -3.622 . . . . 0.0 101.219 173.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.507 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.2 OUTLIER -114.92 13.77 17.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 117.471 -1.692 . . . . 0.0 114.128 -174.196 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -128.85 146.04 51.04 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 120.498 -1.376 . . . . 0.0 108.2 178.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -59.31 132.9 55.41 Favored 'General case' 0 N--CA 1.506 2.339 0 O-C-N 122.08 -0.388 . . . . 0.0 111.902 -179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.96 -17.12 59.83 Favored Glycine 0 N--CA 1.5 2.944 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.192 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -62.83 142.28 58.29 Favored 'General case' 0 N--CA 1.508 2.474 0 CA-C-N 119.987 1.894 . . . . 0.0 108.336 -177.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 30' ' ' LYS . 54.2 p -129.03 156.68 43.45 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 118.328 -1.349 . . . . 0.0 113.015 -177.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -131.46 121.67 24.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 175.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.544 ' HG2' HG13 ' A' ' 28' ' ' VAL . 29.2 mt-10 -113.69 143.64 44.27 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.018 -1.073 . . . . 0.0 110.481 -177.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.77 144.08 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.605 0.717 . . . . 0.0 110.805 179.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.26 130.64 56.69 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 25.8 mt -106.73 142.25 36.68 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.352 -0.843 . . . . 0.0 108.77 -179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 30.3 p -117.56 -39.83 3.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.484 -1.385 . . . . 0.0 110.695 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -66.9 134.05 51.26 Favored 'General case' 0 N--CA 1.507 2.414 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.249 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.97 154.71 31.32 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.368 -0.833 . . . . 0.0 111.179 -177.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.76 -173.37 21.84 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 118.887 -1.625 . . . . 0.0 109.239 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -99.31 141.83 31.57 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.981 -1.305 . . . . 0.0 110.395 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.5 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 19.8 m-85 -122.82 122.2 38.09 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.581 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 69.4 m -98.23 134.1 41.73 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -134.63 167.98 19.84 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.497 -179.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 35.8 p90 -159.25 165.69 32.96 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.169 -1.012 . . . . 0.0 111.232 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.475 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 15.0 t -94.38 125.9 39.31 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 102.945 -2.983 . . . . 0.0 102.945 175.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.794 ' O ' ' HB1' ' B' ' 62' ' ' ALA . 0.9 OUTLIER -60.22 -52.65 71.68 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 120.318 -1.489 . . . . 0.0 113.959 -175.55 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HD2' ' SG ' ' A' ' 84' ' ' CYS . 33.4 Cg_endo -69.06 -18.5 40.26 Favored 'Trans proline' 0 N--CA 1.511 2.503 0 C-N-CA 122.776 2.318 . . . . 0.0 113.184 -177.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.0 m170 -121.27 18.65 11.48 Favored 'General case' 0 N--CA 1.505 2.307 0 CA-C-N 118.402 0.546 . . . . 0.0 112.18 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -61.56 -42.28 98.62 Favored 'General case' 0 N--CA 1.518 2.929 0 O-C-N 120.684 -1.26 . . . . 0.0 109.03 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.899 ' O ' ' HB3' ' B' ' 160' ' ' TYR . . . -64.29 -29.56 75.38 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.534 ' CB ' ' CZ ' ' B' ' 4' ' ' PHE . . . -72.83 -8.94 57.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.546 -2.15 . . . . 0.0 111.872 -179.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.01 9.16 43.23 Favored Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.411 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 12.6 ttt -77.98 84.93 4.23 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.632 1.716 . . . . 0.0 107.057 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 6.5 m -136.88 165.56 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.51 174.43 36.39 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 118.578 -1.772 . . . . 0.0 108.786 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.8 ttpp -148.64 129.81 14.55 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.831 1.316 . . . . 0.0 107.924 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.45 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 5.1 p -116.49 142.09 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.309 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.0 m -113.08 126.66 55.71 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.394 -1.322 . . . . 0.0 109.603 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.0 t -96.19 115.18 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 178.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.484 1.238 0 C-N-CA 118.809 -1.156 . . . . 0.0 111.312 -176.814 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.854 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 5.5 m-85 . . . . . 0 C--O 1.224 -0.245 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.1 -26.13 74.24 Favored 'Trans proline' 0 N--CA 1.481 0.79 0 C-N-CA 121.515 1.477 . . . . 0.0 111.324 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.483 HG23 ' CD1' ' B' ' 4' ' ' PHE . 5.1 tp -71.28 -30.85 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.366 0 O-C-N 121.957 -0.464 . . . . 0.0 110.44 178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.614 ' CZ ' ' HD2' ' B' ' 1' ' ' TYR . 11.8 m-30 -68.67 -34.75 76.23 Favored 'General case' 0 N--CA 1.526 3.352 0 CA-C-N 118.899 0.772 . . . . 0.0 110.493 -178.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.39 -43.8 48.21 Favored 'General case' 0 N--CA 1.501 2.114 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -61.86 -46.44 89.43 Favored 'General case' 0 N--CA 1.51 2.557 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -60.89 -29.15 69.39 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -141.06 26.44 2.03 Favored 'General case' 0 N--CA 1.519 3.005 0 CA-C-N 122.137 2.244 . . . . 0.0 113.816 -177.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -140.3 111.39 7.06 Favored 'General case' 0 N--CA 1.526 3.334 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 174.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -66.25 -39.72 89.7 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.113 -175.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -122.12 135.3 25.29 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.1 Cg_endo -78.2 -16.68 13.77 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 121.545 1.497 . . . . 0.0 112.278 -175.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 11.6 ttp180 -102.57 126.12 49.53 Favored 'General case' 0 N--CA 1.51 2.529 0 CA-C-N 120.1 1.318 . . . . 0.0 110.433 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -86.67 168.63 13.42 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.84 -1.163 . . . . 0.0 110.063 -178.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -25.04 64.02 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.021 -1.049 . . . . 0.0 110.93 -179.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 6.3 p -76.34 -14.23 60.1 Favored 'General case' 0 N--CA 1.516 2.838 0 O-C-N 120.835 -1.166 . . . . 0.0 109.273 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.4 5.74 58.98 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 61.6 mtt-85 -91.55 137.58 32.25 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.583 0.706 . . . . 0.0 110.181 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' B' ' 238' ' ' GLN . 22.5 mt -80.49 139.5 18.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.8 m -55.97 -11.03 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.465 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.14 -25.98 63.72 Favored 'General case' 0 N--CA 1.525 3.279 0 CA-C-N 123.145 2.702 . . . . 0.0 109.292 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.05 -7.53 17.95 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.546 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 58.8 m-80 -76.72 -29.44 56.22 Favored 'General case' 0 N--CA 1.506 2.37 0 O-C-N 121.083 -1.011 . . . . 0.0 109.013 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.9 m -118.16 -28.83 5.73 Favored 'General case' 1 N--CA 1.54 4.041 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 177.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -89.07 92.23 9.13 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 104.963 -2.236 . . . . 0.0 104.963 175.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.42 HD12 ' HB2' ' B' ' 158' ' ' GLN . 33.0 mt -84.72 -17.82 37.18 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -173.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.29 140.39 29.59 Favored 'General case' 0 N--CA 1.522 3.155 0 CA-C-N 122.141 2.246 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 2.2 t -93.28 131.78 38.08 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.059 -1.026 . . . . 0.0 109.722 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.571 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 8.1 mttp -143.16 150.89 53.95 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.5 Cg_endo -72.57 140.77 33.41 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 N-CA-C 116.56 1.715 . . . . 0.0 116.56 -175.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 94.7 t -125.09 145.3 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 112.689 -2.051 . . . . 0.0 107.279 177.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.35 155.42 47.27 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.046 -1.034 . . . . 0.0 109.464 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 tt -147.68 120.42 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.465 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 0.8 OUTLIER -105.4 130.26 53.54 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.591 HG13 ' HD2' ' B' ' 36' ' ' PRO . 24.9 t -139.23 146.14 47.7 Favored Pre-proline 0 C--N 1.298 -1.642 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.591 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.8 Cg_endo -60.57 146.27 97.31 Favored 'Trans proline' 0 C--N 1.321 -0.888 0 O-C-N 122.576 0.777 . . . . 0.0 110.397 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -59.84 -38.15 81.28 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.949 -0.47 . . . . 0.0 110.943 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.64 154.34 41.36 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.091 -0.643 . . . . 0.0 109.643 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 15.5 m -139.43 158.86 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.453 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.9 mm? -100.67 156.17 35.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.828 -0.545 . . . . 0.0 110.012 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.434 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.26 141.21 71.32 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 121.993 1.795 . . . . 0.0 112.712 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 49.2 48.79 20.57 Favored 'General case' 0 N--CA 1.514 2.772 0 CA-C-N 114.9 -1.045 . . . . 0.0 112.636 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 38.2 p -127.99 147.3 50.49 Favored 'General case' 0 N--CA 1.506 2.328 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 177.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.24 139.33 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 118.809 -1.157 . . . . 0.0 109.463 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.65 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 51.7 p90 -137.67 166.32 24.23 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.59 139.15 49.84 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 118.703 -1.199 . . . . 0.0 111.683 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.34 110.96 21.68 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 176.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.465 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 9.6 p -100.85 122.5 52.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 116.62 -2.032 . . . . 0.0 111.152 -176.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 55.4 t -104.29 134.29 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.171 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 37.8 mttm -113.01 126.07 55.1 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 119.799 -0.76 . . . . 0.0 109.433 179.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.402 HD13 HG13 ' B' ' 71' ' ' VAL . 13.5 mt -122.79 77.06 48.54 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 104.464 -2.421 . . . . 0.0 104.464 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.8 Cg_endo -81.53 145.3 14.66 Favored 'Trans proline' 0 N--CA 1.481 0.756 0 C-N-CA 122.454 2.103 . . . . 0.0 113.865 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 35.1 p90 -160.34 153.95 22.44 Favored 'General case' 0 N--CA 1.508 2.441 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.957 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.91 123.2 18.81 Favored 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 9.6 mtm -81.61 5.76 17.17 Favored 'General case' 0 N--CA 1.512 2.64 0 O-C-N 120.277 -1.514 . . . . 0.0 114.782 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -94.68 0.73 55.29 Favored 'General case' 0 N--CA 1.511 2.589 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 40.7 mt -75.33 134.5 41.0 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.533 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -120.6 128.01 52.65 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -97.71 171.83 8.08 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.859 -0.526 . . . . 0.0 109.745 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.0 113.51 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -69.65 166.36 19.25 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 120.678 -1.264 . . . . 0.0 109.109 -179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.794 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -57.78 -7.19 0.65 Allowed 'General case' 0 N--CA 1.503 2.224 0 O-C-N 120.955 -1.091 . . . . 0.0 112.38 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.593 ' CB ' ' HB3' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -116.34 17.54 15.52 Favored 'General case' 0 N--CA 1.509 2.519 0 O-C-N 119.903 -1.748 . . . . 0.0 111.941 -178.686 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.3 -30.68 6.98 Favored Glycine 1 N--CA 1.517 4.082 0 O-C-N 121.015 -1.053 . . . . 0.0 110.655 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 1.3 mmmm -69.06 158.72 34.26 Favored 'General case' 0 N--CA 1.509 2.518 0 O-C-N 120.987 -1.302 . . . . 0.0 110.422 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 44.7 mttm -101.44 140.4 35.79 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.95 -173.22 21.41 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.193 -1.48 . . . . 0.0 111.952 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.38 167.42 21.35 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 122.171 -0.605 . . . . 0.0 110.725 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.451 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.2 mp -97.87 157.36 16.13 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 121.548 0.689 . . . . 0.0 111.992 -177.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.513 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 18.8 m-80 -115.37 154.63 28.85 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.402 HG13 HD13 ' B' ' 51' ' ' ILE . 1.0 OUTLIER -116.06 159.0 16.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.589 -1.319 . . . . 0.0 110.653 -178.518 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.13 156.82 27.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 178.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.29 160.12 42.67 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.169 -1.413 . . . . 0.0 111.801 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.9 122.12 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 7.3 tp -107.1 123.91 48.91 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 118.054 -1.458 . . . . 0.0 109.964 -178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.409 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 13.6 mt -104.85 109.66 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.692 -179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.484 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 11.4 mt -105.11 161.38 22.92 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.908 -0.495 . . . . 0.0 109.758 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.4 Cg_endo -65.84 158.04 55.92 Favored 'Trans proline' 0 N--CA 1.479 0.642 0 C-N-CA 121.749 1.633 . . . . 0.0 109.185 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -65.11 136.26 56.5 Favored 'General case' 0 N--CA 1.505 2.315 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.429 -178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.99 -39.89 2.72 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -177.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.726 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.2 m-85 -77.44 140.71 39.91 Favored 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -154.04 171.26 19.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.404 -0.81 . . . . 0.0 110.636 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 5.1 tp -61.39 129.85 43.22 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.154 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.74 137.49 96.68 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.647 -0.658 . . . . 0.0 109.622 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -68.8 157.75 60.61 Favored 'Trans proline' 0 CA--C 1.548 1.206 0 C-N-CA 122.174 1.916 . . . . 0.0 108.972 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.65 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.2 Cg_endo -60.61 -38.29 73.42 Favored 'Trans proline' 0 N--CA 1.501 1.937 0 C-N-CA 123.179 2.586 . . . . 0.0 113.582 -178.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -65.27 -26.42 68.08 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 121.31 -0.868 . . . . 0.0 110.738 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 26.6 mmm-85 -91.1 -4.35 56.33 Favored 'General case' 0 N--CA 1.517 2.924 0 O-C-N 121.282 -0.886 . . . . 0.0 110.787 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.65 HD12 ' HA ' ' B' ' 86' ' ' PRO . 52.4 mt -88.78 122.58 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 119.254 -0.978 . . . . 0.0 109.973 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . 0.511 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 62.1 p -66.79 157.7 82.83 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.911 -0.493 . . . . 0.0 110.255 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -68.58 -35.91 16.03 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.818 2.345 . . . . 0.0 109.24 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -66.16 -20.15 66.05 Favored 'General case' 0 N--CA 1.511 2.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.511 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 24.7 ttm -97.45 -30.94 12.62 Favored 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.154 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -65.86 -30.89 71.57 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.518 -0.739 . . . . 0.0 111.19 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -75.89 -33.65 59.93 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 177.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.54 -42.98 98.37 Favored 'General case' 0 N--CA 1.51 2.563 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.332 -178.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . 0.442 HG22 ' O ' ' B' ' 127' ' ' THR . 4.5 pt -78.9 7.25 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.468 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.82 -112.31 3.06 Favored Glycine 0 N--CA 1.505 3.239 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -149.51 44.17 0.94 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.644 HD22 HD11 ' B' ' 115' ' ' ILE . 17.4 mt -78.92 148.4 32.71 Favored 'General case' 0 N--CA 1.495 1.801 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.442 -179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 9.0 p -111.87 106.64 15.42 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 177.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -84.34 129.01 34.91 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.43 -0.908 . . . . 0.0 108.555 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -111.56 155.2 23.67 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.976 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -80.07 145.22 32.57 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 118.036 -1.465 . . . . 0.0 107.087 178.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -57.94 -38.22 75.56 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.3 -1.5 . . . . 0.0 107.512 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 11.3 mtt85 -151.43 156.77 34.98 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 102.76 -3.052 . . . . 0.0 102.76 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.36 -25.63 71.23 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 120.29 0.66 . . . . 0.0 112.532 -178.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 5.9 p30 -84.08 -21.1 31.63 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.597 -1.314 . . . . 0.0 109.424 178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 27.7 mmtt -94.27 84.28 4.38 Favored 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 121.984 0.897 . . . . 0.0 109.426 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.8 mttm -81.72 -8.45 59.7 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.489 -0.757 . . . . 0.0 110.059 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -101.0 11.41 39.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.314 -0.866 . . . . 0.0 111.174 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 43.0 mt -125.32 115.41 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 17.8 mt -113.5 142.45 45.92 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.963 -176.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 15.6 m -127.39 149.08 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-O 121.564 0.697 . . . . 0.0 109.889 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.644 HD11 HD22 ' B' ' 100' ' ' LEU . 14.3 tt -149.8 145.42 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.07 166.1 15.73 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 108.234 -1.946 . . . . 0.0 108.234 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.854 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 32.2 Cg_endo -73.03 135.13 38.36 Favored 'Cis proline' 0 N--CA 1.49 1.323 0 O-C-N 124.546 1.814 . . . . 0.0 113.136 -0.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.2 m -128.99 149.06 71.48 Favored Pre-proline 0 N--CA 1.502 2.133 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 177.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.09 129.61 29.31 Favored 'Trans proline' 0 CA--C 1.555 1.528 0 C-N-CA 121.361 1.374 . . . . 0.0 113.118 -177.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.28 94.64 Favored Glycine 1 N--CA 1.521 4.347 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.717 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -56.21 -37.0 69.07 Favored 'General case' 0 N--CA 1.504 2.26 0 CA-C-N 118.653 1.226 . . . . 0.0 110.032 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 2.9 mmmt -93.85 -37.34 11.79 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -117.87 51.02 1.08 Allowed 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.835 -1.165 . . . . 0.0 113.83 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 4.1 m -68.07 -28.82 67.69 Favored 'General case' 0 N--CA 1.517 2.903 0 O-C-N 120.122 -1.612 . . . . 0.0 106.706 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -117.72 126.38 52.37 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 14.7 mt -117.92 143.61 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.507 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . 0.442 ' O ' HG22 ' B' ' 97' ' ' ILE . 8.0 m -110.18 116.6 31.81 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.117 179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -99.04 117.91 63.51 Favored Pre-proline 0 N--CA 1.495 1.813 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.95 109.82 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 N-CA-C 107.665 -1.706 . . . . 0.0 107.665 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.65 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 14.4 mm -110.27 143.73 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 CA-C-O 121.649 0.738 . . . . 0.0 111.352 -177.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 10.5 tp -103.39 121.82 43.57 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.11 134.85 67.17 Favored Pre-proline 0 C--N 1.311 -1.107 0 C-N-CA 119.403 -0.919 . . . . 0.0 108.95 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.486 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.7 Cg_endo -69.92 178.01 5.11 Favored 'Trans proline' 0 C--N 1.325 -0.661 0 O-C-N 123.614 1.323 . . . . 0.0 111.352 -177.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 12.4 t70 -129.11 119.15 19.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.87 -35.98 75.22 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.291 1.994 . . . . 0.0 111.68 -179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.71 -19.08 64.64 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.51 -0.744 . . . . 0.0 109.759 177.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.95 20.22 11.59 Favored 'General case' 0 N--CA 1.524 3.264 0 O-C-N 121.045 -1.034 . . . . 0.0 110.952 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -160.91 108.17 1.51 Allowed 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -73.21 -10.66 60.01 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -177.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.21 -1.94 28.09 Favored 'General case' 0 N--CA 1.514 2.738 0 CA-C-N 121.9 2.136 . . . . 0.0 109.646 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.486 HG11 ' HG2' ' B' ' 133' ' ' PRO . 41.8 t -98.84 130.37 47.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 177.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . 0.461 ' HB2' HD12 ' B' ' 144' ' ' LEU . 87.1 m-70 -129.67 167.68 17.63 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.178 -178.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -78.22 101.88 7.32 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 175.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.461 HD12 ' HB2' ' B' ' 142' ' ' HIS . 9.6 mt -154.41 177.18 11.46 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-O 122.075 0.941 . . . . 0.0 111.949 -174.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.503 ' HG2' HG22 ' B' ' 244' ' ' VAL . 4.7 mttm -90.5 129.13 36.7 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.82 138.93 28.27 Favored Pre-proline 0 C--N 1.307 -1.28 0 C-N-CA 117.672 -1.611 . . . . 0.0 111.664 -175.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.79 146.63 21.06 Favored 'Trans proline' 0 C--O 1.22 -0.396 0 C-N-CA 121.562 1.508 . . . . 0.0 111.343 179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 39.8 mt -130.23 127.92 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.24 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.3 m-85 -117.7 141.01 48.89 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.537 -1.265 . . . . 0.0 110.632 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.63 145.11 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.357 1.075 . . . . 0.0 111.624 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.08 127.82 6.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 106.07 -2.812 . . . . 0.0 106.07 177.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.65 133.35 7.62 Favored Glycine 0 C--N 1.295 -1.731 0 C-N-CA 118.492 -1.813 . . . . 0.0 110.175 -178.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.401 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 20.8 t-20 -132.86 144.18 50.03 Favored 'General case' 0 N--CA 1.497 1.91 0 CA-C-O 121.753 0.787 . . . . 0.0 112.55 -179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.571 ' NH2' ' HB3' ' B' ' 29' ' ' LYS . 0.4 OUTLIER -136.4 126.53 26.24 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 177.095 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.441 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 105.86 159.21 22.59 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 118.093 -2.003 . . . . 0.0 110.346 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.554 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 10.4 mtm105 -75.86 141.21 42.46 Favored 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 121.687 0.756 . . . . 0.0 110.463 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.08 172.17 47.33 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.42 ' HB2' HD12 ' B' ' 26' ' ' LEU . 2.0 mp0 -99.08 -30.46 12.3 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.71 -0.876 . . . . 0.0 111.696 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 22.5 mt -118.12 143.04 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.518 2.968 0 O-C-N 120.739 -1.225 . . . . 0.0 112.604 -177.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.899 ' HB3' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -90.97 171.63 7.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 178.509 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.739 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 19.1 Cg_endo -61.47 -15.06 38.66 Favored 'Trans proline' 0 CA--C 1.563 1.964 0 C-N-CA 121.569 1.513 . . . . 0.0 113.198 176.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.37 -4.34 45.53 Favored 'General case' 0 N--CA 1.53 3.572 0 CA-C-N 120.656 1.571 . . . . 0.0 110.577 179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.19 -9.77 54.4 Favored Glycine 0 N--CA 1.509 3.537 0 N-CA-C 109.943 -1.263 . . . . 0.0 109.943 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . 0.405 ' HB2' ' CD2' ' B' ' 160' ' ' TYR . 1.8 m -69.56 142.82 53.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.602 -0.94 . . . . 0.0 111.09 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 61.4 mttt -83.96 150.67 25.5 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.911 -0.493 . . . . 0.0 110.605 179.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.757 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 17.3 p -95.26 177.91 5.7 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 119.58 -0.848 . . . . 0.0 108.869 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 -86.37 17.39 3.78 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 117.576 -1.65 . . . . 0.0 108.565 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.443 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.4 t-20 -112.68 45.2 1.35 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.937 0.875 . . . . 0.0 108.676 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.471 HG22 ' O ' ' B' ' 166' ' ' SER . 5.5 t -153.39 172.42 17.11 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.124 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 60.3 t -77.21 142.78 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.858 -0.526 . . . . 0.0 109.975 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -104.78 122.2 45.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -103.34 152.12 21.93 Favored 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 117.924 -1.51 . . . . 0.0 111.379 -175.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.429 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.3 131.49 46.23 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.692 -0.63 . . . . 0.0 109.341 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 12.8 p -83.04 -4.86 58.78 Favored 'General case' 0 N--CA 1.512 2.646 0 O-C-N 121.512 -0.743 . . . . 0.0 109.709 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.574 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.61 151.32 31.36 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-O 121.559 0.695 . . . . 0.0 111.131 179.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.73 169.9 43.33 Favored Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.399 -2.28 . . . . 0.0 107.399 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.58 -156.03 24.49 Favored Glycine 0 C--N 1.301 -1.364 0 C-N-CA 117.259 -2.401 . . . . 0.0 111.249 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 5.4 tt -121.5 136.03 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 16.8 mt -74.92 116.36 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 32.2 p -92.97 -18.5 22.64 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.235 -0.916 . . . . 0.0 110.409 -178.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -161.25 145.94 13.59 Favored 'General case' 0 N--CA 1.501 2.094 0 CA-C-O 122.459 1.123 . . . . 0.0 113.091 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' B' ' 217' ' ' GLU . 74.4 mt -131.39 100.22 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 6.5 tp -87.88 109.18 19.58 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.493 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.94 120.47 20.52 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 177.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 46.7 mtmt -77.03 151.89 35.37 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.938 -1.102 . . . . 0.0 113.153 -174.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -50.41 -58.33 5.97 Favored 'General case' 0 N--CA 1.511 2.579 0 CA-C-N 115.364 -0.834 . . . . 0.0 113.113 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -92.03 19.1 7.09 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.809 -1.182 . . . . 0.0 111.084 -177.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 106.54 154.14 20.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.039 -1.553 . . . . 0.0 110.568 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.34 171.23 29.5 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.497 ' CG ' HD11 ' B' ' 213' ' ' LEU . 53.9 m-85 -141.44 161.65 37.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.997 0.904 . . . . 0.0 112.263 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.1 110.85 13.99 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 176.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.497 HD11 HD22 ' B' ' 213' ' ' LEU . 80.6 mt -107.05 122.97 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.701 -1.249 . . . . 0.0 110.397 -176.278 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.8 m -96.38 122.69 39.54 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.443 ' HB ' HG23 ' B' ' 203' ' ' VAL . 18.8 mt -112.04 128.02 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 52.1 t -98.46 100.58 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.237 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -73.45 88.74 1.62 Allowed 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.21 -32.55 71.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.447 -0.783 . . . . 0.0 110.898 -177.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 28.0 m -67.45 -35.25 78.85 Favored 'General case' 0 N--CA 1.508 2.43 0 O-C-N 121.681 -0.637 . . . . 0.0 111.587 -179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -106.34 3.65 27.75 Favored 'General case' 0 N--CA 1.516 2.828 0 O-C-N 121.795 -0.566 . . . . 0.0 110.348 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 49.96 50.68 18.05 Favored 'General case' 0 N--CA 1.506 2.362 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 16.0 ttp-105 -133.66 141.15 47.48 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.549 -178.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 27.1 tt0 -111.95 129.33 56.22 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' B' ' 175' ' ' ALA . 12.1 m -130.06 147.66 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.597 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 17.2 mt -120.14 111.21 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.964 0.888 . . . . 0.0 109.92 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -92.01 128.46 37.86 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 24.0 mt -99.54 135.01 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 C-N-CA 118.914 -1.114 . . . . 0.0 108.973 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.431 HD13 ' CD2' ' B' ' 213' ' ' LEU . 31.0 mt -116.81 132.34 23.46 Favored Pre-proline 0 N--CA 1.492 1.673 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -76.22 165.65 29.11 Favored 'Trans proline' 0 N--CA 1.486 1.077 0 C-N-CA 123.273 2.649 . . . . 0.0 111.827 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -73.49 154.4 39.92 Favored 'General case' 0 N--CA 1.512 2.669 0 CA-C-O 121.532 0.682 . . . . 0.0 112.703 -178.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.9 -6.96 62.56 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 107.792 -2.123 . . . . 0.0 107.792 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.487 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.2 OUTLIER -115.77 142.77 46.32 Favored 'General case' 0 N--CA 1.48 1.056 0 O-C-N 121.999 -0.706 . . . . 0.0 109.989 178.869 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -109.51 139.33 44.63 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.497 HD11 ' CG ' ' B' ' 190' ' ' TYR . 13.5 mt -74.67 150.92 39.36 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.421 -0.799 . . . . 0.0 112.809 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 32.0 mt -111.98 5.91 19.08 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.5 HG11 HD13 ' B' ' 221' ' ' ILE . 11.6 m -120.23 157.07 23.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.204 -0.998 . . . . 0.0 113.108 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 36.6 m -122.33 157.09 32.53 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.281 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.422 ' HG3' HD12 ' B' ' 182' ' ' ILE . 71.6 mt-10 -61.16 143.12 56.1 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.71 -4.06 86.53 Favored Glycine 0 N--CA 1.503 3.119 0 O-C-N 120.882 -1.137 . . . . 0.0 110.735 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -86.83 144.18 27.14 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.96 -1.318 . . . . 0.0 110.887 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 32.6 m -87.03 123.96 32.69 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.5 HD13 HG11 ' B' ' 215' ' ' VAL . 3.1 tp -113.17 149.19 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-O 121.34 0.591 . . . . 0.0 109.816 -179.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -102.04 161.65 13.52 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.09 138.8 58.19 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 118.676 -1.21 . . . . 0.0 109.128 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.36 14.19 9.57 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 121.461 -0.775 . . . . 0.0 111.68 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.434 ' HB3' HG13 ' B' ' 221' ' ' ILE . 4.8 tt0 -76.49 125.43 87.48 Favored Pre-proline 0 N--CA 1.509 2.505 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 178.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -55.85 124.24 15.79 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 121.538 1.492 . . . . 0.0 110.664 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' B' ' 173' ' ' ALA . 68.6 mt -98.85 -11.45 21.74 Favored 'General case' 0 N--CA 1.509 2.501 0 CA-C-O 121.376 0.608 . . . . 0.0 110.157 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 16.9 p -135.82 168.39 19.39 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 122.014 0.911 . . . . 0.0 111.288 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.543 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 19.8 m -73.07 161.98 30.0 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-N 114.873 -1.058 . . . . 0.0 108.935 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -90.91 107.04 17.97 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 177.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' B' ' 229' ' ' SER . 51.0 Cg_endo -86.11 13.72 2.66 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 121.578 1.519 . . . . 0.0 112.859 -175.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -90.75 119.59 31.1 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 119.145 0.884 . . . . 0.0 110.799 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 23.9 m -111.93 3.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.819 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.72 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.4 -162.96 25.39 Favored Glycine 0 N--CA 1.498 2.824 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.63 164.16 25.88 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 84.3 t80 -117.33 147.3 42.72 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.62 161.15 28.48 Favored Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.402 ' HB3' HD12 ' B' ' 19' ' ' ILE . 16.6 pt20 -138.29 155.24 48.78 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.421 -1.047 . . . . 0.0 109.027 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.17 174.89 29.47 Favored Glycine 0 C--N 1.292 -1.904 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -146.52 158.03 43.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 117.748 -1.581 . . . . 0.0 110.177 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -137.02 171.04 15.11 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -129.85 133.75 47.11 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 177.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.16 142.92 39.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 119.295 -0.962 . . . . 0.0 109.421 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.503 HG22 ' HG2' ' B' ' 145' ' ' LYS . 11.9 t -103.78 110.44 30.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.321 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.1 tp -72.3 113.97 9.91 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 103.259 -2.867 . . . . 0.0 103.259 175.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -101.05 142.31 32.69 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -172.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -73.0 129.37 86.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 175.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_endo -66.12 -0.79 4.45 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 121.216 1.277 . . . . 0.0 111.212 -177.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 13.9 mt -111.27 -128.71 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 176.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.366 -1.302 . . . . 0.0 109.599 177.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.554 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 15.7 tt . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.1 0.476 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -102.73 132.16 49.07 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -123.4 125.11 71.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 15.9 mt -84.12 135.1 34.53 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.712 -0.617 . . . . 0.0 110.593 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.1 mt -95.51 97.48 9.81 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 177.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 102.09 125.16 5.56 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 107.421 -2.271 . . . . 0.0 107.421 -176.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -71.92 167.53 19.88 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.454 -1.027 . . . . 0.0 110.66 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -66.92 -15.44 63.68 Favored 'General case' 0 N--CA 1.503 2.222 0 O-C-N 121.7 -0.625 . . . . 0.0 110.731 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -97.49 10.4 39.9 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.312 -0.867 . . . . 0.0 109.505 178.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.05 9.59 82.12 Favored Glycine 0 N--CA 1.499 2.897 0 O-C-N 121.788 -0.57 . . . . 0.0 111.769 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.534 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 8.2 m -69.66 141.65 53.57 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 118.538 1.169 . . . . 0.0 109.391 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.478 ' CD1' HG21 ' B' ' 3' ' ' ILE . 31.9 mt -85.04 85.67 7.46 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.74 155.94 33.97 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.354 0.597 . . . . 0.0 110.911 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 83.0 m-85 -85.92 132.94 33.98 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 176.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 31.1 t -125.42 107.06 27.08 Favored Pre-proline 0 N--CA 1.507 2.415 0 O-C-N 121.002 -1.061 . . . . 0.0 109.863 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 34.9 Cg_endo -78.84 166.65 78.93 Favored 'Cis proline' 0 N--CA 1.491 1.373 0 O-C-N 123.315 1.166 . . . . 0.0 111.664 -1.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.6 p -101.3 -29.13 12.24 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.498 -0.751 . . . . 0.0 110.267 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -123.53 120.48 32.99 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -153.76 167.09 30.78 Favored 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.446 0.641 . . . . 0.0 110.101 -177.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 m -121.71 146.8 46.66 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 179.011 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.6 pt -140.28 161.65 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 CA-C-O 121.331 0.586 . . . . 0.0 109.461 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 m -88.33 160.75 44.74 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 177.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -65.47 133.53 35.03 Favored 'Trans proline' 0 C--N 1.321 -0.904 0 C-N-CA 121.815 1.677 . . . . 0.0 110.992 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 87.86 -9.65 73.42 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -68.81 139.43 55.25 Favored 'General case' 0 N--CA 1.503 2.207 0 CA-C-N 118.477 1.138 . . . . 0.0 108.213 178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -89.58 142.68 27.46 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 122.078 0.942 . . . . 0.0 111.965 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -112.81 117.63 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.9 t -103.42 103.23 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.643 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -84.14 119.65 25.24 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -119.89 132.41 55.54 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.576 -178.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -60.69 121.16 11.55 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 23.4 t30 -118.12 -55.07 2.27 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.563 -0.711 . . . . 0.0 111.298 -177.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.469 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.19 149.44 22.89 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.209 -0.932 . . . . 0.0 110.872 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.84 80.39 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 111.831 -0.508 . . . . 0.0 111.831 178.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.674 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -69.34 169.95 10.51 Favored Pre-proline 0 N--CA 1.509 2.524 0 O-C-N 121.435 -1.038 . . . . 0.0 109.471 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.674 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 28.5 Cg_endo -65.94 152.53 79.99 Favored 'Cis proline' 0 N--CA 1.497 1.691 0 N-CA-C 114.482 0.916 . . . . 0.0 114.482 3.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.435 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.6 m-70 -139.34 163.43 32.52 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.658 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -152.42 165.22 35.7 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.6 mp -122.94 114.58 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HA ' ' HB3' ' A' ' 56' ' ' SER . 14.5 t -121.04 127.74 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.461 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 31.6 m-85 -87.87 134.21 33.75 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.528 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 1.7 t70 -69.75 112.62 6.33 Favored 'General case' 0 N--CA 1.493 1.709 0 CA-C-O 121.451 0.643 . . . . 0.0 109.311 -179.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.87 -29.16 62.68 Favored 'General case' 0 N--CA 1.507 2.386 0 O-C-N 122.122 -0.361 . . . . 0.0 111.457 -179.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -94.67 4.64 53.59 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.644 -0.66 . . . . 0.0 110.573 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -132.56 38.35 3.44 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 120.946 -1.096 . . . . 0.0 111.798 -179.16 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.668 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 6.8 pt -130.89 167.9 19.5 Favored Pre-proline 0 N--CA 1.504 2.254 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 176.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.72 ' HG2' HG21 ' A' ' 50' ' ' VAL . 22.0 Cg_endo -59.76 141.28 96.56 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 121.604 1.536 . . . . 0.0 111.932 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 35.3 m -54.65 136.53 45.45 Favored 'General case' 0 N--CA 1.501 2.096 0 CA-C-N 115.377 -0.828 . . . . 0.0 112.457 -177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.43 -8.96 78.71 Favored Glycine 0 N--CA 1.501 2.976 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.576 178.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.72 HG21 ' HG2' ' A' ' 47' ' ' PRO . 87.1 t -80.82 133.88 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 CA-C-N 119.114 1.457 . . . . 0.0 110.06 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -86.47 111.24 20.36 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.44 -24.06 67.09 Favored 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.662 -0.649 . . . . 0.0 111.502 -178.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.6 p -68.57 -24.24 64.59 Favored 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.541 -0.725 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -81.95 -17.81 45.76 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.73 -0.606 . . . . 0.0 111.739 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.2 pt -123.21 4.81 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.362 0 O-C-N 120.902 -1.124 . . . . 0.0 112.802 -177.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.3 m -130.02 162.83 27.82 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.768 -1.208 . . . . 0.0 112.426 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 44.7 mtp -83.48 160.35 21.54 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.9 t -73.39 148.3 43.48 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.25 -27.94 56.85 Favored 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.706 -0.622 . . . . 0.0 109.87 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -89.74 -5.79 56.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 122.1 -0.375 . . . . 0.0 111.307 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 44.0 m-20 -90.04 145.97 24.69 Favored 'General case' 0 N--CA 1.507 2.396 0 O-C-N 120.998 -1.063 . . . . 0.0 109.354 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 77.4 mt -141.94 147.95 37.86 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.309 -0.869 . . . . 0.0 113.125 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 24.1 mt -98.2 107.57 20.07 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.427 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -111.14 11.35 21.91 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.421 -1.424 . . . . 0.0 113.71 -174.652 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -127.78 145.32 50.96 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.538 -1.351 . . . . 0.0 109.687 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -60.67 130.27 45.66 Favored 'General case' 0 N--CA 1.502 2.163 0 CA-C-O 121.132 0.491 . . . . 0.0 109.79 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 98.01 -15.46 61.55 Favored Glycine 0 N--CA 1.5 2.912 0 CA-C-O 119.6 -0.556 . . . . 0.0 112.323 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.79 139.73 58.31 Favored 'General case' 0 N--CA 1.509 2.49 0 CA-C-N 119.524 1.662 . . . . 0.0 108.462 178.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.4 p -128.42 155.07 45.33 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 122.014 0.911 . . . . 0.0 112.571 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -129.49 118.5 22.19 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -108.9 142.79 38.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 9.5 p -149.67 143.52 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 CA-C-O 121.508 0.671 . . . . 0.0 109.784 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.59 125.87 51.54 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 24.7 mt -102.22 140.2 36.83 Favored 'General case' 0 N--CA 1.502 2.162 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.9 p -116.41 -41.05 3.15 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.462 -0.774 . . . . 0.0 110.939 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -67.39 136.11 54.23 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.158 -0.964 . . . . 0.0 109.52 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.79 153.72 28.98 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.391 0.615 . . . . 0.0 110.015 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.56 -171.14 22.75 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.96 138.21 39.22 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.99 -0.711 . . . . 0.0 110.041 -179.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.469 ' HB2' ' CG1' ' A' ' 96' ' ' VAL . 22.0 m-85 -121.14 119.98 33.94 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.6 m -97.27 128.69 44.35 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -130.7 167.68 18.42 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.328 0.585 . . . . 0.0 109.694 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -161.99 164.65 28.23 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.88 0.848 . . . . 0.0 111.356 -178.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.473 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 42.6 t -95.3 120.85 36.24 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 104.319 -2.474 . . . . 0.0 104.319 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.78 ' OG ' ' HD3' ' A' ' 86' ' ' PRO . 88.6 p -57.56 -50.03 90.44 Favored Pre-proline 0 N--CA 1.51 2.543 0 N-CA-C 113.82 1.044 . . . . 0.0 113.82 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.78 ' HD3' ' OG ' ' A' ' 85' ' ' SER . 33.5 Cg_endo -71.9 -22.6 23.12 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 120.93 1.087 . . . . 0.0 112.509 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.775 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 26.3 m170 -119.19 22.85 11.64 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.9 -1.125 . . . . 0.0 111.674 -179.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.29 -41.97 98.95 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 120.75 -1.219 . . . . 0.0 109.374 179.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.775 ' HA3' HBD2 ' B' ' 253' ' ' HEC . . . -66.93 -23.28 72.66 Favored Glycine 0 N--CA 1.501 3.01 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.732 ' HA ' ' CZ ' ' B' ' 4' ' ' PHE . . . -68.61 -19.67 64.46 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.199 0.524 . . . . 0.0 110.114 178.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 102.39 8.13 44.41 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.501 -2.239 . . . . 0.0 107.501 -177.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 14.8 ttt -77.31 79.53 3.82 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 178.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.8 m -135.05 165.02 32.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.308 -1.314 . . . . 0.0 107.93 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -160.97 172.39 37.24 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -148.14 129.02 14.35 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.469 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 7.4 p -115.43 140.64 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 38.9 m -114.38 122.04 45.44 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.9 t -93.99 110.6 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.8 p30 . . . . . 0 N--CA 1.5 2.061 0 CA-C-O 118.269 -0.872 . . . . 0.0 110.486 -177.852 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.891 ' HB2' ' CE1' ' B' ' 4' ' ' PHE . 12.8 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 27.3 Cg_endo -62.71 -20.85 72.17 Favored 'Trans proline' 0 CA--C 1.544 0.979 0 C-N-CA 122.365 2.043 . . . . 0.0 111.607 179.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.629 HG23 ' CD1' ' B' ' 4' ' ' PHE . 3.2 tp -77.67 -25.13 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.314 0 O-C-N 121.365 -0.834 . . . . 0.0 111.067 179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.891 ' CE1' ' HB2' ' B' ' 1' ' ' TYR . 0.2 OUTLIER -73.59 -37.47 65.46 Favored 'General case' 0 N--CA 1.513 2.71 0 O-C-N 120.648 -1.282 . . . . 0.0 108.893 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' HD2' ' B' ' 9' ' ' TYR . . . -70.11 -42.68 72.33 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -64.93 -40.77 95.55 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 122.058 -0.402 . . . . 0.0 110.45 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -67.17 -29.08 68.68 Favored 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -177.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.99 22.42 2.83 Favored 'General case' 0 N--CA 1.512 2.644 0 O-C-N 120.214 -1.554 . . . . 0.0 114.1 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 73.4 m-85 -137.82 106.88 6.0 Favored 'General case' 0 N--CA 1.505 2.311 0 N-CA-C 105.419 -2.067 . . . . 0.0 105.419 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.83 -41.47 91.42 Favored 'General case' 0 N--CA 1.516 2.857 0 O-C-N 121.228 -0.92 . . . . 0.0 111.485 -177.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -121.52 132.98 24.1 Favored Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 178.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.47 ' HG3' HG21 ' B' ' 112' ' ' ILE . 33.6 Cg_endo -75.65 -18.39 17.42 Favored 'Trans proline' 0 N--CA 1.488 1.184 0 C-N-CA 122.074 1.849 . . . . 0.0 113.816 -175.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -102.42 126.5 49.47 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.099 -1.001 . . . . 0.0 109.186 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -87.59 169.6 12.02 Favored 'General case' 0 N--CA 1.501 2.093 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.93 -27.03 66.42 Favored 'General case' 0 N--CA 1.51 2.566 0 O-C-N 121.735 -0.603 . . . . 0.0 111.886 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 4.7 p -74.68 -14.89 60.8 Favored 'General case' 0 N--CA 1.505 2.314 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.21 4.46 58.5 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 37.6 mtt-85 -92.34 138.24 31.69 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.762 -0.846 . . . . 0.0 109.807 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 238' ' ' GLN . 40.4 mt -81.15 139.5 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.27 -9.41 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.508 2.464 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -175.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 m -70.92 -26.81 63.36 Favored 'General case' 0 N--CA 1.511 2.597 0 CA-C-N 121.212 1.824 . . . . 0.0 108.57 178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.89 -8.3 21.41 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 122.01 -0.431 . . . . 0.0 111.435 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 -76.34 -29.79 57.38 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.459 -0.775 . . . . 0.0 109.889 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 7.5 m -115.45 -33.82 5.13 Favored 'General case' 0 N--CA 1.516 2.848 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -87.51 92.9 9.25 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 104.833 -2.284 . . . . 0.0 104.833 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 30.2 mt -87.19 -19.45 28.38 Favored 'General case' 0 N--CA 1.499 1.982 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -171.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.84 140.1 31.43 Favored 'General case' 0 N--CA 1.502 2.149 0 CA-C-N 121.158 1.799 . . . . 0.0 109.315 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 6.0 t -95.28 128.35 42.05 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.68 -0.638 . . . . 0.0 110.041 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.444 ' O ' ' HA3' ' B' ' 237' ' ' GLY . 10.3 mttp -141.79 147.57 45.82 Favored Pre-proline 0 N--CA 1.497 1.886 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -67.45 141.08 54.62 Favored 'Trans proline' 0 N--CA 1.486 1.074 0 C-N-CA 122.68 2.253 . . . . 0.0 115.469 -173.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 70.5 t -127.09 143.98 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 177.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 2.7 t70 -129.18 154.77 46.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.179 -0.951 . . . . 0.0 109.526 -179.226 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 3.7 tt -146.24 121.55 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.552 -0.717 . . . . 0.0 110.13 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.5 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 2.3 mt-10 -106.38 125.46 51.03 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.644 HG13 ' HD2' ' B' ' 36' ' ' PRO . 4.1 t -133.52 147.61 65.38 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.644 ' HD2' HG13 ' B' ' 35' ' ' VAL . 25.5 Cg_endo -63.12 140.25 77.24 Favored 'Trans proline' 0 N--CA 1.481 0.746 0 C-N-CA 121.095 1.196 . . . . 0.0 110.077 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -53.32 -40.99 65.25 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 122.054 -0.404 . . . . 0.0 111.33 -177.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -145.57 152.86 40.38 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 m -136.42 158.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -97.8 161.48 25.55 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.433 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 21.5 Cg_endo -61.24 138.0 74.5 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 C-N-CA 122.611 2.207 . . . . 0.0 112.395 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 54.19 47.39 23.26 Favored 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.684 0.794 . . . . 0.0 112.438 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 22.9 p -127.89 145.86 50.81 Favored 'General case' 0 N--CA 1.502 2.169 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.2 t -88.65 134.71 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.454 -0.779 . . . . 0.0 109.187 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.543 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.8 p90 -132.53 166.9 21.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.95 135.11 54.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.237 -0.914 . . . . 0.0 110.881 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -108.63 104.58 13.92 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 105.171 -2.159 . . . . 0.0 105.171 176.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.5 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.7 p -94.89 121.11 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.976 0.893 . . . . 0.0 109.933 -177.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.59 131.89 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.435 ' C ' ' HD3' ' B' ' 52' ' ' PRO . 41.9 mttm -112.59 124.16 51.91 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 121.762 0.791 . . . . 0.0 109.887 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.2 mt -120.89 76.97 29.95 Favored Pre-proline 0 N--CA 1.494 1.761 0 N-CA-C 105.317 -2.105 . . . . 0.0 105.317 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.435 ' HD3' ' C ' ' B' ' 50' ' ' LYS . 37.3 Cg_endo -80.47 145.25 16.51 Favored 'Trans proline' 0 N--CA 1.481 0.738 0 C-N-CA 122.792 2.328 . . . . 0.0 113.517 -175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -162.25 153.03 17.42 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -64.31 121.06 13.4 Favored 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 6.3 mtm -80.38 3.29 21.71 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -174.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -93.73 1.82 56.43 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 120.333 -1.479 . . . . 0.0 107.596 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 57.9 mt -77.29 136.14 38.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.677 0.751 . . . . 0.0 111.131 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -121.64 124.91 45.44 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -93.97 170.0 9.86 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.072 0.463 . . . . 0.0 109.967 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.53 113.85 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mp -71.33 166.55 21.39 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.687 -0.633 . . . . 0.0 109.37 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . . . . . . . . . . . -57.37 -8.66 0.82 Allowed 'General case' 0 N--CA 1.512 2.644 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.51 16.21 15.59 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.96 -1.087 . . . . 0.0 111.825 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 94.83 -30.98 7.29 Favored Glycine 0 N--CA 1.502 3.043 0 O-C-N 120.737 -1.227 . . . . 0.0 111.825 178.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -69.66 158.76 34.72 Favored 'General case' 0 N--CA 1.504 2.261 0 CA-C-N 118.665 1.233 . . . . 0.0 110.073 -179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 48.9 mttm -100.36 140.82 34.06 Favored 'General case' 0 N--CA 1.501 2.078 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -150.94 -172.62 20.18 Favored Glycine 0 N--CA 1.502 3.039 0 C-N-CA 120.184 -1.007 . . . . 0.0 111.291 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.3 170.12 17.14 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 122.011 -0.699 . . . . 0.0 110.606 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.423 HD23 ' CA ' ' B' ' 155' ' ' GLY . 6.4 mp -99.49 157.86 16.14 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.632 0.73 . . . . 0.0 110.976 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.461 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 22.4 m-80 -115.23 153.06 31.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 177.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -115.06 154.22 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 CA-C-O 121.934 0.873 . . . . 0.0 110.571 -178.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.82 153.18 24.56 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 107.727 -2.149 . . . . 0.0 107.727 179.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -152.17 157.95 42.24 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.27 -1.135 . . . . 0.0 111.421 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.431 ' O ' HG13 ' B' ' 74' ' ' VAL . 8.8 p -128.32 119.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.9 tp -105.38 121.45 43.92 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.7 mt -103.63 107.88 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.534 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 10.8 mt -102.39 164.61 15.35 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.3 Cg_endo -70.03 156.48 62.55 Favored 'Trans proline' 0 CA--C 1.541 0.874 0 C-N-CA 121.997 1.798 . . . . 0.0 109.308 177.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -62.98 134.54 56.33 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.349 -0.844 . . . . 0.0 109.808 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.57 -38.01 3.42 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.696 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 35.8 m-85 -77.9 140.33 39.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -152.15 172.39 16.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.474 -0.766 . . . . 0.0 109.867 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.94 130.09 43.97 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -63.84 139.12 97.58 Favored Pre-proline 0 N--CA 1.497 1.911 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -70.39 159.47 52.84 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 121.843 1.695 . . . . 0.0 109.883 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.547 ' HA ' HD12 ' B' ' 89' ' ' ILE . 27.7 Cg_endo -62.67 -34.77 72.85 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.426 2.084 . . . . 0.0 113.355 -177.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.17 -25.36 64.32 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.244 -0.91 . . . . 0.0 110.575 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 34.1 mmm-85 -91.6 -5.9 53.2 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.476 -0.765 . . . . 0.0 111.257 -179.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.547 HD12 ' HA ' ' B' ' 86' ' ' PRO . 66.8 mt -88.1 124.39 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 120.964 -1.085 . . . . 0.0 109.603 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 35.8 p -67.26 160.58 70.44 Favored Pre-proline 0 N--CA 1.5 2.073 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.323 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -72.21 -31.54 11.74 Favored 'Trans proline' 0 CA--C 1.541 0.845 0 C-N-CA 122.035 1.823 . . . . 0.0 109.844 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.58 -21.18 63.62 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . . . . . . . . . 22.2 ttm -96.06 -30.59 13.47 Favored 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -65.01 -33.23 75.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.593 -0.692 . . . . 0.0 110.484 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.57 -28.76 56.37 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.013 -1.054 . . . . 0.0 108.549 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.74 -41.09 79.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.969 -0.457 . . . . 0.0 110.174 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 7.6 pt -79.64 5.85 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.507 2.408 0 O-C-N 121.088 -1.008 . . . . 0.0 110.427 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 57.44 -112.27 3.56 Favored Glycine 0 N--CA 1.503 3.145 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -147.33 43.35 1.11 Allowed 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 178.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.664 HD22 HD11 ' B' ' 115' ' ' ILE . 16.7 mt -78.15 148.57 34.06 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.661 -178.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 14.9 p -111.38 102.61 10.98 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -79.94 126.11 30.61 Favored 'General case' 0 N--CA 1.499 2.013 0 N-CA-C 107.483 -1.302 . . . . 0.0 107.483 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.8 mm-40 -108.29 154.26 22.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.623 -0.673 . . . . 0.0 109.491 -179.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 10.1 m-20 -78.71 141.97 37.47 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -52.92 -39.32 62.7 Favored 'General case' 0 N--CA 1.506 2.372 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 18.4 mtt85 -152.26 154.94 32.83 Favored Pre-proline 0 N--CA 1.496 1.841 0 N-CA-C 103.918 -2.623 . . . . 0.0 103.918 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.41 -24.2 78.07 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.483 1.455 . . . . 0.0 112.743 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.1 p30 -85.78 -23.29 27.3 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.48 -0.763 . . . . 0.0 109.555 178.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 33.2 mmtt -93.49 86.35 5.2 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 20.6 mttm -83.54 -7.56 59.5 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.387 -0.82 . . . . 0.0 109.972 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -100.01 5.14 45.11 Favored 'General case' 0 N--CA 1.503 2.224 0 O-C-N 121.593 -0.692 . . . . 0.0 111.492 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.47 HG21 ' HG3' ' B' ' 12' ' ' PRO . 53.6 mt -121.91 116.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 15.7 mt -112.69 142.8 44.88 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.459 0.647 . . . . 0.0 111.146 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 23.6 m -127.25 147.62 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.664 HD11 HD22 ' B' ' 100' ' ' LEU . 12.3 tt -147.81 146.0 18.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.12 167.07 15.26 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.82 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 38.4 Cg_endo -73.57 134.81 37.1 Favored 'Cis proline' 0 N--CA 1.488 1.184 0 O-C-N 123.635 1.334 . . . . 0.0 112.673 0.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.3 m -128.24 151.16 75.85 Favored Pre-proline 0 N--CA 1.493 1.721 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 177.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -62.66 129.31 25.92 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 121.538 1.492 . . . . 0.0 112.259 -177.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.03 94.12 Favored Glycine 0 N--CA 1.503 3.123 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.912 -177.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -56.36 -33.18 65.45 Favored 'General case' 0 N--CA 1.513 2.722 0 CA-C-N 118.76 1.28 . . . . 0.0 110.396 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.5 mmmt -97.06 -37.4 10.16 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -119.43 55.38 0.96 Allowed 'General case' 0 N--CA 1.498 1.967 0 C-N-CA 118.671 -1.212 . . . . 0.0 113.992 -175.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -71.61 -31.39 66.85 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 175.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -117.05 127.05 53.77 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 175.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 26.6 mt -116.95 142.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.548 -0.72 . . . . 0.0 109.495 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 18.4 m -110.19 115.93 30.6 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -97.29 119.48 62.97 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -81.8 106.92 1.69 Allowed 'Trans proline' 0 N--CA 1.479 0.659 0 C-N-CA 122.094 1.862 . . . . 0.0 108.36 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 17.6 mm -108.21 143.76 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.535 -0.728 . . . . 0.0 110.536 -177.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 12.7 tp -104.1 121.98 44.34 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.81 137.29 73.45 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.459 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.5 Cg_endo -72.61 175.39 10.27 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 122.585 2.19 . . . . 0.0 111.283 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.433 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.6 t70 -126.41 122.08 23.79 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.12 -30.53 55.68 Favored 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.242 1.962 . . . . 0.0 111.593 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -69.36 -18.92 63.84 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.56 -0.712 . . . . 0.0 109.511 178.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.1 m -118.94 17.24 13.38 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.587 -0.696 . . . . 0.0 110.219 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -157.74 109.41 2.3 Favored 'General case' 0 N--CA 1.506 2.343 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -74.44 -12.03 60.39 Favored 'General case' 0 N--CA 1.505 2.303 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 -4.88 27.29 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 120.598 -1.314 . . . . 0.0 109.701 178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' B' ' 133' ' ' PRO . 48.7 t -97.49 131.22 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -129.3 166.7 18.95 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.442 -0.786 . . . . 0.0 110.361 -178.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -78.09 95.75 4.96 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 20.6 mt -146.2 177.87 8.66 Favored 'General case' 0 N--CA 1.496 1.845 0 CA-C-O 121.496 0.665 . . . . 0.0 110.205 -176.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.523 ' HG2' HG22 ' B' ' 244' ' ' VAL . 6.4 mttm -91.44 124.46 35.63 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 176.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.486 ' HB3' ' HG3' ' B' ' 78' ' ' PRO . 60.1 m-85 -115.34 139.97 25.22 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.652 -0.655 . . . . 0.0 110.966 -176.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -80.89 142.72 14.11 Favored 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.683 2.255 . . . . 0.0 110.843 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 64.1 mt -127.51 126.1 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 88.6 m-85 -115.14 140.65 48.89 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.323 -0.861 . . . . 0.0 109.968 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 11.5 p -132.79 144.81 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 121.699 0.762 . . . . 0.0 110.681 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 122.88 4.99 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 106.444 -2.662 . . . . 0.0 106.444 177.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -121.79 133.0 9.21 Favored Glycine 0 N--CA 1.502 3.051 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.429 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 22.1 t-20 -132.79 143.91 49.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.911 . . . . 0.0 110.85 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.542 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -138.22 127.2 24.04 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.241 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.423 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 104.91 163.26 24.03 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 120.162 -1.018 . . . . 0.0 110.86 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.792 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 18.7 mtm105 -78.81 143.5 35.97 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.616 0.722 . . . . 0.0 110.464 -179.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.72 175.74 43.82 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -178.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -103.54 -30.81 10.27 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 122.064 -0.668 . . . . 0.0 111.725 -178.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 23.6 mt -118.67 142.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.257 0 O-C-N 121.108 -0.995 . . . . 0.0 110.789 -178.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.717 ' CZ ' ' HA2' ' A' ' 89' ' ' GLY . 5.7 m-30 -91.85 169.42 11.16 Favored Pre-proline 0 N--CA 1.505 2.283 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.701 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 27.1 Cg_endo -63.43 -11.71 27.16 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 122.152 1.901 . . . . 0.0 113.77 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -98.2 -3.31 37.84 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 120.605 -1.31 . . . . 0.0 109.695 177.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.01 -7.67 57.26 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 3.4 m -70.93 143.74 50.81 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.647 -0.914 . . . . 0.0 110.398 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 42.8 mttt -83.09 153.19 24.99 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.599 ' HB3' ' HE1' ' B' ' 160' ' ' TYR . 6.5 p -96.68 179.81 4.85 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -87.64 15.04 7.3 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.234 -0.916 . . . . 0.0 109.034 178.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -110.99 43.17 1.49 Allowed 'General case' 0 N--CA 1.498 1.972 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.414 HG22 ' O ' ' B' ' 166' ' ' SER . 6.6 t -151.06 173.51 14.26 Favored 'General case' 0 N--CA 1.496 1.834 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 49.3 t -79.0 139.88 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -103.52 117.83 35.34 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . 0.474 ' HB3' ' HA ' ' B' ' 224' ' ' ASP . 87.1 m-20 -99.82 151.53 21.17 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.648 0.737 . . . . 0.0 111.328 -176.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -67.8 130.87 44.33 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 17.7 p -82.68 -3.69 56.72 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.691 -0.631 . . . . 0.0 110.012 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.564 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -153.38 150.09 28.5 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 109.873 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.49 171.55 45.75 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 107.18 -2.368 . . . . 0.0 107.18 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 136.47 -151.95 21.03 Favored Glycine 0 N--CA 1.498 2.816 0 O-C-N 120.907 -1.349 . . . . 0.0 110.865 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.3 tt -122.62 136.91 57.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 31.9 mt -75.07 114.03 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 35.6 p -91.15 -18.28 24.74 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.747 -0.595 . . . . 0.0 110.52 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 14.2 ttmt -162.3 144.47 11.02 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.302 -0.874 . . . . 0.0 111.471 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.46 HD12 ' HG3' ' B' ' 217' ' ' GLU . 76.6 mt -130.58 100.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 12.5 tp -88.09 108.55 19.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.462 -0.774 . . . . 0.0 110.384 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 53.0 mtt85 -74.94 119.49 19.19 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -76.44 152.3 36.23 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 122.547 1.165 . . . . 0.0 113.07 -175.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -51.88 -58.36 6.7 Favored 'General case' 0 N--CA 1.502 2.145 0 CA-C-N 114.212 -1.358 . . . . 0.0 112.595 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -92.69 20.32 6.56 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.395 -0.816 . . . . 0.0 112.001 -177.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 105.04 156.65 22.95 Favored Glycine 0 N--CA 1.498 2.805 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 99.44 169.61 30.33 Favored Glycine 0 N--CA 1.497 2.756 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' B' ' 213' ' ' LEU . 67.0 m-85 -141.52 160.21 40.62 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.408 -1.054 . . . . 0.0 111.559 -178.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -126.0 105.8 9.16 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.409 HD11 HD22 ' B' ' 213' ' ' LEU . 93.3 mt -102.68 122.44 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.428 -0.795 . . . . 0.0 110.669 -177.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 17.3 m -96.66 121.12 38.15 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 34.4 mt -110.44 127.45 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 84.4 t -98.76 98.71 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -72.37 86.31 1.12 Allowed 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -58.67 -30.08 67.08 Favored 'General case' 0 N--CA 1.502 2.143 0 O-C-N 122.022 -0.424 . . . . 0.0 111.074 -178.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 48.6 m -69.85 -35.9 75.11 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.733 -0.605 . . . . 0.0 110.694 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 55.3 m-80 -106.42 4.62 28.62 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.314 -0.866 . . . . 0.0 110.569 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 50.71 48.44 22.74 Favored 'General case' 0 N--CA 1.511 2.614 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.3 ttp-105 -131.23 142.57 50.18 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.182 -177.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -111.7 126.79 55.42 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 178.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' B' ' 175' ' ' ALA . 31.9 m -126.47 147.72 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 59.7 mt -120.02 110.93 30.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -92.07 125.77 36.89 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 25.5 mt -98.0 132.7 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 CA-C-O 121.576 0.703 . . . . 0.0 109.657 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.419 HD13 ' CD2' ' B' ' 213' ' ' LEU . 47.5 mt -115.31 131.25 23.68 Favored Pre-proline 0 N--CA 1.494 1.729 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 165.82 29.99 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.469 2.112 . . . . 0.0 112.134 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -73.28 157.54 36.85 Favored 'General case' 0 N--CA 1.503 2.201 0 CA-C-O 121.387 0.613 . . . . 0.0 110.968 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 95.96 -5.33 66.15 Favored Glycine 0 N--CA 1.5 2.939 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.536 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -117.91 142.1 47.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 122.03 -0.688 . . . . 0.0 109.502 -179.544 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -108.59 141.5 40.43 Favored 'General case' 0 N--CA 1.496 1.85 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.517 HD11 ' CG ' ' B' ' 190' ' ' TYR . 15.8 mt -77.33 150.31 35.21 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 121.836 0.827 . . . . 0.0 112.231 -176.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 51.2 mt -111.67 5.31 19.18 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.543 HG11 HD13 ' B' ' 221' ' ' ILE . 9.9 m -121.01 158.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 CA-C-O 121.956 0.884 . . . . 0.0 112.16 -177.218 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 63.2 m -122.99 161.1 24.89 Favored 'General case' 0 N--CA 1.496 1.837 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.2 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.46 ' HG3' HD12 ' B' ' 182' ' ' ILE . 78.8 mt-10 -64.25 140.56 58.88 Favored 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 87.98 -1.19 84.83 Favored Glycine 0 N--CA 1.498 2.817 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.413 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -87.5 145.48 26.23 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 118.773 1.287 . . . . 0.0 110.086 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 25.3 m -87.3 124.1 32.99 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.543 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -112.67 147.95 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.845 -0.534 . . . . 0.0 109.615 -179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -100.29 163.51 12.36 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 15.5 tp -62.89 136.55 57.91 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.088 -1.008 . . . . 0.0 109.267 179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.474 ' HA ' ' HB3' ' B' ' 172' ' ' ASN . 0.1 OUTLIER 68.27 13.94 9.13 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 122.118 -0.364 . . . . 0.0 111.263 179.818 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.456 ' HB3' HG13 ' B' ' 221' ' ' ILE . 12.5 tt0 -74.59 132.38 78.38 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 106.754 -1.572 . . . . 0.0 106.754 177.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -62.33 119.5 6.63 Favored 'Trans proline' 0 N--CA 1.482 0.819 0 C-N-CA 121.998 1.799 . . . . 0.0 111.348 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.437 HD21 HG12 ' B' ' 221' ' ' ILE . 65.5 mt -93.28 -12.96 28.86 Favored 'General case' 0 N--CA 1.497 1.913 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.333 -178.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.421 HG22 HD23 ' B' ' 213' ' ' LEU . 21.8 p -134.51 170.46 15.73 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.44 -0.788 . . . . 0.0 110.278 -178.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.625 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 33.0 m -76.84 162.1 27.9 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.192 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 -88.89 105.68 10.76 Favored Pre-proline 0 N--CA 1.501 2.09 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.625 ' HD3' ' O ' ' B' ' 229' ' ' SER . 40.0 Cg_endo -83.62 11.5 3.28 Favored 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 122.833 2.355 . . . . 0.0 113.131 -176.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -88.54 119.86 29.39 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.93 -1.106 . . . . 0.0 110.585 -178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 25.5 m -112.71 0.87 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -101.11 -162.59 27.57 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . . . . . . . . . . . 170.39 163.64 24.77 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 120.096 -1.05 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.429 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 83.3 t80 -116.38 146.09 42.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -145.33 159.24 27.86 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.415 ' HB3' HD12 ' B' ' 19' ' ' ILE . 12.5 pt20 -137.02 151.08 48.54 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.767 -0.843 . . . . 0.0 109.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -145.39 173.06 25.93 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.205 -1.958 . . . . 0.0 108.205 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -145.17 154.54 42.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.604 -0.939 . . . . 0.0 109.816 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.5 166.5 23.36 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -127.62 127.35 43.67 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . 0.401 HD12 ' CG1' ' B' ' 35' ' ' VAL . 13.4 tt -118.02 142.98 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.523 HG22 ' HG2' ' B' ' 145' ' ' LYS . 17.8 t -104.78 108.08 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 120.011 -0.675 . . . . 0.0 109.968 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.86 109.52 4.49 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 175.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -95.97 143.75 26.87 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -172.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -74.87 133.86 75.67 Favored Pre-proline 0 N--CA 1.485 1.298 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 175.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -68.49 -1.19 6.97 Favored 'Trans proline' 0 CA--C 1.547 1.137 0 C-N-CA 121.465 1.443 . . . . 0.0 111.801 -179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 16.8 mt -110.77 -129.81 0.3 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 176.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.509 2.481 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.129 178.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 0.792 ' O2D' ' HD2' ' B' ' 156' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 N--CA 1.502 2.165 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.07 136.23 42.27 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.16 -1.016 . . . . 0.0 108.734 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.65 126.51 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 16.7 mt -85.53 136.54 33.37 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 121.715 0.769 . . . . 0.0 110.736 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 14.7 mt -95.15 102.92 14.76 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 105.535 -2.024 . . . . 0.0 105.535 177.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 33' ' ' ALA . . . 100.98 122.56 5.01 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 107.151 -2.38 . . . . 0.0 107.151 -176.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' A' ' 11' ' ' SER . . . -74.46 167.26 22.05 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.255 -1.144 . . . . 0.0 111.374 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -65.74 -12.61 55.23 Favored 'General case' 0 N--CA 1.514 2.756 0 O-C-N 120.376 -1.452 . . . . 0.0 112.272 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -99.16 12.01 37.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.119 -1.437 . . . . 0.0 107.119 177.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.04 7.9 86.44 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 120.991 -1.068 . . . . 0.0 111.021 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.531 ' HB2' ' HB3' ' A' ' 7' ' ' ALA . 4.9 m -66.45 144.37 56.54 Favored 'General case' 0 N--CA 1.506 2.37 0 CA-C-N 119.589 1.694 . . . . 0.0 109.479 -178.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.579 HD12 ' CE1' ' B' ' 4' ' ' PHE . 38.8 mt -84.94 85.69 7.45 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.506 -1.371 . . . . 0.0 107.743 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.41 156.4 36.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.286 -0.884 . . . . 0.0 111.99 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CE2' ' HG2' ' A' ' 92' ' ' MET . 79.0 m-85 -87.14 136.84 32.78 Favored 'General case' 0 C--O 1.211 -0.96 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 178.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 71.9 t -131.44 107.75 14.6 Favored Pre-proline 0 N--CA 1.489 1.482 0 C-N-CA 116.005 -2.278 . . . . 0.0 110.536 -177.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 15' ' ' VAL . 35.8 Cg_endo -77.02 167.48 79.8 Favored 'Cis proline' 0 CA--C 1.572 2.416 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.066 0.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 24.6 p -104.29 -22.88 13.29 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.071 -1.018 . . . . 0.0 109.743 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -127.91 122.64 32.98 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -155.46 168.35 27.4 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 119.246 -0.981 . . . . 0.0 110.997 -177.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 32.1 m -121.38 150.19 41.85 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.037 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 5.8 pt -140.91 162.2 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.654 179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 m -89.52 164.31 30.07 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -63.54 136.68 55.72 Favored 'Trans proline' 0 CA--C 1.56 1.817 0 C-N-CA 120.585 0.857 . . . . 0.0 114.131 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.09 -9.73 59.9 Favored Glycine 0 N--CA 1.511 3.671 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -68.99 142.69 54.57 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 119.749 -2.03 . . . . 0.0 107.547 -176.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm -90.86 145.42 24.77 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 117.303 -1.759 . . . . 0.0 112.336 -177.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.2 mt -113.54 120.54 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.514 HG13 ' HG2' ' A' ' 71' ' ' GLU . 22.1 t -105.78 107.43 22.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 118.425 -1.31 . . . . 0.0 108.726 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -86.87 123.97 32.58 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 178.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HB3' HG22 ' A' ' 69' ' ' THR . 0.2 OUTLIER -122.33 130.96 53.65 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 117.969 -1.492 . . . . 0.0 111.59 -178.538 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -59.81 122.39 14.1 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -119.64 -53.12 2.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.671 -0.643 . . . . 0.0 110.279 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.426 ' O ' ' HA3' ' A' ' 6' ' ' GLY . . . -157.6 150.89 23.56 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.139 -0.976 . . . . 0.0 112.63 -178.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.88 14.89 82.13 Favored Glycine 1 N--CA 1.517 4.043 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.684 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.7 p90 -68.92 171.23 6.72 Favored Pre-proline 0 N--CA 1.51 2.555 0 O-C-N 120.198 -1.766 . . . . 0.0 108.441 179.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.684 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 25.8 Cg_endo -65.66 154.97 79.32 Favored 'Cis proline' 0 N--CA 1.498 1.792 0 C-N-CA 125.03 -0.821 . . . . 0.0 113.797 2.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' HA ' ' A' ' 35' ' ' PHE . 96.8 m-70 -145.54 162.99 36.12 Favored 'General case' 0 N--CA 1.503 2.199 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.552 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.0 OUTLIER -151.73 169.07 23.09 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.22 118.98 55.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.787 0 C-N-CA 118.748 -1.181 . . . . 0.0 108.046 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.552 ' CG2' HD21 ' A' ' 38' ' ' ASN . 91.0 t -122.68 131.87 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.409 ' HB2' ' OG ' ' A' ' 56' ' ' SER . 27.3 m-85 -89.32 136.88 32.78 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 118.976 -1.089 . . . . 0.0 109.031 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 7.0 t0 -70.02 113.91 7.68 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 117.766 -1.574 . . . . 0.0 107.945 -178.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.824 ' C ' ' HG2' ' B' ' 187' ' ' LYS . 4.5 pt-20 -51.56 -37.42 49.59 Favored 'General case' 0 CA--C 1.594 2.652 0 C-N-CA 118.266 -1.374 . . . . 0.0 108.242 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.821 ' CA ' ' HB2' ' B' ' 187' ' ' LYS . 0.3 OUTLIER -81.71 -1.25 46.33 Favored 'General case' 1 N--CA 1.546 4.342 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 -176.478 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.639 ' HB3' ' HB2' ' A' ' 81' ' ' SER . 0.5 OUTLIER -131.05 43.57 3.08 Favored 'General case' 0 C--N 1.259 -3.36 0 C-N-CA 117.523 -1.671 . . . . 0.0 110.36 -177.802 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.655 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.4 pt -134.05 164.52 43.38 Favored Pre-proline 0 N--CA 1.485 1.293 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 176.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.722 ' HG2' HG21 ' A' ' 50' ' ' VAL . 18.9 Cg_endo -56.9 142.72 93.14 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 120.837 1.025 . . . . 0.0 111.705 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.4 m -55.76 136.04 51.25 Favored 'General case' 0 N--CA 1.519 2.992 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 -178.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.6 -11.02 72.88 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.722 HG21 ' HG2' ' A' ' 47' ' ' PRO . 92.0 t -79.03 132.41 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.448 0 CA-C-N 119.602 1.701 . . . . 0.0 111.143 -175.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -84.37 113.69 21.34 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 118.107 -1.437 . . . . 0.0 107.792 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.91 -24.43 66.1 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.148 -0.97 . . . . 0.0 112.089 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 77.4 p -67.08 -25.82 66.42 Favored 'General case' 0 N--CA 1.511 2.585 0 O-C-N 121.112 -0.993 . . . . 0.0 109.92 178.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mttm -80.06 -18.0 51.22 Favored 'General case' 0 N--CA 1.514 2.746 0 O-C-N 120.588 -1.32 . . . . 0.0 112.789 -178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.1 pt -121.99 3.14 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.189 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -177.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.479 ' HB3' ' HA ' ' A' ' 40' ' ' VAL . 1.4 m -129.01 164.2 23.73 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-N 119.9 1.227 . . . . 0.0 113.223 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.479 ' CB ' HD22 ' A' ' 38' ' ' ASN . 0.5 OUTLIER -86.83 162.59 17.69 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.204 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.3 t -73.21 152.78 40.93 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 116.94 -1.904 . . . . 0.0 108.785 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.565 ' OE1' ' HG3' ' A' ' 60' ' ' GLU . 0.0 OUTLIER -58.62 -29.2 66.31 Favored 'General case' 0 N--CA 1.506 2.373 0 C-N-CA 118.163 -1.415 . . . . 0.0 111.18 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.565 ' HG3' ' OE1' ' A' ' 59' ' ' GLU . 11.1 mt-10 -85.99 -5.54 59.2 Favored 'General case' 0 N--CA 1.509 2.482 0 C-N-CA 124.135 0.974 . . . . 0.0 111.74 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.7 m-20 -91.82 145.96 24.14 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 120.536 -1.353 . . . . 0.0 109.386 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 71.9 mt -141.35 148.65 40.02 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 121.831 0.824 . . . . 0.0 111.703 -178.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.4 HD22 ' HB3' ' A' ' 68' ' ' GLU . 30.2 mt -100.83 109.96 21.99 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 101.254 -3.61 . . . . 0.0 101.254 173.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.52 ' HB3' ' HB3' ' A' ' 36' ' ' PRO . 0.1 OUTLIER -114.86 14.09 17.26 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 117.239 -1.785 . . . . 0.0 113.783 -174.013 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -129.08 145.87 51.18 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 120.521 -1.362 . . . . 0.0 108.15 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -59.44 132.95 55.55 Favored 'General case' 0 N--CA 1.508 2.456 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.807 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 97.09 -17.23 59.58 Favored Glycine 0 N--CA 1.5 2.924 0 C-N-CA 119.556 -1.307 . . . . 0.0 110.046 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.4 ' HB3' HD22 ' A' ' 63' ' ' LEU . 20.5 mt-10 -62.7 142.19 58.22 Favored 'General case' 0 N--CA 1.511 2.616 0 CA-C-N 120.029 1.914 . . . . 0.0 108.268 -177.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.412 HG22 ' HB3' ' A' ' 30' ' ' LYS . 64.1 p -128.84 156.64 43.32 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 118.067 -1.453 . . . . 0.0 112.848 -177.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -131.69 121.56 24.47 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 175.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.514 ' HG2' HG13 ' A' ' 28' ' ' VAL . 25.9 mt-10 -113.57 143.65 44.2 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.524 -177.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.7 p -149.45 144.08 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.82 179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -117.22 130.81 56.82 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 32.1 mt -106.69 142.39 36.42 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.59 -0.844 . . . . 0.0 108.844 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 12.2 p -117.57 -39.93 3.1 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.292 -1.363 . . . . 0.0 110.654 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -66.78 133.87 51.02 Favored 'General case' 0 N--CA 1.508 2.441 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.221 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.92 154.77 31.35 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.189 -0.944 . . . . 0.0 111.221 -177.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 135.96 -173.51 21.83 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.599 -1.762 . . . . 0.0 109.062 178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -99.32 141.82 31.6 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.993 -1.298 . . . . 0.0 110.331 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.491 ' CZ ' ' HG3' ' A' ' 47' ' ' PRO . 22.7 m-85 -122.57 122.27 38.48 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.639 ' HB2' ' HB3' ' A' ' 45' ' ' SER . 74.4 m -98.11 134.39 41.24 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 178.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -134.47 168.02 19.7 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.211 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.468 ' HB3' HG12 ' A' ' 93' ' ' VAL . 2.1 p90 -159.63 165.99 31.6 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 119.018 -1.073 . . . . 0.0 111.211 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.501 ' SG ' ' HD2' ' A' ' 86' ' ' PRO . 16.2 t -94.6 126.66 40.03 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 103.5 -2.778 . . . . 0.0 103.5 175.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.788 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 1.5 p -62.39 -48.7 86.5 Favored Pre-proline 0 N--CA 1.509 2.477 0 O-C-N 120.445 -1.409 . . . . 0.0 114.533 -175.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' OH ' ' B' ' 1' ' ' TYR . 35.7 Cg_endo -72.02 -17.67 28.22 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.512 1.474 . . . . 0.0 112.642 -179.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.645 ' HD2' ' CE2' ' B' ' 1' ' ' TYR . 33.4 m170 -121.37 18.0 11.4 Favored 'General case' 0 N--CA 1.507 2.402 0 CA-C-N 119.137 0.88 . . . . 0.0 112.407 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.974 ' HB3' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -60.77 -43.5 97.97 Favored 'General case' 0 N--CA 1.524 3.257 0 O-C-N 120.613 -1.304 . . . . 0.0 108.673 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.768 ' O ' ' CG ' ' B' ' 160' ' ' TYR . . . -61.65 -37.53 94.38 Favored Glycine 0 CA--C 1.543 1.841 0 C-N-CA 118.269 -1.92 . . . . 0.0 108.726 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' B' ' 4' ' ' PHE . . . -65.91 -7.66 17.88 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 119.227 -2.337 . . . . 0.0 113.413 -177.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 101.93 8.99 43.9 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.451 ' HG2' ' CE2' ' A' ' 14' ' ' PHE . 13.3 ttt -77.66 84.98 4.0 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 119.644 1.722 . . . . 0.0 106.919 -179.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.468 HG12 ' HB3' ' A' ' 83' ' ' TYR . 17.1 m -136.65 165.72 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -159.79 174.74 36.65 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 118.331 -1.89 . . . . 0.0 108.709 178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 28.6 ttpp -148.89 129.84 14.34 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 119.079 1.44 . . . . 0.0 107.786 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 80' ' ' TYR . 6.3 p -116.1 142.34 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 C-N-CA 118.889 -1.125 . . . . 0.0 109.303 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 44.7 m -113.25 126.55 55.53 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.224 -1.39 . . . . 0.0 109.639 179.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.2 t -96.14 115.1 34.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 178.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 23.2 p30 . . . . . 0 N--CA 1.481 1.085 0 C-N-CA 118.763 -1.175 . . . . 0.0 111.382 -176.764 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.766 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 59.1 m-85 . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.86 -25.97 71.87 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 121.186 1.257 . . . . 0.0 111.426 178.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -71.08 -31.51 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.329 0 O-C-N 122.01 -0.431 . . . . 0.0 110.359 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.579 ' CE1' HD12 ' A' ' 12' ' ' LEU . 22.1 m-30 -67.93 -35.35 78.28 Favored 'General case' 0 N--CA 1.525 3.31 0 CA-C-N 118.84 0.746 . . . . 0.0 110.517 -178.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.19 -43.7 50.64 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -61.82 -46.63 88.69 Favored 'General case' 0 N--CA 1.51 2.526 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -60.82 -29.16 69.31 Favored 'General case' 0 N--CA 1.502 2.141 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -141.15 26.2 2.03 Favored 'General case' 0 N--CA 1.522 3.131 0 CA-C-N 122.292 2.314 . . . . 0.0 113.6 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -140.11 111.3 7.06 Favored 'General case' 0 N--CA 1.529 3.522 0 N-CA-C 103.736 -2.69 . . . . 0.0 103.736 174.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -65.93 -39.68 90.72 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.313 -175.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -122.07 135.35 25.3 Favored Pre-proline 0 C--N 1.307 -1.277 0 N-CA-C 104.718 -2.327 . . . . 0.0 104.718 177.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . 0.477 ' HG3' HG21 ' B' ' 112' ' ' ILE . 32.8 Cg_endo -78.26 -16.76 13.63 Favored 'Trans proline' 0 CA--C 1.543 0.96 0 C-N-CA 121.456 1.437 . . . . 0.0 112.172 -175.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 9.0 ttp180 -102.52 126.12 49.47 Favored 'General case' 0 N--CA 1.51 2.552 0 CA-C-N 120.157 1.344 . . . . 0.0 110.713 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -86.43 168.84 13.42 Favored 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.755 -1.216 . . . . 0.0 110.178 -178.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.78 -24.75 64.36 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.904 -1.123 . . . . 0.0 110.806 -179.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 5.0 p -76.39 -14.33 60.08 Favored 'General case' 0 N--CA 1.517 2.879 0 O-C-N 120.87 -1.144 . . . . 0.0 109.303 179.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.53 5.63 58.87 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 59.8 mtt-85 -91.17 137.34 32.44 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.573 0.701 . . . . 0.0 110.28 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 33.0 mt -80.41 139.5 18.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 27.4 m -56.04 -10.87 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.538 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -177.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 m -70.24 -25.76 63.53 Favored 'General case' 0 N--CA 1.52 3.044 0 CA-C-N 123.52 2.873 . . . . 0.0 109.498 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -7.63 18.6 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.482 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -76.56 -29.72 56.77 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.087 -1.008 . . . . 0.0 109.169 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 2.5 m -117.75 -29.17 5.79 Favored 'General case' 1 N--CA 1.543 4.177 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 177.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -88.62 92.37 9.17 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 175.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 44.2 mt -84.73 -17.98 36.64 Favored 'General case' 0 N--CA 1.502 2.163 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -173.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -87.25 140.44 29.54 Favored 'General case' 0 N--CA 1.523 3.209 0 CA-C-N 122.33 2.332 . . . . 0.0 111.098 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 3.9 t -93.35 131.63 38.33 Favored 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.471 ' HB3' ' NH2' ' B' ' 154' ' ' ARG . 9.8 mttp -142.6 151.51 57.46 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 178.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.436 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 30.8 Cg_endo -72.97 140.79 32.12 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 N-CA-C 116.688 1.765 . . . . 0.0 116.688 -176.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.1 145.23 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 CA-C-N 112.697 -2.047 . . . . 0.0 107.237 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -131.3 155.28 47.46 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 4.1 tt -147.46 120.31 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.652 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.472 ' HB2' ' CG1' ' B' ' 48' ' ' VAL . 1.1 mp0 -105.33 130.41 53.45 Favored 'General case' 0 N--CA 1.482 1.147 0 CA-C-O 122.208 1.004 . . . . 0.0 108.358 177.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' B' ' 36' ' ' PRO . 8.0 t -139.33 146.2 47.65 Favored Pre-proline 0 C--N 1.301 -1.543 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' B' ' 35' ' ' VAL . 26.1 Cg_endo -60.74 146.28 97.57 Favored 'Trans proline' 0 C--N 1.322 -0.823 0 O-C-N 122.649 0.815 . . . . 0.0 110.375 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -59.78 -38.03 80.72 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.81 -0.556 . . . . 0.0 111.07 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -146.62 154.38 41.42 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.753 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 12.2 m -139.56 158.83 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.238 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' B' ' 40' ' ' LEU . 2.8 mm? -100.57 156.09 35.61 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.033 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.421 ' HB2' ' OD2' ' B' ' 134' ' ' ASP . 18.3 Cg_endo -54.07 141.51 68.43 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.986 1.791 . . . . 0.0 112.583 179.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 48.91 48.83 20.11 Favored 'General case' 0 N--CA 1.516 2.834 0 C-N-CA 124.352 1.061 . . . . 0.0 112.542 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 33.9 p -128.17 147.01 50.54 Favored 'General case' 0 N--CA 1.509 2.488 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 176.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 31.4 t -88.87 139.27 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 118.66 -1.216 . . . . 0.0 109.658 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.641 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 50.9 p90 -137.68 166.39 24.06 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.6 138.95 50.04 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 118.652 -1.219 . . . . 0.0 111.909 -178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -111.21 110.79 21.45 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.472 ' CG1' ' HB2' ' B' ' 34' ' ' GLU . 7.6 p -100.52 122.26 52.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 C-N-CA 116.417 -2.113 . . . . 0.0 111.354 -176.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.05 134.47 45.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.493 -0.883 . . . . 0.0 109.174 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -113.09 126.13 55.13 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.747 -0.781 . . . . 0.0 109.415 178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . . . . . . . . . 15.0 mt -122.92 77.05 49.89 Favored Pre-proline 0 N--CA 1.495 1.801 0 N-CA-C 104.429 -2.434 . . . . 0.0 104.429 178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 34.7 Cg_endo -81.57 145.25 14.58 Favored 'Trans proline' 0 N--CA 1.481 0.78 0 C-N-CA 122.381 2.054 . . . . 0.0 113.871 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -160.18 153.86 22.6 Favored 'General case' 0 N--CA 1.51 2.538 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.096 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -64.76 123.4 19.26 Favored 'General case' 0 CA--C 1.564 1.482 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 178.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 8.6 mtm -81.76 5.81 17.39 Favored 'General case' 0 N--CA 1.511 2.594 0 O-C-N 120.312 -1.493 . . . . 0.0 114.808 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -94.65 0.87 55.45 Favored 'General case' 0 N--CA 1.51 2.53 0 O-C-N 120.255 -1.528 . . . . 0.0 106.94 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 52.5 mt -75.1 134.58 41.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.429 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -120.83 128.23 52.65 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -97.77 172.12 7.88 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.769 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . . . . . . . . . 20.1 t -87.18 113.58 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.441 HD22 ' OE1' ' A' ' 59' ' ' GLU . 4.5 mp -69.84 167.0 18.22 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 120.435 -1.415 . . . . 0.0 109.014 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.974 ' HB1' ' HB3' ' A' ' 88' ' ' GLN . . . -58.5 -8.78 1.32 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 120.704 -1.248 . . . . 0.0 112.258 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -113.66 17.95 17.85 Favored 'General case' 0 N--CA 1.505 2.276 0 O-C-N 119.507 -1.996 . . . . 0.0 111.536 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 92.91 -30.34 7.14 Favored Glycine 1 N--CA 1.521 4.301 0 O-C-N 120.747 -1.22 . . . . 0.0 110.479 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -68.9 158.73 34.0 Favored 'General case' 0 N--CA 1.51 2.562 0 O-C-N 120.894 -1.357 . . . . 0.0 110.434 -179.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . . . . . . . . . 46.2 mttm -101.44 140.37 35.81 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.82 -173.42 21.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.128 -1.511 . . . . 0.0 111.973 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.36 167.53 21.2 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 122.298 -0.531 . . . . 0.0 110.621 -179.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . 0.459 ' N ' HD12 ' B' ' 69' ' ' LEU . 6.3 mp -97.93 157.51 16.06 Favored 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.61 0.719 . . . . 0.0 112.053 -177.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.52 ' HB2' ' CGA' ' B' ' 253' ' ' HEC . 23.4 m-80 -115.45 154.73 28.75 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 178.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.92 159.08 16.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 C-N-CA 118.397 -1.321 . . . . 0.0 110.61 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -158.11 156.91 27.81 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 107.731 -2.148 . . . . 0.0 107.731 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -153.27 160.07 42.69 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.861 -178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -128.79 121.92 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 tp -106.9 123.97 48.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 117.869 -1.532 . . . . 0.0 110.257 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 14.6 mt -104.87 109.53 27.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.831 -1.148 . . . . 0.0 108.823 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.491 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 12.1 mt -104.91 161.39 22.9 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.938 -0.477 . . . . 0.0 109.933 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.733 ' HG2' ' CD1' ' B' ' 81' ' ' PHE . 29.5 Cg_endo -65.84 157.86 56.82 Favored 'Trans proline' 0 N--CA 1.478 0.592 0 C-N-CA 121.788 1.659 . . . . 0.0 109.247 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -65.09 136.29 56.55 Favored 'General case' 0 N--CA 1.507 2.377 0 O-C-N 121.56 -0.713 . . . . 0.0 110.55 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.07 -39.95 2.7 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -177.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.733 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 34.0 m-85 -77.52 140.38 39.75 Favored 'General case' 0 N--CA 1.504 2.238 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -153.87 170.97 19.73 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.728 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.95 129.71 42.81 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.373 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.69 137.58 96.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.526 -0.734 . . . . 0.0 109.62 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -68.67 157.95 59.76 Favored 'Trans proline' 0 CA--C 1.548 1.22 0 C-N-CA 122.204 1.936 . . . . 0.0 108.93 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.594 ' HA ' HD12 ' B' ' 89' ' ' ILE . 23.9 Cg_endo -60.86 -37.99 73.38 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 C-N-CA 123.178 2.585 . . . . 0.0 113.642 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -65.57 -26.17 67.75 Favored 'General case' 0 N--CA 1.511 2.614 0 O-C-N 121.352 -0.842 . . . . 0.0 110.677 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 30.3 mmm-85 -91.18 -4.65 55.92 Favored 'General case' 0 N--CA 1.518 2.97 0 O-C-N 121.195 -0.94 . . . . 0.0 110.612 -179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.594 HD12 ' HA ' ' B' ' 86' ' ' PRO . 61.2 mt -88.51 122.6 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.084 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' B' ' 93' ' ' MET . 23.7 p -66.62 157.62 82.37 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.958 -0.464 . . . . 0.0 110.33 179.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -68.67 -35.51 16.53 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.707 2.271 . . . . 0.0 109.301 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -66.51 -20.07 65.94 Favored 'General case' 0 N--CA 1.511 2.622 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.441 ' HB2' ' OG ' ' B' ' 90' ' ' SER . 25.7 ttm -97.32 -31.24 12.5 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -31.07 71.8 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.49 -0.756 . . . . 0.0 111.099 -178.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -75.69 -33.7 60.37 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.13 -43.44 98.38 Favored 'General case' 0 N--CA 1.508 2.467 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.382 -178.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 6.9 pt -78.82 7.19 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.509 2.485 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.092 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.66 -112.2 2.93 Favored Glycine 0 N--CA 1.505 3.247 0 O-C-N 121.222 -0.924 . . . . 0.0 110.907 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -149.45 43.98 0.94 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.661 HD22 HD11 ' B' ' 115' ' ' ILE . 17.7 mt -78.87 148.33 32.81 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.41 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 21.5 p -111.9 106.4 15.11 Favored 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 122.087 0.946 . . . . 0.0 108.532 177.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -84.11 128.82 34.81 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.788 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -111.35 155.16 23.51 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 118.626 -1.23 . . . . 0.0 112.341 -178.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -79.96 145.41 32.61 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 117.854 -1.538 . . . . 0.0 107.296 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -57.9 -38.75 76.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.288 -1.508 . . . . 0.0 107.452 -179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 12.9 mtt85 -150.92 156.96 35.8 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 102.799 -3.038 . . . . 0.0 102.799 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.45 -25.43 70.63 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 CA-C-N 118.721 0.579 . . . . 0.0 112.674 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -83.98 -21.35 31.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.611 -1.305 . . . . 0.0 109.373 178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 32.2 mmtt -93.94 84.13 4.47 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 121.998 0.904 . . . . 0.0 109.653 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 22.3 mttm -81.44 -8.66 59.76 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.558 -0.714 . . . . 0.0 110.266 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 7.1 p-10 -100.89 11.4 39.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.426 -0.796 . . . . 0.0 111.204 -179.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.477 HG21 ' HG3' ' B' ' 12' ' ' PRO . 48.1 mt -125.16 115.26 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.526 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 16.8 mt -113.18 142.44 45.78 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.226 -1.39 . . . . 0.0 112.05 -176.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 19.3 m -127.35 149.05 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 119.996 -0.682 . . . . 0.0 109.995 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.661 HD11 HD22 ' B' ' 100' ' ' LEU . 13.5 tt -149.89 145.4 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.24 166.15 15.62 Favored Glycine 0 N--CA 1.475 1.295 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.766 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 31.2 Cg_endo -73.4 134.93 37.6 Favored 'Cis proline' 0 C--N 1.317 -1.116 0 O-C-N 124.603 1.843 . . . . 0.0 113.173 -0.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 m -128.65 149.22 71.37 Favored Pre-proline 0 N--CA 1.503 2.21 0 N-CA-C 105.603 -1.999 . . . . 0.0 105.603 177.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -61.08 129.73 29.79 Favored 'Trans proline' 0 CA--C 1.554 1.507 0 C-N-CA 121.268 1.312 . . . . 0.0 113.151 -176.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.33 94.73 Favored Glycine 1 N--CA 1.523 4.488 0 C-N-CA 123.552 0.596 . . . . 0.0 112.718 -178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 10.2 mm-40 -56.19 -36.93 68.93 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.708 1.254 . . . . 0.0 110.149 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 5.5 mmmt -93.83 -37.67 11.63 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 -177.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -117.57 50.97 1.07 Allowed 'General case' 0 N--CA 1.507 2.406 0 O-C-N 120.781 -1.199 . . . . 0.0 113.674 -175.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 11.7 m -68.0 -29.07 67.99 Favored 'General case' 0 N--CA 1.517 2.88 0 O-C-N 119.727 -1.858 . . . . 0.0 106.786 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.2 126.26 52.49 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.737 175.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 23.8 mt -117.8 143.63 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 119.019 -1.073 . . . . 0.0 110.754 -178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 11.5 m -110.1 116.54 31.74 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.337 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -99.02 117.49 64.17 Favored Pre-proline 0 N--CA 1.493 1.718 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -81.64 110.01 2.1 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 N-CA-C 107.701 -1.692 . . . . 0.0 107.701 -177.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.641 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 16.3 mm -110.29 143.58 20.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 CA-C-O 121.619 0.723 . . . . 0.0 111.358 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.8 tp -103.35 121.5 42.89 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.83 134.61 68.49 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.056 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.485 ' HG2' HG11 ' B' ' 141' ' ' VAL . 28.6 Cg_endo -69.73 178.06 4.93 Favored 'Trans proline' 0 C--N 1.327 -0.555 0 O-C-N 123.629 1.331 . . . . 0.0 111.24 -177.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' B' ' 41' ' ' PRO . 13.1 t70 -129.17 119.18 19.56 Favored Pre-proline 0 N--CA 1.497 1.909 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.417 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 27.7 Cg_endo -62.1 -35.74 74.01 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 C-N-CA 122.261 1.974 . . . . 0.0 111.651 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -63.82 -18.86 64.55 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.483 -0.761 . . . . 0.0 109.685 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.12 20.1 11.48 Favored 'General case' 0 N--CA 1.525 3.286 0 O-C-N 120.844 -1.16 . . . . 0.0 110.853 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -160.8 108.31 1.54 Allowed 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 80.8 mttt -73.04 -10.74 60.12 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -178.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -103.26 -2.01 27.9 Favored 'General case' 0 N--CA 1.513 2.697 0 CA-C-N 122.224 2.284 . . . . 0.0 109.675 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.485 HG11 ' HG2' ' B' ' 133' ' ' PRO . 45.4 t -98.66 130.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . 0.406 ' HB2' HD12 ' B' ' 144' ' ' LEU . 81.2 m-70 -129.88 167.62 17.87 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.172 -178.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.417 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 52.5 m-85 -78.14 101.54 7.08 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 175.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.406 HD12 ' HB2' ' B' ' 142' ' ' HIS . 14.8 mt -153.46 177.33 11.02 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.194 0.997 . . . . 0.0 112.198 -174.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . 0.54 ' HG2' HG22 ' B' ' 244' ' ' VAL . 5.2 mttm -90.78 129.04 36.89 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 117.867 -1.533 . . . . 0.0 107.139 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -120.77 138.85 28.13 Favored Pre-proline 0 C--N 1.309 -1.187 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.719 -175.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -78.73 146.57 21.19 Favored 'Trans proline' 0 C--O 1.22 -0.383 0 C-N-CA 121.504 1.47 . . . . 0.0 111.389 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.13 127.89 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.336 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.413 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 91.4 m-85 -117.42 141.0 48.86 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.611 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.54 144.96 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 CA-C-O 122.244 1.021 . . . . 0.0 111.71 179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -124.05 127.87 6.64 Favored Glycine 0 N--CA 1.473 1.156 0 N-CA-C 106.236 -2.746 . . . . 0.0 106.236 177.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -128.73 133.3 7.58 Favored Glycine 0 C--N 1.294 -1.774 0 C-N-CA 118.293 -1.908 . . . . 0.0 110.166 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.411 ' CB ' HMB3 ' B' ' 253' ' ' HEC . 21.6 t-20 -132.81 144.1 50.0 Favored 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.677 0.751 . . . . 0.0 112.559 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.4 OUTLIER -136.35 126.31 25.95 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 114.729 -1.123 . . . . 0.0 107.982 177.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . 0.426 ' CA ' HD23 ' B' ' 69' ' ' LEU . . . 106.06 159.28 22.4 Favored Glycine 0 C--N 1.304 -1.201 0 C-N-CA 117.922 -2.085 . . . . 0.0 110.069 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.615 ' HD2' ' O2D' ' B' ' 253' ' ' HEC . 13.9 mtm105 -76.03 140.74 42.09 Favored 'General case' 0 N--CA 1.509 2.494 0 CA-C-O 121.618 0.723 . . . . 0.0 110.621 179.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -71.38 172.53 44.81 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -99.31 -30.58 12.15 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.661 -0.906 . . . . 0.0 111.516 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 21.8 mt -118.13 142.97 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.52 3.026 0 O-C-N 120.62 -1.3 . . . . 0.0 112.52 -177.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.884 ' OH ' ' HA ' ' B' ' 166' ' ' SER . 0.3 OUTLIER -91.89 171.29 8.0 Favored Pre-proline 0 N--CA 1.485 1.279 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.498 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.683 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 18.8 Cg_endo -61.11 -14.96 36.52 Favored 'Trans proline' 0 CA--C 1.561 1.865 0 C-N-CA 121.47 1.446 . . . . 0.0 113.438 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.49 -4.2 45.35 Favored 'General case' 0 N--CA 1.53 3.529 0 CA-C-N 120.675 1.579 . . . . 0.0 110.631 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 103.0 -9.93 55.22 Favored Glycine 0 N--CA 1.51 3.572 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . 0.411 ' HB3' ' CE2' ' B' ' 160' ' ' TYR . 1.2 m -70.04 142.66 52.7 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.616 -0.932 . . . . 0.0 110.995 -176.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 52.8 mttt -83.31 151.89 25.37 Favored 'General case' 0 N--CA 1.503 2.186 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.035 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . 0.884 ' HA ' ' OH ' ' B' ' 160' ' ' TYR . 0.9 OUTLIER -95.98 177.09 5.87 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.516 -0.873 . . . . 0.0 109.098 177.671 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 9.6 p-10 -86.08 16.81 3.95 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 117.584 -1.647 . . . . 0.0 108.223 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -112.65 45.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.964 0.888 . . . . 0.0 108.71 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . 0.49 HG22 ' O ' ' B' ' 166' ' ' SER . 6.4 t -153.48 172.41 17.18 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.24 142.7 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.852 -0.53 . . . . 0.0 109.986 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -104.67 122.02 44.79 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -102.95 152.39 21.37 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 117.66 -1.616 . . . . 0.0 111.393 -175.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.411 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -66.4 131.56 46.35 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.619 -0.675 . . . . 0.0 109.295 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 11.8 p -83.17 -4.81 58.77 Favored 'General case' 0 N--CA 1.512 2.633 0 O-C-N 121.444 -0.785 . . . . 0.0 109.637 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.544 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -151.62 151.16 31.14 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.441 0.639 . . . . 0.0 111.367 178.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -85.47 170.2 44.18 Favored Glycine 0 N--CA 1.479 1.51 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 176.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 139.21 -156.31 24.42 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 117.082 -2.485 . . . . 0.0 111.343 -178.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 7.8 tt -121.35 135.89 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 23.5 mt -74.91 116.18 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.238 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 34.2 p -92.78 -18.57 22.74 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.183 -0.948 . . . . 0.0 110.563 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 10.3 ttmt -161.16 145.85 13.68 Favored 'General case' 0 N--CA 1.502 2.141 0 CA-C-O 122.525 1.155 . . . . 0.0 113.353 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.434 HD12 ' HG3' ' B' ' 217' ' ' GLU . 73.4 mt -131.32 100.29 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 10.2 tp -87.81 109.09 19.49 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.566 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . . . . . . . . . 52.3 mtt85 -74.87 120.28 20.21 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -76.59 151.37 36.29 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 118.797 -1.161 . . . . 0.0 113.162 -174.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -46.21 -57.38 4.59 Favored 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.824 ' HG2' ' C ' ' A' ' 43' ' ' GLU . 7.7 mptt -106.57 30.29 6.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 119.667 -1.896 . . . . 0.0 111.006 -176.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 108.44 151.5 15.51 Favored Glycine 0 C--N 1.292 -1.894 0 C-N-CA 119.45 -1.357 . . . . 0.0 113.353 176.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 100.47 171.91 29.44 Favored Glycine 0 N--CA 1.48 1.581 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.486 ' CG ' HD11 ' B' ' 213' ' ' LEU . 61.1 m-85 -141.05 162.04 36.43 Favored 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 121.954 0.883 . . . . 0.0 112.212 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -126.43 110.66 13.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 105.261 -2.126 . . . . 0.0 105.261 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . 0.433 HD11 HD22 ' B' ' 213' ' ' LEU . 92.2 mt -107.12 122.86 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 120.701 -1.249 . . . . 0.0 110.542 -176.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 9.1 m -96.11 122.9 39.45 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.774 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . . . . . . . . . 27.2 mt -112.3 127.9 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 58.5 t -98.17 100.39 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.484 178.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -73.22 88.5 1.49 Allowed 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -60.18 -32.27 70.91 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.982 -177.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 38.3 m -67.63 -35.21 78.5 Favored 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.708 -0.62 . . . . 0.0 111.577 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -106.24 3.46 27.78 Favored 'General case' 0 N--CA 1.515 2.805 0 O-C-N 121.895 -0.503 . . . . 0.0 110.362 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 50.09 50.44 18.55 Favored 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 22.1 ttp-105 -133.55 141.39 47.69 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.629 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -111.95 129.29 56.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 178.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 175' ' ' ALA . 22.8 m -129.8 147.57 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 44.5 mt -120.08 111.04 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.999 0.904 . . . . 0.0 110.04 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -91.9 128.49 37.76 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 119.149 -1.02 . . . . 0.0 108.276 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 27.2 mt -99.56 135.1 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.011 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . . . . . . . . . 45.5 mt -116.97 132.37 23.48 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -76.2 165.58 29.26 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 123.254 2.636 . . . . 0.0 111.778 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -73.25 154.57 40.15 Favored 'General case' 0 N--CA 1.514 2.728 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 97.58 -6.87 63.19 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.538 HD21 ' HG3' ' B' ' 231' ' ' PRO . 0.3 OUTLIER -115.55 142.77 46.28 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.114 -0.639 . . . . 0.0 109.998 178.689 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -109.72 139.11 45.14 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.389 -0.82 . . . . 0.0 109.093 178.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.486 HD11 ' CG ' ' B' ' 190' ' ' TYR . 17.9 mt -74.01 151.33 40.29 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.354 -0.842 . . . . 0.0 112.927 -178.325 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 41.6 mt -112.04 5.56 18.76 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.52 HG11 HD13 ' B' ' 221' ' ' ILE . 11.7 m -119.86 157.03 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 119.138 -1.025 . . . . 0.0 113.261 -178.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 53.0 m -122.38 157.01 32.77 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.297 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.434 ' HG3' HD12 ' B' ' 182' ' ' ILE . 65.1 mt-10 -61.19 143.09 56.19 Favored 'General case' 0 N--CA 1.5 2.058 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 86.79 -4.21 86.44 Favored Glycine 0 N--CA 1.503 3.121 0 O-C-N 120.916 -1.115 . . . . 0.0 110.728 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -86.75 144.09 27.23 Favored 'General case' 0 N--CA 1.509 2.5 0 O-C-N 120.98 -1.306 . . . . 0.0 110.856 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 29.4 m -86.87 124.01 32.62 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.52 HD13 HG11 ' B' ' 215' ' ' VAL . 3.0 tp -113.22 149.07 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-O 121.296 0.569 . . . . 0.0 109.797 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 22.3 mttp -102.43 161.31 13.81 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.88 138.81 58.12 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.543 -1.263 . . . . 0.0 109.189 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 66.4 14.08 9.53 Favored 'General case' 0 N--CA 1.511 2.608 0 O-C-N 121.514 -0.741 . . . . 0.0 111.668 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.462 ' HB3' HG13 ' B' ' 221' ' ' ILE . 9.0 tt0 -76.51 125.03 87.97 Favored Pre-proline 0 N--CA 1.509 2.512 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -55.77 124.08 15.39 Favored 'Trans proline' 0 N--CA 1.482 0.853 0 C-N-CA 121.496 1.464 . . . . 0.0 110.788 -177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.411 HD11 ' HA ' ' B' ' 173' ' ' ALA . 81.1 mt -98.55 -11.6 22.05 Favored 'General case' 0 N--CA 1.508 2.442 0 CA-C-O 121.468 0.652 . . . . 0.0 110.384 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 24.2 p -135.58 168.21 19.68 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 122.023 0.916 . . . . 0.0 111.477 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.542 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 29.2 m -72.96 161.9 30.14 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.673 -1.149 . . . . 0.0 108.976 178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -91.08 106.76 17.09 Favored Pre-proline 0 N--CA 1.488 1.474 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 177.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 229' ' ' SER . 50.4 Cg_endo -86.03 13.56 2.71 Favored 'Trans proline' 0 CA--C 1.535 0.564 0 C-N-CA 121.448 1.432 . . . . 0.0 112.931 -175.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 46.9 t30 -90.56 119.52 30.89 Favored 'General case' 0 N--CA 1.502 2.143 0 CA-C-N 119.045 0.839 . . . . 0.0 110.959 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 28.6 m -111.76 3.14 8.61 Favored 'Isoleucine or valine' 0 N--CA 1.516 2.864 0 C-N-CA 123.436 0.694 . . . . 0.0 109.808 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -103.43 -163.11 25.37 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.434 ' O ' ' HD2' ' B' ' 154' ' ' ARG . . . 170.79 164.2 26.12 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.401 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 85.3 t80 -117.28 147.36 42.63 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 29' ' ' LYS . . . -147.68 160.9 28.44 Favored Glycine 0 N--CA 1.484 1.876 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 179.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -138.3 154.93 49.01 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.565 -0.962 . . . . 0.0 109.012 -179.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -150.05 174.89 29.37 Favored Glycine 0 C--N 1.293 -1.835 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -146.38 158.15 43.86 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.5 -1.68 . . . . 0.0 110.09 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -136.96 171.1 15.01 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -129.76 133.67 47.15 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 15.9 tt -123.99 142.86 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.556 -179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . 0.54 HG22 ' HG2' ' B' ' 145' ' ' LYS . 12.8 t -103.8 110.4 30.01 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.362 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 9.2 tp -72.22 114.05 9.91 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 175.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -100.99 142.21 32.78 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -172.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -73.07 129.11 86.78 Favored Pre-proline 0 N--CA 1.497 1.903 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 175.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -65.87 -0.85 4.3 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 121.293 1.328 . . . . 0.0 111.106 -177.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 14.8 mt -111.29 -128.8 0.29 Allowed 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 117.148 -1.406 . . . . 0.0 109.634 177.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 253' ' ' HEC . . . . . 1.547 ' CMA' ' C3A' ' B' ' 253' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_